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Abstract 
 
Serine proteases are among the most important proteolytic enzymes and important mediators 
of a wide range of physiological processes. Thus potent and selective inhibitors of these proteases 
are viable therapeutic candidates, since dysregulation of serine proteases has been linked to many 
diseases. The aim of this thesis is to design and synthesize inhibitors of trypsin-like serine 
proteases, including some proteases for which inhibitor development has proved elusive to date, and 
evaluate their effects in enzyme assays relevant to inflammatory and infectious diseases. 
Chapter 1 reviews the biological importance of serine proteases, their mode(s) of action, 
the approaches employed to develop inhibitors and the current status of the field of inhibiting the 
serine proteases: Tryptase, Dengue Virus NS2B/NS3pro, West Nile Virus NS2B/NS3pro and 
Complement Factor B. 
Chapter 2 focuses on human mast cell ß-tryptase, a trypsin-like serine protease implicated 
in airway diseases, inflammatory conditions, cancer and tumour growth. A binding pocket located 
at the S2’ position, not previously exploited in inhibitor development, was examined and 
successfully targeted using two approaches. The first approach involved a rationally designed P1 
scaffold, where moderately active hybrid tryptase inhibitors were produced and the S2’ pocket was 
identified as a viable target pocket. Electrophilic isosteres (aldehyde and α-keto amide) were used 
in a second approach producing potent and selective inhibitors of the human tryptase.  
Chapter 3 describes a peptidomimetic approach to afford inhibitors of two proteases, 
DENV NS2B/NS3pro and WNV NS2B/NS3pro, that are essential for replication of Dengue and 
West Nile viruses respectively. The basic residues of the parent tripeptide inhibitors were replaced 
by non-natural amino acids and the binding requirements of subsites were mapped.  Rationally 
designed amino acid mimetics complementary to the target subsite were identified, and active 
peptidomimetic inhibitors of DENV and WNV NS2B/NS3pro were produced with moderate 
success. 
Chapter 4 examines two isolated serine proteases, DENV NS2B/NS3pro protease and 
complement Factor B protease, that are catalytically inactive at neutral pH and display optimal 
proteolytic activity under basic conditions. The oxyanion holes of these two proteases were found to 
be defective in the ligand-free state, however full restoration of function was observed in a ligand-
bound state. An electrophilic isostere, α-keto amide, was incorporated in peptidic inhibitors to 
target the oxyanion hole residues and to allow occupation of the prime-binding sites of these two 
proteases, but only moderately potent inhibitors were identified for these proteases using this 
approach, despite it being successful for tryptase.   
 iv 
Chapter 5 employs a screening campaign to identify potential new inhibitors of DENV 
NS2B/NS3pro. A library of ~2000 structurally diverse natural products was assayed against DENV 
NS2B-NS3pro. Phloeodictine X was successfully identified as a potent inhibitor of this protease 
(IC50 = 43 nM, substrate (Ac-LKRR-pNa) = 125 µM, pH 9.5, 37 ˚C). The inhibitor binds to the 
protease reversibly and competitively with substrate, indicating that it binds in the substrate-binding 
groove of the enzyme, and it was selective for this enzyme over host trypsin-like serine proteases 
(trypsin, tryptase, thrombin, factor B). 
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1.1 INTRODUCTION  
 
1.1.1 Serine proteases 
Proteases (also known as proteinases) are a group of peptidases that selectively mediate 
hydrolysis of specific peptide main-chain amide bonds.1 These enzymes are found in all organisms 
and are the key regulators of synthesis and turnover of all proteins.1, 2 At present, over 66000 
peptidase protein sequences have been mapped and about 26000 of these peptidases (~30%) are 
serine proteases, denoted by the presence of catalytic triad (Ser–His–Asp) at the active site. More 
specifically, 178 of the 699 proteases found in human are serine proteases.2 Serine proteases are the 
most extensively studied group of proteases due to increasing recognition of their diverse role in a 
plethora of physiological functions. This includes digestion (trypsin), cell differentiation 
(Drasophila trypsin-like enzymes), fibrinolysis (tPA, uPA and plasmin), blood coagulation 
(thrombin, protein C, factor VII, IX, X and XII), apoptosis (granzymes) and inflammation (tryptase, 
chymase).1 Consequently, serine proteases have been linked to a plethora of disease states including 
cancer,3-7 inflammatory diseases,8-17 viral infections,18-21 Alzheimer’s disease22 and arthritis.23-25 
Serine proteases hence represent attractive and promising therapeutic targets for developing 
pharmaceuticals. The immense interest in serine proteases as physiological signals and as drug 
targets is also being fueled by increased understanding of structure-activity relationships and 
enzyme kinetics for this family of enzymes. 
 
(A) (B) 
  
Figure 1.1 (A) Hierarchy of protease classification according to MEROPS. A CLAN contains 
peptidases with common ancestor with evidence as seen in their similarity in tertiary structures, 
order of catalytic-site residues, and common sequence motifs adjacent to the active site. A 
FAMILY is a group of peptidases with significant similarity in amino acid sequence.  (B) Some 
representative branches and their respective members of serine proteases shown in MEROPS 
classification. 
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Aside from conventional classification26 (common ancestry, sequence homology and 
catalytic mechanism) (Figure 1.1), proteases can also be categorised according to their distinctive 
tertiary folded structure (Table 1.1).2 Serine proteases fall into two main structural categories: 
trypsin-like (also termed chymotrypsin-like) and subtilisin-like. Most serine proteases (prokaryotic 
and eukaryotic trypsin-like serine proteases, and some viral serine proteases) are classified as 
trypsin-like (β-proteins), where the catalytic triad is found sandwiched between the interfaces of 
two β-barrels. Other serine proteases (proteinase K, subtilisin Carlsberg, subtilisin BPN and 
thermitase) adopt a subtilisin-fold (Rossman fold), defined by a three-layer αβα fold.2 
 
Table 1.1: Representative members of serine proteases.27 
Structural fold Type Representative members 
Trypsin-like 
(Greek-key β-
barrels) 
Prokaryotic Lysyl endopeptidase, streptogrisin A, streptogrisin B, 
glutamic acid specific, α-lytic 
 Eukaryotic Cathepsin G, thrombin, trypsin, tryptase, elastase, 
kallikrein, plasmin, plasminogen, chymase 
 Viral Hepatitis C, Dengue NS3 
 
Subtilisin-like 
(3-layer sandwich) 
 
 Kumamolisin, proteinase K, subtilisin DY, 
mesentericopeptidase 
Unclassified   
α/β hydrolase  Prolyl oligopeptidase 
α-helical bundle  D-Ala-D-Ala carboxypeptidase 
α + β  Lon peptidase 
All β  LexA peptidase 
4-layer sandwich  Aminopeptidase DmpA 
β-sheet + β-barrel  L,D-Carboxypeptidase 
α-barrel  Rhombois 
 
 
In all serine proteases, the catalytic serine and histidine residues are conserved and 
maintained in an identical geometric orientation, and adjacent functional groups involved in 
transition state stabilisation are arranged in a similar manner (but to a lesser extent). The largest and 
most studied family of serine proteases is the clan PA proteases, which adopt the trypsin-fold. Most 
of the members of this family have trypsin-like substrate specificity and bear strict preference for 
basic amino acids (Arg/Lys) at the P1 position of substrate (Table 1.2).  Some representative 
members include tryptase, thrombin, trypsin, factor Xa, elastase and cathepsin G.2 
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1.1.2 Cleavage-site specificity 
Proteases appear to universally recognise their respective substrates or substrate-like 
inhibitors in a peptide β-strand backbone conformation and bind them in a pocket, where amide 
bond (typically P1-P1’) hydrolysis is carried out (Figure 1.2).1, 2 Most proteases have been found to 
bind substrates in a broadly similar manner. In the late 1960s, a model was proposed to describe the 
interaction of proteases with their substrates by Schechter and Berger.28 In this model, the binding 
site for a polypeptide in an enzyme (substrate recognition site) can be divided into individual 
subsites (S5, S4…S1,S1’…S4’,S5’), where each subsite interacts with one amino acid residue of 
the substrate, correspondingly labeled P5, P4…P1,P1’…P4’,P5’ (Figure 1.2).1, 28 Proteases have 
distinctive requirements for subsite interactions, giving rise to specificity of substrate cleavages.2, 29 
It is important to note that proteases are often promiscuous in substrate selectivity. Trypsin, for 
instance, has broad selectivity for substrates and is capable of cleaving the same substrate at 
multiple sites.2 
 
 
 
 
Figure 1.2: Protease-substrate interactions. Substrate amino acid residues are referred to 
as P (for peptide) while the corresponding subsites on the protease are called S (for 
subsite). Protease-substrate binding extends beyond the S1 pocket, to both prime and non-
prime sides of the peptide binding site. Substrate residues are numbered outwards from the 
active site to the N-terminus as S1, S2, S3 (non-prime side) and S1’, S2’ (prime side) 
towards the C-terminus. 
 
 
For serine proteases and caspases-like cysteine proteases, the S1 site accounts for the 
highest selectivity.30 On the other hand, the S2 site was found to contribute most to selectivity for 
papain-like cysteine proteases. The three major classes of serine protease cleave after a different P1 
residue: (i) trypsin-like (basic amino acids) (ii) chymotrypsin-like (bulky hydrophobic amino acids) 
and (iii) elastase-like (small, aliphatic amino acids). 
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(A) Trypsin-like (B) Subtilisin-like  (C)All β-sheets 
 
 
  
(D) α-helical bundle (E) α/β (F) α-barrel  
 
 
  
Figure 1.3: Structural-fold observed in different class of serine proteases. β-sheets are shown in 
red while α-helices are shown in blue. (A) Trypsin (PDB: 1PTN); (B) Subtilisin Carlsberg (PDB: 
1SCN); (C) LexA peptidase (PDB:1JHC); (D) D-Ala-D-ala-carboxypepridase (PDB: 1NJ5); (E) Ion 
peptidase (PDB: 1QZM); (F) Rhomboid (PDB:2XOV). 
 
 
Table 1.2: Catalytic residue of trypsin-like serine protease and their primary specificity at S1. 
Clan Protease Catalytic  
residue 
# Primary specificity 
PA Trypsin His, Asp, Ser 195 A, E, F, G, K, Q, R, W, Y 
 Tryptase His, Asp, Ser 195 R, K 
SB Subtilisin Asp, His, Ser 221 F, W, Y 
SC Prolyl oligopeptidase Ser, Asp, His 554 G, P 
SE D-A,D-A carboxypeptidase Ser, Lys 62 D-A 
SF LexA peptidase Ser, Lys/His 119 A 
SH Cytomegalovirus assembling His, Ser, His 132 A 
SJ Lon peptidase Ser, Lys 679 K, L, M, R, S 
SK Clp peptidase Ser, His, Asp 97 A 
SP Necleoporin His, Ser Na F 
SQ Aminopeptidase DmpA Ser 250 A, G, K, R 
SR Lactoferrin Lys, Ser 259 K, R 
SS L,D-carboxypeptidase Ser, Glu, His 115 K 
ST Rhomboid His, Ser 201 D, E 
# = Serine residue acting as nucleophile. Information collected from MEROPS database.27 
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1.1.3 Mechanism of action 
The S1 pocket of trypsin-like serine proteases is located adjacent to Ser195, which 
comprises three β-strands (residues 189-192, 214-216, 226-228, trypsin numbering) where Asp189, 
Gly216 and Gly226 form a negatively charged acidic S1 site, accounting for a strict preference for 
basic residues (Arg or Lys) at P1. In contrast, chymotrypsin-like protease has a deep hydrophobic 
pocket (Ser189, Gly216, Gly226) and elastase-like protease has a smaller hydrophobic S1 site 
(Val216, Thr226) leading to a preference for bulky hydrophobic amino acids and aliphatic residues 
at P1 respectively.30 
Proteolytic enzymes catalyse the hydrolytic cleavage of a P1-P1’ peptide bond through 
mediation by the catalytic triad/dyad in the active site (Fig. 1.4). In general, the active site of each 
enzyme comprises a nucleophile and a basic residue (which can also act as a general catalytic 
acid).2 For serine proteases, the catalytic triad (Ser195–Asp102–His57, Chymoytrypsin numbering) 
is found spanning across the active site. The γ hydroxyl group of Ser195 acts as a nucleophile 
during the proteolysis while Asp102 orientates the catalytic histidine (a general base/acid catalyst). 
In addition, the backbone NHs of Gly193 and Ser195 form the oxyanion hole in the catalytic cleft, 
where they form hydrogen bonds to the carbonyl oxygen of the scissile bond. This ultimately leads 
to formation of a free acid product and regeneration of the Ser195-OH leaving group for catalysis.2 
 
 
 
Figure 1.4:  Putative hydrolysis mechanism of serine proteases. During the proteolysis process, the 
carbonyl carbon of the scissile amide bond of the non-covalently bound substrate is attacked by the 
OH group of Ser195, forming a tetrahedral intermediate. The oxyanion pair then stabilizes the 
newly-formed tetrahedral complex through hydrogen-bonding. His57 then transfers a proton to the 
amine of the complex and thus detaches an amine product leaving a covalent acyl enzyme complex. 
This complex then undergoes deacylation in which a new tetrahedral complex is formed through an 
attack by a water molecule assisted by catalysis from His57.  
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1.2 SERINE PROTEASE INHIBITORS DEVELOPMENT 
 
There are two main categories of serine protease inhibitors: endogenous inhibitors 
(macromolecules) and synthetic inhibitors (low molecular weight chemical compounds). In general, 
endogenous inhibitors are proteins or large peptides that bind to the protease either non-covalently 
or covalently to inactivate the protease in a reversible or irreversible manner.31 For instance, 
serpins (Serine protease inhibitors) are a group of structurally-related proteins that inhibit serine 
proteases irreversibly.32 Despite being potent inhibitors of serine proteases, these macromolecules 
are deemed to be non-drug-like based on the Lipinski’s eponymous rule of five (Ro5) due to their 
large molecular weights and chemical structures. Traditionally, Lipinski’s rule is used as a 
barometer of drug-likeness to predict likelihood of oral bioavailability compounds. 33-36 The Ro5 is 
an established drug-likeness filter (Table 1.3) derived from an empirical analysis of initially, around 
2200 drug candidates that reached phase II trials and are in the World Drug Index (WDI). Since 
then, many more compounds have been examined and also fit the rules for a molecule to be orally 
bioavailable with acceptable cell-permeability.36 In contemporary drug design, drug-like leads that 
obey these rules serve as a good starting points for drug development, notwithstanding the many 
exceptions now known.35 Compounds with molecular weight < 500, logP < 5, H-bond donors ≤5, 
H-bond acceptors ≤12 are considered to be most attractive, while the rule of three (Ro3) is used for 
smaller fragments (100-350 g/mol,  cLogP 1-3).36  Two additional parameters34 introduced by Veber 
and colleagues were polar surface area (PSA < 140 Å2) and rotatable bonds (<10 or 12), and these 
further and usefully refined Ro5 predictions. 
 
Table 1.3: Drug-likeness parameters 
Parameters “Lead-like” 
Rule of Three 
“Drug-like” 
Rule of Five 
cLogP < 3 < 5 
Molecular Weight < 300 < 500 g/mol 
Hydrogen-bond donor < 3 ≤ 5 
Hydrogen-bond acceptor < 3 ≤ 10 
 
 Unfortunately, most macromolecules and peptides violate this set of rules and they are often 
bad drug candidates due to low membrane permeability, metabolic instability and poor 
pharmacokinetic profiles. Nevertheless, these natural inhibitors serve as great tools to study 
substrate binding requirements, providing insights to derive more drug-like substrate-based 
synthetic molecules. In drug discovery for serine proteases, inhibitors are commonly developed 
through (a) substrate-based drug design where conversion of substrates into peptidomimetic 
inhibitors is achieved by replacing the scissile amide bond with a transition state isostere, and (b) 
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screening campaigns using compound libraries to identify “hit” inhibitors followed by further 
rounds of chemical modifications to improve inhibitor potency, selectivity and drug-like properties.  
 
 
1.2.1 Substrate based inhibitors 
In substrate-based drug discovery, potent synthetic inhibitors are developed by utilizing 
peptidic targeting-sequences to attain high specificity and selectivity towards the target protease.37, 38 
The peptidic portion serves as the “recognition motif” for the protease where the side chains occupy 
their corresponding binding pockets optimally, and the scissile amide bond is then replaced by non-
scissile isostere to replace the transition state intermediate formed during substrate hydrolysis.38   
For serine proteases, these isosteres comprise an electrophilic carbonyl group that binds 
covalently to the nucleophilic serine hydroxyl of the catalytic triad in the active site, thereby 
mimicking the transition state of amide bond hydrolysis.39 Using peptide aldehyde as an example 
(Figure 1.5), the nucleophilic serine first attacks the electrophilic aldehyde carbonyl group, forming 
a covalent bond with the inhibitor resulting in a tetrahedral hemiacetal analogous to the transition 
state intermediate. The polarized carbonyl group is then stabilised by the oxyanion hole residues.37,39 
 
 
Figure 1.5: C-terminal aldehyde, a precursor to a transition state isostere  
 There are two main classes of electrophilic isosteres, which could either bind to serine 
protease irreversibly or reversibly. Electrophilic isosteres such as halomethyl ketones,40, 41 beta-
lactams42, 43 and benzoxazinone form irreversible covalent bonds with the protease (catalytic serine 
or histidine).44, 45  In certain cases, the nucleophilic serine and/or histidine are acylated or alkylated, 
rendering the protease inactive irreversibly.45  
Electrophiles like aldehydes, trihalomethyl ketones, boronic acid and alpha keto-amide are 
reversible covalent inhibitors of serine proteases.35 These covalent inhibitors are also known to be 
slow binding (reviews by Edwards and Bernstein), with their complex binding kinetics remaining 
elusive.46 It is postulated that hydration (or other equilibrium applicable) of the electrophilic 
carbonyl lowers the concentration of the required keto form, which is essential for interaction with 
the nucleophilic serine hydroxyl, leading to slow onset of full inhibition. There are also obvious 
limitations, where overlapping substrate specificity among proteases leads to poor selectivity. 
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Evidently, compounds employing these strategies have been shown to be potent activators of some 
cysteine proteases.26 
Irreversible electrophilic isosteres 
  
   
Chloromethylketone Halo enol lactone Beta-lactam Benzoxazinone Isocoumarin 
   
 
  
Reversible electrophilic isosteres 
    
Aldehyde Nitrile Trifluoromethylketone Boronic acid 
 
    
Difluoromethylketone α-keto 
R = H, OH, NH2 
 
Oxazole Thiazole 
Figure 1.6: Electrophilic isosteres used to target serine proteases. 
 
It is also noted that these highly reactive electrophiles are non-selective and can also interact 
with a range of nucleophiles (e.g glutathione) circulating in the human body, making them less ideal 
as drug candidates.47 The incorporation of these covalent “serine traps” does however contribute 
considerably to the binding affinity and provide good potency by forming an energetically 
favourable covalent bond with the active site. This often leads to masking of non-optimal 
noncovalent interactions in other portions of the compounds.26 Other inherent issues include 
metabolic instability, chemical degradation, and slow-binding kinetics of these reactive functional 
groups in physiological condition. The presence of reactive functional groups leads to susceptibility 
of these compounds to metabolism. It is also well established that an electrophilic carbonyl at the C-
terminus of peptide derivatives increases the racemization propensity of the P1 α-carbon leading to 
synthetic mixtures.38, 48 
Leupeptin is the first non-selective naturally-occuring peptide aldehyde found to inhibit 
serine proteases (trypsin, Ki = 3.5 nM; plasmin, Ki = 3.4 nM; cathepsin B, Ki = 4.1 nM) 
competitively and reversibily.49 Synthetic peptide aldehyde inhibitors have been developed for 
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many serine proteases. One of the very first is efegatran developed to target thrombin,50 and it has 
entered clinical trials as an intravenous coagulant.26 
 
  
Leupeptin Efegatran 
 
Selective peptide-based serine protease inhibitors have also been reported. Some examples 
are phosphorous-based inhibitors, fluorine-containing inhibitors and peptidyl boronic acid 
derivatives.31 Organophosphorus-based peptidyl compounds are one of the early generation 
selective serine protease synthetic inhibitors. Diisopropylphosphofluoridate (DFP) remains widely 
used as broad-spectrum serine protease inhibitors, however its severe toxicity, lack of selectivity 
within serine proteases and physiological instability led to limited applicability in drug 
development.26  
 A superior group of analogues, α-aminoalkyl diphenylphosphonate esters (Figure 1.7) were 
later discovered and shown to be active inhibitors of chymotrypsin, elastase and thrombin, with no 
activity against cysteine proteases. Fluorine-containing peptidyl analogues with an electrophillic 
carbonyl group are another class of peptide based serine protease inhibitors initiated by 
AstraZeneca with improved metabolic stability and pharmacological properties. Incorporation of 
trifluoromethyl ketones in peptide-based inhibitors has shown activity against elastase, 
chymotrypsin, thrombin and Cathepsin G.26 
 
 
Figure 1.7: Proposed mechanism of action of 
alpha-aminoalkyl diphenylphosphonate esters 
 
One good example of the utilisation of electrophilic isosteres is Telaprevir,51 a recently 
approved hepatitis C protease inhibitor (Figure 1.8). The natural decamer peptide substrate (P6-P4’) 
was first identified.52 A reversible covalent peptide inhibitor (P4-P1’) was derived from this natural 
substrate by introducing an electrophilic aldehyde isostere at the C-terminus of P1,49 in an attempt 
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to downsize the molecule to render it more drug-like. The aldehyde warhead was then replaced with 
an α-keto amide (-CO-CONH-),54 which greatly improved the binding affinity. This might be due to 
the longer half-life of the keto-amide in circulation.52, 53 
Further optimisation of subsites led to the development of Telaprevir, a very potent inhibitor 
(IC50 = 7 nM) of HCV protease, which was approved by FDA and marketed in 2011.55 One of the 
drawbacks of compounds with an electrophilic isostere is the risk of off-target inhibition due to 
their reactive nature. This is evidenced for Bortezomib, a marketed boronic acid proteasome 
inhibitor, which is plagued by side effects due to the presence of a highly reactive boronic acid 
moiety.56 However, telaprevir was shown to exhibit >500-fold selectivity over other host serine 
proteases (thrombin, chymotrypsin, trypsin, plasmin, and kallikrein). This shows that electrophilic 
warheads can be valuable tools in the development of serine protease inhibitors, for which 
selectivity can be attained through optimisation of subsites to minimise off-target inhibition at least 
in vitro, if not in vivo. 
 
 
 
Figure 1.8: Strategy in HCV protease inhibitor development from natural substrate 
to peptidomimetic inhibitor, telaprevir. 
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1.2.2 Non-covalent inhibitors for serine proteases 
Despite immense efforts invested in development of serine protease inhibitors, there are not 
many available clinically on the market. To date, there are no more than ten marketed drugs 
targeting thrombin (BIBR-1048, Argotroban, Ximelagatran), elastase (Elaspol), factor Xa 
(Rivaroxaban), DPP4 (Vildagliptin, Sitagliptin), and broad-spectrum serine proteases inhibitors 
(Gabexate Mesylate, Camostat Mesylate) (Table 1.4). Trypsin-like serine proteases display strong 
affinity for a basic residue (arginine or lysine) at P1 position (Table 1.5), observed in both natural 
substrates and synthetic inhibitors.27 The guanidino moiety of arginine forms strong ionic 
interactions with the highly conserved aspartic acid residue found in the S1 pocket. However, 
incorporation of a P1 basic residue is often linked to low selectivity among trypsin-like serine 
proteases, coupled with poor cell permeability and lack of oral bioavailability. One of the useful 
approaches to counteract this issue is to incorporate an amino acid mimetic as a replacement for the 
basic residues.  
 
Table 1.4: List of drug candidates for serine proteases.1 
Target Drug name Structure Therapy area Status 
Thrombin BIBR-1048 
(Pro-drug of Dabigatran) 
Noehringer Ingelheim 
 
Coagulation Launched 
(2008) 
  
Argatroban 
Mitsubishi Pharma 
 
 
Arterial thrombosis Launched 
(2000) 
 Ximelagatran 
Exanta 
 
Venous thrombosis, 
cerebreal ischaemia 
Launched & 
Withdrawn 
(2004) 
 Desirudin 
Norvatis 
Polypeptide (65 amino acid residues) 
isolated from leech Hirudo medicinalis 
Coagulation Launched 
(1998) 
Elastase Elaspol 
Ono Pharmaceutical Co 
Ltd 
 
SIRS, inflammation Launched 
(2001) 
 Midesteine 
Medea Research 
 
Emphysema Phase III 
(2005) 
 POL-6014 
Polyphor Ltd 
N/A Asthma; Chronic 
obstructive 
pulmonary disease 
Discovery 
Factor Xa Rivaroxaban 
Bayer 
 
Coagulation Launched 
(2008) 
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 DX-9065a 
Daiichi 
 
Thrombosis Phase II 
(2006) 
 DPC-906 
(Razaxaban) 
BMS 
 
Thrombosis Phase II 
(2006) 
Chymotrypsin 
Cathepsin G 
SUPG-032 
Sparta Pharmaceuticals 
Inc 
N/A Cerebrovascular 
ischemia; Lung 
inflammation; 
Myocardial 
infarction; 
Pancreatitis 
Not reported 
DPP4 Vildagliptin 
(LAF-237) 
Novartis 
 
Diabetes Launched 
(2008) 
 Sitagliptin 
Merck 
 
Diabetes Launched 
(2006) 
HCV NS3 
protease 
Boceprevir 
Schering-Plough 
Research Institute 
 
 
 
Hepatitis C virus 
infection 
Launched 
Plasmin 
 
Bikunin 
(AER-002) 
Bayer Corp 
 
N/A Chronic obstructive 
pulmonary disease; 
Cystic fibrosis; 
Thrombosis 
 
Phase 2 Clinical 
(2004) 
Serine protease; 
 
Troponin I 
VT-111 
University of Alberta 
 
N/A 
 
Coronary artery 
disease; 
Inflammatory bowel 
disease; Organ 
transplantation; 
Restenosis; 
Rheumatoid 
arthritis; Transplant 
rejection 
Phase 2 Clinical 
(2010) 
Urokinase WX-671 
Wilex AG 
 
 
 
Breast tumor; 
Metastasis; Pancreas 
tumor; Solid tumor 
 
Phase 2 Clinical 
Mannan-
binding lectin 
serine protease-
2 
MASP-2 inhibiting 
monoclonal antibodies 
University of Leicester 
N/A Inflammatory 
disease 
Discovery 
Broad spectrum Gabexate mesylate 
Ono Pharmaceutical Co 
Ltd 
 
 
Pancreatitis 
 
 
Launched 
 FOY 305 (Camostat) 
Ono Pharmaceutical Co 
Ltd 
 
 
Esophagitis; 
Pancreatitis 
 
Launched 
 MDCO-2010 
Curacyte AG 
 
N/A 
 
Bleeding Phase 1a Clinical 
(2009) 
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 Molecular properties of the native basic residues can be rationally modified in order to 
interact with their corresponding binding pockets optimally and selectively. Structural properties of 
these mimetics can be modified to achieve specific orientation and rigidification, and their 
physiochemical properties (polarity and acid-base character) can be optimised. Furthermore, these 
structural manipulations could potentially allow the mimetics to “pre-organise” into the preferred 
binding conformation, hence lowering the binding entropy penalty.48 This section discusses current 
trypsin-like serine proteases inhibitors reported, focusing on their approaches in basic P1 residue 
modifications. 
 
Table 1.5: Binding specificities of trypsin-like serine proteases 
Trypsin-like serine protease P4 P3 P2 P1 P1’ P2’ 
Coagulation Factor Xa - - G R - - 
Thrombin - - P R S - 
Granzyme A - A S R S G 
Trypsin - - - K/R - - 
U-plasminogen activator - S G R - - 
Plasmin - - - R - - 
Tryptase P R N K G F 
*Information extracted from MEROPS database.27 
 
 
1.2.2.1 Highly basic P1 residue 
The majority of the reported inhibitors for trypsin-like serine proteases utilise a highly basic 
moiety (guanidine, amidine and amine) as their P1 residue to form a salt bridge with Asp189 in the 
S1 pocket. Some classic examples are seen in thrombin inhibitors (Argatroban57, NAPAP58), where 
Argatroban was launched for treatment of arterial thrombosis in Japan in 2000. Some of the broad 
spectrum serine protease inhibitors on the market, such as Gabexate mesylate and Camostat 
mesylate for the treatment of pancreatitis also conserve the basic guanidine moiety (Table 1.4).59 
 
  
Argotroban NAPAP 
 
 
N
OH
O
O
H
N
NH
H2
N N
H
S
O
O
HN
S2 pocket
S3 pocket
O
O
Asp189
S1 pocket
H2
N
N
HN
N
O
O
N
H
S
S2 pocket
O
O
Asp189
S1 pocket
O
O
S3 pocket
	   15	  
Many potent Factor Xa inhibitors also incorporate a highly basic amidino moiety, which 
confers exceptional potency against the enzyme. DX-9065a (Compound 1.1) is the first reported 
potent Factor Xa inhibitor (Ki = 41 nM) with excellent thrombin selectivity (>500-fold) and 
moderate trypsin selectivity (15-fold).26 It contains an amidine moiety at each terminus of the 
molecule, with the napthamidine moiety targeting S1 (salt bridge interaction with Asp189) while 
the positively charged acetimidoyl group of the pyrrolidine ring binds to the S4 pocket, forming an 
interaction with the Glu97 residue. Modest bioavailability was noted in baboons but DX-9065a is 
nevertheless now in a Phase II clinical trials for thrombosis.60 
 
 
  
 
1.1 1.2 1.3 
 
 
For satisfactory oral activity to be realised, less basic and less polar substituents would need 
to be found to replace the highly basic amidines of the inhibitor. To counteract this, one or both 
amidines was replaced with a non-basic moiety. 1.2 employed an isoxazoline central scaffold, with 
a meta-benzamidine targeting the S1 pocket, and a non-basic biarylsulfonamide was introduced to 
interact with the S4 pocket.61, 62 Using a similar strategy, compound 1.3 utilized 3-(S)-amino-2-
pyrrolidinone as the core scaffold instead.58 These compounds were highly potent with elimination 
of one of the basic functionalities being tolerable, however conservation of a highly basic P1 
residue was critical to maintain potency against the enzyme. The presence of the highly basic 
functionalities may lead to poor oral bioavailability rendering them unsuitable for transcellular 
transport. To counteract these issues, the second-generation trypsin-like serine protease inhibitors 
employed two different optimization strategies to improve the physiochemical properties of P1 
residue: (1) reduction of basicity, or (2) a pro-drug approach. 
 
 
1.2.2.2 Reduction of P1 basicity 
Several approaches have been employed to replace highly basic P1 residues with neutral or 
weakly basic synthetic side chains in order to overcome the high basicity of guanidine, amidine and 
alkyl amine moieties. For example, Bristol-Myers Squibb replaced the guanidine moiety of 
Argatroban with 2-aminopyridine to afford 1.4.48 1.4 is equipotent to Argatroban, and this 
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modification led to improved cell permeability however its oral activity and efficacy have not been 
reported.  
 
1.4 
 
 Aminopyridine, a less polar and less basic P1 heterocyclic group, has also been utilized in 
replacing the highly basic P1 residue of D-Phe-Pro-Agmatine (1.5), a non-covalent tripeptide to a 
structurally similar thrombin inhibitor (1.6),64 in order to improve the oral activity. Replacement of 
P3 by incorporating a more lipophilic diphenylalanine led to increase of potency, while having an 
aminopyridine led to a significant decrease in Ki (from subnanomolar to submicromolar range).26 In 
practice, complete deletion of the basic P1 residue often lead to a decrease of at least three orders of 
magnitude in inhibitory potency.  
    
1.5 1.6 1.7 1.8 
  
Lumma et.al reported a potent and highly selective inhibitor with a non-basic 2,5-
dichlorophenyl P1 residue (1.7).65 The complete elimination of a basic P1 residue was tolerated, 
compensated for introduction of chloro substituents to form favourable interactions with the S1 
pocket (Tyr228).65 1.8 replaced the highly lipophilic diphenylalanine P3-residue with D-
cyclohexylglycine and extra polar substituent for hydrogen bonding was introduced through an 
ether link to the 2-position of P1.66 The stepwise reduction and complete elimination of basicity at 
the P1 position proved to be successful, where promotion of alternative binding by introducing non-
basic moieties compensated for loss of critical Asp189-P1 interactions. This indicates that the 
assumption that the requirement for a positively charged moiety P1 residue is insurmountable for 
high affinity binding can be challenged. Indeed, complete elimination of a basic P1 residue (boxed) 
with retention of excellent potency against the enzyme can also be seen in Rivaroxaban,67-70 which 
has been approved by Health Canada and the European Commission for the treatment of venous 
thromboembolism.70 
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Rivaroxaban 
(Non-basic P1 residue is boxed) 
 
1.2.2.3 Pro-drugs 
The highly basic amidino functional group is one of the strongest known organic bases, with 
exceptional stability towards hydrolysis but it is also very hydrophilic.71 Incorporation of this 
functional group in drugs often leads to weak absorption in the gastrointestinal tract making it 
unsuitable for oral application. Two main prodrug approaches have been utilized to enhance their 
bioavailability profiles (Figure 1.9). Firstly, the amidino group can be converted into amidoxime, as 
seen in the conversion of melagatran to ximelagatran.72 The resulting molecules are thus uncharged 
at physiological pH leading to more efficient gastrointestinal absorption. The amidoxime group is 
then metabolised by liver microsomes (and other organs) to return to its highly basic amidine, hence 
“activating” the pro-drug. Ximelagatran is the first oral thrombin inhibitor approved for the 
treatment of venous thromboembolic events in France,73 but has been withdrawn from the market 
recently due to undisclosed issues.74 Other inhibitors employing this strategy include compound 
1.10 (Factor Xa) and sifrafiban (Fibrinogen inhibitor).75 The second approach involved acylation of 
the amidine double-bonded nitrogen to produce a neutral carbamate, which is hydrolysed back to 
the active amidino form by esterases after absorption. This strategy was used in the transformation 
of Dabigatran to BIBR-1048,76 which is on the market for the treatment of coagulation diseases. 
Lefradafiban, a fibrinogen inhibitor, employed a similar prodrug strategy. 
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FACTOR XA INHIBITORS 
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Figure 1.9: Prodrugs of amidino-based inhibitors. 
 
1.3 STATUS OF SERINE PROTEASE INHIBITORS 
 
1.3.1 Tryptase 
Tryptase is a tetrameric trypsin-like serine protease found almost exclusively in mast cells, 
where it comprises four identifical subunits.77-79 Considerable interest in inhibiting tryptase as a 
therapeutical target has been noted in past decades, especially in the treatment of allergic asthma,12 
cancer and inflammatory diseases.80 To date, very few tryptase inhibitors have entered human 
clinical trials, but a peptidic peptide tryptase inhibitor (APC-366) has been reported in Phase IIa for 
allergic asthma, then discontinued as with other candidates.81 APC366 maintained an arginyl 
sidechain to form a salt bridge with Asp189, where one molecule of the inhibitor was reported to 
bind to each monomer of tryptase tetramer (4:1). It was shown to inhibit tryptase irreversibly (Ki = 
300 nM), and attenuate early and late broncho-constriction responses in sheep. This supported a 
role for tryptase in treating allergic asthma. However, potent inhibition of trypsin and thrombin was 
also reported, and formulation issues led to the discontinuation of APC366 development.  
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APC-366 RWJ-56423 
 
RWJ-56423 (Ki = 10 nM) has also entered clinical trials for asthma.82 The guanidine moiety 
formed an ionic interaction with Asp189, and the activated benzthiazole ketone formed a reversible 
covalent bond with Ser195. In addition, the hydroxyproline moiety formed several hydrogen bonds 
with the S2 pocket. It must be noted that RWJ-56423 was also active against trypsin (Ki = 8 nM). A 
key issue with these peptidomimetic inhibitors was their lack of selectivity for tryptase. Both of 
these peptides targeted S1 and S2 pockets, which are similar in tryptase and trypsin. Also, although 
the binding of the arginyl side chain was critical to form a key interaction with the S1 pocket 
(Asp189), this requirement is a common feature of trypsin-like serine proteases and does not 
contribute to any protease selectivity. 
The next section discusses the general approaches employed in the development of tryptase 
inhibitors: (1) active site bridging (2) non-prime side pocket targeting and (3) prime side pocket 
targeting (Fig. 1.10). 
 
 
Figure 1.10: Strategies employed in tryptase inhibitors development. The 
tetrameric structure is represented by the schematic diagram (the identical 
monomers are highlighted in red, or black).  
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1.3.1.1 Active site bridging 
Close examination of the crystal structure of tryptase (PDB: 2FS9) revealed that the closest 
distance between the adjacent active sites is about 20 Å apart.83 This unique tetrameric 
configuration of tryptase potentially allows a strategic approach to tryptase inhibitor design, where 
monomeric molecules acting as terminal P1 nitrogen bases to target the S1 pocket of adjacent 
monomers can be tethered with a suitable scaffold, hence “bridging” the active sites. As tryptase is 
the only known serine protease with this structural feature, this pharmacophore may confer 
excellent selectivity over other trypsin-like serine proteases. Several classes of active site bridging 
inhibitors for tryptase have been reported, including a bis-benzamidine series84 and a bis-
phenylguanidine series.85 
The first series of dibasic “active site bridging” inhibitors was reported by Axys 
Pharmaceutical, where a hydrophobic C2-symmetry cis-1,5-substituted cyclo-octane core (APC-
1390) was utilized as a conformationally flexible central linker, and a phenylguanidine base at each 
terminus of the scaffold was incorporated as P1.85 To project the P1 residues into the active site, 
scaffold rigidification was induced by incorporating piperazine rings (positioned above Trp215 of 
S4 pocket) with the cyclo-octane scaffold spanning the remaining distance, making van der Waals 
contacts with the two “90s loops” (residue 96 and 98 of adjacent monomers). 
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Interestingly, removal of one of the P1 phenylguanidine groups led to a dramatic loss in 
potency, suggesting that the central cyclo-octane scaffold had made a minimal contribution towards 
to overall binding energy. This approach led to generation of exceptionally potent (Ki = 0.85 – 8.7 
nM), selective, competitive, and reversible inhibitors for tryptase, however poor oral absorption and 
metabolic stability of the phenyguanidine moiety were major disadvantages. APC-2059, a 
competitive, potent and reversible tryptase inhibitor employing a similar approach, entered a phase 
II clinical trial for psoriasis as a topical cream, however it was ultimately discontinued as there was 
no significant effect compared to placebo.85, 86 
In 1999, Burgess et al reported the bis-benzamidine series, where the two terminal 
benzamidine groups function as isosteres for the guanidine side chain of two arginines that bind 
readily to each of the adjacent S1 pockets via an amidine/carboxylate salt bridge with Asp189.84, 87 
Benzamidine alone was known to inhibit tryptase (Ki = 22 µM), however with limited selectivity 
over other trypsin-like serine proteases (bovine trypsin, Ki = 33 µM; plasmin, 22% inhibition at 100 
µM).84 Incorporation of benzamidine as the terminal P1 residues with appropriate linkage such as 
bis-ether (Ki = 0.01 – 1 nM), mono-ether (Ki = 375 nM) or mono-amidines (Ki = 1.0 – 1.2 µM) (in 
order of preference) proved the concept of active site bridging. Compound 1.11 effectively reduced 
hyperresponsiveness in a guinea pig model for allergic asthma when delivered intrathecally at 
1mg/kg. These studies suggested that the concept of active bridging could be promising, provided 
that selectivity and potency were achieved. The obvious limitation of these symmetrical dibasic 
inhibitors is their high molecular weight, leading to cell permeability and drug delivery issues 
rendering them unattractive as drug candidates.87  
To counter high molecular weight, a novel hydrogen-bond linker approach (compound 1.12) 
was reported by Vaz and colleagues.88 In this strategy, a benzylamine derivative was used as the P1 
residue and a di-metasubstituted benzamide as the central scaffold. The amide functional group 
attached to the central scaffold is positioned at the interface of the two adjacent tryptase monomers, 
where it makes favourable hydrogen bond interactions with the equivalent amide of an adjacent 
inhibitor molecule (total distance = 23 Å), hence forming a hydrogen-bond-stabilised active site 
bridge. The inhibitor was very potent (Ki = 1.3 nM), however the selectivity remains unreported. 
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1.12 
 
1.3.1.2 Tryptase inhibitors targeting non-prime binding sites 
In order to improve the potency of these early generation tryptase inhibitors, structure-
directed optimisation was pursued through close examination of the tryptase substrate-binding 
grooves and identification of new binding pockets. Hopkins et al. reported an indole inhibitor (1.13) 
with good potency and selectivity.89 The benzylamine group as P1 nitrogen base was the key 
component for activity, maintaining interactions with Asp189 and the carbonyl group of Gly219. 
The N-indole group formed a hydrophobic interaction with the S4 pocket of tryptase where it 
interacted with Tyr95. This compound has been shown to be orally bio-available, but no further 
development was reported.  Levell et al. then reported a structurally similar beta-amidoester 
benzamidine inhibitor (1.14), with excellent potency (Ki = 1.5 nM) and good selectivity (IC50 > 100 
µM for Factor Xa, thrombin, trypsin, elastase and chymase).90 
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In 2008, Costanzo et al. reported an orally active tryptase inhibitor (1.15) with excellent 
potency (IC50 = 3.6 nM) and selectivity (>8000 over trypsin).91 From the reported crystal structure 
(Figure 1.11), the benzylamine group formed a critical salt bridge with Asp189, and the amide 
carbonyl group interacted with Gly219. The piperidine linker adopted a chair conformation and 
projected the rigid 5-phenylethylnyl group into an induced hydrophobic pocket by disrupting the 
interaction between Glu217 and Tyr95. 
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1.15 
 
Figure 1.11: Crystal structure91 of compound 1.15 (blue) bound to tryptase 
(PDB:2ZA5). The benzylamine residue is in the S1 pocket, and the rigid ring 
interacts with the non-prime pocket. The ether oxygen was solvent-exposed. 
 
1.3.1.3 Tryptase inhibitors targeting prime binding sites 
Slusarchyk et al. reported an azetidinone tryptase inhibitor (BMS-363131) targeting a distal 
prime side binding pocket located around S4’, consisting of a loop (Val59-Leu64) and two beta-
sheets (Leu33-Gly37, and Tyr37B-Phe41).92 This unique pocket is not present in trypsin. The 
conformationally constrained guanidine group at C-3 targeted the S1 pocket, while the extended 
substituent appended to the piperazine at N1 targeted the S4’ hydrophobic pocket. BMS-363131 
was potent (Ki <1.7 nM), selective against trypsin, thrombin, Factor Xa and Plasmin, and was 
efficacious in a guinea pig model of asthma.  Sutton et al. also reported a similar tryptase inhibitor 
(Ki = 1 nM), with a hexylamine at P1, and it was >300 fold selective over trypsin and >33000 over 
thrombin.93 
 
BMS-363131  
 
The discovery of the unique distal prime hydrophobic pocket led to more selective and 
potent tryptase inhibitors. Sperandio et al. afforded a structurally similar α-ketoheterocyclic 
compound (1.16), which inhibited tryptase (Ki = 2.7 µM) but without selectivity (trypsin, Ki = 0.68 
µM).94 The benzyl carbamate moiety was postulated to bind to the S2 pocket, while the phenyl 
capping group attached to the alpha-ketoheterocycle was thought to extend towards P’ binding sites. 
Further optimization resulted in a highly selective and potent tryptase inhibitor (1.17, Ki = 5.4 nM; 
trypsin, Ki = 190 nM; chymotrypsin, elastase, chymase, urokinase, Ki > 150 µM). The phenyl cap 
was extended to form van der Waals interactions with the distal hydrophobic pocket. In addition, 
replacement of the P2 benzyl carbamate by ethyl carbamate greatly reduced activity against trypsin, 
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while preserving potency against tryptase, where it was suggested that the benzyl group did not 
bind tightly to the S2 pocket. 
 
 
 
1.16 1.17 
 
In the same year, Lee et al. reported two similar tryptase inhibitors employing an alpha-
ketoheterocycle as a scaffold (Compound 1.18).95 Compound 1.18 was found to be a potent and 
moderately selective tryptase inhibitor (Ki = 2.8 nM; Trypsin, Ki = 170 nM), with a smaller P2 
residue contributing to selectivity over trypsin. The dihydro-indene capping group was thought to 
bind to the aforementioned distal prime side hydrophobic pocket (Fig. 1.12). 
 
 
 
 
1.18 
 
Figure 1.12: Crystal structure of compound 18 bound to mast cell tryptase (PDB: 2FS9)  
 
1.3.1.4 Zinc-mediated tryptase inhibitors 
In the late 1970s, a series of zinc-mediated potent serine protease inhibitors was reported 
(Figure 1.13).96 The most outstanding inhibitor of this series, Bis-(5-amidino-2-
benzimidazoylyl)methane (BABIM)) was reported to inhibit trypsin with Ki = 90 nM in the 
presence of zinc, but its Ki was greatly reduced to 19 µM without zinc. BABIM was also found to 
be inhibitory against tryptase (Ki = 5 nM) and thrombin (Ki = 23 nM).  
Using this approach, Axys Pharmaceutical developed a potent inhibitor for tryptase, 
BAY443428 (Ki = 6 nM) (Figure 1.13C) with >1000 fold selectivity over other related serine 
proteases.81 BAY443428 comprised a benzylamine P1 nitrogen base, and a hydrophobic 
naphthalene side chain that formed favourable pi-stacking van de Waals interactions with a distal 
prime side hydrophobic pocket (Phe41, Val35 and Leu64). BAY443428 was discontinued due to 
toxicity issues. Celera reported a structurally similar non-basic inhibitor (CRA-9249) (Figure 
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1.13D) for tryptase.86 The P1 residue was devoid of polar functionalities with excellent oral 
bioavailability. Further information regarding this inhibitor remains undisclosed. 
 
(A) (B) (C) (D) 
 
 
  
 
Figure 1.13: Zinc-mediated inhibitors. (A) BABIM. Modelling studies revealed that the 
amidinobenzene portion of BABIM served as a replacement for a basic P1 residue and form 
salt bridge with Asp189. In addition, the zinc atom acted as a chelating agent and formed a 
distorted tetrahedral complex with NHis57 and OSer195 coordinated by the nitrogen atom from 
each of the benzimidazoles, as seen in BABIM at pH 8.2. (B) Keto-Babim  (C) BAY443428 
(D) CRA-9249 
 
 
1.3.2 Flaviviral NS2B/NS3pro proteases 
 
Dengue virus (DENV) and West Nile virus (WNV) are mosquito-borne human pathogens 
that cause hemorrhagic fever and neuroinvasive diseases, such as encephalitis and meningitis, that 
can be fatal.97 There are four dengue serotype (DENV 1-4) and 50-100 millions dengue infections in 
humans are estimated annually.98 It has been estimated that 2.5 billion people residing in the 
tropical areas are at risk of infection by flaviviruses.99 There are no effective vaccines or therapeutic 
agents available yet to treat DENV or WNV infections.97, 98  DENV NS2B/NS3 protease (a complex 
of NS3 protease and NS2B co-factor) is a trypsin-like serine protease that has been implicated in 
viral replication and virion maturation.100 Therefore, it serves as a promising target for developing 
an antiviral agent against DENV infections. The N-terminal NS3pro domain comprises 180 amino 
acids and adopts a chymotrypsin-like fold (two β-barrels, each formed by six β-strands). The NS2B 
cofactor is an integral component that participates in the formation of the catalytic active site of the 
DENV NS2B/NS4pro complex.98  
The NS3 protease constitutes around 18% of the entire dengue flavivirus polyprotein (about 
70 kDa) and it is situated in the middle of the polyprotein.  30% of the N-terminus of NS3 is pivotal 
for enzymatic activity, while the remainders are thought to be non-essential.  The essential cofactor 
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NS2B (14 kDa) is located adjacent to the N-terminus of NS3 protease within the polyprotein. It is 
rich in hydrophobic residues that renders it membrane-bound, thereby explaining why the linked 
NS3 protease is membrane-localized.101 While the NS2B sequence is not highly conserved amongst 
the flaviviruses, the central domain of this cofactor is relatively conserved and plays a critical role 
in stabilizing and activating the NS3 protease.98  Previous structural studies revealed that DENV 
NS2B/NS3pro exists in two forms: a catalytic competent “closed” form, and an inactive “open” 
form.  In the closed form, the NS2B C-terminus is bound to the protease and forms part of the 
substrate binding sites (S2 and S3 pockets). In the open form, the NS2B cofactor dissociates from 
the NS3 domain. The active site is disfigured and unable to process substrate, rendering the protease 
inactive. In earlier studies, it was suspected that the closed form could be induced in an inhibitor-
bound state.102, 103 In WNV NS2B/NS3pro, the two states (open and closed) exist in a dynamic 
equilibrium, and the active “closed form” predominates independent of an inhibitor.  On the 
contrary, the inactive “open form” seems to prevail in DENV protease in aqueous environment.98, 104  
Two main approaches have been utilized to develop dengue virus protease inhibitors. The 
first was through a peptidomimetic approached based on native substrate residues, and the second 
involved high-throughput screening of small molecule libraries to identify an active DENV protease 
inhibitor. The next section focuses on substrate-based inhibitors. Synthetic molecules targeting 
DENV protease will be discussed in Chapter 5. 
 
1.3.2.1 DENV NS2B/NS3pro substrate-based inhibitors 
The initial inhibitor development involved the conversion of the natural substrate sequence 
into peptide DENV NS2B/NS3pro inhibitors.  It was observed that there was a crucial requirement 
of a basic amino acid at both P1 and P2 (Table 1.6).105 This dibasic requirement is atypical in most 
host trypsin-like serine proteases which mostly prefer a basic residue at P1 solely. 
 
Table 1.6: Native polyprotein processing sites of DENV  NS2B/NS3pro protease.105   
Site DENV 1 DENV 2 DENV 3 DENV 4 
2A/B KIWGRK SWPLNE RTSKKR SWPLNE DRLKRR SWPLNE KGASRR SWPLNE 
2B/3 QKKQRR SVGLWD EVKKQR AGVLWD QKQTQR SGVLWD QVKTQR SGALWD 
3/4A FAAGRR SVSGDL FAAGRK SLTLNL FAAGRK SIALDL FASGRK SIRLDI 
4B/5 LGGGRR GTGAQG TTNTRR GTGNIG VGTGKR GTGSQG AQTPRR GTGTTG 
*Requirement of a basic residue (Arg or Lys) at P2 and P1, highlighted in red, are observed. 
 
 
A series of hexapeptide substrates with a chromophore (para-nitroaniline) at the P1-P1’ C-
terminal derived from native polyprotein processing sequence was first developed in-house (Table 
1.7)101  and the most rapidly processed substrate was found to be Ac-TTSTRR-pNa.  
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Table 1.7: Chromogenic substrates of DENV protease.106  
Site ID Substrate Km (µM) Kcat (s-1) Kcat/Km (M-1S-1) 
2A/2B 1.19 Ac-RTSKKR-pNa 96 ± 7 0.0087 ± 0.001 903 ± 56 
2B/3 1.20 Ac-EVKKQR-pNa 984 ± 40 0.216 ± 0.002 220 ± 6 
3/4A 1.21 Ac-FAAGRK-pNa 100 ± 9 0.043 ± 0.001 425 ± 30 
4B/5 1.22 Ac-TTSTRR-pNa 326 ± 10 0.288 ± 0.001 883 ± 22 
 
 
Subsequently, a series of reversible covalent inhibitors (Table 1.8) was derived from these 
natural cleavage sequence through incorporation of an electrophilic isostere, such as an alpha-keto 
amide or aldehyde, C-terminal to P1.106 The strategy was to gain binding affinity by having a 
reactive species to form a covalent bond with the catalytic Ser135, while appending peptidic 
portions to target prime and non-prime binding sites to allow study of binding specificities.  In the 
α-keto amide series (1.23-1.25), the best inhibitor was found to be Ac-FAAGRR-ketoamide-SL-
NH2 while a drastic decrease in potency was observed in Ac-TTSTRR-ketoamide-SL-NH2. This 
finding was different from substrate studies discussed previously, where TTSTRR was deemed to 
be the more optimal P6-P1 segment for substrate processing.105 Replacing the α-keto amide moiety 
with an aldehyde afforded the best inhibitor in this series, Ac-FAAGRR-CHO (1.26, Ki = 16 µM), 
which was three-fold more potent than Ac-FAAGRR-ketoamide-SL-NH2. This suggested that the 
prime residues (P1’-P2’) may not play an important role in protease binding, though it was also 
possible that the prime-targeting sequence was non-optimal and led to a detrimental effect in 
inhibitor binding and/or potency. However, it is important to note that the α-keto amide moiety may 
be less sterically favourable compared to the C-terminal aldehyde, as it effectively lengthens the 
distance between P1 and P1’ by an extra C-C bond length. This could lead to the displacement of 
the prime binding sequence, which may explain their inferior activities. 
 
Table 1.8:  α-keto amides as DENV protease inhibitors. 
ID Inhibitor Ki (µM) 
1.23 Ac-FAAGRR-ketoamide-SL-NH2 47 ± 3 
1.24 Ac-TTSTRR-ketoamide-SL-NH2 220 ± 55 
1.25 Ac-TTSTRR-ketoamide-GTGN-NH2 368 ±47 
1.26 Ac-FAAGRR-CHO 16 ±3 
 
In later studies, the substrate specificities from P4 to P1 were profiled (Table 1.9) and all 
four dengue serotypes displayed similar substrate specificities.107 Unlike most trypsin-like serine 
proteases, DENV NS2B/NS3 protease has a marked preference for dibasic residues at P1 (Arg) and 
P2 (Arg), but this motif is also commonly recognized by furin proteases.108 Nevertheless, this 
requirement may provide some selectivity over most other host serine proteases. The optimal non-
prime sequence (P4-P1) was found to be Bz-Nle-Lys-Arg-Arg (Km = 12 µM).107  
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Table 1.9: Substrate specificity of DENV NS3/NS2B 
Serotype Optimal residue Ref. P7 P6 P5 P4 P3 P2 P1 P1’ P2’ P3’ P4’ Km (µM) 
DENV1   Bz n K R  R Amc     107 
    n K R R S D S N  107 
DENV2 Ac E V K K Q R pNA    1079 106 
   Bz n K R  R Amc    12 107 
    n K R R S G S>N G  107 
   Abz R R R R S A G nY 5 103 
   Abz A K R R S Q EDDnp  31 109 
DENV3   Bz n K R  R Amc     107 
    n K R R S D S>N G  107 
DENV4   Bz L K R R Amc     107 
    n K R R S G S G  107 
 
Using this information, Yin et al. developed a moderately active tetrapeptide aldehyde inhibitor, 
Bz-Nle-Lys-Arg-Arg-CHO (Ki= 5.8 µM).110 The inhibitor was co-crystallised with DENV 
NS2B/NS3pro protease (PDB: 3U1I, Figure 1.14) to understand their specific interactions.97 The 
active site of DENV NS2B/NS3pro protease was shallow and highly acidic (Figure 1.14a), thereby 
explaining the requirement for basic residues at P2 and P1. The P1-Arg formed a strong ionic 
interaction with Asp129, coupled with a postulated pi-interaction with Tyr161 whereas P2-Arg 
formed a hydrogen-bond interaction with Asn152 and Gln35. A requirement for a third basic 
residue, P3-Lys was also noted, where it was thought to form hydrogen-interaction with Met84. The 
P4-Nle was postulated to form a van der Waals interaction with the hydrophobic S4 groove 
(Val154, Val155), while the P5-benzoyl cap was found to be projected away from the active site, in 
a “solvent-exposed” state. 
(A) 
 
(B) 
 
Figure 1.14: (A) Co-crystal structure of Bz-Nle-Lys-Arg-Arg-CHO bound to DENV NS2B/NS3 
protease (B) Interactions of Bz-nle-Lys-Arg-Arg-CHO with DENV NS2B/NS3 protease. (PDB: 
3u1I). 
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 To elucidate the role of side chains in binding, each residue was substituted by alanine, 
phenylalanine, lysine or proline (Table 1.10).  It was found that substitution of P1-Arginine was 
tolerated, where replacement by a phenylalanine (1.29, Ki = 15.9 µM) or lysine (1.30, Ki =20.5 µM) 
led to 3-4 fold increase in Ki value. P2-Arginine was found to be sensitive towards substitutions, 
where introduction of alanine (1.32) rendered the peptide inactive, while replacement by 
phenylalanine (1.33, Ki = 40.7 µM), lysine (1.34, Ki = 41.3 µM), and proline (1.35, Ki = 109 µM) 
led to 8-20 fold increase in Ki value. On the other hand, substitutions at P3 (1.37-1.39) and P4 
(1.44-1.52) were well tolerated with no drastic reduction in binding potency, suggesting a minor 
contribution of these side chains in enzyme binding. In agreement, truncation of P3-P4 (1.43) led to 
only slight loss of potency. Interestingly, the tripeptide aldehyde (1.42) achieved an improved 
binding potency (Ki =1.5 µM).111  
 
Table 1.10: Subsite inhibitor specificity of DENV protease. 
ID Variant Peptide Inhibitor Ki (µM) IC50 (µM) Ref 
1.27  Bz-nKRR-CHO 5.8 9.5 99, 111 
1.28 P1 Bz-nKRA-CHO 193 - 111 
1.29  Bz-nKRF-CHO 16 - 111 
1.30  Bz-nKRK-CHO 21 - 111 
1.31  Bz-nKRr-CHO 51 - 111 
1.32 P2 Bz-nKAR-CHO >500 - 111 
1.33  Bz-nKFR-CHO 41 - 111 
1.34  Bz-nKKR-CHO 41 - 111 
1.35  Bz-nKPR-CHO 109 - 111 
1.36  Bz-nKrR-CHO 115 - 111 
1.37 P3 Bz-nARR-CHO 22 - 111 
1.38  Bz-nFRR-CHO 16 - 111 
1.39  Bz-nkRR-CHO 29 - 111 
1.40 P4 Bz-AKRR-CHO 5 - 111 
1.41  Bz-FKRR-CHO 7 - 111 
1.42 Truncation Bz-KRR-CHO 2 - 111 
1.43  Bz-RR-CHO 12 - 111 
1.44 P4-Cap Phenacetyl-KRR-CHO - 6.7 95 
1.45  4-aminobenzoyl-KRR-CHO - 201 95 
1.46  Acetyl-KRR-CHO - 58 95 
1.47  Propionyl-KRR-CHO - 218 95 
1.48  4-phenylphenylacetyl-KRR-CHO - 23 95 
1.49  4-aminophenylacetyl-KRR-CHO - 11 95 
1.50  2-naphthoyl-KRR-CHO - 27 95 
1.51  Cinnamoyl-KRR-CHO - 16 95 
1.52  Phenylpropionoyl-KRR-CHO - >300 95 
*Substitutions are highlighted in red.  
 
To investigate the N-terminal cap requirement for DENV, Schuller et al. introduced a series 
N-terminal caps94 (1.44-1.52) with different physiochemical properties such as length, polarity, 
flexibility and size to the tripeptide sequence X-KRR-CHO in a similar approach to Stoermer et al., 
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(Table 1.11, section 1.3.3.2).112 In agreement with Yin et al., Bz-n-KRR-CHO (IC50 = 9.5 µM) was 
active against DENV protease at micromolar concentrations (Ki was previously reported at 5.8 µM). 
Unfortunately, introduction of these N-terminal caps did not yield any significant improvement in 
potency as opposed to observations for WNV. For DENV NS2B/NS3pro, bulky caps (1.44, 1.48 
and 1.49) were tolerated, while flexible caps (1.52) led to inactivity. On the other hand, small 
alipathic caps (1.46, 1.47) were found to be undesirable, where a significant loss of activity was 
noted. Having a polar cap (1.45, 1.49) was inconclusive, where a drastic loss of potency was 
observed in 4-aminobenzoyl (1.45), while 4-aminophenylacetyl (1.49) was equipotent to the 
reference inhibitor. Phenacetyl-KRR-CHO (1.44, IC50 = 6.7 µM) was equipotent to the reference 
peptide (IC50 = 9.5 µM).  
Despite having an electrophilic aldehyde warhead traditionally used to produce high affinity 
inhibitors for proteases, these covalent peptide inhibitors fared poorly against DENV 
NS2B/NS3pro. Different electrophilic warheads such as aldehyde, benzoxazole, thiazole, 
trifluromethylketone, and boron esters have also been used to target DENV protease to afford 
covalent tetrapeptide inhibitors.110 The only potent inhibitor was found to be Bz-Nle-Lys-Arg-Arg-
B(OH)2  (Ki = 0.043 µM) containing a C-terminal boronic acid isostere. More recently, retropeptide 
inhibitors with aromatic moieties have also been utilized and they were found to be moderately 
active against DENV protease, despite lacking an electrophilic isostere to bind covalently with the 
protease.113  Another strategy involved constraining peptides derived from conesnail conotoxins 
with reported antiviral activity.114  The most effective inhibitor was a cyclised heptapeptide 
(CGKRK↑SC) formed by inducing a disulfide bond between the terminal cysteine sidechains with 
moderate potency (Ki = 1.4 µM). Molecular modeling studies suggested that the P1-Lys formed an 
ionic interaction with Asp129, and a hydrogen bond with the carbonyl of Phe130. The P2-Arg on 
the other hand formed a putative hydrogen bonding interaction with the amide backbone of Gly82 
and the P3-Lys interacted with the backbone of Asp81. The oligopeptide inhibitor was found to be 
selective towards DENV protease with no inhibition against trypsin, however it is noted that the 
disulfide bond was susceptible to cleavage in the reducing environment of the cytoplasm. Based on 
the information where disulfide peptides could be useful as DENV protease inhibitor, Rothan et al. 
tested retrocyclin-1, a disulphide cyclic peptide, against DENV NS2B/NS3pro.115 Retrocyclin-1 is a 
known antimicrobial agent and it has also been reported to block HIV-1 entry.116 The circular 18-
residue peptide was found to have some weak inhibitory activity against DENV protease (IC50 = 14 
µM) at 40 oC, but the inhibitor activity decreased at lower temperatures.115 
In summary, the main strategy (Figure 1.15) employed in developing DENV NS2B/NS3pro 
protease inhibitors involved identification of natural peptide substrates, derivatization to a 
reversible covalent peptide inhibitor by incorporating an electrophilic isostere, followed by 
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truncation of the non-prime residues to afford a moderately potent tetrapeptide inhibitor. Due to the 
acidic surface of the binding site, these peptides contained several positively charged amino acids 
that reduce membrane permeability. Replacing such charged residues remains a major challenge to 
developing potent and selective peptidomimetic inhibitors against DENV NS2B/NS3pro protease in 
vivo. 
 
 
Figure 1.15: Development of substrate-based DENV protease inhibitors 
 
 
1.3.2.2 WNV NS2B/NS3pro inhibitors 
The development of WNV NS2B/NS3pro inhibitors had earlier employed similar strategies 
as just discussed for DENV protease, albeit with more success.  Two general strategies were 
employed: peptide-based inhibitors derived from substrate binding sequence99, 112, 117, 118 and 
identification of active inhibitors through high-throughput screening studies119-122. From the native 
polyprotein processing sites (Table 1.11), it was discovered that WNV NS2B/NS3pro recognises a 
dibasic motif in substrate processing, where it has a preference for a P1-Arg and a P2-Lys. On the 
other hand, a variety of residues was present at P3 (Arg, Thr, Gly, Leu) and P4 (Asn, Thr, Ser, Gly). 
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Table 1.11: Native polyprotein processing sites of WNV protease 
Component Cleavage site 
C/prM TKQKKR GGTAGF 
NS2A-2B DPNRKR GWPATE 
NS2B-3 LQYTKR GGVLWD 
NS3A-3B SAAQRR GRIGRN 
NS3-4A FASGKR GQIGLI 
NS4A-4B EPEKQR SQTDNQ 
NS4B-5 KPGLKR GGAKGR 
*Requirement of a basic residue (Arg or Lys) at P2 and P1. 
Knox et al. reported a series of substrate-based tetrapeptide aldehyde inhibitors derived from 
the substrate processing sequence,118 and it was discovered that residues (e.g arginine) capable of 
forming hydrogen-bonding and pi-stacking interactions were favourable at P1. A positively charged 
residue was preferred at P2 position, where a lysine was preferred over arginine, in contrast with 
DENV NS2B/NS3pro.  The best inhibitor out of the series was reported to be Bz-Ala-Lys-Lys-Arg-
CHO (IC50 = 700 nM). In another studies by Chappell et al., a highly efficient tripeptide substrate, 
2-Naphthoyl-KKR-pNA (Km = 20 µM) was successfully identified.123 Based on these studies, 
Stoermer et al. then reported a superior series of tripeptide WNV protease inhibitors based on the 
tetrapeptide aldehydes (Table 1.12).112   
 
Table 1.12: Substrate-based tetrapeptide inhibitors of WNV protease. 
ID Variant Peptide inhibitor IC50 (nM) 
  P4-Cap P3 P2 P1 P1’  
1.53  Phenylacetyl Lys Lys  Arg CHO 51 
1.54 P2 Phenylacetyl Lys hArg Arg CHO 297 
1.55  Phenylacetyl Lys Cit Arg CHO 11565 
1.56  Phenylacetyl Lys Orn Arg CHO 73 
1.57  Phenylacetyl Lys Arg Arg CHO 325 
1.58 P3 Phenylacetyl hArg Lys Arg CHO 245 
1.59  Phenylacetyl Cit Lys Arg CHO 619 
1.60  Phenylacetyl Orn Lys Arg CHO 255 
1.61  Phenylacetyl Arg Lys Arg CHO 154 
1.62 P4 2-naphthoyl Lys Lys  Arg CHO 231 
1.63  4-phenyl-phenacetyl Lys Lys  Arg CHO 32 
1.64  Benzoyl Lys Lys  Arg CHO 271 
1.65  2-aminobenzoyl Lys Lys  Arg CHO 891 
1.66  cinnamoyl Lys Lys  Arg CHO 580 
 
The truncation of the P5-benzoyl cap and the replacement of the P4-Ala with a hydrophobic 
cap led to a highly potent tripeptide, PhAc-KKR-CHO (1.53, IC50 = 51 nM), which was 12-fold 
more potent than the reported tetrapeptide inhibitor. To examine if all of the three basic residues 
(Lys-Arg-Arg) were critical for activities at P3-P1 position, arginine and lysine analogues were 
introduced. It was found that there was an absolute requirement for positively-charged residues at 
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P2 and P3, with citrulline (non-basic counterpart of arginine) leading to reduced potency at both 
positions. In addition, there was a distinct preference for lysine at both P2 and P3, over arginine 
(1.57, 1.61) or homoarginine (1.54, 1.58).  It was also discovered that flexible caps (phenacetyl, 4-
phenylacetyl) were preferred over rigid capping groups (benzoyl, 2-aminobenzoyl, cinnamoyl). 4-
phenyl-phenylacetyl-Lys-Lys-Arg-CHO (1.63, IC50 = 32 nM) was the most potent WNV 
NS2B/NS3 inhibitor of this series. The development of these peptide inhibitors was summarized in 
Figure 1.16. 
The presence of an aldehyde warhead in these peptide aldehydes prompted Lim et al. to 
develop a small set of non-covalent peptidomimetic inhibitors,117 as reactive electrophilic isostere is 
notoriously known for its lack of selectivity amongst serine and cysteine proteases, and is unstable 
under physiological conditions.34  The C-terminal aldehyde was removed completely, resulting in a 
decarboxylated arginine termed “agmatine” at P1 position. The elimination of the electrophilic 
warhead proved to be detrimental. The resulting tripeptide, 4-phenyl-phenacetyl-Lys-Lys-
Agmatine, was found to suffer a 100-fold reduction in potency (IC50 = 4.7 µM). This suggested that 
the binding affinity of the tetrapeptide and tripeptide aldehyde inhibitors was largely contributed by 
the covalent bond formed between the aldehyde and the catalytic Ser135, and further optimization 
of the peptide portion is needed. 
 
 
Figure 1.16: Development of WNV protease peptidic inhibitors 
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 In other studies by Kang et al., 4-phenyl-phenacetyl-KKR-CHO was further truncated to 
give Ac-KR-CHO (IC50 = 170 nM) to understand minimum binding requirements for tight 
binding.124 The much smaller dipeptide aldehyde was only 3-fold less active compared to the 
tripeptide inhibitor. This suggested that the P3 residue may not be essential for inhibitor activity. 
NMR experiments were also employed to study conformation changes in WNV protease in 
response to the dipeptide binding. It was found that significant chemical shift perturbations (> 0.1 
ppm) were observed for residues found in S3 (Q86, N84, A164, V154) and S1 (Y161, D129) 
pockets, in comparison with the tripeptide. The absence of a P3-Lys led to major chemical shifts at 
the S3 pocket region. These observations suggested that inhibitor played a pivotal role in 
maintaining the integrity of the protease active site. The changes made on inhibitors could promote 
synergistic conformational arrangement of the protease binding loops, hence “redefining” the active 
site. The conformational malleability of WNV protease implied that successful inhibitors have to 
interact with the relevant binding loops in order to compete with the substrate. The conformational 
behavior of WNV protease remains difficult to understand, and it was concluded that allosteric 
inhibitors may be the answer for future inhibitor design to lock the protease in a conformation 
incapable of substrate processing.124 
 These early studies successfully identified peptide-based inhibitors containing two or more 
basic residues with good inhibitory activity against WNV protease in vitro. Due to the presence of a 
reactive electrophilic group, these substrate-based peptides are plagued with short half-lives and 
high clearance rates in vivo, curtailing their viability as drug candidates.  To address this issue, 
several studies reported non-peptidic inhibitors for WNV protease identified through high-
throughtput screening. Using this strategy, several moderately potent synthetic molecules were 
discovered as WNV protease inhibitors.  A group of compounds with isothiourea,121 guanidine, 8-
hydroxyquinone125, and isoquinoline126 scaffolds was identified as competitive inhibitors of WNV 
protease with micromolar potency.  Uncompetitve inhibitors have also been successfully identified. 
Samanta et al.  reported a series of compounds with 9,10-dihydro-3H,4αH-1,3,9-tetraaza-
phenanthren-4one as central scaffold with low micromolar potency.127 The most successful 
screening campaign was reported by Johnston and co-workers, where a set of potent sulfonyl 
pyrazolyl derivatives (1.67, IC50 = 105 nM) was identified as uncompetitive inhibitors of WNV 
protease.119  Despite their excellent inhibitory properties, these molecules were prone to rapid 
chemical degradation in both assay buffer and physiological condition, their binding site was 
unknown and attempts to improve their chemical stability were futile. 
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Compound 1.67 
IC50 = 105 nM 
Pubchem SID: 852843 
 
 
 
1.3.3 Complement Factor B 
 
Complement Factor B (Figure 1.17) is a chymotrypsin-like serine protease involved in 
monocyte activation, macrophage spreading and B cell growth factors in the complement system.128 
The human complement system is formed by a network of plasma proteins with pivotal roles in 
immune defence, cooperatively effecting recognition, opsonization, destruction and removal of 
pathogens.128, 129 Dysregulation of complement activation can lead to immunoinflammatory and 
neurodegenerative disorders.5 It was therefore of interest to develop inhibitors against Factor B as 
tool compounds to provide better understanding of the regulation of the alternative complement 
activation pathway, and may provide further characterization of the role of Factor B in the 
complement system.  
 
 
Figure 1.17: Complement activation pathways.130 Alternative pathway convertase 
C3bBb is formed when factor B (B) combines with C3b, followed by the activation 
of factor B by Factor D. 
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One of the key proteases in this cascade, Factor B, is circulated in human serum as an 
inactive zymogen that is converted into its active form through a stepwise assembly process.131 The 
protease is a zymogen-like serine protease at physiological pH on its own, however it exhibits full 
catalytic competence in the presence of cofactors. It contains the same catalytic core as in C3 
convertase.129, 130  
The inactive zymogen first binds to C3b in the presence of Mg2+, forming a 
conformationally incomplete intermediate. Factor D then cleaves this intermediate at a single 
cleavage site (Arg234-Lys235), resulting in two fragments (Ba and Bb). Ba detaches from the 
complex while Bb remains bound to the C3b, forming the catalytically active complex C3bBb 
which displays chymotrypsin-like behaviour. Interestingly, it was discovered that Factor B displays 
catalytic activity at a basic pH with good stability in its own right, similar to that of DENV and 
WNV NS2B/NS3pro proteases.130	  
 
 
 
Figure 1.18: Domain topology and crystal structure of Factor B. Ba fragment is highlighted in 
yellow, and Bb fragment is highlighted in blue. 
 
1.3.3.1 Factor B inhibitors 
The C3bBb complex is involved in the processing of C3 to the fragments C3a and C3b in 
the alternative pathway of complement activation.129, 132 The native cleavage sequence was found to 
be QHARASHLGLAR↓SNLD, where Factor B was found to be capable of cleaving truncated 
derivatives of the nature substrate.132 Le et al. first reported a series of the chromogenic peptides 
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(Table 1.13) derived from the native cleavage sequence as Factor B substrates.131 Ac-
ARASHLGLAR-pNA was sequentially truncated and the processing of the shorter peptides by 
Factor B was evaluated. The most efficient substrate was found to be a heptapeptide, Ac-
SHLGLAR-pNA. Further truncation of the heptapeptide led to a decrease in processing efficiency.  
 
Table 1.13: Substrates of Factor B131 
ID Substrate kcat (s-1) Km(µM) kcat/Km  
1.68 Ac-ARASHLGLAR-pNa 12.6 12.4 1016 
1.69 Ac-RASHLGLAR-pNa 12.8 15.8 810 
1.70 Ac-ASHLGLAR-pNa 10.2  2.19  4666  
1.71 Ac-SHLGLAR-pNa 8.4  1.05  8315  
  
The initial strategy of inhibitor development involved converting the heptapeptide substrate 
into a peptide inhibitor by replacing the pNa at the C-terminus with an electrophilic aldehyde.130 
The resulting peptide aldehyde, Ac-SHLGLAR-CHO, was found to be moderately active against 
Factor B (IC50 = 19 µM). The residues in this heptapeptide aldehyde were then systematically 
replaced from P7 to P1 to investigate their effects on inhibitory activity (Table 1.14).  
 
Table 1.14: Substrate specificities of Factor B130. 
Subsites Preference Interacting protease residues 
P1 Arg > Lys > Phe Asn668, Thr669, Cys670, Gly695, 
Val697, Ala713, Arg714, Asp715 
P2 Ala >Gly > Lys, Nle, Nva > Val > Leu His501, Tyr548 
P3 Leu > Nle, Tba >Cha > Aib, Tbg, Pro Pro693, Gly695, Val696, Val697 
P4 Tba > Leu, Nle, Ile, Cha > Thr, Phe > 
Ser, Ser(Bzl) 
Glu546, Tyr548, Tyr641, Trp694 
P5 Leu Ill-defined 
P6 Arg > Tyr, Lys, Ala > Cha, Lys(Ac) Leu544, Pro545, Gly640, Lys643 
Nle = norleucine, Nva = norvaline, Aib = aminoisobutyric acid, Tbg = tert-butyl glycine, Tba = tert-butyl alanine, Cha 
= cyclohexylalanine. 
 
Substitution at P3 was found to be highly tolerable, where small (serine, alanine), aliphatic 
(leucine, proline), bulky hydrophobic (phenylalanins, tyrosine) or basic side chains (lysine) were 
found to exhibit similar potency. This suggested that P3 may not play a substantial role in inhibitor 
potency. A strong preference for a bulky aliphatic residues (Cha, Leu) was noted at P4, where 
greater potency was achieved as compared to subsitutions with other residues such as Gly, Ala, Aib, 
Tbg, Lys, His, Phe, Trp and Tyr.  Cha and Leu was found to exhibit similar potency at P4, with Ac-
SHLLLAR-CHO being more soluble and was chosen as the preferred residue. At P5 position, it 
was found that branched (tert-butyl glycine, valine), small (alanine) or acidic (glutamate) side 
chains were undesirable, whereas leucine, norleucine and phenylanine were well-tolerated.130 
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The non-prime residues were then truncated one by one, and it was noted that truncation of 
P7 (Ac-HLLLAR-CHO) and P6 (Ac-LLLAR-CHO) did not affect the inhibitor potency 
significantly, however truncating three N-terminal residues (Ac-LLAR-CHO) led to substantial loss 
in potency. It was found that replacing histidine with arginine at P6 led to a more active compound, 
Ac-RLLLAR-CHO (IC50 = 0.6 µM), which was beneficial in improving the water solubility of the 
highly hydrophobic peptide.130 
The most potent compound, Ac-RLLLAR-CHO, was docked onto the crystal structure of 
Factor B (PDB:2RKK) to understand specific interactions between the side chains and the protease.  
The ligand adopted a beta-sheet extended conformation, commonly recognized by most 
proteases.133 The P1 arginine was predicted to form an ionic interaction with Asp715 located at the 
S1 pocket. S2 pocket was observed to be small and non-prominent formed by His501 and Tyr548, 
to which the Ala made a weak van der Waals contact. S3 was also found to be quite shallow, where 
P3-Leu interacted with Pro639, Gly695, Val696 and Val697. 
 
(A) (B) 
 
 
 
Figure 1.19: Predicted interactions of Ac-RLTbaLAR-CHO with Factor B (PDB: 2RRK)125. (A) 
Ac-RLTbaLAR-CHO docked into factor B (PDB: 2RKK). (B) Schematic diagram of their 
predicted interaction. 
  
On the other hand, S4 pocket was found to be quite prominent, flanked by Glu546, Tyr548, 
Tyr641 and Trp694.  The S5 and S6 pockets were not well defined and the specific interactions 
with the corresponding P5 and P6 side chains remains elusive. Lastly, it was noted that the S7 
pocket was non-existent, explaining why the truncation of the P7 residue had little effect on 
inhibitor potency.130 Further modifications of Ac-RLLLAR-CHO was then carried out, without 
improvements were observed in P1, P2, P3, P5 and P6. Substitution of P4-Leu by tert-butyl alanine 
(Tba) led to the most potent compound of the series, Ac-RL(Tba)LAR-CHO (IC50 = 250 nM).  
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However, this series of compounds was found to be non-selective for Factor B, with inhibition of 
other serine proteases (thrombin, trypsin) also observed at comparable concentrations.130 
In summary, the strategy employed in the development of Factor B inhibitors (Figure 1.20) 
involved the initial identification of natural peptide substrate, followed by conversion of the peptide 
substrate to a peptide aldehyde to achieve reversible competitive inhibition. A series of 
modifications, involving truncation and subsite optimisations was then carried out to successfully 
produce a highly potent hexapeptide inhibitor, Ac-RL(Tba)LAR-CHO. 
 
 
 
Figure 1.20: Development of Factor B inhibitor. 
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1.4 AIMS OF THESIS 
 
Due to the importance of serine protease in mediating a plethora of physiological processes 
and their involvement in a range of diseases, the general aim of this thesis was to design, synthesize 
and evaluate serine protease inhibitors. Firstly, the aim was to apply and develop methods to 
produce novel, potent and selective trypsin-like inhibitors. The second objective was to improve the 
drug-like properties of lead inhibitors, where structural and chemical properties were rationally 
modified to potentially increase cell-permeability.  
Chapter 2 employs two strategies to develop novel, potent and selective tryptase inhibitors 
through targeting of an unexploited S2’ binding pocket. In the first strategy, the P1-Arginine 
commonly used in tryptase inhibitors was replaced by an unnatural P1 amino acid mimetic, with 
incorporation of a non-cleavable P1-P1’ amide bond to successfully convert the hybrid peptide into 
an inhibitor. In the second strategy, the scissile amide bond P1-P1’ bond was replaced by an 
electrophilic isostere (aldehyde or α-keto amide) to allow more robust screening of the P2’ binding 
specificity.  
Chapter 3 builds upon the methodology employed in Chapter 2, where basic amino acid 
mimetics were used to replace arginine or lysine in DENV (PhAc-Lys-Arg-Arg-CHO) and WNV 
NS2B/NS3pro (PhAc-Lys-Lys-Arg-CHO) aldehyde inhibitors. The most potent inhibitors known 
for these two flaviviral proteases comprise three basic residues at P3, P2 and P1 positions, but their 
highly-charged and hydrophilic nature render their bioavailability profiles undesirable. The primary 
aim was to improve the binding of the inhibitors through optimisation of subsite interactions. The 
side chains were replaced with mimetics with structural modifications (shortened, elongated and/or 
structurally constrained) to afford optimal occupation of the binding pockets. The secondary aim 
was to improve the drug-like properties of the hydrophilic tetrapeptide inhibitors by introducing 
mimetics with chemical (reduced or eliminated basicity) modifications.  
Chapter 4 examines the use of an alternative electrophillic isostere (α-keto amide), 
previously employed in Chapter 2 for tryptase, in the development of inhibitors for a pair of 
atypical trypsin-like serine protease, DENV NS2B/NS3pro protease and Complement Factor B 
protease. An internal α-keto amide isostere was employed as a tool to explore the prime binding 
pockets to establish structure-activity relationships with the proteases. The aim was to gain 
additional binding interactions with the proteases to improve inhibitor potency.  
Chapter 5 reports a small throughput screening campaign to identify novel natural products 
that might inhibit DENV NS2B/NS3pro protease. In this discovery program, a library of 2000 
natural products was screened for inhibitory activity against DENV protease through enzymatic 
assay, and “hits” were further verified through a series of validation, kinetic and selectivity studies. 
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 ABSTRACT 
Tryptase is a trypsin-like serine protease found predominantly in mast cells. It has trypsin-
like specificity, with a preference for an arginine or a lysine at P1 in both substrates and inhibitors. 
Current clinical indications include airway diseases, inflammatory conditions, cancer and tumour 
growth.1 A large number of tryptase inhibitors targeting two well-explored pockets (prime and non 
prime) has been reported, and these strategies have produced potent and selective tryptase 
inhibitors. The aim of this chapter was to identify a novel binding pocket in tryptase, profile the 
binding requirement at the pocket, and ultimately exploit the pocket to afford more potent and more 
selective inhibitors. 
A binding pocket situated at the S2’ position that has not been previously targeted was 
identified. Using a rationally-designed scaffold (4-aminomethylanthranilic acid, 4-AMAA) as a P1 
residue, a prime peptidic binding sequence was attached to its meta-position (relative to 4-
aminomethyl moiety). A para-position tethered the P1’-Gly and P2’-D-Phe, where it was found that 
a D-configuration was preferred at the P2’ position due to the distortion of C-terminus caused by 
the planar nature of the aromatic scaffold. The distortion of the C-terminal P1-P1’ amide bond also 
rendered it non-scissile and successfully produced a moderately active hybrid tryptase inhibitor 
(Ac-PRN(4-AMAA)Gf-NH2, IC50 = 12 µM). Introduction of D-Phe led to improvement of inhibitor 
potency, suggesting that there was potential in utilizing the S2’ pocket in tryptase as an inhibitor-
binding pocket. 
To further profile the binding requirement at the S2’ pocket, the non-cleavable amide bond 
was replaced by an α-keto amide at P1-P1’ position. A series of non-peptidic hydrophobic moieties 
was introduced at the P2’ position to target the hydrophobic S2’ pocket. A highly potent tryptase 
inhibitor (Ac-PRNR-α-keto amide-Gbenzylamine, IC50 = 610 pM) was successfully identified, 
proving that targeting the S2’ pocket could lead to improvement of binding affinity. It was also 
discovered that having the non-prime binding sequence (Ac-PRNR-α-keto amide, IC50 = 65 nM) 
was suffice to attain good selectivity for tryptase against trypsin.  
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2.1 INTRODUCTION 
 
2.1.1 Mast cell tryptase 
Mast cell tryptase is a serine protease discovered in the late 19th century.1 There are four 
closely related tryptases (ßI, ßII, ßIII, and α isoenzymes) in the human body and they are widely 
distributed as a heterogenous population throughout the body. 2 In particular, tryptase is found at 
high concentrations in mast cells, both in connective and mucosal tissues where physical 
injury/foreign body invasion is likely to occur.1, 3 Biological roles of tryptase (Table 2.1) include 
tissue remodeling, recruitment of eosinophils, neutrophils and mast cells, tumour growth, wound 
healing and bronchoconstriction activity in the lung.2   
Mast cell tryptase is secreted together with heparin upon mast cell degranulation. The 
release of tryptase into the extracellular milieu leads to interactions of ß–tryptase with a plethora of 
cell types/substrates, resulting in propagation and perpetuation of pro-inflammatory responses.2, 4 
Indeed, the elevated level of tryptase in the circulation has been linked to many inflammatory 
diseases (asthma, psoriasis, rhinitis, multiple schlerosis).  In fact, ß–tryptase was reported to share a 
genetic link with airway reactivity4, and clinical studies have provided evidence that ß–tryptase 
plays an immediate role in the pathogenesis of asthma. According to World Health Organisation 
(WHO), it is estimated that 235 million people are currently suffering from asthma, affecting their 
quality of life and causing a great economic and health burden.5 ß–tryptase is therefore an attractive 
drug target for the treatment of airway diseases, and other inflammatory disorders. 2 
 
Table 2.1: Biological targets of tryptase.1 
Target Activity Biological effect 
Peptides VIP, PHM, CGRP Decrease of endogenous 
bronchodilatory activity in lung 
 
Proteins Kinin 
pro-MMP 3 and pro-urokinase 
Fibronectin and collagen 
Fibrinogen 
Vascular permeability enhancing 
Tissue remodelling and tumour invasion 
Tissue remodelling 
Clotting prevention 
 
Cells  
(dependent/ 
independent 
PAR-2 
activation) 
Proliferation of fibroblast, smooth 
muscle cells and epithelial cells. 
Release of cytokines 
Fibrosis, tissue remodelling 
Recruitment of eosinophils, neutrophils 
and mast cells 
 
 
Tissues Capillary tube formation  
(angiogenesis) 
Solid tumour growth, wound healing 
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Tryptase is perhaps the most abundant serine protease found in the human1 and has a 
distinctive tetrameric structure.6 This mast cell protease is released as a complex with the 
negatively-charged heparin proteoglycans that stabilizes the tetrameric configuration of the 
enzyme.7 Without heparin, the tetrameric enzyme is highly unstable and would rapidly dissociate to 
form four catalytically incompetent zymogen-like monomers.8,9  The four monomers (monomer A-
D, 27.5 kDa each) are identical (Figure 2.1A), with monomer A and B (hence C and D) being 
mirror images of each other. The tetrameric configuration leads to the formation of a narrow central 
pore (40 Å x 20 Å), to which the active sites project.6, 7, 9 This unique feature of tryptase limits the 
accessibility for natural biological macromolecule inhibitors (fibronectin, urokinase-type 
plasminogen activator and stromelysin), hence tryptase has a longer half life in the circulation after 
being released from degranulated mast cells.10 
 
 
Figure 2.1: (A) Tetrameric structure of tryptase. The active sites face a central pore (40 Å x 20 Å). 
(B) Key residues of tryptase involved in catalysis. Asp189 is located at the base of S1 pocket, and 
the catalytic triad (His57, Asp102 and Ser195) is found at the surface of the S1 pocket. The 
catalytic triad facilitates the hydrolysis of tryptase substrates. (PDB: 2GDD) 
 
2.1.1 Tryptase binding specificity 
Tryptase displays a strict preference for a basic residue (arginine or lysine) at P1, as found in 
its reported substrate cleavage site (Table 2.2). 11 The substrate specificities of tryptase have been 
well-studied for the non-prime binding side, where the most optimal sequence was found to be Pro-
Arg-Asn-Lys (P4 to P1).12 The optimal specificities for the prime side are not so well-established, 
with varying residues were seen in natural substrates/inhibitors without selectivity over other serine 
proteases. 
(A) (B) 
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Table 2.2: Sequence of tryptase substrates and inhibitors.13  
Type Species Uniprot ID Cleavage site P4 P3 P2 P1 P1’ P2’ 
Natural Substrate Pro-urokinase P00749 P R F K I I 
 VIP P01282 T R L R K Q 
 Par-2 P00585 S K G R S L 
Synthetic Substrate - P R N K Acc  
Natural inhibitor LDTI P80424 A C P K I L 
 
2.1.2 Current inhibitors  
The current status of tryptase inhibitors was previously discussed in Chapter 1. In essence, 
several classes of inhibitors have been successfully identified as tryptase inhibitors (Figure 2.2), 
such as metal-chelating inhibitors,14 active-site bridging inhibitors,15 and inhibitors that targeted 
either a prime binding pocket16 (S4’) or a non-prime17 (S4) binding pocket. A review of the 
available biological data on tryptase inhibitors indicated that there was primary interest in tryptase 
as a clinical target for allergic asthma and inflammatory disorders in particular, resulting from 
cellular and in vivo action of tryptase as a pro-inflammatory mediator.18-20 
 
 
Metal chelator Active site bridge 
 
 
 
BABIM   
Ki = 1.8 nM 
Preclinical trial airway inflammation 
 
APC-2059  
Ki = 0.1 nM 
Phase II for psoriasis 
 
Non-Prime Prime Irreversible 
 
 
 
  
Compound 2.1 
IC50 = 3.6 nM 
Preclinical trials for asthma 
 
Compound 2.2 
Ki =  2.8 nM 
Preclinical trial 
 
APC-366 
IC50 = 300 nM 
Phase IIa for asthma 
(discontinued) 
Figure 2.2: Representative tryptase inhibitors in clinical trials 
 
Despite considerable efforts by numerous pharmaceutical companies, no tryptase inhibitor 
has completed Phase III clinical trials and none is available on the market yet.  APC-366 progressed 
the furthest to Phase IIa clinical trials for the treatment of asthma, however it was discontinued for 
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undisclosed reasons.21 It is evident that current inhibitors of tryptase are associated with a basic 
motif contributing to sub-optimal pharmacokinetic profiles, and they are burdened by a lack of 
selectivity amongst other drug targets in some cases. This imparts the need to identify tryptase 
inhibitors with novel modes of interaction with tryptase in order to enhance the potency and 
selectivity of new inhibitors towards tryptase.   
 
2.2 IDENTIFICATION OF NOVEL BINDING POCKET 
A review on tryptase inhibitors in Chapter 1 revealed two distinct hydrophobic pockets (a 
non-prime-side pocket, and a distal prime-side pocket) as inhibitor binding pockets (Figure 2.3). 
The properties of the known binding pockets, and their binding requirements are summarized in 
Figure 2.4. In a bid to promote further substrate-enzyme interactions with human mast cell tryptase,  
the active site was closely inspected. It was noted that there was an unexplored hydrophobic pocket 
at S2’ defined by residues Leu73, Leu151, Trp141 and Gly142 (Figure 2.4D). This observation 
suggested that exploiting the putative hydrophobic S2’ pocket could provide a novel strategy for 
targeting tryptase. It was hypothesized that introduction of a hydrophobic P2’ residue could 
promote further favourable interactions at S2’ with tryptase, and potentially provide additional 
binding affinity and potency in future inhibitors of tryptase.   
 
 
Figure 2.3: Superimposition of tryptase inhibitors. The non-prime side pocket is 
positioned between the interface of adjacent monomers and favours hydrophobic 
interactions. The distal prime side hydrophobic pocket is located about 20 Å from the deep 
S1 pocket, and hydrophobic interaction is strongly preferred. The enzyme surface 
represents atom identities (red = oxygen, blue = nitrogen, grey = carbon, yellow = sulphur). 
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The lack of optimisation of the P2’ inhibitor substituents in the literature was a concern, but 
could be justified by general approaches used in peptidic substrates/inhibitors for selective binding 
to tryptase. The C-terminus of the P1 residue in these peptides has mainly been replaced by 
chromophores or fluorophores (ACC, MCA, pNa) as a marker of hydrolysis in assays, or by 
electrophilic isosteres such as boronic acid and chloromethyl ketone (CMK) to convert a substrate 
into an inhibitor.22 Such efforts did not require a prime side component in substrates or inhibitors. 
 
Pocket Summary 
(A) S1 pocket 
 
 
The well-defined S1 pocket contained the conserved 
Asp189. Aliphatic (aliphatic amidine, lysine side chain) and 
heterocyclic (piperidine, imidazole) and aromatic 
(benzylamine, benzamidine) moieties were tolerated in this 
pocket.16, 17, 23-25 The P1 nitrogen base was critical for potency 
against tryptase, however this requirement did not 
discriminate between other serine proteases. 
 
(B) Prime binding pocket 
 
 
The prime side pocket (residues Leu106, Val85, Leu64, and 
Phe41) was situated around S4’ (~18Å away from S1) and it 
was specific to tryptase. This distal pocket was quite 
prominent and was able to accommodate bulky hydrophobic 
groups such as naphthalene, phenyl, and dihydroindene 
groups.16, 23, 26, 27 Utilization of this tryptase-specific pocket 
led to excellent selectivity and potency.  
 
(C) Non-prime binding pocket 
 
 
The non-prime binding pocket was situated around S4 
(~15Å away from S1), and hydrophobic interactions were 
favourable at this position. This pocket was quite large and 
could tolerate bulky aromatic groups such as a phenyl ring or 
a biphenyl moiety.17, 24, 28 
 
(D) S2’ pocket 
 
The S2’ pocket was prominent and hydrophobic, flanked by 
hydrophobic residues (Gly142, Trp141, Lue73 and Leu151). 
This pocket was relatively spacious and it was predicted that 
large hydrophobic residues would be favourable at this 
position to engage in a van der Waals interactions with the 
S2’ residues. 
Figure 2.4: Summary of key binding pockets in tryptase, the key protease residues and their 
preferred interactions/residues.  The enzyme surface represents atom identities (red = oxygen, 
blue = nitrogen, grey = carbon, yellow = sulphur). (PDB: 2GDD) 
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Nevertheless, it was crucial that the putative S2’ pocket was structurally distinct for tryptase 
in order to attain selectivity for tryptase. The S2’ of tryptase was thus compared with that of other 
trypsin-like serine proteases (Table 2.3, Figure 2.5). The shallow and acidic S2’ pocket of trypsin 
was different from tryptase, indicating that selectivity towards tryptase could be gained by targeting 
the hydrophobic S2’ pocket of the latter. The promininent hydrophobic S2’ pockets of thrombin and 
urokinase were strikingly similar to tryptase, and thrombin has a strong preference for a 
hydrophobic residue (Phe) at P2’ position. This implied that selectivity for tryptase against these 
two proteases may be difficult to achieve solely through targeting of S2’. The S2’ pocket of plasma 
kallikrein and factor Xa were characterized by a shallow pocket with slightly polar (factor Xa) and 
slightly basic (plasma kallikrein) surfaces. Both proteases have a strong preference for a 
hydrophobic residue (Val) at P2’, suggesting that selectivity for tryptase against these proteases 
may be difficult to achieve by solely targeting the S2’ pocket. Ultimately, these observations 
suggested that the tryptase S2’ pocket was not unique among serine proteases, and thus may have 
limited potential for providing selectivity for tryptase over some other serine proteases. As tryptase 
and trypsin were known to process a great number of the same biological substrates (PAR-229, 
fibrinogen30), the primary interest was therefore to gain selectivity for tryptase over trypsin, given 
that the hydrophobic S2’ pocket of tryptase was well distinguished from the anionic S2’ site in 
trypsin. Selectivity over other proteases might be derived by optimising for the other binding sites 
of the tryptase active site over other enzymes in future studies.  
 
Table 2.3: S2’ pocket residues of trypsin-like serine proteases, and their respective cleavage sites. 
Serine protease Cleavage specificity site S2’ pocket residues 
P2 P1 P1’ P2’ 
Tryptase N K/R X  Leu151, Gly142 , Trp141, Phe153  
Trypsin  K/R X  Tyr151, Asn74, Pro152, Ile73, Trp141 
Factor Xa G R T V Gly193, Asn 151, Gly40, Phe41 
Thrombin  R S F Glu232, Gly233, Asp234, Gly178, Asn179, 
Leu 62, Trp177 
Urokinase G R R  Tyr151, Phe141, Leu73, Tyr40, Phe30 
Plasma Kallikrein F R V V Gln193, His40, Leu41 
*S2’ pocket residue: Non-italic residues signify involvement of main side chain to form the pocket. 
Residues shown in italic are defined by the role of their amide backbone in forming part of the 
pocket. Information collected from MEROPS.13 
 
The main aim of this chapter was to design, synthesize and evaluate potent inhibitors of 
mast cell tryptase by targeting the S2’ pocket as a novel approach to gaining additional potency and 
selectivity over other trypsin-like serine proteases. To achieve this aim, two main approaches were 
employed: (1) incorporation of a novel P1 scaffold that allowed attachment of non-prime and 
prime-targeting binding moieties separate sites in tryptase, with the S2’ subsite being the primary 
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target. (2) incorporation of an α-keto amide transition state isostere in place of the P1-P1’ scissile 
amide bond to afford substrate-based inhibitors capable of mapping the binding specificities at S2’ 
pocket in a robust manner. The electrophilic isostere was intentionally employed as an efficient 
method to probe the S2’ pocket due to its high affinity for the protease, and its comparatively 
efficient synthesis. 
 
(A) Tryptase  (B) Trypsin 
  
(C) Factor Xa  (D) Thrombin  
  
(E) Urokinase  (F) Plasma Kallikrein 
  
 
Figure 2.5: Putative S2’ pocket of selected trypsin-like serine proteases. (a) Tryptase (PDB: 
2GDD). The S2’ pocket of tryptase has a hydrophobic surface flanked by Leu73, Trp141, Phe151 
and Gly142. (b) Trypsin (PDB: 3M35). The S2’ pocket of trypsin was smaller, with a polar surface 
due to the presence of Trp141, Ile73, and Tyr151. (c) Factor Xa (PDB: 2WYG) The S2’ pocket was 
prominent and slightly polar defined by the residues Gln151, Gly40, and Phe41. (d)Thrombin 
(PDB: 3DA9). The S2’ pocket has a slightly acidic surface flanked by Trp177 and Leu62. 
(e)Urokinase (PDB: 1W0Z). The S2’ pocket was hydrophobic surface defined by Tyr40, Leu73 and 
Tyr151. (f) Plasma Kallikrein (PDB:2ANY). The S2’ pocket has a slightly basic surface, defined by 
His40, Leu41 and Ile151. Electrostatic potential surface was generated using Pymol (Red= acidic, 
blue = basic, grey = hydrophobic). 
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2.4 DEVELOPMENT OF EVALUATION ASSAY 
Initially, a broad-spectrum trypsin-like serine protease substrate, Nα-Benzoyl-L-arginine 4-
nitroanilide (BapNa)31, was used to install an absorbance-based assay for evaluation of in-house 
tryptase inhibitors. Single-substrate kinetic studies were carried out. It was observed that BapNa 
induced a positive cooperativity when bound to tryptase, as determined by Hill plot analysis, where 
deviations from standard Michaelis-Menten and Lineweaver-Burk plots were observed (Fig. 2.6A-
B). 
 
(A) (B) (C) 
   
Figure 2.6: (A) Michaelis-Menten Plot for BAPNA. (B) Lineweaver-Burk double reciprocal 
plot for BAPNA.  (C) Hill Plot for BAPNA. Assay was carried out in 0.1 M HEPES buffer, 0.1 
mg/mL heparin, 0.01% triton X-100 v/v, 0.02% NaN3, pH 7.5 and 28 ˚C. Error bars represent 
mean ± SEM of at least three independent experiments.  
 
 
In multimeric enzymes, cooperative structural changes in adjacent active sites can be 
induced once a single substrate molecule binds to a tryptase monomer. For positive cooperativity, 
favourable structural changes and increased affinity towards substrates are noted in the other active 
sites, while negative cooperativity leads to the opposite. The Hill constant, h, is defined by the slope 
of the Hill plot and is indicative of the mode of cooperativity (Table 2.4).32 From the Hill plot, the 
Hill coefficient (slope) was found to be 3.6 (>1 and < number of active sites), suggesting there was 
positive cooperativity in the binding of BAPNA to tryptase with 3-4 substrate molecules binding to 
the enzyme. The experimental Km of BAPNA was found here to be 0.9 mM (Lit. value33 1.19 mM). 
 
Table 2.4: Co-operativities observed in multimeric enzymes derived from the slope of Hill 
Plot34 
Hill coefficient, h Indications 
= number of active sites Extreme positive co-operativity 
>1; < number of active sites Positive co-operativity exists, but not extremely cooperative. 
= 1 No co-operativity 
<1 Negative  co-operativity 
 
A more specific tryptase substrate, Tos-GPR-pNa was synthesized and used to replace the 
broad spectrum assay in order to provide a more relevant evaluation of competitive and selective 
Michaelis-Menten Plot
0.5 1.0 1.5 2.0
0.0
0.5
1.0
1.5
2.0
2.5
[S] mM
Ve
lo
ci
ty
 (m
M
/s
) x
 1
0-
4
Lineweaver-Burk Plot
0.5 1.0 1.5 2.0
0
10
20
30
1/s mM-1
1/
v 
(m
M
-1
s)
  x
10
4 
Hill plot
-0.2 0.0 0.2 0.4
-1
0
1
2
log [S] M
lo
g[
v/
(V
m
ax
-v
)]
 64 
potential inhibitors for tryptase.12 Interestingly, the single-substrate kinetic studies revealed that 
there was no positive co-operativity observed for Tos-GPR-pNa (Fig. 2.7). It was speculated that 
the additional P3-Gly and P2-Pro residues may have formed a more rigid induced-fit complex with 
tryptase monomer that restricted the favourable conformational changes of the adjacent monomers 
that led to previously observed enhanced binding affinity. A Km value of 121 µM (pH 7.6, 28 oC) 
was obtained, as compared to the reported 49 µM (pH 7.4, 37 oC).12 
 
(A) (B) 
  
Figure 2.7: (A) Michaelis-Menten Plot of Tos-GPR-pNA (B)Lineweaver-Burk 
Plot of Tos-GPR-pNa. Assay was carried out in 0.1 M HEPES buffer, 0.1 mg/mL 
heparin, 0.01% triton X-100 v/v, 0.02% NaN3, pH 7.5 and 28 ˚C. Error bars 
represent mean ± SEM of at least three independent experiments. 
 
 
2.5 CHARACTERIZATION OF REFERENCE INHIBITOR 
A selective and potent inhibitor for tryptase, compound 2.1 (IC50 = 3.6 nM), was selected 
from the literature as the reference inhibitor in the evaluation assays for in-house inhibitors.  The 
synthesis was carried out according to the protocol reported17 (Scheme 2.1), with some 
modifications to improve yield and purity. Boc-piperidone was reacted with phenylsulfinylmethyl 
lithium (step a) (formed by reacting phenylmethylsulfoxide with N-butyllithium), which then 
underwent a [2,3]-rearrangement under treatment with potassium tert-butoxide (step b) to form the 
allyl acohol. Treatment of the allyl alcohol with thionyl chloride (step c) led to the unstable 
chloride, which was coupled immediately with 4-hydroxyl-3-bromobenzonitrile. The coupling 
reaction (step d) required a phase transfer catalyst, tetrabutylammonium iodide, with potassium 
carbonate and dry acetonitrile forming a heterogeneous solution. This was followed by a critical 
radical-based cyclization step (step e), where tributyltinhydride and a radical initiator (1,1'-
Azobis(cyclohexanecarbonitrile), ACCN) were added to form a 0.02M solution. It was crucial that 
the concentration of tributyltinhydride remained diluted, as reduction may occur in the presence of 
concentrated tributyltin hydride. Removal of tin residues was achieved by chromatography methods 
where 10% KF was added into silical gel. The nitrile group was reduced to a primary amine (step f), 
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and further protected with phathalimide (step g) before removing the Boc group (step h) to yield 
free amine product.  The amine was then coupled with 5-phenylethynyl-2-furoic acid (step i). 
 
 
Scheme 2.1. Synthesis of 2.1. Reagents and conditions: (a) (i) PhS(O)Me, LiN(i-Pr)2, THF, -
75 to 23 oC (ii) Recrystallized from MeCN (62%) (b) (i) KOt-Bu, t-BuOH, reflux (ii) HPLC 
(60%) (c) SOCl2, PhMe, 60 oC (44%) (d) (i) K2CO3, MeCN, Bu4N+I-, reflux, 72h (ii) 
Recrystallized from i-PrOH (47%) (e)(i) Bu3SnH, ACCN, PhME, 80 oC (ii) HPLC, (45%) 
(f)Raney Nickel, 50 psig H2, 3N NaOH, EtOH, 17 h (88%) (g)Phthalic anhydride, PhMe, 
DIPEA, reflux 24h (62%) (h)(i)TFA(2h), HCl (55%) (i) (i) BOP-Cl, DIPEA, DCM (83%) (ii) 
Hydrazine hydrate, 4-pentenol, EtOH, r.t  (iii) PhCOOH, recrystallised from ethanol (31%) 
 
A final phthalimide deprotection step using hydrazine hydrate yielded the final product. 
During the deprotection, it was noted that the acetylene triple bond (~5%) had been reduced to a 
double bond. It has been previously reported that the use of hydrazine hydrate in phthalimide 
deprotection could lead to reduction of acetylene bonds. To counteract this, a sacrificial olefin 
scavenger, 5-pentenol, was added and no reduction side product was formed. 
The reference inhibitor was tested against tryptase using Tos-GPR-pNa as substrate (Figure 
2.8). The IC50 was determined to be 9.60 nM ± 0.02 as compared to the reported value of 3.6 nM. 
The substrate used in-house, Tos-GPR-pNa (Km= 49 µM), was more than ten times more efficient 
than the non-selective substrate (hexahydrotyrosol-Ala-Arg-pNa, Km= 580 µM) used in the 
literature17. A higher concentration of inhibitor was needed to displace the substrate competitively 
resulting in the  higher IC50 value observed 
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Figure 2.8: Concentration-response curve for inhibition by 2.1 against 
tryptase-mediated cleavage of substrate Tos-GPR-pNa. 2.1 was pre-
incubated for 5 min with tryptase. Conditions were [E] tryptase, 0.1 
µg; [S] Tos-GPR-pNa, 100 µM, 0.1 M HEPES buffer, pH 7.5, 28 ˚C, 
with 0.1 mg/mL heparin, 0.01% triton X-100 v/v, 0.02% NaN3.  Error 
bars represent mean ± SEM of at least three independent experiments. 
 
 
2.6 HYBRID PEPTIDE AS TRYPTASE INHIBITORS 
 
2.6.1 Design of hybrid inhibitor 
To achieve the primary aim of targeting the S2’ pocket with inhibitors, the first strategy was 
to develop hybrid peptide inhibitors consisting of three main components: (1) a P1 scaffold; (2) a 
binding sequence targeting the prime binding sites (S2’ in particular); and (3) an active sequence 
targeting the non-prime binding sites. 
 
 
 
Figure 2.9: Central design of tryptase hybrid inhibitors. 
 
2.6.1.1 Design of P1 scaffold 
The design of a P1 scaffold must meet several key requirements in order for the hybrid 
peptide inhibitors to target the non-prime binding sites and the S2’ pocket successfully. Firstly, it 
must serve as an effective base to form critical ionic interaction(s) with the highly conserved 
Asp189 of the S1 pocket. In addition, it should be of an appropriate size and length to target the S1 
pocket to mimic arginine or lysine (equally preferred at this position).  Secondly, it must allow for 
correct projection of binding moieties targeting the non-prime and prime binding sites to achieve 
optimal occupation of their corresponding binding pockets. Last but not least, the mostly peptidic 
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hybrid inhibitor must remain intact upon binding to tryptase in order to inhibit tryptase 
competitively. Therefore it must contain a P1-P2’ amide bond that is not susceptible to cleavage by 
tryptase. 
 
(A) 
 
(B) (C) 
 
 
Figure 2.10: (A) Schematic diagram of the key interactions of inhibitor 2.1, mostly targeting the 
non-prime binding sites (red) and inhibitor 2.2, mostly targeting the prime binding sites (blue), with 
tryptase. The P1 residues are shown in black, where interactions with Asp189 occur. The oxygen 
atoms shown in green was found to form a hydrogen bonding interaction with Ser195. (B) Crystal 
structures of inhibitor 2.1 (blue, PDB:2ZA5) and 2.2 (yellow, PDB:2FS9) bound to tryptase. (C) 
Central scaffold design, 4-aminomethylanthranilic acid (4-AMAA), derived from the hybrid 
inhibitor. The non-prime binding moiety is attached to the “meta” position (relative to aminomethyl 
moiety), while the prime binding moiety is attached to the “para” position. The enzyme surface 
represents atom identities (red = oxygen, blue = nitrogen, grey = carbon, yellow = sulphur). 
 
To meet these requirements, a non-peptidic central scaffold was designed based on two 
reference inhibitors (Figure 2.10A), targeting either the non-prime binding sites17 (2.1, red, S1-S4) 
or the prime binding sites15 (2.2, yellow, S1-S4’). The common structural/chemical motif of the 
basic P1 residues of reference inhibitors was studied to give molecular insights for simultaneously 
targeting both non-prime and prime binding sites. Using this information, a hybrid scaffold could be 
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derived to achieve the aim of targeting the S2’ pocket while maintaining key interactions with the 
non-prime binding pockets. 
From the inhibitor-bound crystal structures, it was observed that the di-substituted 
benzylamine group (2.1) acted as P1 residue, and the non-prime binding moiety (S4-S1) stemmed 
from meta-position. Superimposition studies (Figure 2.10) revealed that the prime-targeting arm of 
compound 2.2 was “positioned” at the para position of the P1-benzylamine moiety of compound 
2.1. Therefore, it was postulated that a benzylamine derivative, 4-aminomethylanthranilic acid (4-
AMAA) (Figure 2.10B), would possibly serve as an appropriate central scaffold design. It retained 
an aminomethyl moiety as the nitrogenous base to target the S1-Asp189, a binding sequence 
targeting the non-prime binding sites could be attached to the meta-position, and a prime targeting 
arm could be attached onto para-position.  
4-AMAA (Figure 2.11A) was a good structural replacement for the native P1-Lys (Figure 
2.11B) based on superimposition studies. However, it must be noted that the meta-“N-terminus” of 
4-AMAA was two carbon-bonds apart from the para-“C-terminus”, unlike the typical configuration 
in natural amino acids. The overall distance between the C- and N-terminus and 4-AMAA was 2.7 
Å , slightly longer than that for lysine (2.4 Å) (Figure 2.11C).  In addition, the planar nature of 4-
AMAA led to distortion of spatial relationship between the termini (Figure 2.11D), compared to the 
configuration of natural amino acids. Due to the atypical spatial arrangement of the termini, it was 
predicted that the subsequent P1-P2’ amide bond (meta-position) may be distorted in a manner 
where recognition by tryptase as a “scissile amide bond” was unlikely.  
 
    
(A) (B) (C) (D) 
 
Figure 2.11: (A) Scaffold 4-AMAA (B) Superimposition of native lysine (Orange) and 
scaffold 4-AMAA (Green) (C) Distance between the two termini (D) Angle between 
the termini of lysine, and the subsequent deviation observed in the position of N-
terminal of scaffold 4-AMAA  
 
2.6.1.2 P1’ and P2’ residues 
There were limited substrate specificity studies reported in the literature on the exploration 
of prime binding site of tryptase substrates, most having focused on the non-prime binding sites. 
One example was a leech-derived peptidic inhibitor (LDTI), which was found bound to tryptase 
H2N
CO OH
NH2
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with a P1’ Ile and P2’ Leu.35 As the S2’ pocket was found to be large and non-polar in nature, 
introduction of different hydrophobic residues (such as leucine, phenyalanine, or non-peptidic 
hydrophobic components) could be a good strategy to target the pocket. Ligand docking studies 
were thus conducted to predict suitable P1’ and P2’ residues to be attached onto 4-AMAA. As the 
planar nature of the 4-AMAA may distort the subsequent P1-P1’ amide bond, the preferred 
configurations (D- or L-amino acid) of the residues were also investigated.  
 
(A) (B) 
   
Figure 2.12: Preferred configurations at P1’ and P2’. (A) Ac-4-AMAA-Ile-Leu-NH2. P1’-Ile and 
P2’-Leu were solvent-exposed. (B) Ac-4-AMAA-D-Ile-D-Leu-NH2. P1’-D-Ile and P2’-D-Leu 
were projected into their corresponding binding pockets. P2’-D-Leu did not fully occupy the S2’ 
pocket. Electrostatic potential surface was generated using Pymol (Red= acidic, blue = basic, 
grey = hydrophobic). 
 
 Incorporating a P1’-Ile and a P2’-Leu based on the reported LDTI inhibitor, Ac-(4-AMAA)-
Ile-Leu-NH2 was docked onto the protease active site (Figure 2.12A). As predicted, the L-
configurations were no longer favourable due the rigidity of 4-AMAA, with both P1’ and P2’ 
residues found to be “solvent-exposed”. On the contrary, the side chains of Ac-(4-AMAA)-D-Ile-D-
Leu-NH2 were correctly projected into their intended binding pockets (Figure 2.12B), reaffirming 
that D-configuration was preferred at both P1’ and P2’ positions. It was also observed that the P2’ 
D-Leu did not achieve full occupation of the S2’ pocket, therefore introduction of bulkier 
hydrophobic residues may be beneficial.  
In this study, glycine was chosen as the P1’ residue. The rationale was to provide minimal 
interference while investigating the effect of varying P2’ residues, in addition to S1’ pocket being 
less pronounced in nature. From the modelling studies, the P2’ residue (D-Phe) (Ac-(4-AMAA)-
Gly-D-Phe-NH2) successfully docked into the S2’ pocket. It was again noted that a D-configuration 
(Figure 2.13A) was preferred at P2’ over the L-isomer (Figure 2.13B).  In addition, 4-phenyl-D-
phenylalanine (D-Bip) (Figure 2.13C) was docked onto S2’ pocket and was found to fully extend 
into and occupy the pocket. 
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(A) (B) (C) 
   
Ac-(4-AMAA)-Gf-NH2 Ac-(4-AMAA)-GF-NH2 Ac-(4-AMAA)-G-D-Bip-NH2 
Figure 2.13: Docking studies of P2’ hydrophobic residues onto S2’ pocket. (A) Ac-(4-AMAA)-Gf-NH2. P2’-D-Phe 
was projected correctly into the S2’ pocket, however full occupation of the pocket was not achieved. (B) Ac-(4-
AMAA)-GF-NH2. L-Phe was solvent-exposed and not favoured as P2’. (C) Ac-(4-AMAA)-G-(D-Bip)-NH2. The 
bulkier P2’-D-Bip occupied the S2’ pocket optimally. Electrostatic potential surface was generated using Pymol (Red= 
acidic, blue = basic, grey = hydrophobic). 
 
2.6.1.3 Non-prime binding residues 
To target the non-prime binding sites, the optimal P4-P2 binding sequence (Pro-Arg-Asn) 
was introduced to the N-terminus of 4-AMAA as the tryptase-targeting or “recognition” sequence. 
The aim was to maintain potency and selectivity towards tryptase. In essence, the central design of 
the hybrid inhibitors comprised: (1) an optimal substrate sequence, Pro-Asn-Lys, at P4-P2; (2) a 
lysine mimetic, 4-AMAA, at P1; (3) an achiral glycine at P1’; and (4) a variety of hydrophobic 
residues at P2’ to target the tryptase S2’ pocket (Figure 2.14). 
 
Figure 2.14: Central design of hybrid peptide inhibitor. The non-prime targeting moiety 
(P4-P3-P2) is shown in red, while the prime side binding moiety (P1’-P2’) is shown in 
blue. The P1 residue is the scaffold 4-AMAA shown in black. 
 A series of hybrid peptide was synthesized to inhibit tryptase. Compound 2.3, Ac-PRN(4-
AMAA) Gf-NH2, was first synthesized as an initial proof of concept. L-Phe (2.4) was then 
introduced at P2’ to determine the configuration of amino acid preferred (D-Phe, abbreviated as “f”) 
at this position.  The hybrid peptide was then systematically truncated from the C-terminus (2.5, 
2.6) and the N-terminus (2.7-2.9) to identify key residues in inhibitor binding, and to determine the 
shortest active binding sequence. 
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Table 2.5: Hybrid peptides (2.3-2.9) as prospective tryptase inhibitors 
ID Variant Compounds 
2.3 P2’ Ac-PRN(4-AMAA)Gf-NH2 
2.4  Ac-PRN(4-AMAA)GF-NH2 
2.5 Truncation of C-terminus Ac-PRN(4-AMAA)G-OH 
2.6  Ac-PRN(4-AMAA)-NH2 
2.7 Truncation of N-terminus Ac-RN(4-AMAA)Gf-NH2 
2.8  Ac-N(4-AMAA)Gf-NH2 
2.9  Ac-(4-AMAA)Gf-NH2 
 
2.6.2 Synthesis of hybrid inhibitor 
2.6.2.1 Synthesis of central scaffold  
The synthesis of scaffold 4-AMAA followed a modified seven-step literature procedure 
outlined in Scheme 2.2.36 Conversion of 4-methyl-2-nitrochlorobenzene to an aryl nitrile followed 
standard cyanation reaction conditions using copper cyanide. This was followed by an alpha-
bromination, where a more efficient alpha-bromination agent (NBS) together with a radical initiator 
(ACCN) was used to achieve 61% yield, instead the reported method using bromine (30% yield). 
The nitrile group was hydrolysed to a carboxylic acid, followed by an ammonolysis to convert to 
alpha-bromomethyl group to an aminomethyl group. The primary amine was then protected using 
Boc, followed by nitro reduction to yield the building block. It was found that the use of sodium 
dithionite as a reducing agent in the reported protocol led to the formation of unidentified side 
products. Instead, a standard nitro-reduction using activated carbon on palladium was more efficient 
and obviated the need for complicated work up. 
 
 
 
 
Scheme 2.2. Synthesis of 4-AMAA. Reagents and conditions: (a) CuCN, 
DMA, 80h (32%) (b)(i)NBS, ACCN (61%) (ii) CH3COONa (36%) (c) 
HBr, refluxed, 80h  (33%) (d) NH3, EtOH, 80h  (53%) (e) Boc2O (80%) 
(f) H2/Pd/C (88%) 
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2.6.2.2 Synthesis of hybrid inhibitor  
The synthesis of hybrid peptides (Scheme 2.3) followed a standard solid phase peptide 
synthesis (SPPS) protocol.37 Coupling of common amino acids was performed using standard 
conditions (DIPEA/HBTU/DMF). Coupling of the scaffold to the resin-bound peptide required 
longer reaction times due to the deactivated nature of the aromatic carboxylic acid group and a 
more efficient coupling reagent (DIPEA/HATU/DMF) was used instead.   
 
Scheme 2.3 Synthesis of hybrid peptide. Reagents and conditions: (a)(i) Fmoc-AA-COOH, 
DIPEA, HBTU, DMF (ii) Piperidine/DMF (1:1) (iii) DIPEA, HATU, DMF, 72h (b) HATU,DIPEA, 
30% Toluene in DMF, 72h (d) (i) repeat (a)(i) and (ii) for desired sequence (ii) TFA/TIPs/Water 
(95:2.5:2.5) followed by rp-HPLC. 
   
 Another possible explanation for the slow coupling was steric hindrance due to the presence 
of a bulky trityl protecting group on the Asn residue. It was previously reported that the 
introduction of an N-trityl protecting group could lead to introduction of steric crowding at the 
adjacent carbonyl group39 making the coupling rate slow. It was postulated that the trityl group 
might form a pi-stacking hydrophobic interaction with the resin bead (made of polystyrene), hence 
“blocking” access to the carbonyl group and impeding the coupling reaction. To counteract this 
issue, 30% benzene in DMF was used instead of pure DMF during this particular coupling. The 
strategy was to dissociate the pi-stacking interaction between the trityl protecting group and resin 
by having benzene molecules dispersed between the trityl aromatic rings and resin. This would 
allow the trityl aromatic rings to rotate more freely, hence “unblocking” the carbonyl group and 
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allowing coupling to proceed smoothly. Evidently, the new solvent mixture reduced the reaction 
time to 3 days (3-fold improvement). 
 
 
 
 
Figure 2.15: Nucleophillic attack of the aromatic amine on the carbonyl of the activated C-terminal 
carboxylic acid. The trityl protecting group is in proximity and causes steric hindrance for efficient 
nucleophilic attack to occur. 
 
2.6.3 Evaluation of hybrid inhibitor 
Compound 2.3 (Ac-PRN(4-AMAA)Gf-NH2) was moderately active against tryptase, with an 
IC50 of 12 µM. As the hybrid peptide contained a potentially scissile P1-P1’ amide bond, it was 
crucial to determine whether 2.3 was behaving competitively as a substrate or an inhibitor. The 
species present in the assay wells were therefore analysed using mass spectroscopy (Table 2.6). The 
predominant species found was the cleavage product of the chromogenic substrate (Tos-GPR-pNa 
à Tos-GPR-OH + pNa), where no intact substrate (602 m/z) was noted. Intact inhibitor was still 
observed, indicating that the P1-P1’ ((4-AMAA)-Gly) amide bond was not hydrolyzed by the 
enzyme leading to the inhibition observed. This was in agreement with the intial prediction that the 
distorted P1-P1- amide bond would not be recognized by tryptase. 
 
    Table 2.6: Species present in assay wells after 24 h 
Component Compound Species observed  Mass observed [M+H] 
Substrate 
 
Tos-GPR-pNa 
 
Tos-GPR-OH 482.9 (Major species) 
Free p-nitroanilide 139.0 (Trace amount) 
 
Hybrid inhibitor 
 
Ac-PRN(4-
AMAA)Gf-NH2 
 
Ac-PRN(4-AMAA)Gf-
NH2 
779.8 (Minor species) 
Ac-PR-OH  314.0 (Trace amount) 
H-N(4-AMAA)Gf-NH2 484.5 (None observed) 
*Residues underlined are recognized as basic P1 residue by tryptase. Assay conditions were [E] tryptase, 0.1 µg; [S] 
Tos-GPR-pNa, 100 µM, 0.1 M HEPES buffer, pH 7.5, 28 ˚C, with 0.1 mg/mL heparin, 0.01% triton X-100 v/v, 0.02% 
NaN3.  Aliquot of the assay mixture was analysed 24 h after the reaction as initiated using LC-MS technique. 
 
However, trace amounts of a hydrolysed side product were also noted (AcPRNXGf-NH2 à 
Ac-PR-OH + H-NXGf-NH2), where the supposed P3-P2 (Arg-Asn) amide bond was recognized as 
the “scissile P1-P1’ amide bond” instead and was subsequently cleaved by tryptase. A time-
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dependent inhibitor assay was therefore carried out to examine the extent of the side hydrolysis in 
prolonged incubation, and the subsequent effect on inhibitory properties of compound 2.3 (Table 
2.7).  
 
Table 2.7: Effect of prolonged incubation on inhibition of tryptase by 2.3. 
Incubation time (min) Relative inhibition 
5 100% 
20 80 % 
60 60 % 
120 53 % 
2.3 (20 µM) was pre-incubated with tryptase at a single concentration at varying duration (5, 20,, 60, 
120 min). The standard pre-incubation time (5 min) was normalized as 100%. Assay conditions were 
[E] tryptase, 0.1 µg; [S] Tos-GPR-pNa, 100 µM, 0.1 M HEPES buffer, pH 7.5, 28 ˚C, with 0.1 
mg/mL heparin, 0.01% triton X-100 v/v, 0.02% NaN3. 
Under prolonged incubation, compound 2.3 was observed to suffer significant loss of 
activity, where a larger portion of the inhibitor was cleaved (at P3-P2 position) leaving less intact 
inhibitor available to inhibit the protease. After 24 h, it was noted that there was only 14% of intact 
inhibitor left (Table 2.8). Due to the issue with side hydrolysis, all of the inhibitors were pre-
incubated with the protease for 5 min to maintain optimal inhibition and minimize partial substrate 
activity.  
 
Table 2.8: Percentage of intact inhibitor vs hydrolyzed inhibitor after 24 h 
Species Sequence Mass Percentage 
Hydrolyzed inhibitor Ac-[PR]-H + H-[N(4-AMAA)Gf]-NH2 485.1 86% 
Intact inhibitor Ac-PRN(4-AMAA)Gf-NH2 780.3 14% 
*Species detected using LC-MS methods shown in bold. Aliquot of the assay mixture was analysed 24 h after 
the reaction as initiated using LC-MS technique, the percentage of species was quantified by measuring peak 
area. Assay conditions were [E] tryptase, 0.1 µg; [S] Tos-GPR-pNa, 100 µM, 0.1 M HEPES buffer, pH 7.5, 28 
˚C, with 0.1 mg/mL heparin, 0.01% triton X-100 v/v, 0.02% NaN3. 
 
Consistent with the modelling studies, having L-Phe at P2’ (2.4) was not favourable, leading 
to complete loss of activity at 100 µM. On the other hand, removal of P2’ residue Ac-PRN(4-
AMAA)G-NH2 (2.5, IC50 = 50 µM) was found to suffer a 4-fold loss of potency. This reaffirmed 
that targeting the S2’ pocket was indeed a viable approach to improve binding affinity of the 
inhibitor. Further truncation of P1’ residue (2.6) led to complete loss of activity, suggesting that 
both P1’ and P2’ played an important role in inhibitor binding. 
To investigate the role of the non-prime residues in inhibitor binding, the N-terminal 
residues were truncated systematically. Surprisingly, removal of the P4-Pro (2.7) led to complete 
inactivity, and a similar observation was noted for further truncations (2.8-2.9). This suggested that 
the non-prime residues were absolutely critical for inhibitor binding and potency. It was postulated 
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that the non-prime binding sequence was the “recognition motif” of the inhibitor, and was therefore 
the major contributor of binding affinity.  
 
Table 2.9: Evaluation of hybrid peptides as tryptase inhibitors. 
ID Sequence IC50 (µM) 
2.3 Ac-PRN(4-AMAA)Gf-NH2 12 ± 0.51 
2.4 Ac-PRN(4-AMAA)GF-NH2 >100  
2.5 Ac-PRN(4-AMAA)G-OH 50 µM ± 1 
2.6 Ac-PRN(4-AMAA)-NH2 >100  
2.7 Ac-RN(4-AMAA)Gf-NH2 >100  
2.8 Ac-N(4-AMAA)Gf-NH2 >100 * 
2.9 Ac-(4-AMAA)Gf-NH2 >100 *  
Inhibitors were pre-incubated for 5 min with tryptase. Conditions were [E] tryptase, 0.1 µg; [S] Tos-GPR-pNa, 100 µM, 
0.1 M HEPES buffer, pH 7.5, 28 ˚C, with 0.1 mg/mL heparin, 0.01% triton X-100 v/v, 0.02% NaN3. The above values 
were calculated from at least three independent experiments (n ≥ 3) with statistical significance of P ≤ 0.05. *2.8 and 
2.9 remained inactive after prolonged incubation (5-120 min). 
 
In general, these hybrid inhibitors performed poorly against tryptase, with the best inhibitor 
of the series (Ac-PRN(4-AMAA)Gf-NH2) having IC50 12 µM. Traditionally, substrate-based 
inhibitors with an optimized peptidic sequence are expected to be potent and more specific than 
most non-peptidic inhibitors.40 This is because the optimal sequence is specific to its target enzyme, 
and therefore allowing maximal favourable interactions with the corresponding binding grooves. 
This was however not observed for the hybrid peptides here, suggesting that there might be 
incompatibility issues with the incorporation of the rigid 4-AMAA scaffold as the P1 residue. 
 From the modelling studies (Figure 2.16B), it was predicted that the amino methyl group of 
4-AMAA of 2.3 was able to engage in an ionic interaction with Asp189 (3 Å). Due to the distortion 
of the P1-P1’ amide bond, the oxygen atom of hydroxyl group of Ser195 was now located ~3.0 Å 
away from the P1’- carbonyl group, suggesting that a nucleophillic attack by Ser195 (which 
required a shorter distance) was unlikely. Introduction of 4-AMAA therefore successfully 
converted the hybrid peptide into an inhibitor as reflected in the inhibitor evaluation assay. Close 
examination of the interaction of the P1-P1’ amide bond of 2.3 with the protease revealed that the 
carbonyl oxygen atom of the amide bond was now pointed away from the oxyanion hole (backbone 
NHs of Gly193 and Ser195). However, disengagement with the oxyanion hole was evidently 
compensated with a hydrogen-bonding interaction between the carbonyl oxygen of P1’-Gly and the 
NH backbone of Gly193. The failure to engage with the oxyanion hole residues may explain why 
the hybrid peptide did not undergo subsequent hydrolysis by the protease.  While the lack of 
recognition by the oxyanion hole was considered beneficial to prevent hydrolysis of the amide 
bond, it was thought that the loss of a hydrogen-bonding network with the oxyanion hole residues 
may have resulted in significant loss of binding affinity for the protease. This implied that having an 
 76 
amide bond (albeit distorted) at this position might not have been helpful in producing a highly 
potent inhibitor. 
 
(A) (B) 
  
Figure 2.16: (A) Compound 2.222 bound to tryptase with key interactions and their respective 
distances shown. (PDB:2FS9) (B) Model of Ac-X-Gly-(D-Phe)-NH2 docked onto tryptase 
(PDB:2GDD), with key interactions with the catalytic residues (S1-Asp189; Catalytic residue-
Ser195; Oxyanion pair: NHs of Ser195 and Gly193) highlighted. 
 
The lack of success of the hybrid peptide 2.3 could also be attributed to the unfavourable spatial 
distribution of the inhibitor side chains due to the distortion of the P1-P1’ amide bond and the P2-
P1 amide bond influenced by the 4-AMAA scaffold. Based on the observed side hydrolysis of the 
P3-Arg - P2-Asn amide bond, it was thought that the P4-P2 recognition sequence might have failed 
to “align” the 4-AMAA residue into the S1 pocket due to steric hindrance (Figure 2.17A).  Instead, 
the S1 pocket was more accessible by the less hindered P3-Arg, thereby explaining the occurrence 
of the side hydrolysis (Figure 2.17B). Ultimately, this again suggested that the 4-AMAA was not 
optimal as the P1 scaffold, as it failed to provide the right projection of the binding arms to achieve 
optimal occupation of the binding sites. 
(A) (B) 
  
 
Figure 2.17: Schematic view of the speculated interactions of 2.3 with tryptase. (A) The predicted 
interactions between 2.3 and tryptase. 4-AMAA was designed to interact with the S1-Asp189 
however it may be sterically unfavourable at this position.  (B) Observed side interactions between 
2.3 and tryptase that contributes to partial substrate activity. The P3-Arg of 2.3 was able to form 
ionic interactions with the S1 pocket due to side chain flexibility.   
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 On a side note, it was also thought that the length of the extended conformation of the 
heptapeptide (~19 Å) might also have played a role in the lack of potency observed. The central 
pore of tryptase tetramer has a rectangular dimension of 40 Å x 15 Å, where each heptapeptide is 
supposed to enter one active site and get independently hydrolysed. The Hill slopes of both Ac-
PRNXGf-NH2 (2.3) and Ac-PRNXG-NH2 (2.5) were found to be < 1.0, which is indicative of 
negative cooperativity (Table 2.10). 
 
Table 2.10: Hill slopes of compound 2.3 and 2.5 
ID Compound IC50 ± SEM Hill slope 
2.3 Ac-PRN(4-AMAA)Gf-NH2 12 µM ± 0.51 0.14 
2.5 Ac-PRN(4-AMAA)G-NH2 50 µM± 0.95 0.14 
Conditions were [E] tryptase, 0.1 µg; [S] Tos-GPR-pNa, 100 µM, 0.1 M HEPES buffer, pH 7.5, 28 ˚C, 
with 0.1 mg/mL heparin, 0.01% triton X-100 v/v, 0.02% NaN3. The above values were calculated from at 
least three independent experiments (n ≥ 3) with statistical significance of P ≤ 0.05. Hill slopes were 
calculated using GraphPad Prism 6. 
 
 
  Negative Hill slopes have been related to issues with physical/chemical attributes of 
inhibitors.32 It was thought that the large heptapeptide induced certain conformational changes at the 
adjacent monomers, resulting in reduced binding affinity. The reported active site bridging 
compounds with high molecular weight however did not report any cooperativity issues.15, 19 Their 
inhibition mechanism involved the targeting of two adjacent active sites, hence making them 
compatible with the tetrameric configuration of tryptase without any negative cooperativity issues. 
In summary, it was demonstrated that incorporation of 4-AMAA as P1 scaffold has 
successfully converted a substrate-based hybrid peptide into a moderately active tryptase inhibitor 
(Ac-PRN(4-AMAA)-Gf-NH2, IC50 = 12 µM). Despite the moderate potency achieved in this series, 
it was shown that having a hydrophobic P2’ contributed to additional binding potency, indicating 
that targeting the S2’ pocket was useful in promoting further binding interactions with the enzyme. 
Therefore, further optimization of the S2’ binding specificities were to be carried out to achieve 
maximal binding potency. However, it was also discovered that the design of the scaffold was not 
complementary to the aim of targeting both the non-prime and prime binding site, where it was 
postulated that 4-AMAA did not project the non-prime and prime binding arms in the right 
orientation to interact optimally with their corresponding binding sites. 
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2.7 α-KETO AMIDES AS TRYPTASE INHIBITORS  
To target the S2’ pocket efficiently, the second strategy was to introduce an internal α-keto 
amide isostere in place of the scissile peptide bond. This strategy could allow the robust probing of 
both non-prime and prime binding sites. Alpha-keto amide is a highly electrophilic structural 
moiety found in a plethora of biologically important natural products such as cyclotheonamides, 
keramamides, eurystatin and rapamycin.41,42 It was discovered that incorporation of this 
electrophillic alpha-keto amide isostere in synthetic compounds could led to inhibitory effect 
against certain enzymes, as seen in other electrophillic isosteres (peptidyl aldehyde, fluorinated 
ketone, α-keto acids and α-keto esters).41 The hydroxyl group of the catalytic serine (in serine 
protease) formed a covalent bond with the carbonyl of the α-keto amide isostere, forming a 
reversible tetrahedral complex mimicking the transition state, stabilized by the electron-
withdrawing effect of the second carbonyl moiety.43 Since then, the α-keto amide moiety has been 
utilized extensively in serine and cysteine protease inhibitors, where high biochemical specificity 
was attained with moderate to low chemical reactivity.44 In addition, an α-ketoamide can be 
incorporated at an internal position (P1-P1’) of a peptide backbone as compared to other terminal 
electrophilic isosteres (e.g. aldehydes, boronic acid, trifluoromethylketone), thus allowing the 
exploration of both prime and non-prime binding pockets. This is extremely useful in the 
development of protease inhibitors as full utilization of both sides of the active site is critical to 
attain selectivity. Therefore, α-keto amide was chosen as the serine-binding electrophile component 
in compounds designed to target both non-prime and S2’ binding pockets of tryptase in this chapter. 
 
2.7.1 Development of novel synthesis of P1-arginine alpha-keto amide  
The synthesis of terminal and internal alpha-keto amide peptides has been extensively 
studied previously,45 and methods reported for P1-Arginine keto-amide peptides have included both 
solution phase and solid phase peptide syntheses employing mainly Boc-chemistry.46 Leung et al. 
previously reported utilization of solid-phase Boc chemistry on solid phase support in the synthesis 
of P1-arginine α-keto amide (Scheme 2.5). 46 This method allows introduction of the keto-amide 
moiety into peptide backbone in a convergent manner, making it an attractive strategy to generate a 
library of keto-amide peptides in a high-throughput manner. However, the deprotection of side 
chains and peptide cleavage in this method requires a HF cleavage as a final step. The use of HF is 
undesirable due to safety considerations and its highly toxic nature, with specialized equipment 
required due to incompatibility of HF with normal laboratory glassware.  
To counter these issues, the method reported was modified and solid-phase Fmoc chemistry 
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was applied instead. Fmoc-protected nitroarginine-α-hydroxy acid was synthesized as the P1-
ketoamide building block to be inserted between two amino acid units in desired peptides (Scheme 
2.6). Commercially available N-α-Boc-L-Nitroarginine-OH was converted into a Weinreb amide 
through coupling with N,O-dimethylhydroxylamine hydrochloride using HBTU as the coupling 
reagent. The Weinreb amide intermediate was then treated with lithium aluminum hydride at 0 oC to 
afford the aldehyde. Treatment with potassium cyanide led to formation of the cyanohydrin, which 
was then hydrolyzed to the diastereomeric α-hydroxy acid using concentrated HCl, in which the 
Boc protecting group was removed simultaneously. The exposed amino group was then protected 
using Fmoc-Osu to afford the desired N-α-Fmoc-L-nitroarginine-D,L-hydroxy acid, which was now 
fully compatible for solid phase Fmoc-chemistry.  
 
 
 
 
Scheme 2.4 Synthesis of P1-Arginine α-keto amide building block. Reagents and 
conditions: (a) N,O-dimethylhydroxylamine hydrochloride, HBTU, DIPEA, DMF, overnight. 
85% yield.  (b) Lithium aluminium hydride, THF, N2., 90% yield.  (c) Potassium cyanide, 
EtOAC:MeOH:H2O (50:25:25), overnight. 70% yield. (d) Concentrated hydrochloric 
acid:dioxane (50:50), 100 oC, overnight, 55% yield.  (e) (i) Fmoc-Osu, pH 9, sodium 
bicarbonate:acetone (1:1), overnight, 65% yield. (ii) Prep-HPLC 
 
 
An acid-labile Rink-amide MBHA resin commonly used in Fmoc-chemistry was used. 
Amino acids were coupled to the resin using standard Fmoc-chemistry protocol.37 The P1 N-α-
Fmoc-nitroarginine-hydroxy acid was coupled to the P1’ residue using HATU as the coupling 
reagent, followed by coupling of the non-prime residues using standard protocol monitored by 
Kaiser test. The N-terminus was acetylated using acetic acid as previous studies reported that the 
use of acetic anhydride could lead to side acetylation of the alpha-hydroxyl group.46 Once the 
coupling was completed, the α-hydroxy amide group was oxidized to the corresponding α-keto 
amide functional group by shaking the resin in Dess-Martin periodinane in anhydrous DCM for 2 
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hours. The oxidation progress was monitored by LC-MS. The oxidized peptide was then cleaved 
from the resin using TFA:water:para-cresol (90:5:5), which removed all the side chain protecting 
groups except for nitroarginine. The peptide was purified using rp-HPLC, followed by an overnight 
hydrogenation to convert the nitroarginine to an arginine. The peptide was dissolved in MeOH and 
underwent hydrogenation at 50 p.s.i. It was important to note that addition of 5% acetic acid was 
absolutely crucial for the smooth deprotection of nitroarginine. In the absence of acetic acid, no 
deprotection was observed even after 2 days of hydrogenation. It was also observed that the 
deprotection process had to be monitored closely, as the alpha-keto amide could also be reduced 
back to the alpha-hydroxylamide precursor under prolonged hydrogenation. Lastly, the crude 
unprotected peptide was purified using rp-HPLC to afford the desired final product. 
 
 
 
 
 
Scheme 2.5. Solid phase synthesis of arginine α-keto amide using Boc-chemistry. 
Reagents and conditions: Solid phase synthesis of P1-Arginine alpha-keto amide inhibitors 
employing BOC-chemistry. (a) Boc-AA-OH, HBTU, DIPEA, DMF (b) TFA (c) Boc-AA-
OH, HBTU, DIPEA, DMF (d) TFA (e) Boc-Arg(Tos)-(OH)COOH, Pybop, DIPEA, DMF (f) 
repeat b and c (g) Dess-Martin periodinane, DMSO, 1h (h) HF, para-cresol 
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Scheme 2.6. Modified synthesis of arginine α-keto amides using Fmoc-chemistry. 
Reagents and conditions: (a) Fmoc-Arg(NO2)-hydroxyacid, HATU, DIPEA, DMF, overnight 
(b) Piperidine:DMF (1:4), 5 min, two repeats (c) Fmoc-amino acid, HBTU, DIPEA, DMF, 30 
min. Repeat steps b and c as required. (d) Dess-Martin periodinane, anhydrous DCM, 2h (e) 
(i) TFA:water:anisole (90:5:5), 1h (ii) semi-prep HPLC (f) (i) H2, MeOH:AcOH (4:1), parr 
hydrogenation, 50 p.s.i, 48h (ii) Semi-prep HPLC 
 
 
2.7.2 Design and synthesis of α-keto amide inhibitors 
Firstly, alpha-keto amide moiety was incorporated to replace the normally cleavable P1-P1’ 
amide bond. The optimized non-prime P4-P2 residues11 (Pro-Arg-Asn) was incorporated on the 
non-prime side, and arginine-α-keto amide was introduced as P1 residue. An achiral residue 
(glycine) was maintained at the P1’ position, and the binding specificities of S2’ binding pocket 
were probed by introducing varying residues. (Figure 2.18) 
 
Figure 2.18: Central design of α-keto amide inihibitors 
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Table 2.11 tabulates the first series of peptides that was constructed as covalent tryptase 
inhibitors. Ac-PRNR-CHO (2.10) incorporated the optimal non-prime sequence with a C-terminal 
aldehyde as the electrophilic isostere interacting with the nucleophilic Ser195 residue.  The C-
terminal aldehyde was then replaced by α-keto amide (2.11) to determine the viability of using the 
isostere to target tryptase. 
 
Table 2.11: Tryptase inhibitors with electrophilic isosteres 
 ID Inhibitor 
 2.10 Ac-PRNR-CHO 
Series 1 2.11 Ac-PRNR-α-keto amide 
 2.12 Ac-PRNR-α-keto amide-G-NH2 
 2.13 Ac-PRNR-α-keto amide-GF-NH2 
 2.14 Ac-PRNR-α-keto amide-Gf-NH2 
 2.15 Ac-PRNR-hydroxyamide-GF-NH2 
 2.16 Ac-PRN(nitroR)-α-keto amide-Gf-NH2 
 2.17 Ac-PRNR-α-keto amide-G(Bip)-NH2 
Series 2 2.18 Ac-PRNR-α-keto amide-G-benzylamine 
 2.19 Ac-PRNR-α-keto amide-G-phenylethylamine 
 2.20 Ac-PRNR-α-keto amide-G-4-phenylbenzylamine 
 2.21 Ac-PRNR-α-keto amide-G-3-phenylbenzylamine 
 2.22 Ac-PRNR-α-keto amide-G-2-phenylbenzylamine 
 
Previous attempts to probe the S2’ pocket using 4-AMAA as P1-scaffold led to a key 
observation. It was found that D-phenylalanine was preferred over L-phenylalanine at the P2’ 
position due to the rigid P1-P1’ amide bond introduced along with the 4-AMAA scaffold.  While 
the distortion of amide bond was not a likely issue for the α-keto amides, the isostere was 
considered a “beta” amino acid which may have an effect on the configuration preference of the 
prime binding residues. To assess which isomer was preferred, L-phenylalanine (2.13) and D-
phenylalanine (2.14) were introduced at P2’. The diastereomeric α-hydroxy amide intermediate 
(2.15) was also examined, as it has been extensively used as an amide bond isostere in protease 
inhibitors.47, 48 The nitro protecting group of the P1 arginine was left intact (2.16) to decrease the 
number of charged residues (P3-Arg and P1-Arg) in a bid to improve cell permeability. As 
previously discussed, the S2’ pocket was quite prominent in tryptase and modeling studies 
predicted that larger and bulkier hydrophobic residues may be favoured to promote optimal 
occupation of the S2’ pocket. (4-phenyl)phenylalanine (BIP) was therefore introduced at P2’ to 
achieve optimal occupation of the binding pocket (2.17). 
The second series (2.18-2.22) examined the effect of introducing non-peptidic hydrophobic 
moiety at P2’ position.  The global strategy involved incorporation of the optimized P4-P1 sequence 
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(Pro-Arg-Asn-Arg), an alpha-keto amide isostere at P1-P1’, a glycine at P1’ and a variety of non-
peptidic hydrophobic amines at P2’ position (Figure 2.19).   
 
 
Figure 2.19: Central design of α-keto amide hybrid inhibitors 
 
To mimic the P2’-Phe, benzylamine (2.18) or phenylethylamine (2.19) were introduced at 
P2’ position, and the effect of shortening the alkyl chain was assessed. To achieve optimal 
occupation of the S2’ pocket, a series of benzylamine derivatives was introduced where a phenyl 
subtituent was introduced at para (2.20), meta (2.21) and ortho (2.22) positions. The aim was to 
identify the more optimal analogue that achieved more favourable projection of the phenyl 
subtituent into the S2’ pocket. 
The hybrid alpha-keto amide inhibitors were synthesized using a fragment-coupling 
strategy.  The fully protected P4-P1’ peptidic portion (Ac-[PRNR-α-hydroxy amide–G]-OH) was 
synthesized using chlorotrityl resin to afford a free carboxylic acid C-terminus for further coupling 
with the P2’ amine moiety (Scheme 2.7). Standard SPPS chemistry with Fmoc protection was 
employed to yield the desired P4-P1’ peptide fragment. The relatively unreactive P1-P1’ α-hydroxy 
amide was deliberately left unoxidised as a protecting group strategy, as the desired α-keto amide 
isostere was highly reactive. The peptide fragment was cleaved from the highly acid-labile 
chlorotrityl resin using 0.1% TFA in DCM to ensure the protecting groups of P3-Arg (Pbf), P2-Asn 
(Trt) and P1-Arg (nitro) remained intact to prevent unfavourable side reactions. 
The fully protected P4-P1’ peptide fragment was then coupled to non-peptidic amines in 
solution phase (Scheme 2.8). As P1’-Gly was the C-terminal residue, there was no risk of 
racemization in the fragment-coupling. The C-terminal carboxylic acid peptide fragment was 
dissolved in DMF and pre-activated using HATU as coupling reagent in the presence of DIPEA, to 
which the non-peptide amine was added. The mixture was stirred overnight and the coupled product 
was purified using rp-HPLC. The nitro-protecting group of P1 arginine was first removed through 
hydrogenation. The α-hydroxy amide was then oxidized to the desired alpha-ketoamide moiety 
using Dess-Martin periodinane in a nitrogen atmosphere. The rest of the acid-labile protecting 
groups (Pbf and trityl) were then removed using the standard cleavage cocktail, TFA:water:para-
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cresol (95:2.5:2.5). The crude peptide was purified using rp-HPLC to afford to enantionmerically 
pure alpha-keto amide peptides, where the carboxylic acid terminus was omitted.  
 
 
 
 
Scheme 2.7. Solid phase synthesis of tryptase α-keto amide inhibitors. Reagents and conditions: 
Synthesis of P4 to P1’ peptide fragment. (a) Fmoc-Gly-COOH, DCM, DIPEA, overnight (b) (i) 
Piperidine:DMF (1:1) (ii) Fmoc-Arg(NO2)-OHCOOH, HATU, DIPEA, DMF (c) (i) 
Piperidine:DMF (1:1) (ii) Fmoc-AA-COOH, HBTU, DIPEA, DMF (e) 0.1% TFA in DCM, 2 min x 
5  
 
 
 
 
 
 
 
 
 
Scheme 2.8. Synthesis of hybrid α-keto amide inhibitors. Reagents and conditions: Synthesis of 
hybrid ketoamide inhibitors through fragment-coupling. (a) HATU, DIPEA, DMF (b) H2/Pd, 
MeOH, 50 p.s.i, 24h (c) Dess-Martin periodinane, DCM, 1h (d) TFA:water:para-cresol 
(95:2.5:2.5), rp-HPLC 
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2.7.3 Evaluation of α-keto amide inhibitors 
The initial approach of replacing the P1-P1’ amide bond with an electrophilic isostere 
proved to be successful (Table 2.11). Ac-PRNR-CHO (2.10) was found to be highly potent with 
IC50 = 4.1 nM while the α-keto amide  (2.11, IC50 = 65 nM) counterpart was found to be 16-fold 
less potent (Table 2.12). As aldehydes and α-keto amides shared similar electrophilic properties in 
vitro38, it was unclear why the former compound exhibited stronger inhibition. It was thought that 
the aldehyde may be more sterically accessible to the nucleophilic attack by Ser195. Nevertheless, 
this validated the α-keto amide moiety as a suitable replacement for the scissile P1-P1’ amide bond 
in order to inhibit tryptase. Introduction of a P1’-Gly (2.12) proved to be beneficial, where Ac-
PRNR-α-keto-amide-G-NH2  (IC50 = 3 nM) was found to be 60-fold more potent than 2.11. 
However, addition of P2’ residues failed to improve the potency with compounds 2.13 and 2.14 
being equipotent. Surprisingly, it was found that L-phenylalanine (2.13, IC50 = 5 nM) and D-
phenylalanine (2.14, IC50 = 3 nM) were equally tolerated at P2’ with no marked difference in 
inhibitor potency. The keto-amide backbone was less rigid compared to the “distorted amide bond” 
in the 4-AMAA scaffold, and the flexibility of the keto-amide backbone may allow both isomers to 
be projected into the considerably spacious S2’ pocket (or adjacent prime binding pocket) despite 
the conformational differences. Overall, this suggested that the chiral center at the P2’ position 
could be eliminated, allowing attachment of bulkier and commercially available non-peptidic P2’ 
hydrophobic fragments (2.18-2.22).  
Replacement of the α-keto amide in 2.13 (IC50 = 4.6 nM) with its diastereomeric α-hydroxy 
amide precursor (2.15, IC50 = 156 nM) led to ~50-fold reduction in potency. The α-hydroxy amide 
was not capable of forming covalent bond with the nucleophillic Ser195, and the loss of this 
interaction may explain why it was less potent than the electrophilic α-keto amide parent 
compound. However, it must be noted that the α-hydroxy amide compound was tested as a 
diastereomeric mixture, and the active component (although not further identified or pursued) could 
be twice as potent (IC50 = 78 nM) if it is 1:1 diastereomeric mixture. Nevertheless, the α-hydroxy 
amide was still highly potent despite losing the covalent bond with the protease. This suggested that 
the peptide sequence was indeed a good recognition motif for tryptase. It was also thought that the 
hydroxyl amide moiety maintained the capability to form hydrogen-bond networks with the 
oxyanion holes residues, despite not forming a covalent bond with the serine residue, thereby 
exhibiting relatively good inhibition of the protease.  
To examine the effect of masking the basic guanidine group of the P1-Arginine, the nitro 
protecting was left intact in the most potent inhibitor (Ac-PRN(nitro)R-ketoamide-Gf-NH2). 
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Elimination of the charged group would potentially improve the cell-permeability of the peptidic 
inhibitor. Not surprisingly, a nitroarginine at P1 was detrimental with a great loss of inhibitory 
potency observed in the in vitro enzymatic assay. This again highlighted the importance of 
maintaining the ionic interaction with Asp189 in the S1 pocket to retain binding affinity and 
potency. However, it was possible that the singly charged 2.16 may have more favourable drug-like 
properties, such as increased cell-permeability compared to the doubly-charged 2.14, and the former 
may have better inhibitory performance in a cell-based assay or in vivo. 
 
Table 2.12: Evaluation of tryptase inhibitors 
ID Inhibitor pIC50 ± SEM IC50 (nM) 
2.10 Ac-PRNR-CHO 8.38 ± 0.14 4 
2.11 Ac-PRNR-α-keto amide 7.19 ± 0.19 65 
2.12 Ac-PRNR-α-keto amide-G-NH2 8.58 ± 0.28 3 
2.13 Ac-PRNR-α-keto amide-GF-NH2 8.34 ± 0.21 5 
2.14 Ac-PRNR-α-keto amide-Gf-NH2 8.50 ± 0.15 3 
2.15 Ac-PRNR-hydroxyamide-GF-NH2 6.80 ± 0.15 156 
2.16 Ac-PRN(nitroR)-α-keto amide-Gf-NH2 ND 81% at 30 µM 
2.17 Ac-PRNR-α-keto amide-G(Bip)-NH2 7.83 ± 0.12 15 
2.18 Ac-PRNR-α-keto amide-G-Benzylamine 9.21 ± 0.11  0.6 
2.19 Ac-PRNR-α-keto amide-G-Phenylethylamine 8.67 ± 0.11 2.1 
2.20 Ac-PRNR-α-keto amide-G-4-phenylbenzylamine 8.75 ± 0.12 1.8 
2.21 Ac-PRNR-α-keto amide-G-3-phenylbenzylamine 9.13  ± 0.11 0.7 
2.22 Ac-PRNR-α-keto amide-G-2-phenylbenzylamine 8.46 ± 0.06 3.5 
ND = Not determined. Inhibitors were pre-incubated for 5 min with tryptase. Assay conditions were [E] tryptase, 0.1 
µg; [S] Tos-GPR-pNa, 100 µM, 0.1 M HEPES buffer, pH 7.5, 28 ˚C, with 0.1 mg/mL heparin, 0.01% triton X-100 v/v, 
0.02% NaN3.The above values were calculated from at least three independent experiments (n ≥ 3) with statistical 
significance of P ≤ 0.05. 
 
The effect of incorporating prime binding residues on inhibitor potency was examined 
(Table 2.13). A P1’ residue (2.12, IC50 = 3 nM) significantly improved the potency of the parent α-
keto amide compound (2.11) by 20-fold. On the other hand, incorporating a P2’ residue (2.18) was 
found to gain only 5-fold increase in potency compared to 2.12. This suggested that the P1’ residue 
was the key contributor of binding affinity in this case, where a P1’ glycine was sufficient for 
excellent inhibitor binding. It was postulated that the amide backbone of glycine was involved in 
key hydrogen-bonds with the S1’ pocket, and the P2’ moiety had only a minor role in enhancing 
binding affinity for the protease. 
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Table 2.13: Effect of targeting the prime binding sites. 
ID Inhibitor PIC50 ± SEM IC50 (nM) 
2.11 Ac-PRNR-ketoamide 7.19 ± 0.19 65 
2.12 Ac-PRNR-ketoamide-G-NH2 8.58 ± 0.28 2.6 
2.18 Ac-PRNR-ketoamide-G-Benzylamine 9.21 ± 0.11  0.6 
Inhibitors were pre-incubated for 5 min with tryptase. Assay conditions were [E] tryptase, 0.1 µg; [S] Tos-GPR-pNa, 
100 µM, 0.1 M HEPES buffer, pH 7.5, 28 ˚C, with 0.1 mg/mL heparin, 0.01% triton X-100 v/v, 0.02% NaN3.The above 
values were calculated from at least three independent experiments (n ≥ 3) with statistical significance of P ≤ 0.05. 
 
 
Figure 2.20: Predicted interaction of P1’ and P2’ residues of 
Ac-PRNR-α-keto amide-Gf-NH2 with tryptase. The enzyme 
surface represents atom identities (red = oxygen, blue = 
nitrogen, grey = carbon, yellow = sulphur). (PDB:2GDD). 
 
 Indeed, docking studies of Ac-PRNR-α-keto-amide-Gf-NH2 (2.14) showed that the amide 
backbone (-CONH-) of the P1’-Gly was engaged in a hydrogen-bonding interaction with Gly207. 
The P2’ residue (D-Phe) was projected into the S2’ pocket and it was noted that the C-terminal 
amide of P2’ was not engaged in any interaction with the surrounding protease residues.  Based on 
the observation where L- and D- amino acids were indiscriminately tolerated at S2’ pocket, achiral 
aromatic amines were introduced at P2’ position. This led to the elimination of a chiral centre and 
the decarboxylation of the C-terminus. Introduction of benzylamine (2.18, IC50 = 610 pM) yielded a 
highly potent tryptase inhibitor, more favourable than phenylethylamine (2.19, IC50 = 2.1 nM). 
Introduction of the achiral moiety proved to be well tolerated and the decarboxylation of the P2’ C-
terminal was observed to be beneficial for improvement of inhibitor binding. This again showed 
that the P2’ amide group was less important and may not be sterically favoured at this position.   
To fully occupy the S2’ pocket, a phenyl substituent was introduced to the P2’-benzylamine 
in different positions. The meta-substituted benzylamine (2.21, IC50 = 740 pM) was found to be 
most favourable compared to the ortho-substituted (2.22, IC50 = 3.49 nM) and para-subsituted (2.20, 
IC50 = 1.77 nM) analogues. It was postulated that the meta-substituted analogue has the most 
optimal vector to extend the aromatic moiety into the S2’ pocket. Nevertheless, all of the analogues 
were highly potent. A closer examination of the prime binding sites indicated that S3’ and S4’ 
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pockets were also quite prominent and hydrophobic in nature. This suggested that the large phenyl-
benzylamine groups could be well accommodated at either the intended S2’ pocket, or could reside 
at the S3’ and S4’ pockets.  In the absence of an inhibitor-bound crystal structure, it could not be  
concluded that the P2’ moiety was occupying the S2’ pocket. Nevertheless, it seemed that a bulkier 
group did not significantly improve potency, where Ac-PRNR-α-keto-amide-G-benzylamine (IC50 
= 610 pM) and Ac-PRNR-α-keto-amide-F(3-phenyl)benzylamine (IC50 = 740 pM)  were found to 
be equipotent.  This again emphasized the diminutive role of the P2’ residue in binding affinity, and 
that adding substituents at this position to improve potency may not be effective as it led to 
increased molecular liability (size and drug-like properties) in these peptides.   
It was successfully demonstrated in this study that electrophilic isosteres, such as aldehyde 
and α-keto amide, were good tools to produce highly potent covalent peptidic inhibitors of tryptase. 
Using α-keto amide as the P1-P1’ linker to target the S2’ pocket has led to the most potent inhibitor 
of the series, Ac-PRNR-keto-amide-G-benzylamine (IC50 = 610 pM) in agreement with the 
hypothesis. It was also shown that removal of the covalent bond to the catalytic Ser195 residue was 
tolerated, where incorporation of α-hydroxy amide (2.15) has successfully produced a potent 
inhibitor of tryptase.  Further optimization of the hydroxy amide compound may lead to more 
potent, drug-like non-covalent inhibitors of tryptase.  
Traditionally, covalent inhibitors have been considered unfavourable due to their tendencies 
to cause off-target inhibition.41 The application of covalent interactions in drug development 
remains to be avoided due to potential toxicities arising from interactions with other nucleophiles, 
despite the successful generation of some marketed covalent drugs (esomeprazole, clopidogel).42  
While covalent interactions have conferred great potency against tryptase, it was crucial that the 
remainder of the α-keto amide inhibitors be fully utilized judiciously to gain selectivity towards the 
target through non-covalent interactions.  
The core design of the α-keto amide inihibitors involved the use of an optimal non-prime 
site binding sequence for tryptase, and it was postulated that targeting the S2’ pocket could enhance 
selectivity for tryptase against trypsin. To achieve good selectivity for tryptase, the peptidic portion 
of the molecule must first achieve initial molecular recognition by the protease, followed by the 
formation of the covalent bond. Ac-PRNR-α-keto-amide was found to be selective for tryptase 
(IC50 = 65 nM), while it has much lower inhibitory potency (IC50 > 3 µM) against trypsin (Table 
2.14). On the other hand, Ac-PRNR-α-keto-amide-Gf-NH2 was found to be a moderately active 
inhibitor of trypsin (IC50 = 791 nM), but >260 times more selective towards tryptase (IC50 = 3.1 
nM).  This suggested that, although having the extra prime residues was beneficial for inhibitor 
affinity, it did not contribute to improvement of selectivity. In fact, having the additional prime 
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residues also led to better inhibition of trypsin, suggesting that the P2’-D-Phe was well-
accommodated by the trypsin S2’ pocket. This indicated that the improvement of binding affinity 
was compromised by slight loss of selectivity for tryptase against trypsin. It was possible that a 
compound with a bulkier P2’, such as Ac-PRNR-ketoamide-G-(3-phenylbenzylamine), may have a 
better selectivity profile as the much larger hydrophobic residue was expected to be less tolerated 
by trypsin. Nevertheless, it was evident that the non-prime residues provided an efficient 
recognition motif for tryptase, and having these residues alone was sufficient to provide good 
inhibitory potency and selectivity for tryptase.  
 
Table 2.14: Selectivity studies for inhibitors of tryptase 
ID Compound Tryptase Trypsin 
pIC50 ± SEM IC50 (µM) pIC50 ± SEM IC50 (µM) 
3.11 Ac-PRNR-α-keto amide 7.19 ± 0.19 0.065 < 5.52 > 3 
3.14 Ac-PRNR-α-keto amide-Gf NH2 8.50 ± 0.15 0.0031 6.10 ± 0.07 0.79 
Inhibitors were pre-incubated for 5 min with the proteases. Tryptase. Assay conditions were [E] tryptase, 0.1 µg; [S] 
Tos-GPR-pNa, 100 µM, 0.1 M HEPES buffer, pH 7.5, 28 ˚C, with 0.1 mg/mL heparin, 0.01% triton X-100 v/v, 0.02% 
NaN3. Trypsin. Assay conditions were [E] trypsin, 100 nM; [S] BapNa, 500 µM, TRIS buffer, pH 7.5, 28 ˚C, with 150 
mM NaCl. The above values were calculated from at least three independent experiments (n ≥ 3) with statistical 
significance of P ≤ 0.05. 
 
2.8 SUMMARY AND FUTURE DIRECTIONS 
In summary, two approaches have been employed to successfully produce potent and selective 
tryptase inhibitors. The first approach utilized a novel P1 scaffold that successfully converted a 
peptide into a moderately active inhibitor though introduction of an atypical P1-P1’ amide bond. In 
line with the proposed hypothesis, it was established in the study that the S2’ pocket was indeed a 
viable target to achieve additional binding affinity for tryptase, where Ac-PRN(4-AMAA)-Gf-NH2 
(IC50 = 12 µM) was found to be active against tryptase, compared to the inactive Ac-PRNR(4-
AMAA)-NH2. A second strategy involved incorporation of an internal α-keto amide isostere in 
place of the scissile amide bond, thereby successfully providing an efficient method for targeting 
the S2’ pocket. Highly potent and selective inhibitors were developed, where it was found that 
introducing P2’ residues enhanced binding affinity and decarboxylation of the P2’ C-terminal was 
advantageous for inhibitor binding.  Whilst S2’ pocket was a viable target binding pocket, it was 
discovered that targeting this binding pocket did not enhance selectivity towards tryptase. 
Therefore, it was concluded that the strategy of exploiting the S2’ pocket may not be beneficial for 
drug development for tryptase. The increase in molecular weight by adding an appendage to target 
the prime binding sites would decrease the ligand efficiency ultimately without significant 
advantage in inhibitor binding and selectivity. Thus far, these inhibitors have been assessed using 
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solely enzymatic assays, providing a good preliminary evaluation of the α-keto amides as tryptase 
inhibitors in an in vitro environment. In future studies, cell-based assays (using mast cells), serum 
stability studies and toxicity assessment (cytochrome P450 inhibition assay) may be warranted to 
assess the vivo performance of the highly potent α-keto amide inhibitors. This is crucial for 
determining the potential of these candidates for drug development, as these studies would be 
indicative of the bioavailability (cell-permeability), metabolic stability and toxicity of these reactive 
electrophilic inhibitors.” 
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2.9 EXPERIMENTAL SECTION 
2.9.1 General Procedure 
Protected amino acids and resins (Rink-amide and 2-chlorotrityl) were purchased from 
Auspep, Iris Biotech, PepChem, Chem-Impex Ltd and Novabiochem. Other reagents including 
TFA, piperidine, DIPEA, and DMF were obtained from AUSPEP. All the reagents used were 
reagent grade unless stated otherwise. Anhydrous DCM was obtained from an in-house anhydrous 
solvent dispenser. Crude peptides were purified using Shimadzu LC-20AP reversed-phase high 
performance preparative liquid chromatography on a Phenomenex Luna C18 semi-preparative 
column (100 Å, 250 x 10 mm, 5 micron), using a gradient of solvent A (0.1% TFA/water) and 
solvent B (0.1% TFA/ 10% water/ 90% acetonitrile). Final purified peptides were characterized 
using analytic HPLC, high-resolution mass spectrometry (HRMS) and NMR experiments. 
Analytical HPLC was performed using Shidmazu LCMS-2020 (SIL-30AC autosampler, BM-20A 
controller, and a SPD-M20A diode array detector) using a reverse-phase C18 Agilent column (2.1 x 
75 mm, 5 micron). Equilibration was ran for 1 minutes (100% solvent A) at 0.4mL/min, followed 
by a linear gradient (0-100% solvent B) over 6 minutes, and lastly washed with 100% solvent B. 
Electrospray ionisation high-resolution mass spectra (ESI-HRMS) measurements were obtained on 
a Bruker microTOF mass spectrometer equipped with an Agilent 1100 Series LC/MSD mass 
detector in positive ion mode by direct infusion in MeCN at 100 µL/h using sodium formate 
clusters as an internal calibrant.  NMR was recorded on a Bruker Avance 600 spectrometer at 298 K 
unless stated otherwise, and spectra were processed using TOPSPIN software (Bruker, Germany). 
 
2.9.2 Molecular modelling studies 
Crystal structures of tryptase were retrieved from Protein DataBank (RCSB.org), and the 
template (PDB:2GDD) was prepared using Hermes (GoldSuite5.1) where water molecules were 
deleted and the energy of the protein was re-minimized. The three dimensional structures of ligands 
were generated using OMEGA2 (OpenEye Suite), to which the energy of the structure was 
minimized using Sybylx1.3. Superimposition studies were conducted using ROCS (OpenEye Suite). 
Docking studies were done using GOLD (GoldSuite5.1). The model was examined using 
MacPymol (X11, Schrodinger, LCC) through visual inspection. 
 
2.9.3 NMR spectroscopy and concentration determination 
NMR spectroscopic characterization. The peptide solutions were prepared in 600 µL of 
D2O/H2O (1:9). The proton NMR was recorded on a Bruker Avance 600 spectrometer at 298 K 
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unless stated otherwise, and the proton chemical shifts were referenced to DSS (δ 0.00 ppm) in 
water. Suppression of water resonance under low power irradiation during relaxation delay (1.5-3.0 
s) was achieved through WATERGATE NMR experiments. Spectra were processed using 
TOPSPIN software (Bruker, Germany). Peptide concentration determination. The concentration of 
peptides was determined for further assay purposes using PULCON experiments ran using DRX-
600 Mhz spectrometer. The 90˚ pulse of NMR samples was measured carefully by alternating the 
360˚ pulse. This resulted in a null water signal in standard 1D proton experiments. For each peptide, 
the 90˚ was remeasured with the following default settings: relaxation delay of 30s, receiver gain 
64-512, 32-64 scans at 298 K. A Watergate pulse sequence was employed to suppress the water 
peak. Spectra were processed using TOPSPIN, where manual correction of phase and integration of 
individual signals were carried out for concentration calculations.  
 
2.9.4 Analysis of data 
All data was processed using Graphpad Prism V.6 (Graphpad Software Inc. CA) to generate 
dose response curves and statistical analysis. Data was represented by at least three experiments (n 
≥ 3) unless otherwise stated, and was expressed as the mean of all experiments ± SEM. The log 
concentrations were expressed with 95% confidence interval (p ≤ 0.05).  
 
2.9.5 Initial assay development 
BapNa as substrate. BAPNA was purchased from Sigma Aldrich and recombinant beta-
lung tryptase was purchased from Promega Inc. The assay buffer contained 0.1 M HEPES, 10% 
glycerol v/v, 0.1 mg/mL Heparin, 0.01% Triton X-100 v/v, 0.02% NaN3 w/v, pH 7.5. The 
concentration range of BAPNA used was 0.5, 0.75, 1, 1.5 and 2 mM using a 20 mM substrate stock, 
and the enzyme concentration was kept constant at 0.1 µg per well (10 µL of a 0.01 µg/µL stock). 
The assay was conducted at 28 ˚C at pH 7.5, with a total volume of 200 uL (Table 2.14). 
Absorbance measurement was detected using FLUOstar Optima (BMG Labtech) at 405 nm.  
 Tos-GPR-pNa as substrate. Similar assay condition was used as BAPNA. The substrate 
concentration range (from 10mM stock) used was 0.025, 0.05, 0.25, 0.375 and 0.5 mM. The 
percentage of DMSO was maintained at 5%.   
 
2.9.6 Protease inhibition assay 
Inhibitors (100 pM - 100 µM) were pre-incubated with tryptase (0.1 µg per well) at pH 7.5 
and 28  oC for 5 min. Pro-longed incubations (30 and 60 min) did not afford improved inhibitory 
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activity. The assay buffer used contains 0.1 M HEPES, 10% glycerol v/v, 0.1 mg/mL Heparin, 
0.01% Triton X-100 v/v, 0.02% NaN3 w/v, pH 7.5. Chromogenic substrate, Tos-GPR-pNa (100 
µM), was added to initiate the reaction giving a final volume of 200 µL. The reaction progress was 
measured by release of the para-nitroaniline, which was quantitated by absorbance at l = 405 nm 
using a PHERAstar Optima spectrometer (BMG Labtech). 
 
2.9.7 Synthesis of chromogenic substrate 
The commercially available 2-chlorotrityl resin (0.76 mmol/g) was added to anhydrous 
DCM. 1,4-phenylenediamine (4 eq) and DIPEA (8 eq) were added to resin and the mixture was 
stirred under nitrogen atmosphere at room temperature for 24 h. The resin was washed with DMF, 
and the unreacted sites were capped by shaking the resin with DCM/MeOH (9:1, 10 mL) for 30 
min. The resin was then washed with methanol, followed by DCM.  Desired amino acid was 
coupled onto the derivatised resin by shaking the resin with a solution of Fmoc amino acid (4 eq), 
DIPEA (8 eq) and HBTU (4 eq) in DMF for 15 min.  The completion of the coupling was 
monitored using Ninhydrin test. The fmoc protecting group was removed using Piperidine/DMF 
(1:1) (2 x 5 min). The coupling cyclic was repeated to give the desired para-aminoanilide peptide. 
The peptide was cleaved from the resin using TFA:water:TIPS (95:2.5:2.5). The para-aminoanilide 
crude peptide was oxidized to para-nitroanilide by dissolving the peptide in water/acetonitrile (1:1) 
and Oxone® (6 eq.), and the mixture was stirred overnight. The mixture was purified using rp-
HPLC C18 column, with an initial wash with 2 void volume of solvent A to desalt the compound, 
following by a linear gradient (0-100% solvent B) to afford the pure chromogenic substrate.  
 
2.9.8 Synthesis of reference inhibitor  
2.9.8.1 Starting materials 
Phenylmethylsulfoxide. Methylphenyl sulfide (12.4 g, 0.1 mol) was dissolved in ethanol. 
To the solution, HNO3 (3.3 mL) and H2O2 (4.6 mL) was added slowly. The mixture was stirred at 
room temperature overnight. The solution was concentrated and purified using column 
chromatography (10-30% EtOAc in Pet. Ether). An orange oil was obtained (8.4 g, 60%) 1H NMR 
(600 MHz, CDCl3) δ 2.72 (s, 3H), 7.57 (m, 3H), 7.68 (m, 2H). 
5-bromo-2-furoic acid. 2-furoic acid (10 g, 89 mmol) was dissolved in chloroform and 
stirred under reflux in nitrogen atmosphere. Bromine (8 mL, 24 g, 150 mmol) was diluted in 
chloroform and added to the solution dropwise over 3 h. The mixture was stirred and refluxed at 90 
oC. The crude product was obtained as a tan solid, and pure product was obtained by crystallization 
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in water. (10.2 g, 60%) 1H NMR (400 MHz, CDCl3) δ  6.77-6.78 (d, J = 3.2 Hz, 1H), 7.22-7.23 (d, 
J = 3.2 Hz, 1H). 
Methyl 5-bromofuran-2-carboxylate. 5-bromo-2-furoic acid (7 g, 37 mmol) was dissolved 
in methanol and thionyl chloride (1.8 mL) was added. The mixture was stirred for 2 h under N2 
atmosphere. The solution was concentrated in vacuo and partitioned between water and ethyl 
acetate. The organic layer was washed with brine and dried (MgSO4). The product was obtained as 
a tan solid. (5.3 g, 71%) 1H NMR (400 MHz, CDCl3) δ 3.91 (s, 3H), 6.46–6.47 (d, J = 3.2 Hz, 1H), 
7.12-7.14 (d, J = 3.2 Hz, 1H). 
Methyl 5-(phenylethynyl)furan-2-carboxylate. In a three-necked round bottom flask, 
methyl 5-bromofuran-2-carboxylate (2.5 g, 12 mmol) and CuI (220 mg) was dissolved in THF and 
stirred vigorously. PdCl2(PPh3)2 (400 mg) and phenylacetylene (2.5 mL) were added and allowed to 
heat to 45 oC. The mixture was stirred for 30 min to allow the exotherm to reach 65 oC. The solution 
was heated at 65 oC for another 1.5 h. The mixture was filtered and washed with ethyl acetate. The 
organic layer was collected and concentrated in vacuo to afford the crude product as a brown solid. 
The compound was then purified by recrystallisation in isopropanol. (2.3 g, 83%) 1H NMR (400 
MHz, CDCl3) δ 3.93 (s, 3H), 6.70-6.71 (d, J = 3.2 Hz, 1H), 7.20-7.21 (d, J = 3.2 Hz, 1H), 7.32-7.40 
(m, 3H), 7.50-7.56 (m, 2H).  
 5-(phenylethynyl)furan-2-carboxylic acid. Methyl 5-(phenylethynyl)furan-2-carboxylate 
(2.3 g, 10 mmol) was dissolved in 20 mL of THF:MeOH (5:1) at 8 oC. 2.5N NaOH (5 mL) was 
slowly added and the solution was allowed to warm to 19 oC. The solution was stirred for 2 h. The 
solution was concentrated in vacuo and partitioned between water and ethyl acetate, washed with 
brine, dried (MgSO4) and finally concentrated in vacuo to afford the final product as a tan solid. 
(1.5 g, 70%) 1H NMR (400 MHz, CDCl3) δ 6.73-6.74 (d, J = 3.2 Hz, 1H), 7.30-7.31 (d, J = 3.2 Hz, 
1H), 7.38-7.41 (m, 3H), 7.54-7.56 (m, 2H). 
4-hydroxyl-3-bromobenzonitrile. 4-hydroxylbenzonitrile (10 g, 50 mmol) was dissolved in 
chloroform and stirred under reflux in nitrogen atmosphere. Bromine (6.5 mL, 20 g) was diluted in 
chloroform and added to the solution dropwise over 1 h. The reaction was quenched once the brown 
solution turned clear. The crude compound was recrystallized in water to give to the pure 
compound as white solid.  (11 g, 66%) 1H NMR (400 MHz, CDCl3) δ 6.44-6.46 (d, J = 5.8 Hz, 1H), 
7.31 (s, 1H), 7.56-7.58 (d, J = 5.78 Hz, 1H).  
 
2.9.8.2 Compound 2.1 
Tert-butyl-4-hydroxy-4-((phenylsulfinyl)methyl)piperidine-1-carboxylate. n-
Butyllithium (39 mL, 2.0 M in hexane, 51 mmol) was added to a solution of diisopropylamine (8.2 
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mL, 59 mmol) in THF dropwise at -75 oC. The mixture was allowed to stir for 30 min under 
nitrogen atmosphere. Methylphenyl sulfoxide (5.5 g 39 mmol) was dissolved in THF (7 mL) and 
the mixture was added to the solution and stirred at 5 0C for 20 min. The mixture was then cooled 
back down to -75 oC and to this solution 1-boc-4-piperidone (8.9 g, 45 mmol) was added. The 
resulting yellow suspension was stirred and allowed to warm to room temperature over 18 h. The 
light yellow suspension was quenched by the addition of ammonium chloride and the mixture was 
concentrated in vacuo. The crude solid was partitioned between water and ethyl acetate, washed 
with brine and dried (MgSO4) to afford an off-white solid. The compound was recrystallized in 
acetonitrile. (8.0 g, 62%). 1H NMR (600 MHz, CDCl3) δ 1.46 (s, 9H), 1.66-1.70 (m, 2H), 1.80-1.85 
(m, 1H), 2.13-2.19 (m, 1H), 2.67-2.70 (d, 13.4 Hz, 2H), 3.03-3.05 (d, 13.4 Hz, 2H), 3.14-3.40 (m, 
2H), 4.80-4.05 (m, 2H), 4.20 (br, s, 1H), 7.51-7.66 (m, 5H). 
 Tert-butyl 3-hydroxy-4-methylenepiperidine-1-carboxylate. Tert-butyl 4-hydroxy-4-
((phenylsulfinyl)methyl)piperidine-1-carboxylate (5g) and potassium tert-butoxide (2.15g, 44 
mmol) was dissolved in tert-butanol refluxed for 5 hours. The reaction mixture was quenched by 
adding ammonium chloride. The resulting amber solution was concentrated in vacuo, partitioned 
between water and EtOAc, washed with brine, dried and filtered to afford a brown solid. The crude 
solid was purified using column chromatography to give to a light yellow solid. (1.9 g, 60%)  1H 
NMR (600 MHz, CDCl3) δ 1.46 (s, 9H), 1.95 (br, s, 1H), 1.95 (br, s, 1H), 2.42-2.46 (m, 1H), 3.20-
3.27 (m, 2H), 3.40-3.65 (m, 1H), 4.14 Hz, 1H), 3.74-3.76 (dd, J = 12.9 Hz), 4.11-4.13 (m, 1H), 4.88 
(s, 1H), 5.02 (s, 1H). 
 4-chloromethyl-3,6-dihydro-(2H)-pyridine-1-carboxylic acid tert-butyl ester. Tert-butyl 
3-hydroxy-4-methylenepiperidine-1-carboxylate (1.9 g, 8.9 mmol) was dissolved in toluene and to 
this mixture was added thionyl chloride (0.80 ml, 11 mmol) The reaction mixture was stirred for 25 
minutes. The solution was quickly cooled to 5 oC, poured onto cooled NaHCO3 solution. The 
organic layer was washed with NaHCO3, brine, and dried to afford an orange oil as the product. 
(0.90 g, 44%) 1H NMR (600 MHz, CDCl3) δ 1.47 (s, 9H), 2.21-2.36 (m, 2H), 3.53 (m, 2H), 3.93 
(m, 2H), 4.03 (s, 2H), 5.70-5.80 (br, s, 1H).  
 Tert-butyl 4-((2-bromo-4-cyanophenoxy)methyl)-5,6-dihydropyridine-1(2H)-
carboxylate. 4-chloromethyl-3,6-dihydro-(2H)-pyridine-1-carboxylic acid tert-butyl ester (0.31g, 
1.3mmol) and 3-bromo-4-hydroxylbenzonitrile (0.29g, 1.50 mmol) was dissolved in acetonitrile 
(10mL). To this solution, K2CO3 (0.53 g, 38mmol) and a phase transfer catalyst 
tetrabutylammonium iodide (TBAI) (0.30g ) were added and the reaction mixture was stirred for 60 
h under reflux in nitrogen atmosphere. The reaction mixture remains heterogenous throughout the 
reaction. The reaction mixture was filtered, partitioned between 10% K2CO3 and EtOAC. The 
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organic layer was washed with K2CO3, brine and dried (MgSO4) to afford a tan solid. (0.25 g, 47%) 
1H NMR (600 MHz, CDCl3) δ 1.48 (s, 9H), 5.70-5.80 (br, s, 1H), 3.53 (m, 2H), 3.95 (m, 2H), 4.55 
(s, 2H), 5.83 (br, s, 1H), 6.91-6.92 (d, J = 8.6 Hz, 1H), 7.56-7.58 (dd, J = 2.2; 8.7, 1H), 7.83-7.84 
(d, J = 2 Hz, 1H). 
 Tert-butyl 5-cyano-2H-spiro[benzofuran-3,4'-piperidine]-1'-carboxylate. Tert-butyl 4-
((2-bromo-4-cyanophenoxy)methyl)-5,6-dihydropyridine-1(2H)-carboxylate (0.250 g, 0.64 mmol) 
was dissolved in toluene and tributyltin hydride (0.25 mL, 0.95mmol)  was added. To this mixture, 
ACCN (20mg) was added, and the reaction mixture was allowed to reflux for 5h under nitrogen 
condition. The resulting solution was concentrated in vacuo, dissolved in EtOAc and cooled to 5 oC. 
DBU was added, and bromine was added dropwise until a brown end point was reached. The 
precipitate formed was filtered. The filtrate was washed with 10% Na2S2O4, brine and dried 
(MgSO4) to afford a brown yellow solid. The crude product was purified using column 
chromatography and afford a white solid. (90 mg, 45%) (1H NMR (400 MHz, CDCl3) δ 1.50 (s, 
9H), 1.65-1.95 (m, 4H), 2.83-2.96 (m, 2H), 4.03-4.16 (m, 2H), 4.50 (s, 2H), 6.85-6.87 (d, J = 8.4 
Hz, 1H), 7.31-7.38 (m, 2H), 7.46-7.50 (dd, J = 1.6; 8.4 Hz, 1H). 
 Tert-butyl 5-(aminomethyl)-2H-spiro[benzofuran-3,4'-piperidine]-1'-carboxylate. Tert-
butyl 5-cyano-2H-spiro[benzofuran-3,4'-piperidine]-1'-carboxylate (90 mg, 0.29 mmol) was 
dissolved in ethanol (3.6 mL). To this solution, Raney Nickel (0.1 g) and 3N aqueous NaOH (1.4 
mL) was added. The reaction mixture was placed on a Parr hydrogenator at 50 psi for 17 h. The 
mixture was filterd and the filtrate was concentrated in vacuo. The residue was partitioned between 
water and chloroform, washed with brine and dried (MgSO4) to afford a colourless oil. (80 mg, 
88%)  1H NMR (600 MHz, CDCl3) δ 1.49 (s, 9H), 1.60-1.99 (m, 4H), 2.80-3.05 (m, 2H), 3.80 (s, 
2H), 4.08 (br, 2H), 4.40 (s, 2H), 6.75 – 6.77 (d, J = 8.1 Hz), 7.08 – 7.09 (m, 2H).  
 1-(tert-butoxy)carbonyl-5’-(1,3-dioxo-1,3-dihydro-soindol-2-ylmethyl)-spiro[piperidine-
4,3’-(2H)-benzo[b]furan]. Tert-butyl 5-(aminomethyl)-2H-spiro[benzofuran-3,4'-piperidine]-1'-
carboxylate (80 mg, 0.25 mmol) was dissolved in toluene in a round bottom flask fitted with a 
Dean-Stark apparatus. Phthalic anhydride (37 mg, 0.25 mmol) and DIPEA (61 uL, 0.35 mmol) were 
added and the mixture was stirred under reflux in nitrogen atmosphere overnight. The mixture was 
allowed to cool to room temperature and the solution was extracted with 10% citric acid, brine, 
dried with MgSO4, filtered and concentrated in vacuo to obtain an off white solid. (70 mg, 62%) 1H 
NMR (600 MHz, CDCl3) δ 1.49 (s, 9H), 1.60-1.95 (m, 4H), 2.80-2.95 (m, 2H), 4.00-4.20 (m, 2H), 
4.38 (s, 2H), 4.76 (s, 2H), 6.72-6.73 (d, J = 8.22 Hz, 1H), 7.20-7.35 (ov, m, 2H), 7.67-7.71 (m, 2H), 
7.79-7.84 (m, 2H).  
 2-((2H-spiro[benzofuran-3,4'-piperidin]-5-yl)methyl)isoindoline-1,3-dione. 1-(tert-
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butoxy)carbonyl-5’-(1,3-dioxo-1,3-dihydro-soindol-2-ylmethyl)-spiro[piperidine-4,3’-(2H)-
benzo[b]furan] (70 mg, 0.16 mmol) was dissolved in DCM (1mL) and to this solution TFA (200 
uL) was added and stirred under nitrogen atmosphere for 1h and concentrated in vacuo. The residue 
was dissolved in methanol and 4N HCL in dioxane was added. A white precipitate was formed and 
the solution was removed in vacuo. The procedure was repeated three times to afford a white 
suspension. Diethyl ether was then added to the white precipitate and the suspension was stirred for 
16 h. Ether was removed through filtration to afford a white solid. (30 mg, 55%) 1H NMR (600 
MHz, CDCl3) δ 1.94 – 1.97 (m, 2H), 2.05-2.11 (m, 2H), 3.10-3.15 (dt, J = 3.2; 13.0 Hz, 2H), 3.42-
3.45 (m, 2H), 4.48 (s, 2H), 4.77 (s, 2H), 6.74-6.75 (d, J = 8.2 Hz, 1H), 7.23-7.27 (m, 2H), 7.80-7.86 
(m, 4H). 
 (5-(aminomethyl)-2H-spiro[benzofuran-3,4'-piperidin]-1'-yl)(5-(phenylethynyl)furan-2-
yl)methanone. 2-((2H-spiro[benzofuran-3,4'-piperidin]-5-yl)methyl)isoindoline-1,3-dione (30 mg, 
0.078 mmol) was dissolved in DCM. To this solution, coupling reagent BOP (23.7 mg, 0.093 
mmol) and DIPEA (60 uL, 0.34 mmol) was added and the reaction was stirred under nitrogen 
atmosphere for 2h. The resulting amber solution was concentration, partitioned between EtOAc and 
10% citric acid. The organic layer was then washed with NaHCO3 and dried (MgSO4) to afford a 
tan solid. (35 mg, 83%) 1H NMR (600 MHz, CDCl3) δ  1.75-1.85 (m, 2H), 1.92-2.04 (m, 1H), 3.90-
3.30 (br, 2H), 4.46 (s, 2H), 4.53-4.55 (m, 2H), 4.78 (s, 2H), 6.72-6.73 (d, J = 3.5 Hz, 1H), 6.74-6.76 
(d, J = 8.2 Hz, 1H), 7.08-7.09 (d, J = 3.5 Hz, 1H), 7.34-7.39 (m, 2H), 7.52-7.55 (m, 1H), 7.67-7.68 
(m, 1H), 7.70-7.81 (m, 1H),  
 1-(5-phenylethylnyl-furan-2-yl)carbonyl-5’-aminomethyl-spiro[piperidine-4,3’-(2H)-
benzo[b]furan] (Compound 2.1). (5-(aminomethyl)-2H-spiro[benzofuran-3,4'-piperidin]-1'-yl)(5-
(phenylethynyl)furan-2-yl)methanone (42 mg, 0.077 mmol) was dissolved in methanol. Hydrazine 
hydrate and 4-penten-1-ol was added and the reaction was allowed to stir for 24 h at room 
temperature. The resulting yellow solution was concentration in vacuo and purified using reversed 
phase chromatography to give the product as a TFA salt. (10 mg, 31%) 1H NMR (600 MHz, CDCl3)  
δ 1.89-1.94 (m, 2H), 2.16-2.18 (m, 3H), 4.04 (s, 2H), 4.52 (s, br, 2H), 4.61 (s, 1H), 6.83-6.84 (d, J = 
8.3 Hz, 1H), 6.86-6.87 (d, J = 3.6 Hz, 1H), 7.11 (d, J = 3.6 Hz, 1H), 7.23-7.24 (dd, J = 1.9; 8.2 Hz, 
1H), 7.31 (d, J = 1.86 Hz, 1H), 7.41-7.42 (m, 3H), 7.50-7.53 (m, 2H). HRMS calculated for 
[M+1H]+  = 413.1860 (found 413.1857). 
 
2.9.9 Synthesis of 4-AMAA 
4-methyl-2-nitrobenzonitrile. 4-chloro-3-nitrotoluene (9 mL, 52 mmol) was dissolved in 
DMF (15 mL). Copper cyanide (5.4 g, 60 mmol) was added and the mixture was stirred and 
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refluxed under nitrogen atmosphere overnight. The resulting brown mixture was poured onto ice-
water forming a dark brown precipitate. The mixture was filtered and the solid collected was stirred 
in DCM for 1 h. The mixture was filtered to remove insoluble impurities, and then dried using 
MgSO4. The solution was filtered and then treated with activated charcoal and alumina. The solvent 
was removed and crude product was purified using column chromatography (10-30% EtOAC:Pet. 
Ether). Product was obtained as a yellow crystal. (3.0 g, 32%) 1H NMR (600 MHz, CDCl3) δ 2.57 
(s, 3H), 7.60-7.62 (dd, J = 1.7; 7.9 Hz, 1H), 7.79-7.80 (d, J = 7.9 Hz, 1H), 8.14 (s, 1H). 
 4-(bromomethyl)-2-nitrobenzonitrile. 4-methyl-2-nitrobenzonitrile (3.0 g, 19 mmol) was 
dissolved in CCl4 and stirred for 30 minutes under reflux. To this solution, NBS (3.3 g, 19 mmol) 
and ACCN (283 mg, 0.9 mmol) were added. The mixture was stirred overnight, concentrated in 
vacuo to obtain an amber solid. The ratio of the starting material and product was found to be 1:2. 
The product was used without further purification in the next step. (2.7 g, 61%) 1H NMR (600 
MHz, CDCl3) δ 4.55 (s, 2H), 7.83-7.85 (dd, J = 1.7; 7.9 Hz, 1H), 7.90-7.91 (d, J = 7.9 Hz, 1H), 8.35 
(s, 1H).  
 4-cyano-3-nitrobenzyl acetate. 4-(bromomethyl)-2-nitrobenzonitrile (2.7 g, 11 mmol) and 
sodium acetate(3g) was dissolved in acetic acid (20 mL). The mixture was refluxed and stirred for 5 
h under nitrogen atmosphere. The resulting amber solution was poured onto ice-water, resulting in 
the formation of yellow slurry. The aqueous layer was extracted with diethyl ether (x2) and dried 
using MgSO4 to give to a light yellow/amber solid. The crude product was then purified using 
column chromatography (100%-75% EtOAC:Pet. Ether). The unreacted starting material and 
dibrominated product from the previous step was eluted first, and the product was eluted last. The 
product was obtained as a yellow/orange solid. (0.90 g, 36%) 1H NMR (600 MHz, CDCl3) δ 2.21 (s, 
3H), 5.28 (s, 2H), 7.83-7.84 (dd, J = 1.7; 7.9 Hz, 1H), 7.95-7.96 (d, J = 7.9 Hz, 1H), 8.34 (s, 1H).  
 (4-(bromomethyl)-2-nitrobenzoic acid. 4-cyano-3-nitrobenzyl acetate (0.90 g, 4 mmol) 
was refluxed in 48% HBr (20 mL) and water (5 mL) overnight. The aqueous solution was extracted 
using diethyl ether, washed with water, dried with MgSO4 and finally concentrated in vacuo to give 
to an amber solid. (0.35 g, 33%) 1H NMR (600 MHz, CDCl3) 4.52 (s, 2H), 7.70-7.72 (dd, 1H), 
7.87-7.88 (d, 1H), 7.89 (s, 1H), 10.13 (s, 1H). 
 4-(aminomethyl)-2-nitrobenzoic acid. (4-(bromomethyl)-2-nitrobenzoic acid (0.35 g, 1.36 
mmol) was dissolved in ethanol and transferred into a dropping funnel. The solution was slowly 
added dropwise into a 28% ammonia solution (20 mL) with vigorous stirring over 2 h. The mixture 
was allowed to stirred in r.t for 48 h, giving the product as a light orange solid. (0.14g, 53%) 1H 
NMR (600 MHz, CDCl3) δ 4.31 (s, 2H), 7.56-7.57 (m, 1H), 7.81-7.82 (d, 1H), 8.18 (s, 1H), 10.02 
(s, 1H). 
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 4-(((tert-butoxycarbonyl)amino)methyl)-2-nitrobenzoic acid. 4-(aminomethyl)-2-
nitrobenzoic acid (0.14 g, 0.70 mmol) was dissolved in H2O:THF (1:1) and 1N NaOH. To this 
solution, di-tert-butyl carbonate (0.18 g, 0.82 mmol) was added at one go. The mixture was stirred 
for 2 h and THF was removed in vacuo. The pH of the aquoues solution was then adjusted to pH 1-
2 using KHSO4, and extracted with ethyl acetate, dried (MgSO4) and concentrated in vacuo. The 
product was obtained as a light-orange solid. (0.17 g, 80%)S 1H NMR (600 MHz, CDCl3)  δ 1.47 (s, 
9H), 4.43-4.44 (d, J = 5.7 Hz, 2H), 7.60-7.58 (m, 1H), 7.74 (s, 1H), 7.80-7.79 (m, 1H), 10.13 (s, 
1H). 
 2-amino-4-(((tert-butoxycarbonyl)amino)methyl)benzoic acid. 4-(((tert-
butoxycarbonyl)amino)methyl)-2-nitrobenzoic acid (0.17 g, 0.64 mmol) was dissolved in ethanol 
and activated palladium on charcoal (60 mg) was added. Hydrogenation was carried out at 50 p.s.i 
for 5 h. (0.15 g, 88%) 1H NMR (600 MHz, CDCl3)   δ 1.47 (s, 9H), 4.44-4.43 (d, J = 5.7 Hz), 7.60-
7.58 (m, 1H), 7.74 (s, 1H), 7.62-7.61 (d, J = 8.2 Hz, 1H).  
 
2.9.10 Synthesis of hybrid peptide 
Manual stepwise solid phase synthesis and Fmoc chemistry were employed to synthesize a 
series of hybrid peptides incorporating the central scaffold, 4-AMAA. Rink-amide MBHA resin 
(substitution 0.45 mmol/g) was used, under HBTU/DIPEA activation. Fmoc deprotection was 
achieved through treatment with DMF:Piperidine (1:1) for 5 minutes twice. Coupling of common 
amino acid. Coupling of common amino acids was achieved by adding four equivalents of amino 
acid and four equivalents of DIPEA as base. Each successive coupling steps was monitored using 
quantitative ninhydrin assay, where double or multiple coupling was carried out when the coupling 
yield was below 99.6%.  Coupling of Scaffold 4-AMAA. Coupling of scaffold 4-AMAA was 
carried out by the addition of two equivalent 4-AMAA building block, four equivalent of DIPEA 
and two equivalent HATU in DMF. Longer preactivation time was needed (10-15 min) as the 
aromatic carboxylic acid is relatively unreactive as compared to normal amino acid. Coupling of the 
scaffold was monitored by ninhydrin test, where successful coupling should afford a clear, yellow 
solution with no trace of dark blue resin beads. As aromatic amines are insensitive to ninhydrin test, 
a further chloranil test designed for detection of secondary and aromatic amines was employed, 
where a dark brown/green resin should be observed in the presence of these amines. As chloranil 
test does not provide good sensitivity in the detection of ortho-substituted aromatic amine, the 
coupling of 4-AMAA precursor can only be accurately monitored using mini-cleavage strategy. 
Around 1-3 mg of washed and dried resin was extracted from the reaction vessel, to which 500 uL 
of 100% TFA was added and stirred for 2 h to cleave the peptide from the resin and deprotects the 
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respective protecting group of the amino acids. The TFA solution was removed by blowing with 
nitrogen, and the residues formed was dissolved in 70% MeCN in water and analyzed using LC-MS 
to determine to ratio of coupled and uncoupled peptide. Double coupling was carried out if 
necessary. Coupling of Fmoc-Asn(trt)-OH. Four equivalent of Fmoc-Asn(trt)-OH was pre-
activated in 4 equivalent of HATU, 4 equivalent of DIPEA and the solvent used is 30% benzene in 
DMF. Ninhydrin test is inapplicable in this coupling as the free amine of 4-AMAA and the Asn-
coupled resin bound peptide would both give a clear yellow solution. The coupling was monitored 
using the aforementioned mini-cleavage and LC-MS analysis strategy.Purification.Purifications of 
crude peptides was done using reverse phase HPLC on a Vydac (C 18, 10-15 um, 300 A, 50 x 250 
mm) column, where a gradient mixture of solvent A (0.1% TFA in water) and solvent B (0.1% TFA 
and 10% water in acetonitrile) from 100% to 55% A over 40 minutes was used at 214 nm. Purity of 
compounds was evaluated using analytic LC-MS where a linear gradient (20-100B) over 15 
minutes at 1mL/min was ran. 
  
2.9.10.1 Characterizations of hybrid peptides 
Compound 2.3 Ac-PRN(4-AMAA)Gf-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.12-1.13 (d, J = 4.7 Hz, 1H), 1.49-1.54 (m, 1H), 1.81 (s, 
3H),  1.87-1.92 (m, 1H), 2.03 (m, 1H), 2.54-2.64 (m, 1H), 2.82-.2.86 (dd, J = 9.3; 13.6 Hz, 1H), 
3.01-3.05 (dd, J = 7.5; 14 Hz, 1H), 3.07 (m, 1H), 3.83-3.87 (dd, J = 7.0; 17 Hz, 1H), 3.92-3.96 (dd, 
J =7.1; 17 Hz, 1H), 4.05-4.08 (m, 2H), 4.27-4.29 (dd, J = 3.4; 8.4 Hz, 1H), 4.45-4.48 (m, 1H), 4.60-
4.63 (m, 1H), 6.93-6.95 (d, J = 7.2 Hz, 1H), 7.14 (s, 1H), 7.18-7.19 (d, J = 7.9 Hz, 1H), 7.22-7.23 
(d. J = 7.8 Hz, 1H), 7.42-7.43 (d, J = 6.4 Hz, 1H),  7.51 (s, br, 1H), 7.82-7.84 (d, J = 8.1 Hz, 1H),  
8.10-8.14 (m, 1H), 8.17-8.18 (d, J = 7.3 Hz, 1H), 8.24 (s, br, 1H), 8.28-8.30 (d, J = 8.2 Hz, 1H), 
8.57 (s, 1H), 8.95-8.97 (t, J = 5.5 Hz, 1H). HRMS calculated for [M+H]+  = 778.3875 (found 
778.3876). Rt = 3.1 min. 
 
Compound 2.4 Ac-PRN(4-AMAA)GF-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.10-1.13 (d, J = 4.6 Hz, 1H), 1.50-1.54 (m, 1H), 1.90 (s, 
3H),  1.84-1.92 (m, 1H), 2.02(m, 1H), 2.54-2.65 (m, 1H), 2.81-2.89 (dd, J = 9.4; 13.5 Hz, 1H), 
3.00-3.03 (dd, J = 7.6; 14 Hz, 1H), 3.04 (m, 1H), 3.85-3.88 (dd, J = 7.2; 16 Hz, 1H), 3.91-3.96 (dd, 
J = 7.1; 16 Hz, 1H), 4.05-4.09 (m, 2H), 4.25-4.27 (dd, J = 3.2; 8.1 Hz, 1H), 4.46-4.49 (m, 1H), 
4.53-4.60 (m, 1H), 6.93-6.95 (d, J = 7.3 Hz, 1H), 7.20 (s, 1H), 7.21-7.24 (d, J = 7.7 Hz, 1H), 7.25-
7.27 (d. J = 7.7 Hz, 1H), 7.40-7.41 (d, J = 6.5 Hz, 1H),  7.49 (s, br, 1H), 7.72-7.74 (d, J = 8.1 Hz, 
1H),  8.01-8.12 (m, 1H), 8.17-8.19 (d, J = 7.4 Hz, 1H), 8.25(s, br, 1H), 8.28-8.29 (d, J = 8.2 Hz, 
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1H), 8.47 (s, 1H), 8.85-8.91 (t, J = 5.6 Hz, 1H). HRMS calculated for [M+H]+  = 778.3875 (found 
778.3875). Rt = 3.0 min. 
 
Compound 2.5  Ac-PRN(4-AMAA)G-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.44-1.57 (m, 2H), 1.91 (s, 3H), 3.03-3.16 (m, 1H), 3.44-
3.54 (m, 1H), 3.79-3.88 (dd, J = 20.2 Hz, 1H), 4.05 (s, 2H), 4.10 (s, br, 1H), 4.60-4.62 (m, 1H), 
7.22-7.23 (d, J = 9.84 Hz, 1H), 7.42 (1H, br), 7.51 (s, br, 1H), 7.87-7.89 (d, J = 7.9 Hz, 1H), 8.11-
8.12 (d, J = 9.8 Hz, 1H), 8.14-8.16 (d, J = 12.2 Hz, 1H), 8.57 (s, 1H), 8.97-9.02 (t, J = 6.0 Hz, 1H). 
HRMS calculated for [M+H]+  = 631.3190 (found 631.3189). Rt = 3.0 min. 
 
Compound 2.5  Ac-PRN(4-AMAA)-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.39-1.51 (m, 2H), 1.89 (s, 3H), 2.89-3.34 (m, 4H), 3.49-
3.60 (m, 2H), 4.05 (br, 2H), 4.18-4.55 (m, 2H), 7.19-7.20 (d, J = 8.9 Hz, 1H), 7.39 (br, 2H) 7.84-
7.86 (m, 1H), 8.09-8.10 (m, 1H), 8.12-8.14 (d, J = 12.0 Hz, 1H), 8.50 (m, 1H). HRMS calculated 
for [M+H]+  = 574.2976 (found 574.2975). Rt = 2.8 min. 
 
Compound 2.7 Ac-RN(4-AMAA)Gf-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.38-1.53 (m, 2H), 1.61 (m, 1H), 1.67-1.71 (m, 1H), 1.84 
(s, 3H), 2.77-2.85 (m, 4H), 2.98-3.08 (m, 2H),  4.04-4.05 (d, J = 7.2 Hz, 1H), 4.35-4.47 (m, 2H), 
4.57-4.60 (t, J = 7.2 Hz, 1H), 5.06-5.13 (m, 1H), 7.13-7.16 (d, J = 8.0 Hz, 1H), 7.40 (br, 2H), 7.80-
7.82 (d, J = 8.5 Hz, 1H), 8.03-8.06 (t, J = 9.9 Hz, 1H), 8.12-8.14 (d, J = 8.5 Hz, 1H), 8.20 (s, br, 
1H), 8.30-8.37 (d, J = 14.1 Hz, 1H), 8.55 (s, 1H), 8.92-8.94 (t, J = 5.7 Hz, 1H). HRMS calculated 
for [M+H]+  = 681.3347 (found 681.3345). Rt = 2.1 min. 
 
Compound 2.8 Ac-N(4-AMAA)Gf-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.82 (s, 3H), 2.36-2.38 (m, 1H), 2.55-2.56 (d, J = 5.0 Hz, 
1H), 2.59-2.60 (t, J = 4.4 Hz, 1H), 2,62-2.63 (d, J = 5.6 Hz, 1H), 3.75-3.79 (dd, J = 9.3; 15.6 Hz, 
1H), 2.99-3.02 (dd, J = 5.5; 14.9 Hz, 1H), 3.75-3.79 (dd, J = 7.2; 15.6 Hz, 1H), 3.90-3.95 (dd, J = 
5.9; 16.7 Hz, 1H), 4.30-4.47 (m, 1H),  4.49 (s, 2H), 4.51-4.56 (m, 1H), 4.60-4.61 (m, 1H), 6.91 (s, 
1H), 7.10-7.11 (d, J = 7.4 Hz, 1H), 7.15-7.16 (m, 1H), 7.32-7.34 (d, J = 7.6 Hz, 1H), 7.44 (s, 1H), 
7.75-7.77 (d, J = 7.8 Hz, 1H), 8.26-8.27 (d, J = 7.1 Hz, 1H), 8.36-8.37 (d, J = 8.6 Hz, 1H), 8.49 (s, 
1H), 8.89-8.90 (t, J = 6.3 Hz, 1H). HRMS calculated for [M+H]+  = 525.2300 (found 525.2301). Rt 
= 2.1 min. 
 
Compound 2.9 Ac-(4-AMAA)Gf-NH2 
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1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.91 (s, 3H), 2.84-2.85 (dd, J = 3.8; 9.5 Hz, 1H ), 3.02-
3.05 (dd, J = 4.6; 13.8 Hz, 1H), 3.77-3.81 (dd, J = 6; 16.5 Hz, 1H), 3.91-3.95 (dd, J = 6; 16.5Hz, 
1H), 4.05 (s, 2H), 4.44-4.47 (m, 1H), 4.52 (m, 1H), 7.15 (s, br, 1H), 7.17-7.18 (d, J = 4.1 Hz, 1H), 
7.20 (m, 1H), 7.21 (m, 1H), 7.70-7.72 (d, J = 9.2 Hz, 1H), 8.15 (s), 8.19 (br, 2H), 8.21-8.23 (d, J = 
8.4 Hz,  1H), 8.43 (s, 1H), 8.90-8.93 (t, J = 5.9 Hz, 1H). HRMS calculated for [M+H]  = 411.1907 
(found 411.1905). Rt = 1.9 min. 
 
2.9.11 Synthesis of α-keto amide inhibitors 
2.9.11.1 P1-ketoamide building block (Scheme 2.5) 
Boc-Arg(NO2)-weinreb amide. Boc-Arg(NO2)-COOH (5.0 g, 15.6mmol) N,O-
dimethylhydroxylamine hydrochloride (1.54g, 15.6mmol) and DIPEA (8.2 mL, 62.6 mmol) were 
dissolved in DMF (20 mL). HBTU (6 g, 15.8 mmol) were added to mixture and the reaction 
mixture was stirred at room temperature overnight. Ethyl acetate (200 mL) and water (200 mL) was 
added, and the layers separated. The organic layer was washed with sodium bicarbonate ( 2 x100 
mL), 1N HCl (2 x 100 mL) and brine (2 x 100 mL). The organic layer was collected, dried with 
magnesium sulphate, filtered and finally concentrated in vacuo to afford amber solid as the product 
(4.1g, 72%). The crude compound was used in the next step without purification.  
Boc-Arg(NO2)-aldehyde. Boc-Arg(NO2)-weinreb amide (4.1g,  11.3 mmol) was dissolved 
in anhydrous THF (30 mL) and stirred under nitrogen atmosphere at -10 ˚C. LAH (64 mg, 1.5 meq) 
was slowly added and the temperature was maintained below 0 ˚C. After the effervescence ceased, 
the reaction mixture was stirred for 0.5h. Once the reaction went to completion, 2M potassium 
hydrogen sulphate solution (20 mL) was added carefully to quench to reaction. The solution was 
stirred for another 15 min. Ethyl acetate (200 mL) was added and the layers separated. The organic 
layer was washed with 2M potassium hydrogen sulphate solution (3 x 100 mL), followed by 
sodium bicarbonate solution (2 x 100 mL) and brine (2 x 100 mL). The organic layer was collected, 
dried with magnesium sulphate, filtered and finally concentrated in vacuo to afford amber solid as 
the product (2.8g, 81%). The crude compound was used in the next step without purification. 
Boc-Arg(NO2)-cyanohydrin. Boc-Arg(NO2)-aldehyde (2.8g,  9.2 mmol) was dissolved in 
50 mL of EtOAc:MeOH:water (2:1:1). Potassium cyanide (0.60g, 9.3 mmol) was added and the 
mixture was stirred for 3h. Ethyl acetate (100 mL) was added and the layers separated. The organic 
layer was washed with sodium bicarbonate (2 x100 mL), 1N HCl (2 x 100 mL) and brine (2 x 100 
mL). The organic layer was collected, dried with magnesium sulphate, filtered and finally 
concentrated in vacuo to afford thick oil as the product (2.7 g, 89%). 1H NMR (600 MHz, CD3OD): 
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δ =1.37 (s, 9H), 1.53 (m, 2H), 1.70 (m, 2H), 3.19 (m, 2H), 3.65 (m, 1H), 4.29 (d, J = 7.0 Hz, 0.4H), 
4.48 (d, J = 4 Hz, 0.6H).  
Fmoc-Arg(NO2)-hydroxylacid. Boc-Arg(NO2)-cyanohydrin (2.7g, 8.1 mmol) was 
dissolved in 1,4-dioxane (20 mL). Concentrated hydrochloric acid (20 mL) was slowly added and 
the mixture was stirred  at room temperature for 3 days. After the completion of hydrolysis, the 
solvent was removed under high-vacuum. The product was redissolved in water and lyophilized to 
the white fluffy solid as the diasteromeric products. The crude was subject to N-α-fmoc protection 
without purification (1.2g, yield=58%). The solid was dissolved in 50 mL of THF:water (1:1), and 
5 mL of saturated sodium bicarbonate. The mixture was chilled in ice-bath, and Fmoc-Osu (3.2 g, 2 
meq) was added portionwise with vigorous stirring. The reaction mixture was allowed to warm to 
room temperature overnight. Ethyl acetate (300 mL) was added and the layers separated. The 
organic layer was discarded, and the aqueous layer was acidified to pH 2.0. The aqueous layer was 
extracted with ethyl acetate (2 x 200 mL). The collected organic layer was then washed with brine 
(2 x 200 mL), dried with magnesium sulphate, filtered and concentrated in vacuo to give the crude 
product as thick oil. The oil was dissolved in water:MeCN (1:1), purified using rp-HPLC and 
lyophilized to give the product as white fluffy solid. (1.5 g, 53%) 1.24-1.27 (m, 4H), 2.75-2.84 (m, 
2H), 4.10-4.15 (q, J = 7.1 Hz, 1H), 4.23-4.25 (t, J = 6.8 Hz , 0.3H), 4.33-4.36 (t, J = 7.6 Hz , 0.7H), 
4.40-4.42 (d, J = 7.0 Hz, 1H), 4.56-4.58 (d, J = 7.5 Hz, 1H),  7.30-7.46 (m, 4H), 7.59-7.65 (m, 2H), 
7.75-7.81 (t, J = 6.8 Hz, 2H). 
 
2.9.11.2 Characterisations of α-keto amide peptide 
Compound 2.10 Ac-PRNR-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.17 – 1.97 (m, 12H), 2.00 (s, 3H), 2.14-2.24 (m, 2H), 
2.60-2.75 (m, 3H), 3.03-3.21 (m, 4H), 3.39-3.49 (m, 2H), 3.51-3.55 (t, J = 6.8 Hz, 1H), 3.70-3.76 
(m, 1H), 3.80 -3.87(m, 2H), 3.95-4.00(m,1H), 4.18-4.30 (m, 1H), 5.33 (s, 1H), 6.79-7.12 (br, 7H), 
7.52 (s, br, 1H), 7.79-7.82 (d, J = 8.0 Hz, 1H), 7.94-7.98 (d, J = 8.0 Hz, 1H) 8.28-8.30 (d, J = 6.7 
Hz, 1H), 8.37-8.39 (d, J = 7.3 Hz, 1H), 8.89 (s, 1H). HRMS calculated for [M+2H]2+  = 284.6693 
(found 284.6689). Rt = 3.1 min. 
 
Compound 2.11 Ac-PRNR-α-keto amide 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.34-1.97 (m, 12H), 2.01 (2H), 2.09-2.26 (m, 1H), 2.60-
2.74 (m, 2H), 3.02-3.15 (m, 3H), 3.26-3.50 (m, 2H), 3.52-3.56 (t, J = 6.9 Hz, 1H), 3.69-3.71 (m, 
1H), 4.06-4.10 (m, 1H), 4.21-4.30 (m, 2H), 5.59 (s, 1H), 6.73-7.22 (m, 8H), 7.46-7.68 (m, 2H), 
7.78-7.81 (d, J = 10.6 Hz, 1H), 8.21-8.40 (m, 2H), 8.54-8.56 (d, J = 9.2 Hz, 1H). HRMS calculated 
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for [M+2H]2+  = 306.1723 (found 306.1720). Rt = 2.9 min. 
 
Compound 2.12 Ac-PRNR-α-keto amide-G-NH2 
1H NMR (600 MHz, DMSO-D6, 9:1): δ = 1.23-1.95 (m, 14H), 2.00 (s, 3H), 3.08 (m, 6H), 3.68-3.70 
(d, J = 4.2 Hz, 2H), 3.70-3.72 (d, J = 3.6 Hz, 2H), 3.78 (br, 2H), 3.81-3.84 (m, 2H), 3.91-3.94 (dt, J 
= 2.5; 10.6 Hz, 4H), 4.03-4.07 (t, J = 8.2 Hz, 1H), 4.20-4.31 (m, 2H), 4.40-4.57 (m, 2H), 4.86 (br , 
1H), 5.07  (br, 1H), 7.24-7.60 (m,3H), 7.79-8.34 (m, 4H), 8.84-8.92 (m, 1H). HRMS calculated for 
[M+2H]2+  = 334.6830 (found 334.6834). Rt = 2.9 min. 
 
Compound 2.13 Ac-PRNR-α-keto amide-GF-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.74-1.96 (m, 12H), 2.00 (s, 3H),  2.10-2.23 (m, 1H), 2.58-
2.70 (m, 2H), 2.86-2.92 (m, 1H), 2.97-3.13 (m, 4H), 3.19-3.42 (m, 2H), 3.52-3.55 (t, J = 6.5 Hz, 
1H), 3.69-3.76 (m, 2H), 3.86-3.91 (m, 2H), 3.97-4.00(m, 1H), 4.19-4.31 (m, 1H), 6.79 (s, 1H), 
6.98-7.10 (m, 3H), 7.18-7.20 (d, J = 7.8 Hz, 2H), 7.21-7.23 (d, J = 7.4 Hz, 1H), 7.25-7.28 (t, J = 7.4 
Hz, 2H), 7.50 (s, 1H), 7.56 (br, 1H), 7.78-7.81 (d, J = 7.5 Hz, 1H), 8.19-8.23 (t, J = 7.1 Hz, 1H), 
8.33-8.39 (m, 2H), 8.71-8.75 (m, 1H). HRMS calculated for [M+2H+H2O]2+  = 417.2225 (found 
417.2224). Rt = 3.0 min. 
 
Compound 2.14 Ac-PRNR-α-keto amide-Gf-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.17-1.97 (m, 14H), 2.00 (s, 3H), 2.10-2.23 (m, 2H), 2.57-
2.71 (m, 2H),  2.84-2.94 (m,1H), 2.99-3.13 (m, 5H), 3.50-3.55 (t, J = 6.9 Hz, 1H), 3.77-3.82 (m, 
2H), 3.94-4.03 (m, 1H), 4.19-4.29 (m, 2H), 5.89 (s, 1H), 6.82 (br, 1H), 6.99-7.10 (m, 3H), 7.15-
7.32 (m, 5H), 7.46-7.57 (m, 2H), 7.71-7.80 (m, 2H), 8.11-8.41 (m, 4H), 8.62-8.65 (m, 1H). HRMS 
calculated for [M+2H]2+  = 417.2225 (found 417.2227). Rt = 3.2 min. 
 
Compound 2.15  Ac-PRNR-α-hydroxy amide-GF-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.95-1.95 (m, 12H), 2.00 (s, 3H),  2.09-2.20 (m, 1H), 2.56-
2.70 (m, 2H), 2.85-2.90 (m, 1H), 2.97-3.10 (m, 4H), 3.16-3.40 (m, 2H), 3.50-3.54 (t, J = 6.5 Hz, 
1H), 3.68-3.75 (m, 2H), 3.85- 4.33 (m, 4H), 7.00-7.13 (m, 3H), 7.16-7.21 (d, J = 7.5 Hz, 2H), 7.21-
7.24 (d, J = 7.0 Hz, 1H), 7.26-7.31 (m, 2H), 7.50 (s, 1H), 7.79-7.80 (d, J = 7.3 Hz, 1H), 8.17-8.35 
(m, 3H), 8.73-8.75 (m, 1H). HRMS calculated for [M+2H+H2O]2+  = 418.2304 (found 418.2300). Rt 
= 3.0 min. 
 
Compound 2.16 Ac-PRNnitroR-α-keto amide-GF-NH2 
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1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.29-1.93 (m, 14H), 2.00 (s, 3H), 2.13-2.23 (m,1H), 2.58-
2.72 (m, 2H), 2.85-2.93 (m, 1H), 3.03-3.18 (m, 5H), 3.49-3.57 (m, 1H), 3.71-3.90 (m, 2H), 3.95-
4.04 (m, 2H), 4.17-4.30 (m, 2H), 6.82 (br, 1H), 6.99-7.09 (m, 1H), 7.15-7.30 (m, 5H), 7.48 (s, 1H), 
7.53 (br, 1H), 7.68-7.72 (m, 1H), 7.79-7.84 (m, 1H), 8.15-8.19 (m, 1H), 8.23-8.33 (m, 2H), 8.35-
8.40 (m, 1H). HRMS calculated for [M+2H]2+  = 430.7098 (found 430.7099). Rt = 3.3 min. 
 
Compound 2.17 Ac-PRNR-α-keto amide-G(Bip)-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.14-1.97 (m, 12H), 2.00 (s, 3H), 2.07-2.22 (m, 1H), 2.49-
2.70 (m, 1H) 2.84-3.22 (m, 4H), 3.37-3.54 (m, 2H), 3.67-4.28 (m, 5H), 6.68-6.80 (m, 2H), 6.89-
7.11 (m, 4H), 7.24-7.31 (m, 2H), 7.31-7.35 (t, J = 7.2 Hz, 1H), 7.40-7.44 (dt, J = 2.0; 7.9 Hz, 2H), 
7.54-7.66 (m, 5H), 7.78-7.80 (d, J = 10.0 Hz, 1H), 8.04-8.06 (d, J = 7.4 Hz, 1H), 8.10-8.12 (t, J = 
8.0 Hz, 1H), 8.15-8.38 (m, 3H), 8.65-8.80 (m, 1H). HRMS calculated for [M+2H]2+  = 428.7654 
(found 428.7655). Rt = 3.4 min. 
 
Compound 2.18 Ac-PRNR-α-keto amide-G(Benzylamine) 
1H NMR (600 MHz, DMSO-D6, 9:1): δ = 1.20-1.96 (m, 12H), 1.99 (s, 3H), 2.98-3.12 (m, 5H), 3.45 
-4.03(m, 3H), 4.15-4.58 (m, 5H), 6.92-6.98 (m, 2H), 7.21-7.51(m, 7H), 7.83-8.49 (m, 4H), 8.75-
8.82 (m, 1H). HRMS calculated for [M+2H+H2O]2+  = 388.7118 (found 388.7119). Rt = 3.3 min. 
 
Compound 2.19 Ac-PRNR-α-keto amide-G(phenylethylamine) 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.13-1.98 (m, 10H), 2.0 (s, 3H), 2.02-2.20 (m, 2H), 2.68-
2.78 (m, 3H), 3.02-3.12 (m, 6H), 3.47-4.08 (m, 4H), 4.18-4.59 (m, 3H), 7.21-7.31 (m, 5H), 7.34-
7.59 (m, 5H), 7.83-8.36 (m, 4H), 8.69-8.72 (m, 1H). HRMS calculated for [M+2H]2+  = 386.7143 
(found 386.7143). Rt = 3.3 min. 
 
Compound 2.20 Ac-PRNR-α-keto amide-G(4-phenylbenzylamine) 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.13-1.96 (m, 12H), 1.99 (s, 3H), 2.67 (s, 2H), 2.99-3.13 
(m,3H), 3.44-3.58 (m,1H), 3.67-4.04 (m, 4H), 4.19-4.61 (m, 5H), 6.93-7.13 (m, 4H), 7.33-7.49 (m, 
6H), 7.59-7.6 (m, 4H), 7.85-8.54 (m, 4H), 8.78-8.81 (m, 1H). HRMS calculated for [M+2H+H2O]2+  
= 426.7275 (found 426.7276). Rt = 3.4 min. 
 
Compound 2.21 Ac-PRNR-α-keto amide-G(3-phenylbenzylamine) 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.13-1.97 (m, 12H), 2.00 (s, 3H), 2.91-3.11 (m, 5H), 3.45-
3.56 (m, 2H), 3.72-3.87 (m, 2H), 4.20-4.56 (m, 5H), 6.92-7.03 (m, 2H), 7.22-7.29 (m, 2H), 7.35-
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7.39 (m, 2H), 7.40-7.44 (t, J = 7.7 Hz, 2H), 7.45-7.50 (t, J = 7.7 Hz, 2H), 7.53-7.58 (m, 2H), 7.64-
7.67 (d, J = 7.4 Hz, 2H), 7.84-8.35 (m, 3H), 8.51-8.55 (m, 1H), 8.79-8.83 (m, 1H). HRMS 
calculated for [M+2H]2+  = 417.7221 (found 417.7224). Rt = 3.5 min. 
 
Compound 2.22 Ac-PRNR-α-keto amide-G(2-phenylbenzylamine) 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.11-1.94 (m, 12H), 1.99 (s, 3H), 2.07 (s, 2H), 2.98-3.10 
(m, 2H), 3.42-3.55 (m, 2H), 3.67-3.81 (m, 1H), 3.96-4.57 (m, 5H), 6.92-7.10 (m, 1H), 7.21-7.23 (d, 
J = 7.3 Hz, 1H), 7.32-7.43 (m, 8H), 7.43-7.47 (t, J = 6.8 Hz, 2H), 7.84-8.42 (m, 5H), 8.72-8.76 (m, 
1H). HRMS calculated for [M+2H+H2O]2+  = 426.7275 (found 426.7276). Rt = 3.5 min. 
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ABSTRACT 
 
DENV NS2B/NS3pro is a non-structural proteolytic enzyme that plays a pivotal role in viral 
maturation and has been identified as a viable drug target for treating dengue viral infections.1 A 
substrate-based peptide aldehyde inhibitor (PhAc-KRR-CHO) of DENV3 NS2B/NS3pro has been 
previously reported with moderate inhibitory activity (IC50 = 6.7 µM).2 This is an analogue of 
compounds discovered by Stoermer et al. to be two-three orders of magnitude more potent 
inhibitors of the corresponding West Nile Virus NS2B/NS3pro enzyme.3 The highly charged 
peptide has low cell-permeability and a poor pharmacokinetic profile. The aim of this chapter was 
to improve inhibitor potency by optimizing subsite interactions with the protease by introducing 
rationally-designed amino acid mimetics in place of the basic residues (P3-Lys, P2-Arg, P1-Arg) in 
DENV and WNV protease inhibitors.  
It was proposed that the binding conformation of the P1-Arg bound to DENV NS2B/NS3 
protease was contorted and not fully extended as in other classic trypsin-like serine protease (e.g 
trypsin, tryptase, thrombin). Arginine mimetics with reduced length and different constraints were 
therefore introduced at this position to mimic the putative atypical contorted conformation. 
However arginine remained the optimal residue, whilst a longer analogue (homoarginine) was 
similarly tolerated at P1 (PhAc-KRhR-CHO, IC50 = 15 µM). A non-basic mimetic (3,4-
chlorophenylalanine) introduced at P1 to engage in an alternative pi-interaction with Tyr161 was 
much less effective. Introduction of homoarginine at P2 to form a more effective ionic interaction 
with S2-Asp75 was no more active an inhibitor (PhAc-KhRR-CHO, IC50 = 7 µM). The charged 
Lys-group at P3 was removed based on observations where only polar interactions were noted in 
this region. However, polar mimetics (homohomoserine, norcitrulline) failed to maintain inhibitor 
potency, whilst nitroarginine (IC50 = 30 µm) was more favoured.  A study reported after the 
completion of this project revealed that the P3-Arg of aprotinin was engaged in ionic interactions 
with the previously neglected (and absent in reported crystal structure) acidic region (E89-E91) of 
NS2B at its C-terminus. This suggested that future inhibitor design could incorporate basic moieties 
with appropriate structural constraints and backbone modifications to target the acidic region.  
Peptidomimetics generated for WNV protease were significantly less potent (>30-fold) as 
compared to the parent peptide (PhAc-KKR-CHO, IC50 = 51 nM), however they were much more 
tolerated than their DENV protease counterparts. The most potent peptidomimetic, PhAc-3AMF-
KR-CHO (IC50 = 1.5 µM), was 30-fold less potent than the parent compound. Overall, it seemed 
that introduction of rigid aromatic mimetics was undesirable in both DENV and WNV proteases, 
where it was thought to be sterically incompatible with the polar and shallow surface of the 
flaviviral proteases. 
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3.0 INTRODUCTION 
For the past decades, exploration of natural endogenous peptides has provided many 
inhibitors of protease4,5 that prevent the cleavage of polypeptides and thereby regulate protein 
synthesis, turnover and function. Many protease inhibitors have advanced into clinical studies, but 
issues such as poor metabolic stability under physiological conditions, lack of bioavailability due to 
high molecular weight and polarity, and promiscuous interactions with other biological targets in 
part from conformational flexibility,6 have hindered the development of peptide-based inhibitors of 
proteases.  To circumvent limitations associated with peptide-based protease inhibitors, they can be 
transformed into exogenous peptidomimetics that contain essential elements that mimic the peptide 
in three dimensional space while retaining the same biological activities.7 The modus operandi of 
peptidomimetic inhibitors stems from their ability to compete with the natural substrate in the active 
site. 
 In general, the systematic transformation of a bioactive natural peptide to a peptidomimetic 
protease inhibitor involves the initial development of structure-activity relationships (SARs) that 
identify the minimal active sequence, followed by introduction of conformationally-constrained 
amino acids, replacement of amide bonds with uncleavable isosteres, or cyclization to probe the 
structural arrangements of the key pharmacophore elements. These endeavours have successfully 
produced tailored peptidomimetic inhibitors with superior metabolic stability, increased potency 
and selectivity, and improved bioavailability.7, 8 Fundamentally, the rational design of 
peptidomimetics relies heavily on the knowledge of the conformation, electronic and topochemical 
properties of the parent peptide and its corresponding target active site. Two key factors that dictate 
the design of a bioactive peptidomimetic are: (1) formation of a favourable complementary spatial 
fit with the corresponding binding sites, which in some cases requires rigidification to stabilize the 
required binding conformations, and (2) strategic placement of functional groups (polar, non-polar 
or ionic) in certain region to achieve the required interactions (hydrogen bonds, van der Waals 
interactions, or ionic contacts). In essence, mapping of the steric features of the binding sites of the 
target protease, and knowledge of the conformation of the active peptide are the essential pre-
requisites in the development of bioactive peptidomimetics.8 
Peptidomimetics have proven to be valuable tools to generate and study trypsin-like serine 
protease inhibitors, including peptide-based inhibitors often plagued with poor selectivity and oral 
bioavailability due to the requirement for a basic residue at P1.9, 10 Translation of a highly basic 
parent peptide into more drug-like peptidomimetic inhibitor has been successfully achieved through 
strategic manipulation of ionic function and structural properties. The use of basic amino acid 
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mimetics in trypsin-like serine protease peptidomimetic drug candidates (e.g. argatroban) in clinical 
trials was briefly discussed in Chapter 1 (Section 1.2.2).  
In this chapter, the targets for inhibitor studies were two flaviviral trypsin-like serine 
proteases, DENV2 NS2B/NS3pro (serotype 2) and WNV NS2B/NS3pro. Both flaviviral proteases 
shared similar substrate specificities, where they recognized a dibasic motif11, 12 at both P1 and P2 
positions (Figure 3.1). The binding specificities for DENV protease have been previously 
investigated, and it was found to prefer three consecutive basic residues from P3-P1 (PhAc-Lys-
Arg-Arg-CHO, IC50 = 6.7 µM). 
 
(A) 
 
  
(B) 
 
  
 
Figure 3.1: Illustration of DENV2 and WNV protease active site from crystal structures of 
inhibitor-bound flaviviral proteases. (A) Crystal structure of Bz-nKRR-CHO (green) bound 
to DENV NS2BNS3pro (electrostatic surface) (PDB: 3U1I). The specific interactions 
between the peptide aldehyde and the protease are shown in schematic diagram (right) (B) 
Crystal structure of 2-Naphthoyl-KKR-CHO (yellow) bound to WNV NS2B/NS3pro (PDB: 
3E90).  The schematic illustration of their interactions was depicted on the right. 
Electrostatic potential surface was generated using Pymol (Red= acidic, blue = basic, grey 
= hydrophobic). 
 
 
On the other hand , WNV protease has a marked preference of Lys at P2 (PhAc-Lys-Lys-
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positions is not commonly observed in human proteases, with only a few enzymes (e.g. furin, 
certain convertases) known to share this characteristic.12 Therefore, this could be an useful point of 
discrimination for selective inhibition of these viral proteases. 
These tri-basic flaviviral peptide inhibitors are highly-charged and hydrophilic. They are 
deemed to be unsuitable drug leads due to their lack of oral bioavailability. To address these issues, 
peptidomimetics have been generated in a bid to increase their drug-likeness. Gouvea et al. first 
reported a series of modified fluorogenic substrates, Ac-X-Arg-AMC, where basic amino acid 
mimetics was introduced at the P2 (X) position to gain more knowledge for DENV2 protease 
inhibitor design (Figure 3.2).11 The P1-arginine was not replaced due to concern about preserving 
the native residue essential for substrate recognition. These mimetics retained the basic moiety 
(amine or guanidine) required to form the key ionic interactions with Asp129 of the S1 pocket, 
coupled with either an aromatic (3.2-3.5) or an aliphatic substituent (3.6-3.8) to replace the native 
arginine side chain.  The basic group retained in the mimetics was designed to mimic the charged 
guanidino group in native arginine, and the constraint introduced was to allow pre-organisation of 
the side chain to adopt the preferred binding conformation.  
 
    
3.1 
pK >12 
kcat =  0.109 S-1 
Km = 247 µM 
kcat/Km = 0.44 mMS-1 
3.2 
pK = 10.2 
kcat = 0.013 S-1 
Km = 26 µM 
kcat/Km = 0.50 mMS-1 
3.3 
pK > 11 
kcat =  0.035 S-1 
Km = 490 µM 
kcat/Km = 0.07 mMS-1 
3.4 
pK = 10.5 
kcat =  0.033 S-1 
Km = 354 µM 
kcat/Km = 0.06 mMS-1 
 
 
 
  
3.5 
pK = 4.9 
kcat =  0.002 S-1 
Km = 43 µM 
kcat/Km = 0.05 mMS-1 
3.6 
pK = 10.2 
kcat =  0.172 S-1 
Km = 298 µM 
kcat/Km = 0.58 mMS-1 
3.7 
pK = 10.5 
kcat =  0.014 S-1 
Km = 216 µM 
kcat/Km = 0.07 mMS-1 
3.8 
pK = 10.2 
kcat = 0.013 S-1 
Km = 27 µM 
kcat/Km = 0.48 mMS-1 
 
Figure 3.2: Mimetics used to substitute P2 of DENV protease substrate, Ac-X-Arg-Amc. 
  
Kinetic parameters for these peptide substrates were analyzed. All of the P2-substituted 
peptides were found to have lower kcat/Km values (i.e lower enzyme efficiency) compared to the 
native arginine, except for compounds 3.2 (4-aminomethylphenylalanine), 3.6 (L-trans-4-
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aminomethylcyclohexyl-alanine) and 3.8 (L-4-aminocyclohexyl-alanine). Despite having a marked 
preference for arginine over lysine at P2, it was found that compounds bearing an amino moiety 
(3.2, 3.5, and 3.8) had a much lower Km value than one with a guanidino functional group (3.3). 
Interestingly, replacement of a P2-Arg with 4-aminomethylphenylalanine (4-AMF) led to a ten-fold 
decrease in Km value signifying that it had greater binding affinity compared with arginine. In 
addition, having 4-AMF in the substrate led to no change in enzyme efficiency (comparable Kcat/Km 
values) 
In 2006, Chappell et al. reported a series of modified substrates for WNV NS2B/NS3pro  
(Table 3.1) with a focus on substituting native basic residues at P3 (Lys) and P2 (Lys) with 
mimetics based on the newly discovered optimal tetrapeptide substrate, 2-Naph-Lys-Lys-Arg-pNa 
(Km = 25 µM).13 Substitution at P3 with non-native amino acids was generally well-tolerated. 
Replacement of P3-Lys with a longer mimetic with charge (3.13, homoarginine) or no charge (3.10, 
citrulline) led to no notable change in binding affinity, however the enzyme efficiency suffered a 3-
fold decrease. Introduction of shortened mimetic with basic group (3.11, ornithine) or reduced 
basicity (3.12, 3-pyridylalanine) was also tolerated in this position with no significant increase in 
Km value. These observations suggested that having a charged group was not essential for substrate 
binding affinity at P3. This indicated that the charged group at P3 could be eliminated to decrease 
the number of charged groups in the substrate, which in turn could potentially improve the cell-
permeability of the peptide. For the P2 variants, the elimination of a charged group proved to be 
detrimental. Introduction of an amino acid with no charge (3.14, citrulline) or reduced basicity 
(3.17, 4-aminophenylalanine) led to a significant decrease in binding affinity and enzyme 
efficiency. Shortened  (3.15, ornithine) or lengthened (3.16, homoarginine) basic mimetics of the 
native lysine side chain seemed to be well tolerated. Compound 3.15 showed comparable binding 
affinity and enzyme efficiency to the parent substrate. 
In summary, these studies strengthened the belief that basic amino mimetics could be 
suitable replacements for native basic residues, potentially generating more potent and drug-like 
peptidomimetic inhibitors for flaviviral proteases. Evidently, basic native residues could be replaced 
with less basic or non-basic mimetics, while retaining or even improving the binding affinity for the 
protease. Introduction of mimetics with molecular diversity could also allow the probing of binding 
requirements at specific protease pockets in inhibitor design. Such an approach was employed in 
Chapter 2, where it was successfully demonstrated that rationally designed mimetic (4-AMAA as 
P1) could be incorporated to generate active mast cell ß-tryptase inhibitors.  
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Table 3.1: Substitutions of basic residues of WNV NS2B/NS3pro inhibitor, 2-Naph-KKR-pNa. 
Compound Variant Substrate Km 
(µM) 
kcat 
(s-1) 
kcat/Km 
(M-1s-1) 
3.9 Native 2-Naph-Lys-Lys-Arg-pNa 25 1.08 42603 
3.10 P3 2-Naph-Cit-Lys-Arg-pNa 21 0.32 15128 
3.11  2-Naph-Orn-Lys-Arg-pNa 38 0.98 25743 
3.12  2-Naph-3Pya-Lys-Arg-pNa 66 0.96 14617 
3.13  2-Naph-hArg-Lys-Arg-pNa 48 0.11 2294 
3.14 P2 2-Naph-Lys-Cit-Arg-pNa 3423 0.43 127 
3.15  2-Naph-Lys-Orn-Arg-pNa 37 1.58 42889 
3.16  2-Naph-Lys-hArg-Arg-pNa 43 0.89 20382 
3.17  2-Naph-Lys-aPhe-Arg-pNa 2303 0.30 131 
 
In this chapter, the aim was to improve the potency of the parent peptide inhibitors of two 
flaviviral NS2B/NS3pro proteases, DENV NS2B/NS3pro (PhAc-KRR-CHO, IC50 = 10 µM), and 
WNV NS2B/NS3pro (PhAc-KKR-CHO, IC50 = 51 nM), with the former being the primary focus. 
DENV NS2B/NS3pro inhibitors (peptide-based and synthetic alike) had failed to achieve good 
inhibitory potency (IC50 at micromolar concentration) against this protease.  It was proposed that 
introduction of basic amino acid mimetics in place of the native basic residues might allow 
improvement of inhibitor potency by achieving more optimal occupation of their corresponding 
pockets. Previous studies have focused on P4-P2 positions of the DENV parent peptide inhibitor, 
and this study attempted to generate potent peptidomimetic inhibitors by incorporating mimetic at 
P4-P1 (P1 in particular) to investigate binding requirement at these positions. 
 
 
3.1 MATERIALS AND METHODS 
 
3.1.1 Synthesis of chromogenic substrates 
Peptide para-nitroanilides (pNa) and 7-amino-4-methylcoumarins (AMC) have been widely 
utilized as substrate tools to study enzyme kinetics and specificity.14 The chromogenic substrate 
system employing pNa as the chromophore was chosen based on their more robust synthesis and 
higher overall yield despite the fluorogenic AMC system providing a more sensitive assay 
measurement. The pNa substrate is cleaved by a protease at the scissile P1-P1’ amide bond, 
releasing para-nitroaniline which absorbs at λ = 405 nm, thereby allowing the progress of the 
proteolysis to be monitored at A405nm by spectrophotometric measurements. Ac-LKRR-pNA and Ac-
LKKR-pNA, were synthesized as substrates for DENV2 and WNV proteases using methods15 
described by Abbenante and co-workers. Commercially available tritylchloride (TCP) resin was 
first reacted with 1,4-phenylenediamine, and standard Fmoc-chemistry synthesis was carried out on 
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the derivatised resin to afford the desired peptide, where it proceeded smoothly with >99.6% 
completion in each coupling monitored by a Ninhydrin test. The peptide was cleaved from the resin 
using TFA:water:triisopropylsilane (95:2.5:2.5), which removed the acid-labile side chain 
protecting group simultaneously. The crude peptide was lyophilized and was used in the next step 
without further purification. The para-aminoanilide group was oxidized using 6 equivalents of 
Oxone® in water (< 50% acetonitrile was added for increased solubility of the crude peptide). The 
oxidized peptide was then subjected to rp-HPLC purification to give the pure peptide para-
nitroanilde.   
 
  
Scheme 3.1: Synthesis of para-nitroanilide substrate. Reagents and conditions: 
(a) 1,4-phenylenediamine, DCM, TCP resin, overnight, N2 (b)(i) Fmoc-AA-COOH, 
DIPEA HBTU, DMF, 0.5 h, rt;(ii) piperidine/DMF (5:5), rt, 0.5 h. (c) 
TFA/water/TIPS (9.5:2.5:2.5), 1 h, rt (d) Oxone (6 eq), water/acetonitrile (1:1), 6 h.  
 
3.1.2 Recombinant DENV2 and WNV Proteases 
The recombinant DENV2 and WNV proteases were kindly provided by Dr Keith J Chappell 
(University of Queensland). The proteases were constructed, expressed and purified (The 
University of Queensland) using methods previously developed and reported by Dr Chappell.3  The 
DENV protease (DENV2 NGC strain) comprised the hydrophilic region NS2B cofactor (residues 
49-95), a glycine linker (GGGGSGGG), and the NS3pro protease (residues 1-185). The WNV 
protease (WNV NY99-4132 strain, European Molecular Biology Laboratory access code 
FM867587) comprised residues 50-93 of NS2B, the same glycine linker, and the NS3pro protein 
(residues 1-184).  
 
3.1.3 Synthesis of peptidomimetic inhibitors 
3.1.3.1 Amino acid building block 
A series of amino acid mimetics was incorporated into the parent tetrapeptide aldehydes to 
generate peptidomimetic inhibitors for DENV protease and WNV protease. Commercially available 
amino acid building blocks were purchased, and non-commercially available building blocks were 
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synthesized (Figure 3.3).  The N-α-amino group of the amino acids was Fmoc-protected, and their 
side chains were protected with a TFA-labile protecting group. The pKa of these mimetics was 
predicted using MarvinSketch (ChemAxon, Hungary). The arginine mimetics comprised of shorter, 
longer, and constrained analogues, maintaining a basic terminal guanidine moiety to mimic the side 
chain of the native arginine. A masked nitroarginine analogue was also introduced to examine to the 
effect of removing the basic charge.  On the other hand, the lysine analogues consisted of aliphatic 
(homohomoserine and norcitrulline) and constrained mimetics.  
 
Arginine mimetics 
 
 Lysine mimetics 
 
 
 
 	    
Arg hArg 
 
 Lys hhSer 
 
 
 
	    	    
AGB 
 
AGP  norCit 3-AMF 
 
 
 
 	  
 
 
4-AMF 4-aPhe 
4-GNF noArg  
  
 
Non-basic mimetic 
 
 
 3-PyA 4-PyA 
cPhe    
 
Figure 3.3: Amino acid building blocks used to replace P1, P2 and P3 of DENV (PhAc-Lys-Arg-
Arg-CHO) and WNV (PhAc-Lys-Lys-Arg-CHO) protease inhibitors. Arg = arginine, hArg = 
homoarginine, AGB = (s)-2-amino-4-guanidinobutyric acid. AGP = (s)-2-amino-4-
guanidinopropanoic acid, 4-GNF = 4-guanidinophenylalanine, noArg = nitroarginine, cPhe = 3,4-
dichlorophenylalanine, Lys = lysine, hhSer=homohomoserine, norCit = norcitrulline, 3-AMF = (3-
aminomethyl)phenylalanine, 4-AMF = (4-aminomethylphenylalanine), 3-PyA = 3-pyridylalanine, 
4-PyA = 4-pyridylalanine. PhAc = phenylacetyl (C6H5-CH2-CO-). 
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Norcitrulline was synthesized (Scheme 3.2) using a microwave-assisted method.16 The Boc-
protecting group of the commercially available Fmoc-DAB(Boc)-OH building block was removed 
using 50% TFA in DCM. The urea moiety was introduced by reacting the terminal nitrogen with 
potassium cyanate under microwave irradiation to give the fully protected norcitrulline (Fmoc-N-α-
L-norcitrulline-COOH), compatible with Fmoc-chemistry and SPPS.   
Homo-homoserine was derived (Scheme 3.3) from a commercially available Fmoc-
Lys(Cbz)-OH. The Cbz protecting group was deprotected through hydrogenation, followed by 
conversion of the terminal amine into a primary alcohol using sodium nitroprusside in the presence 
of aqueous base. The hydroxyl group was left unprotected for further coupling, which proceeded 
smoothly without side reactions.  
Constrained lysine mimetics were also selected to examine the effect of pre-organising the 
side chain location and orientation through introduction of an aromatic moiety. N-α-Fmoc-(Boc-4-
aminomethyl)phenylalanine-OH was synthesized (Scheme 3.4) using a modified protocol.17 
Diethylacetamido malonate was first deprotonated using sodium ethoxide as base, to which 4-
cyanobenzyl bromide was added. The intermediate formed was decarboxylated, giving a racemic 
product. The acetyl cap of the L-isomer was selectively removed by treating the stereoisomer 
mixture with acylase extracted from aspergillus sp. and the unprotected L-isomer was separated 
from the N-α-acetyl proctected D-isomer using ion-exchange resin (DOWEX-50). The N-α-amine 
of the pure L-isomer was then protected using Fmoc-Osu, and the cyano group was reduced to 
aminomethyl group using Parr hydrogenation in the presence of palladium-on-charcoal catalyst. It 
was noted that the reaction had to be closely monitored, as the Fmoc protecting group could also 
underwent a hydrogenolysis side reaction. The aminomethyl group was protected using (Boc)2O to 
yield N-α-Fmoc-(Boc-4-aminomethyl)phenylalanine-OH (4-AMF), which was compatible with 
Fmoc-chemistry and SPPS. 
The amino acid building blocks were used without chemical modifications for substitutions 
at P2 and P3 positions. The P1 aldehyde building blocks were generated through a simple two-step 
reaction from fully protected amino acids (Scheme 3.5). In general, these amino acids contained a 
N-α-Fmoc-protecting group, and acid-labile side chain protecting groups suitable for Fmoc-
chemistry. The fully protected amino acids were first converted to the Weinreb-amide by treatment 
with N,O-dimethylhydroxylamine in the presence of HBTU, DIPEA and DMF. The intermediate 
was then subjected to a reduction using lithium aluminium hydride to produce the protected 
aldehyde.  
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Scheme 3.2. Synthesis of Fmoc-norCitrulline-COOH. Reagents and conditions: (a) TFA/DCM 
(1:1), 0.5h (b) KOCN, 1N HCl/H2O (2:1), microwave irradiation, 80˚C, 1h 
 
 
 
Scheme 3.3. Synthesis of Fmoc-homohomoserine-COOH. Reagents and conditions: (a) H2/PD, 
MeOH, 3h (b) Sodium nitroprusside, NaOH, water, 5h (c) Fmoc-Osu, NaOH, H2O/THF (1:1) 
 
 
 
Scheme 3.4. Synthesis of Fmoc-Phe(Boc-4-aminomethyl)-COOH. Reagents and conditions: 
(a) Diethylacetamido malonate, NaOEt, EtOH, N2, 3h (b) 4-cyanobenzyl bromide (c)  NaOH, 
EtOH (d) HCl (e) Acylase, aspegillus sp. (f) Fmoc-Osu, NaOH, H2O /THF (g) Pd/C, MeOH, 40 
p.s.i, overnight (h) Boc anhydride, NaHCO3, H2O/THF 
 
 
 
 
Scheme 3.5.  Synthesis of P1 aldehyde building block. Reagents and conditions: (a) N,O-
dimethylhydroxyl hydrochloride, DIPEA, HBTU, DMT, rt, overnight (b) LiAlH4, anhydrous 
THF, 0 oC, 1h 
 
 
 
 
Scheme 3.6.  HCAM resin preparation. Reagents and conditions: (a) CDI, DMF, rt, 3h (b) 
AM resin, DMR, rt, overnight (c) (i) TFA/DCM (1:1), 0.5h, rt (ii) DIPEA, DCM 
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3.1.3.2 Solid phase synthesis of peptide aldehyde inhibitors 
The peptide aldehydes were synthesized using a previously reported hydrazine-carbonyl-
amino-methylated polystyrene (HCAM) resin methodology.18 The HCAM resin was derivatised 
from commercially available amino methylated polystyrene resin (AM-resin, CHEM-IMPEX) 
(Scheme 3.6).   
Tert-butyl carbazate was treated with 1,1’-carbonyldiimidazole, followed by the addition of 
AM-resin. The Boc-protecting group of the intermediate was removed using trifluoroacetic acid to 
give the desired AM resin. The aldehyde was attached to the AM-resin by mixing them in 
anhydrous DCM under nitrogen atmosphere overnight (Scheme 3.7). The P1 aldehyde building was 
attached to the resin by forming a semicarbazone linker.  The resin was then treated with piperidine 
in DMF to expose the free amine, ready for coupling with the next amino acid. Standard coupling 
and deprotection protocols in Fmoc-chemistry were employed to afford to the desired peptide. The 
peptide was then capped using phenylacetic acid. The capped peptide was finally cleaved from the 
resin using TFA/water (9:1) mixture, where the side chain protecting groups were removed 
simultaneously. The crude peptide aldehyde was purified using rp-HPLC to afford pure peptide 
aldehydes, which exist in three forms (hydrated, aldehyde, dehydrated) in equilibrium.   
 
 
 
Scheme 3.7. Synthesis of peptide aldehyde. Reagents and conditions: (a) HCAM-resin, 
anhydrous DCM, overnight. (b) piperidine/DMF (5:5), rt, 0.5 h. (c) (i) Fmoc-amino acid, 
DIPEA HBTU, DMF, 0.5h, rt. (ii) piperidine/DMF (5:5), rt, 0.5 h. (d) TFA/water (9:1). 1 
h, rt.  
 
 
3.2 CHARACTERISATION OF PEPTIDOMIMETICS 
 
A series of peptidomimetics was synthesized as flaviviral protease inhibitors (Table 3.2) 
based on the reported tetrapeptide inhibitors for DENV and WNV to investigate the effect of 
modifying physiochemical and structural properties of the basic residues at P1, P2, and P3 positions 
on the inhibitor potency of the parent compounds. The P4-cap was also replaced by aliphatic, 
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heterocyclic and aromatic substituents to establish structure activity relationship for DENV 
protease.  
 
Table 3.2: Peptidomimetics as putative flaviviral protease inhibitors. 
ID Variant Substitutions 
P4 P3 P2 P1 P1’ 
DENV NS2B/NS3pro 
3.18 Reference PhAc Lys Arg Arg CHO 
3.19 P1 PhAc Lys Arg noArg CHO 
3.20  PhAc Lys Arg AGP CHO 
3.21  PhAc Lys Arg AGB CHO 
3.22  PhAc Lys Arg hArg CHO 
3.23  PhAc Lys Arg 4-GNF CHO 
3.24  PhAc Lys Arg 3-AMF CHO 
3.25  PhAc Lys Arg 4-AMF CHO 
3.26  PhAc Lys Arg cPhe CHO 
3.27 P2 PhAc Lys hArg Arg CHO 
3.28  PhAc Lys 4-GNF Arg CHO 
3.29  PhAc Lys 3-AMF Arg CHO 
3.30  PhAc Lys 4-AMF Arg CHO 
3.31  PhAc Lys noArg Arg CHO 
3.32  PhAc Lys 4-aPhe Arg CHO 
3.33  PhAc Lys 4-PyA Arg CHO 
3.34  PhAc Lys 3-PyA Arg CHO 
3.35 P2, P3 PhAc Lys hArg AGP CHO 
3.36  PhAc Lys hArg AGB CHO 
3.37 P3 PhAc 3-AMF Arg Arg CHO 
3.38  PhAc 4-AMF Arg Arg CHO 
3.39  PhAc 4-PyA Arg Arg CHO 
3.40  PhAc 3-PyA Arg Arg CHO 
3.41  PhAc hhSer Arg Arg CHO 
3.42  PhAc norCit Arg Arg CHO 
3.43  PhAc noArg Arg Arg CHO 
3.44 P4 Hexanoyl Lys Arg Arg CHO 
3.45  4-methylpentanoyl Lys Arg Arg CHO 
3.46  Pentanoyl Lys Arg Arg CHO 
3.47  3-methylbutanoyl Lys Arg Arg CHO 
3.48  Cyclopentoyl Lys Arg Arg CHO 
3.49  Cyclohexoyl Lys Arg Arg CHO 
3.50  Furoyl Lys Arg Arg CHO 
3.51  2-Naphthoyl Lys Arg Arg CHO 
3.52  4-phenoxybenzoyl Lys Arg Arg CHO 
3.53 Truncated  Ac Arg Arg CHO 
3.54   Cbz Arg Arg CHO 
WNV NS2B/NS3pro 
3.55 Reference PhAc Lys Lys Arg CHO 
3.56 P1 PhAc Lys Lys 4GNF CHO 
3.57  PhAc Lys Lys cPhe CHO 
3.58 P3 PhAc 4AMF Lys Arg CHO 
3.59  PhAc 3AMF Lys Arg CHO 
3.60 Truncated  Ac 4AMF Arg CHO 
 
	   124	  
Systematic replacement of the P4-P1 residues was carried out based on the following steps: 
(1) examination of the space available in the target binding pocket, (2) identification of the likely a 
binding conformation of the corresponding side chain, and (3) incorporation of mimetics deemed to 
be suitable as replacements to improve inhibitor potency and drug-like properties. In this chapter, 
the crystal structure of an inhibitor-bound (Bz-Nle-Lys-Arg-Arg-CHO) DENV3 protease (PDB: 
3U1I) was examined to understand the key binding requirements at P4-P1 position, and rationally 
designed mimetics were either purchased or synthesized to afford peptidomimetic aldehydes as 
putative DENV2 protease inhibitors. Standard SPPS Fmoc-chemistry protocol was employed in the 
synthesis of the peptidomimetic aldehydes.18, 19 
The majority of the peptide aldehydes contained a P1-argininal, which existed in a mixture 
of three equilibrium structures in water20, 21: aldehyde form, diastereomeric hemiaminal forms, and 
hydrate form (Figure 3.4). Due to the propensity of these P1-arginal compounds to interconvert 
between these three isoforms, their corresponding NMR spectra are quite complex.  
 
 
 
 
Figure 3.4: Equilibrium structures of P1-Argininal 
 
 
The diagnostic NMR signals indicative of the interconverting forms were highlighted in 
Figure 3.5, using compound 3.33 (PhAc-Lys-4Pya-Arg-CHO) as an example. At the region from 
9.0 – 9.4 ppm, two peaks corresponding to the NH of the hemiaminal form (9.03 ppm) and the 
CHO of the free aldehyde form (9.31 ppm) were noted. In addition, the peaks assigned for CH-OH 
of the diastereoisomeric hemiaminal forms were observed at 5.16 and 5.28 ppm. Due to severe 
overlapping of signals between the free aldehyde and the hemi-aminal species, full assignments of 
NMR chemical shifts of the peptidomimetics were not carried out. Instead, the purity of the 
compounds was further determined using analytic HPLC (single peak) and mass spectrometry. 
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Figure 3.5: 1H Watergate NMR (600 MHz) spectra of PhAc-Lys-4Pya-Arg-CHO measured in 
H2O:D2O (9:1), showing the equilibrium forms of the peptide aldehyde 
 
 
 
 
Table 3.3: 1H NMR spectra assignments for PhAc-Lys-Arg-Arg-CHO (aldehyde form) in 
H2O:D2O (9:1) at 298 K. 
 Residue αNH αH Hβ Others 
P1  Arg-CHO 8.35 (6.54) 4.05(m) 1.72 (ov) 
1.61 (ov)  
NH 7.40 (br), H∂ 3.35 (ov) 
P2 3-Pya 8.00 (7.74) 3.78 (ov) 1.97 8.45 (6.72), 8.41 (6.78), 
7.76(ov) 
P3 Lys 8.60 (7.80) 3.78(ov) 1.48 (ov) H∂ 3.13-3.43 (ov) 
P4 PhAc -- -- 3.53 7.02-7.31 (m) 
Blue font indicates 3JNHCH (Hz), red font indicates 3JHH (Hz)α 
 
 
Table 3.4: 1H NMR spectra assignments for PhAc-Lys-Arg-Arg-CHO (hemiaminal form) in 
H2O:D2O (9:1) at 298 K. 
 Residue αNH αH Hβ Others 
P1 
  
8.30 (6.84) 3.92  1.81, 2.06 NH 7.40 (br), OH  6.86 , CH-
OH 5.28, H∂ 3.41 (ov), HΥ 
2.06 (6.6) 
1.81 
P2 3-Pya 7.99 (ov) 3.64 (ov) 1.98 8.41(ov), 7.76(ov) 
P3 Lys 8.55 (7.62) 3.64 (ov) 1.48 (ov) H∂ 3.13 (ov) 
P4 PhAc - - 3.54 7.02-7.31 (ov) 
Blue font indicates 3JNHCH (Hz), red font indicates 3JHH (Hz)α 
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3.3 STRUCTURES OF FLAVIVIRAL PROTEASES 
To date, several ligand-free and inhibitor-bound crystal structures have been solved for 
DENV protease (serotype 1, 2, and 3). For DENV1 and DENV2, the free protease was found to be 
in an inactive form (Figure 3.6A-B), where the NS2B cofactor was found detached from the NS3 
protease domain leading to disruption of the formation of active sites especially at the S2 and S3 
region. Two inhibitor-bound crystal structures, with an inhibitor bound (Bz-Nle-Lys-Arg-Arg, 
PDB:3U1I; aprotinin, PDB:3U1J) in the active site, have been solved for DENV3.22 The NS2B 
adopted a closed form where it formed a “hairpin” around the NS3 domain, where it stabilized the 
complex and formed part of the S2 and S3 binding sites (Figure 3.6C).  It was previously reported 
that a large fraction of DENV proteases was in the “open” inactive form in solution, as compared to 
the more stable and catalytically superior WNV protease where it existed predominantly in closed 
form. It was previously postulated that the presence of inhibitors could stabilize the “closed” 
conformation of DENV proteases.  
 
(A) DENV1 (B) DENV2 (C) DENV3 (D) WNV 
   
 
“Open” “Open” “Closed” “Closed” 
 
Figure 3.6: Crystal structures of flaviviral proteases. (A) DENV1 NS2B/NS3pro (PDB:3L6P). 
The free protease is in an open conformation, where the NS2B is detached rendering the complex 
inactive. (B) DENV2 NS2B/NS3pro (PDB:2FOM).  The NS2B cofactor is attached to the NS3 
protease to form part of the active site. (C) DENV3 NS2B/NS3pro (PDB:3U1I). The NS2B 
cofactor is attached to the NS3 domain and form part of the S2 and S3 pockets. (D) WNV 
NS2B/NS3pro (PDB:3E90). The NS2B cofactor is attached to the NS3 domain and form part of 
the S2 and S3 pockets. 
 
There was no crystal structure for DENV2 protease (the target serotype) in its active form. 
The structures of the NS3 domain of DENV2 (Figure 3.6B) and DENV3 (Figure 3.6C) proteases 
are very similar, and sequence alignment studies (Figure 3.7) revealed that they shared good 
sequence identity in the NS3 (71%) domain and the NS2B cofactor region (51%).  Therefore, the 
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active DENV3 protease crystal structure was used in the modeling studies performed in this chapter 
to allow accurate prediction of inhibitor-protease interactions. 
 
 
Figure 3.7: Sequence alignment of NS3pro domain of flaviviral proteases. DENV1 (PDB: 3L6P), 
DENV2 (PDB: 2FOM), DENV3 (PDB:3U1I), WNV (PDB: 3E90). The sequence alignment was 
generated using ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
 
 
 
Figure 3.8: Sequence alignment of NS2B cofactor of flaviviral proteases. DENV1 (PDB: 3L6P), 
DENV2 (PDB: 2FOM), DENV3 (PDB: 3U1I), WNV (PDB: 3E90). The sequence alignment was 
generated using ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
 
Table 3.5: The percentage of sequence similarity between the flaviviral proteases at the NS2B 
cofactor region. 
 3U1I 3L6P 2FOM 3E90 
3U1I 100% 57* 51% 35% 
3L6P 57% 100% 55% 29% 
2FOM 51% 55% 100% 33% 
3E90 35% 29% 33% 100% 
 
 
Table 3.6: The percentage of sequence similarity between the flaviviral proteases at the NS3pro 
domain. 
 3U1I 3L6P 2FOM 3E90 
3U1I 100% 77% 71% 59% 
3L6P 77% 100% 69% 53% 
2FOM 71% 69% 100% 52% 
3E90 59% 53% 52% 100% 
CLUSTAL 2.1 multiple sequence alignment
3L6P>           ----SGVLWDTPSP----------GIYRILQRGLLGRSQVGVGVFQEGVFHTMWHVTRGA 46
3U1I>           ----SGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGA 56
2FOM>           ----AGVLWDVPSPPPVGKAELEDGAYRIKQKGILGYSQIGAGVYKEGTFHTMWHVTRGA 56
3E90>           SGGGGGVLWDTPSPKEYKKGDTTTGVYRIMTRGLLGSYQAGAGVMVEGVFHTLWHTTKGA 60
                    .*****.***          * ***  :*::*  * *.**  **.***:**.*:**
3L6P>           VLMYQGKRLEPSWASVKKDLISYGGGWRFQGSWNAGEEVQVIAVEPGKNPKNVQTAPGTF 106
3U1I>           VLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGTF 116
2FOM>           VLMHKGKRIEPSWADVKKDLISYGGGWKLEGEWKEGEEVQVLALEPGKNPRAVQTKPGLF 116
3E90>           ALMSGEGRLDPYWGSVKEDRLCYGGPWKLQHKWNGQDEVQMIVVEPGKNVKNVRTKPGVF 120
                .*     *::* *..**:* :.*** *::. .*:  :***::.:***** : .:* ** *
3L6P>           KTPEGEVGAIALDFKPGTSGSPIVNREGKIVGLYGNGVVTTSGTYVSAIAQAKASQEGPL 166
3U1I>           QTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPT 176
2FOM>           KTNTGTIGAVSLDFSPGTSGSPIVDKKGKVVGLYGNGVVTRSGAYVSAIANTEKSIED-N 175
3E90>           KTPEGEIGAVTLDFPTGTSGSPIVDKNGDVIGLYGNGVIMPNGSYISAIVQGKRMDEPIP 180
                :*  * :**::*** .*******::::*.::*******:  .* *:*.*.: :   :   
3L6P>           PEIEDEVFRK-------- 176
3U1I>           PELEEE------------ 182
2FOM>           PEIEDDIFRK-------- 185
3E90>           AGFEPEMLGSRSHHHHHH 198
                . :* :            
CLUSTAL 2.1 multiple sequence alignment
3U1I>           GPLG--SDLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENIL- 51
3L6P>           GAHM--ADLSLEKAAEVSWEEEAEHSGASHNILVEVQDDGTMKIKDEERDDTL- 51
2FOM>           GSHMLEADLELERAADVRWEEQAEISGSSPILSITISEDGSMSIKNEEEEQTL- 53
3E90>           --MG--TDMWIERTADISWESDAEITGSSERVDVRLDDDGNFQLMNDPGAGGGG 50
                      :*: :*::*:: **.:** :* *  : : :.:**.: : ::       
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3.4 RESULTS AND DISCUSSION 
 
3.4.1 Architecture of S1 pocket: Flaviviral vs Host Serine Proteases  
To design an appropriate amino acid to replace the native basic residues, it was crucial to 
first determine the binding requirement of the corresponding binding pockets. Manipulation of the 
size of the mimetic based on the shape and depth of the binding pocket could allow optimized 
occupation of the pocket, and in certain cases selectivity could be achieved if the target S1 pocket 
was structurally different from other serine proteases. Accessibility of the S1 aspartic acid residue 
was also an important factor, where flexibility of the side chain could be altered to enhance the 
ionic interaction between the mimetic and the acidic S1 residue. In certain cases, interactions with 
the aspartic acid can be omitted, where non-basic mimetics could be introduced to achieve 
alternative interactions with other residues in the S1 pocket, as seen in rivaroxaban (previously 
discussed in Chapter 1). 23 
 
(A) Trypsin (B) uPa (C) Tryptase (D) Factor XIa 
    
 
(E) Thrombin (F) Plasmin (G) Granzyme A 
   
 
Figure 3.9: Features of the S1 pocket of trypsin-like serine proteases. The conserved S1 aspartic 
acid residue (red) is found at the bottom of the S1 pocket. (A) Trypsin (PDB:1NC6).(B) 
urokinase-activated plasminogen (PDB:1LMW). (C) Tryptase (PDB:2FS9). (D) Factor XIa 
(PDB:12OM). (E) Thrombin (PDB:1A5G). (F) Plasmin (PDB:1BUI). (G) Granzyme A 
(PDB:1ORF).  Electrostatic potential surface was generated using Pymol (Red= acidic, blue = 
basic, grey = hydrophobic). 
 
 
	   129	  
The S1 pockets of trypsin-like serine proteases were examined (Figure 3.9). In general, the 
S1 pockets were found to be prominent and well defined. The conserved aspartic acid residue (red) 
was found at the bottom of the S1 pocket, which has a wide opening rendering the S1 aspartic acid 
residue easily accessible.  At first glance, slight variation in the shape of the S1 pocket was noted 
amongst these trypsin-like serine proteases. Trypsin, urokinase-activated plasminogen, tryptase and 
factor XIa (Figure 3.9) shared a high level of structural similarity, with thrombin (Figure 3.9E) 
having a slightly smaller S1 pocket, while the S1 pocket of plasmin (Figure 3.9F) and granzyme A 
(Figure 3.9G) were much wider and deeper. Due to the structural difference in the trypsin-like 
serine protease S1 pockets, it was speculated that this might affect the binding conformation of P1-
arginine, where specific conformational change in the side chain may be adopted to fit into the 
corresponding pocket optimally. Theoretically, a significant difference in binding conformation can 
be exploited to achieve selectivity towards the target of interest. Rationally-designed mimetics that 
mimic the preferred P1-arginine binding conformation in the target of interest can be introduced in 
place of the promiscuous arginine and therefore reduce off-target binding. It was noted that some of 
the protease structures were extracted from inhibitor-bound crystal structures and may not reflect 
the true S1 pocket profile of the free protease in solution, and these predictions must be approached 
with caution. 
The conformations of the P1-arginines bound to serine proteases were therefore examined. 
The P1-arginine residues of substrate/inhibitor bound to the target proteases were extracted from 
their crystal structures to examine their binding conformations (Figure 3.10).  
 
(A) (B) 
  
Figure 3.10: Conformation of P1-arginine bound to the S1 pocket. (A) Binding conformation 
of P1-arginine of trypsin-like serine protease (trypsin (PDB:1NC6), thrombin (1A5G), uPa 
(PDB:1LMW), granzyme A (PDB:1ORF), factor XIa (12OM), tryptase (PDB:2FS9)) bound in 
their corresponding S1 pockets. The guanidine moiety formed bimodal ionic interaction with 
Asp189. The side chain is fully extended. (B) An alternative mode of binding observed in 
thrombin. The arginine side chain is engaged in a unimodal ionic interaction with Asp189, 
stabilized by a hydrogen-bond with the carbonyl backbone of Gly219.  
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 Despite the structural difference in S1 pockets, all of the P1-arginine side chains seemed to 
adopt a similar (if not identical) binding conformation. The arginine side chains were fully 
extended, and engaged in a bimodal interaction with the S1 aspartic acid residue (Figure 3.10A). 
Interestingly, unimodal interaction between the arginine side chain and the S1 aspartic acid was also 
observed in certain cases, as seen in thrombin (Figure 3.10B). These observations suggested that the 
well-defined S1 pockets were able to accommodate the extended arginine side chain in these 
proteases, with no distinct difference noted in conformational requirement for P1-side chain 
binding. As a result, selectivity towards the serine protease of interest was likely to be attained 
through occupation of surrounding binding sites.   
The targets of interest here were two flaviviral trypsin-like proteolytic enzymes, DENV2 
NS2B/NS3pro and WNV NS2B/NS3pro proteases. Both proteases exhibited a strict dibasic 
preference at P1 and P2 position, atypical of most host serine proteases.  In order to determine the 
structural and chemical requirements of an appropriate arginine mimetic for these proteases, their 
binding sites were examined (Figure 3.11). In both DENV and WNV proteases, the substrate 
binding sites were characterized by a shallow groove. The S1 and S2 pockets were found to be 
acidic in nature, thereby explaining the dibasic requirement for Arg/Lys at P1 and P2 positions. 
Unlike the highly conserved prominent S1 pocket as previously discussed, the DENV and WNV S1 
pockets were shallow grooves. 
 
(A) DENV NS2B/NS3PRO  (B) WNV NS2B/NS3PRO  
  
Figure 3.11: Binding sites of flaviviral proteases. (A) DENV protease (PDB:3U1I). (B) WNV 
protease. (PDB:3E90). The S1 and S2 pockets are shallow and acidic in nature. Electrostatic 
potential surface was generated using Pymol (Red= acidic, blue = basic, grey = hydrophobic). 
 
 
The highly conserved S1 aspartic acid residue was near the surface of the S1 pocket helping 
to define the pocket in both DENV and WNV proteases (Figure 3.12B-C). This atypical structure 
led to a requirement for a “constricted” conformation in order for P1-Arg to fit into the shallow S1 
pocket. It was also noted that the P1 arginine side chain did not form a typical bimodal ionic 
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interaction with the Asp129, instead making a uni-modal interaction with Asp129. In addition, the 
guanidinium group was postulated to potentially form a pi-interaction with Tyr161.   
 
(A) Trypsin  (B) DENV (C)WNV  
   
   
Figure 3.12: Comparison of S1 pocket in serine proteases. The distance between alpha-carbons of 
Asp129 and the P1-arginine is shown in black bracket. The distance between the alpha carbon of 
P1-arginine and its terminal nitrogens, and between the terminal nitrogens and the carboxylate of 
Asp129 are highlighted by dotted red lines. (A) Trypsin (PDB:1NC6). S1 pocket is prominent and 
deep, and the P1-arginine was fully-extended and engaged in a bimodal ionic interaction with 
Asp189. (B) DENV protease (PDB:3U1I). The S1 pocket is partially formed by the Asp129 residue 
(red), resulting in a shallow groove. The P1-arginine is constricted and engaged in a unimodal 
interaction with Asp129 (C) WNV protease (PDB:3E90). Similar to DENV protease. Electrostatic 
potential surface was generated using Pymol (Red= acidic, blue = basic, grey = hydrophobic). 
 
 
The conformation of the P1-arginine bound to DENV and WNV protease was examined and 
compared to the classic extended conformation adopted as seen in trypsin. In trypsin, the distance 
between the α-carbon of S1-Asp129 and α-carbon of the P1-arginine was 10.9 Å, allowing the 
arginine side chain to adopt a fully extended conformation (distance between the arginine alpha-
carbon and terminal nitrogens measured at ~6.5 Å). This led to a distance between the terminal 
nitrogens and the carboxylate group of Asp129 of 2.7 – 3.0 Å, consistent with a salt bridge 
(typically ~3 Å). On the other hand, the distance between the α-carbon of Asp129 and the α-carbon 
of P1-arginine in DENV (8.5 Å) and WNV (9.0 Å) proteases was significantly shorter. As a result, 
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the side chain was bent to fit into the smaller pocket. In DENV protease, the distance between the 
terminal nitrogens and the α-carbon of the P1 arginine was 4.6 Å and 6.3 Å, and one of the terminal 
nitrogens was pointing away from the Asp129. This resulted in a unimodal ionic interaction with 
the Asp129 residue, where the terminal nitrogen was 3.2 Å away from Asp129 allowing a salt 
bridge to form. Similar observations were made for WNV protease.  
Due to the unusual architecture of the flaviviral S1 pocket, it was hypothesized that the 
length of the native arginine was too long and non-optimal, as it had to adopt a contorted and 
unfavourable high-energy conformation in order to fit into the shallow S1 pocket. It was therefore 
postulated that introducing a mimetic with a shorter side chain might afford a more optimal 
interaction with the S1 pocket. As the unusual constricted binding conformational requirement was 
distinct for DENV NS2B/NS3pro protease, introducing a structural mimic may afford selectivity 
against other serine proteases with a preference for an extended arginine side chain. 
 
3.4.2 Peptidomimetics as DENV protease inhibitors 
3.4.2.1 Substitutions at P1 
PhAc-KRR-CHO (3.18) was first synthesized and evaluated as the reference inhibitor. 
Initially, the less-basic nitroarginine (3.19) was introduced in place of the highly basic arginine to 
investigate whether the masking of the guanidine moiety could afford similar inhibitor potency 
towards the protease. If successful, the removal of a charge group could potentially improve the 
cell-permeability of the hydrophilic peptide aldehyde. 
To test the hypothesis that the S1 pocket may have a preference for shorter basic residues, 
smaller compounds (3.20-3.21) and constrainted mimetics (3.23-3.25) were introduced at P1. In the 
first approach, the native arginine was progressively shortened to produce two shorter derivatives, 
(S)-2-amino-4-guanidinobutyric acid (AGB) and (S)-2-amino-4-guanidinopropanoic acid (AGP). 
These two analogues were selected as P1 mimetic mimetics. To further test the hypothesis that a 
shorter side chain was preferred in S1, a longer arginine analogue (3.22, homoarginine) was also 
introduced. These analogues retained the basic guanidino group allowing them to maintain their 
ability to form a salt bridge with S1 Asp129. 
In another approach, mimetics with a constraint were introduced to mimic the constricted 
conformation of native arginine observed at P1 and place the terminal basic moiety at an optimal 
distance from the S1-Asp to form a salt bridge. A set of phenylalanine derivatives containing 
guanidino and amino substituents (3.23-3.25) was introduced as P1 replacements.  As the native 
arginine was observed to form a unimodal interaction with Asp129, it was thought that having a 
guanidino group may not be an absolute requirement as the amino group may achieve similar 
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unimodal binding with the S1 pocket. In addition, the introduction of an aromatic ring may be 
beneficial if it provided an additional pi-stacking interaction with S1-Tyr161. Based on previous 
studies where haloaromatics were utilized to interact with highly conserved S1-tyrosine in host 
serine proteases (e.g rivaroxaban), a non-basic mimetic (3.26, 3,4-dichlorophenylalanine) was also 
incorporated at P1 to target Tyr161.  
 
Table 3.7: Inhibition of DENV NS2B/NS3pro by analogues of PhAc-Lys-Arg-Arg-CHO with 
substitutions at P1 position. 
ID Compound pIC50 ± SEM  IC50 (µM) 
P4-Cap P3 P2 P1 P1’ 
3.18 PhAc Lys Arg Arg CHO 4.99 ± 0.72 10 (6.7*) 
3.19 PhAc Lys Arg noArg CHO <4 10%**  
3.20 PhAc Lys Arg AGP CHO <4 Inactive 
3.21 PhAc Lys Arg AGB CHO <4   Inactive 
3.22 PhAc Lys Arg hArg CHO 4.81 ± 0.09 15  
3.23 PhAc Lys Arg 4-GNF CHO <4 30%** 
3.24 PhAc Lys Arg 3-AMF CHO <4 20%** 
3.25 PhAc Lys Arg 4-AMF CHO <4 17%** 
3.26 PhAc Lys Arg cPhe CHO 4.21 ± 0.34 61  
*The reported IC50 for PhAc-Lys-Arg-Arg-CHO. ** percentage of inhibition at 100 µM. ND = not determined. Inhibitors 
were pre-incubated with DENV NS2B/NS3pro for 15 min. Assay conditions were [E] DENV2 NS2B/NS3pro, 50 nM; 
[S] Ac-LKRR-pNa, 500 µM, 50 M HEPES buffer, 37 ˚C, pH 9.5, with 10 mM NaCl and 30% glycerol. The above 
values were calculated from at least three independent experiments (n ≥ 3) with statistical significance of p ≤ 0.05. 
 
The IC50 of the parent compound (PhAc-KRR-CHO) was determined as 10 µM, in 
agreement with the reported value (6.7 µM). Compound 3.19 was found to suffer a drastic decrease 
in potency (10% inhibition at 100 µM), and it was postulated that the nitro functional group may 
not be tolerated by the S1 pocket sterically. It was previously established2 that one of the basic 
terminal nitrogens of the arginine guanidine functional group was important in making a salt bridge 
interaction with the Asp129 residue as previously discussed. Therefore, much weaker hydrogen-
bonding interactions between the non-basic nitroarginine and the acidic S1 pocket may have led to 
the observed decrease in potency. Two shorter arginine mimetics, AGP (3.20) and AGB (3.21), 
were introduced at P1 to identify whether they occupied the S1 pocket more optimally. From 
modeling studies, AGB (3.21) mimicked the “constrained” arginine conformation and seemed to 
occupy the S1 pocket quite well (Figure 3.13), with the guanidine moiety appropriately positioned 
for interaction with Asp129. Unfortunately, both compounds were found to be completely inactive 
at 100 µM. It was possible that the shorter arginine mimetics were not able to project the guanidine 
functional group into the right orientation to interact with Asp129, despite the modeling studies 
predicting otherwise. It was also suspected that the shortened side chain may fail to position the 
terminal conjugated guanidine group at the right position to form pi interactions with Tyr161, 
leading to inactivity.   
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3.20 
AGP 
Inactive 
3.21 
AGB 
Inactive 
Figure 3.13: Shortened arginine mimetic (AGB, green) docked into the S1 pocket 
and superimposed with P1-arginine (cyan). Electrostatic potential surface was 
generated using Pymol (Red= acidic, blue = basic, grey = hydrophobic). PDB:3U1I. 
 
Surprisingly, introduction of homoarginine (3.22, IC50 = 15 µM)) was tolerated at P1 
position, where it was found to be equipotent to the parent compound. Despite the contorted P1-
arginine in the inhibitor-bound crystal structure suggesting that a shorter analogue would be more 
favourable, the opposite was observed in the protease inhibition assay. This may be because both 
Arg and homoArg side chains are able to bend around and still make the requisite ionic contact with 
the S1-Asp129, and perhaps the model has incorrectly predicted the constraint required to allow this 
interaction. It must be noted that the protease is malleable and can adopt an induced fit upon 
inhibitor binding. The second strategy was to introduce a structural constraint to rigidify the side 
chain to interact with Asp129 while maintaining a similar side chain length as in arginine, but with 
an aromatic moiety that can also potentially form a pi-interaction with S1-Tyr161. A series of basic 
aromatic amino acid mimetics, 3.23-3.25 (Figure 3.14), were introduced at P1. 4-
guanidinophenylalanine (3.23), 3-aminomethylphenylalanine (3.24) and 4-aminophenylalanine 
(3.25) resulted in a significant decrease in potency (17 – 30% inhibition at 100 µM). It seemed that 
rigidification of the side chain failed to direct the basic moiety (amine or guanidine) correctly to 
interact with Asp129. As the aromatic ring is planar, the lack of flexibility may prevent the basic 
moiety from achieving the optimal orientation. 
 
3.23 3.24 3.25 3.26 
    
4-GNF 
pKa = 10.42 
30% at 100 µM 
3-AMF 
pKa = 9.77 
20% at 100 µM 
4-AMF 
pKa = 9.77 
17% at 100 µM 
cPhe 
Non basic 
61 µM 
Figure 3.14. Constrained mimetics (3.23-3.26) docked into the S1 pocket and superimposed 
with P1-arginine (purple).   
O
H2N
NH
H2N
OH
NH
O
H2N
NH
OH
NH2
HN
	   135	  
From the modeling studies (Figure 3.14), it seemed that the S1 pocket was able to 
accommodate the aromatic amino acids. However, it was also noted from modeling studies that the 
aromatic ring was not “in plane” with the S1 Tyr161 failing to engage in pi-interaction with Tyr161, 
which may explain why these aromatic mimetics performed poorly against DENV protease.   
Finally, a non-basic P1 mimetic 3,4-dichlorophenylalanine (3.26) was introduced in place of 
the P1-arginine to engage in a putative pi-interaction with Tyr161.  Interestingly, it exhibited 
superior inhibitory activity (IC50 = 61 µM) compared to the other basic aromatic mimetics (3.23-
3.25), but it was still 6-fold less potent than the parent compound (Phac-KRR-CHO; IC50 = 10 µM).  
This gave some confidence that elimination of a basic group at P1 might still be viable and that 
further optimization may afford more potent inhibitors, albeit this would have to be further 
examined in future work beyond this chapter. 
 
3.4.2.2 Substitutions at P2 
The S2 pocket is a key binding pocket that dictates the ligand selectivity for DENV protease 
versus WNV protease.2 DENV protease prefers a P2-Arginine while WNV protease has a 
preference for a lysine at this position (Figure 3.15A-B).24 Unlike the contorted conformation 
observed in the P1-Arg targeting S1 pocket of DENV protease, the P2-Arg side chain adopted a 
fully extended conformation observed in the crystal structure (Figure 3.15C). One of the terminal 
nitrogens from the guanidine moiety was observed to form hydrogen-bonding interactions with 
Asn152 and the carbonyl backbone of Gly82.   
 
(A) WNV NS2B/NS3pro (B) DENV NS2B/NS3pro (C) DENV NS2B/NS3pro 
   
Figure 3.15: Interactions between P2-Arginine and S2 pocket residues in flaviviral proteases. (A) 
WNV NS2B/NS3pro. (B) DENV NS2BNS3/pro. (C) Key interactions between P2-Arg and DENV 
NS2B/NS3pro S2 pocket observed in inhibitor-bound crystal structure. Electrostatic potential 
surface was generated using Pymol (Red= acidic, blue = basic, grey = hydrophobic). (PDB:3U1I) 
 
In WNV protease, the P2-lysine formed an ionic interaction with Asp75, and a hydrogen 
bond with Asn84. On the other hand, the terminal guanidine functional group of P2-Arg was 
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situated too far away from Asp75 (4.4 Å) to form an ionic interaction with DENV protease. 
Therefore, it was hypothesized that the length of the arginine side chain might be non-optimal, and 
elongation of the side chain may enable an additional ionic interaction with Asp75. 
To test this hypothesis, elongated mimetics such as homoarginine (3.27) and a series of 
aromatic basic mimetics (3.28-3.30) were first introduced at P2 position. A series of less basic 
mimetics (3.31-3.34) was also introduced, where their side chains contained hydrogen bond donors 
capable of interacting with Asn152, and it was postulated that the rigidified side chain might reduce 
the binding entropy of the inhibitors. The less basic mimetic with reduced polarity would also 
potentially allow improvement of cell permeability.  
 
Table 3.8 Inhibition of DENV NS2B/NS3pro by analogues of PhAc-Lys-Arg-Arg-CHO with 
substitutions at P2 position. 
ID Compound pIC50 ± SEM IC50  (µM) 
P4-Cap P3 P2 P1 P1’ 
3.18 PhAc Lys Arg Arg CHO 4.99 ± 0.72 10  
3.27 PhAc Lys hArg Arg CHO 5.15 ± 0.31 7.0  
3.28 PhAc Lys 4-GNF Arg CHO ND 50%* 
3.29 PhAc Lys 3-AMF Arg CHO <4 15%*  
3.30 PhAc Lys 4-AMF Arg CHO ND 51%*  
3.31 PhAc Lys noArg Arg CHO <4 25%*  
3.32 PhAc Lys 4-aPhe Arg CHO <4 25%*  
3.33 PhAc Lys 4-PyA Arg CHO <4 5%*  
3.34 PhAc Lys 3-PyA Arg CHO <4 40%*  
*Percentage of inhibition at 100 µM. ND = not determined. Inhibitors were pre-incubated with DENV NS2B/NS3pro 
for 15 min. Assay conditions were [E] DENV2 NS2B/NS3pro, 50 nM; [S] Ac-LKRR-pNa, 500 µM, 50 M HEPES 
buffer, 37 ˚C, pH 9.5, with 10 mM NaCl and 30% glycerol. The above values were calculated from at least three 
independent experiments (n ≥ 3) with statistical significance of p ≤ 0.05. 
 
 
In agreement with the hypothesis, introduction of homoarginine (3.27) was found to be 
desirable, where a slight improvement in potency (IC50 = 7 µM) was observed. It was postulated 
that the terminal nitrogens of the elongated side chain were able to form an additional ionic 
interaction with Asp75.  On the other hand, introducing aromatic mimetics (3.28-3.30) of arginine 
was found to be undesirable with significant decreases in potency. Incorporating less basic 
mimetics (3.31-3.34) was also much less effective. Introduction of nitroarginine (3.31) and 4-
aminophenylalanine (3.32) led to a decrease in potency (25-30% inhibition at 100 µM). From 
modeling studies (Figure 3.16), it was found that the para-amino group of 3.32 was able to form a 
hydrogen bond with Asn84, however the hydrogen bond with Gly82 was now lost due to the 
increased distance between the Gly82 carbonyl and the amino group (3.7 Å). This may have 
contributed to the loss of activity observed.  
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3.18 3.32 3.33 3.34 
    
Arginine 
IC50 = 10 µM 
4-aPhe 
25% at 100 µM 
4-PyA 
5% at 100 µM 
3-PyA 
40% at 100 µM 
 
Figure 3.16. Less basic mimetics docked into the S2 pocket of DENV NS2B/NS3pro. 
Electrostatic potential surface was generated using Pymol (Red= acidic, blue = basic, grey = 
hydrophobic). (PDB:3U1I) 
 
Substitution with 4-PyA (3.33) led to near complete inactivity at 100 µM, whereas 
substitution with 3-PyA (3.34) was more favoured with 40% inhibition noted at the same 
concentration. The modeling studies (Figure 3.16) suggested that the position of the nitrogen in the 
ring was important for inhibitory activity. In 4-Pya, the nitrogen was positioned too far away (3.5 -
4.8 Å) from all of the interacting S2 pocket residues (Asp75, Asn84 and Gly82). In 3-PyA, it was 
observed that the nitrogen was now positioned “correctly” where it was able to form a putative 
ionic interaction with Asp75, however the hydrogen-bonding interactions with Asn84 and Gly82 
were eliminated. Combining the information from compounds 3.32 and 3.34, it was therefore 
possible to introduce an aminopyridine analogue (Figure 3.17) to maintain hydrogen-bonding 
interactions with Asn84 and Gly82 while achieving a partial ionic interaction with Asp75 in future 
studies. Overall, it seemed that maintaining the charged group was important for activity at this 
position, and rigidification of side chain was not well tolerated.  It was also suspected that 
introducing an aromatic group may not be sterically desirable at the polar S2 pocket. 
 
   
aPhe 3-PyA Aminopyridine 
 
Figure 3.17: Potential mimetic to target S2 pocket derived 
from 3.32 and 3.34. 
 
In the previous section, introduction of AGP (3.20) and AGB (3.21) to mimic the contorted 
P1-Arg led to unexpected abolition of inhibitory activity. It was postulated that introduction of the 
P2-homoarginine may afford a positive synergistic effect on the distribution of shortened P1 side 
H2N
NH2
OH
O
H2N
N
OH
O
H2N
N NH2
OH
O
	   138	  
chains, thus allowing optimal occupation of the S1 and S2 pockets.  Unfortunately, compounds 3.35 
and 3.56 were completely inactive (Table 3.9).  
 
Table 3.9 Inhibition of DENV NS2B/NS3pro by analogues of PhAc-Lys-Arg-Arg-CHO 
with substitutions at P1 and P2 positions. 
ID Compound Activity 
P4-Cap P3 P2 P1 P1’ 
3.35 PhAc Lys hArg AGP CHO >100 µM 
3.36 PhAc Lys hArg AGB CHO >100 µM 
Inhibitors were pre-incubated with DENV NS2B/NS3pro for 15 min. Assay conditions were [E] DENV2 
NS2B/NS3pro, 50 nM; [S] Ac-LKRR-pNa, 500 µM, 50 M HEPES buffer, 37 ˚C, pH 9.5, with 10 mM NaCl and 30% 
glycerol. The above values were calculated from at least three independent experiments (n ≥ 3) with statistical 
significance of p ≤ 0.05. 
 
 
3.4.2.3 Substitutions at P3  
A preference for lysine was noted at P3 where it formed a hydrogen bond with the carbonyl 
of Met84 (Figure 3.18A-B) in the S3 pocket of DENV protease.2 The amine acted as a hydrogen-
bond donor and the carbonyl backbone of Met84 behaved as its hydrogen-bond acceptor , and there 
was no salt bridge formed with the surrounding residues. It was therefore postulated that having a 
positively charged residue was not crucial at this position. Introduction of a polar and non-charged 
moiety can potentially maintain the hydrogen-bonding interaction, and allow the elimination of the 
charged residue to promote cell permeability. From the crystal structure (PDB:3U1I), it was also 
observed that the lysine chain was fully extended, and the S3 pocket was not fully occupied. 
Therefore, introduction of a bulkier mimetic may be beneficial at this position. 
 
(A) (B) 
  
Figure 3.18: Interaction of P3-Lysine with S3 pocket. (A) Bz-nKRR-CHO bound to 
DENV protease. (B) Hydrogen bonding interaction between P3 Lysine and Met84 of the 
S3 pocket. Electrostatic potential surface was generated using Pymol (Red= acidic, blue 
= basic, grey = hydrophobic). (PDB:3U1I) 
	   139	  
 A series of aromatic mimetics (3.37-3.40) was introduced at the P3 position. Compounds 
3.37 and 3.38 maintained a basic terminal amino group to mimic the native lysine residue. Two less 
basic mimetics, 4-pyridylalanine (3.39) and 3-pyridylalanine (3.40) were introduced next. The 
nitrogen in the pyridine ring was significantly less basic, however the nitrogen was still able to 
behave like a hydrogen bond donor25 to interact with the carbonyl backbone of Met84. A pair of 
aliphatic mimetics (3.41 and 3.42) was introduced next to replace the terminal nitrogen with 
moieties with comparable hydrogen-donor properties, where homohomoserine (3.41) had a terminal 
hydroxyl group while 3.41 comprised an urea moiety.  Both of these compounds maintained a 
similar side chain length as the native lysine residue. Non-basic nitroarginine (3.43) was introduced 
at P3 to investigate the effect of side chain elongation and charge elimination on inhibitor potency. 
 
Table 3.10 Inhibition of DENV NS2B/NS3pro by analogues of PhAc-Lys-Arg-Arg-CHO with 
substitutions at P3 position. 
ID Compound pIC50 ± SEM IC50 (µM) 
P4-Cap P3 P2 P1 P1’ 
3.18 PhAc Lys Arg Arg CHO 4.99 ± 0.72 10  
3.37 PhAc 3-AMF Arg Arg CHO <4 10%* 
3.38 PhAc 4-AMF Arg Arg CHO <4 12%*  
3.39 PhAc 4-PyA Arg Arg CHO ND 55%*  
3.40 PhAc 3-PyA Arg Arg CHO <4 30%*  
3.41 PhAc hhSer Arg Arg CHO <4 5%*  
3.42 PhAc norCit Arg Arg CHO <4 14%*  
3.43 PhAc noArg Arg Arg CHO 4.53 ± 0.22 30  
*Percentage of inhibition at 100 µM. ND = not determined. Inhibitors were pre-incubated with DENV NS2B/NS3pro 
for 15 min. Assay conditions were [E] DENV2 NS2B/NS3pro, 50 nM; [S] Ac-LKRR-pNa, 500 µM, 50 M HEPES 
buffer, 37 ˚C, pH 9.5, with 10 mM NaCl and 30% glycerol. The above values were calculated from at least three 
independent experiments (n ≥ 3) with statistical significance of p ≤ 0.05. 
 
Introduction of 3-AMF (3.37) and 4-AMF (3.38) led to drastic reductions in inhibitor 
potency (10-12% inhibition at 100 µM). From modeling studies (Figure 3.19), the incorporation of 
the aromatic ring in 3-AMF and 4-AMF proved to be undesirable, and it was observed that the 
rigidification of the side chain led to incorrect projection of the aminomethyl functional group that 
failed to interact with Met84.  
3.37 3.38 
  
Figure 3.19: 3-AMF (3.37, yellow) and 4-AMF (3.38, blue) docked into 
S3 pocket of DENV NS2B/NS3pro (PDB:3U1I). No interactions noted.  
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Interestingly, incorporation of the smaller and less basic pyridine mimetics (3.39, 3.40) was 
more tolerated as compared to the larger basic aromatic mimetics (3.37, 3.38). This suggested that 
the larger basic mimetic may not be sterically tolerated in the S3 pocket. 3-PyA (3.40) was found to 
be more potent at with 55% inhibition at 100 µM compared to 4-pya (3.39, 30% inhibition at 100 
µM). From modeling studies (Figure 3.20), it was found that the nitrogen of the more favourable 3-
Pya was positioned correctly to form hydrogen-bonding interactions with Met84, whereas the 
nitrogen at the para position in the ring was pointing away and failed to engage with Met84. On the 
other hand, substitution with homohomoserine (3.41) and norcitrulline (3.42) led to almost 
complete loss of activity. This was unexpected as both of the lysine mimetics contained hydrogen 
donors at the same position as lysine, which in theory would maintain the hydrogen-bonding 
interaction with the S3-Met84. 
 
3.39 3.40 3.43 
   
4-pya  
55% at 100 µM 
3-pya 
30% at 100 µM 
noArg 
IC50 = 30 µM 
Figure 3.20: 4-PyA (turquoise), 3-PyA (yellow) and noArg (beige) docked into S3 pocket 
of DENV NS2B/NS3pro. Electrostatic potential surface was generated using Pymol (Red= 
acidic, blue = basic, grey = hydrophobic). (PDB: 3U1I) 
 
Nitroarginine (3.43) was the most tolerated mimetic (IC50 = 30 µM) at this position. From 
modeling studies, it was noted that the terminal nitrogen (masked by the nitro functional group) 
made a putative hydrogen bond with the Met84 carbonyl backbone. In addition, the nitro group was 
found to form an additional hydrogen bond with the side chain of Arg85. This may explain why 
nitroarginine was much more tolerated in this position due to the hydrogen bond network formed.	  
Overall, this series of DENV NS2B/NS3pro inhibitors performed poorly against the 
protease. This led to speculations where ectopic cleavage of the tribasic inhibitor might have 
occurred. It was possible that the P3-P2 basic residues have been recognized as P2-P1 instead 
(Phac-KRR-CHO) leading to inhibitor degradation. In other words, the tribasic peptide aldehyde 
might be recognized by the protease as a substrate, where the P3-P2 amide bond hydrolysis were 
carried out. However, it was well-established that DENV NS2B/NS3pro has a strict preference for 
Arg at P2 position, therefore P3Lys-P2-Arg was unlikely to be recognized as P2-P1. In theory, 
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having a non-basic P3 would prevent P3-P2 from being recognized as the dibasic cleavage 
sequence and prevent inhibitor degradation, thereby producing better inhibitory activity. However, 
this was clearly not seen in 3.41 and 3.42. In addition, the formation of a covalent bond between the 
C-terminal aldehyde and the nucleophilic serine residue would serve as a good anchoring point, 
rendering the “misplacement” of the peptide highly unlikely. Futhermore, the S1’ pocket was small 
and not well-defined, and it would not be able to accommodate an arginine (Phac-KRR-CHO) if 
ectopic cleavage was to occur. Due to time constraints, analysis of assay contents was not carried 
out however future experiments will be carried out to eliminate this possibility. 
 
3.4.2.4 Substitutions at P4 
The P4 residue was observed to be solvent exposed in both WNV (P4-Naphthoyl cap, 
Figure 3.21A) and DENV (P4-Leu, Figure 3.21B) protease. Opimizations of the P4-cap was 
previously reported3 for WNV protease (2-naphthoyl-KKR-CHO) where it was found that non-
flexible capping groups (e.g. phenylacetyl) were preferred over flexible capping groups (e.g. 
benzoyl). From the inhibitor-bound crystal structure (PDB: 3E90), there was no noticeable 
interaction between the 2-naphthoyl group and the protease, where the only hydrophobic residue in 
proximity was Ile155 (4.6 Å). Despite this observation, previous studies attempted optimization at 
this position and some SAR was observed. Similarly, the P4-norleucine was also found to be 
solvent exposed in DENV protease, with Val155 situated 4.5 Å away from the hydrophobic side 
chain. Based on a previous strategy2 used in development of potent WNV protease tripeptide 
inhibitors (Chapter 1), Bz-nKRR-CHO (IC50 = 9.5 µM) was truncated to give a slightly more 
potent peptide aldehyde DENV protease inhibitor, PhAc-KRR-CHO (IC50 = 6.7 µM).  Similar to 
WNV protease, non-flexible caps (e.g. phenacetyl, 4-phenylphenylacetyl) were more favourable at 
the P4 position.2 
To further test whether the substituent at the P4 position could enhance interactions with the 
protease, the phenacetyl cap was replaced with a series of aliphatic, heterocyclic and aromatic 
moieties (Table 3.11). The aliphatic moieties (3.44-3.47) were incorporated to mimic the P4-
norleucine in Bz-nKRR-CHO, constraint (3.48-3.50) was introduced to rigidify the side chain, and 
big bulky aromatic groups (3.51-3.52) were introduced to probe the space occupation around the S4 
pocket. Introduction of hexanoyl cap (3.44, IC50 = 36 µM) led to 3-fold decrease in potency, while 
its structural isomer (3.45, 4-methylpentanoyl) suffered a complete loss of potency. It was 
postulated that a branched aliphatic chain may not be favourable at this position. However, the 
shorter pentanoyl cap (3.46, IC50 = 32 µM) and its branched analogue 3-methylbutanoyl (3.47, IC50 
= 26 µM) were equipotent to the hexanoyl cap. The cyclic aliphatic rings, cyclopentanoyl (3.48, 
IC50 = 20 µM) and cyclohexanoyl (3.49, IC50 = 31 µM), were equipotent and well-tolerated.  
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(A) WNV NS2B/NS3pro (B) DENV NS2B/NS3pro 
  
Figure 3.21: (A) WNV NS2B/NS3pro. The 2-napthoyl cap was solvent-exposed and was 
not engaged in any noticeable interaction with the protease. Residue Ile155 was 4.6 Å 
away from the cap. (B) DENV NS2B/NS3pro. The P4-norLeu was solvent-exposed and 
was in proximity with Val155 (4.5 Å). Electrostatic potential surface was generated using 
Pymol (Red= acidic, blue = basic, grey = hydrophobic). 
 
  
 Introduction of a heterocycle proved to be detrimental, with a furoyl group (3.50, IC50 = 92 
µM) leading to a 10-fold decrease in potency. Substitutions of the P4-cap with an aromatic group 
led to mixed results, with the incorporation of 2-naphthoyl (3.51, IC50 = 25 µM) tolerated and 
producing a 2-fold decrease in potency, while introduction of a bulkier 4-phenoxybenzoyl (3.52) 
completely abolished inhibitory activity. 
 
Table 3.11. Inhibition of DENV NS2B/NS3pro by analogues of PhAc-Lys-Arg-Arg-
CHO with substitutions at P4 position. 
ID Compound pIC50 ± SEM IC50 (µM) 
P4-Cap P3 P2 P1 P1’ 
3.18 PhAc Lys Arg Arg CHO 4.99 ± 0.72 10 µM  
3.44 Hexanoyl Lys Arg Arg CHO 4.44 ± 0.65 36 
3.45 4-methylpentanoyl Lys Arg Arg CHO <4 >100  
3.46 Pentanoyl Lys Arg Arg CHO 4.50 ± 0.31 32 
3.47 3-methylbutanoyl Lys Arg Arg CHO 4.59 ± 0.41 26 
3.48 Cyclopentanoyl Lys Arg Arg CHO 4.71 ± 0.07 20 
3.49 Cyclohexanoyl Lys Arg Arg CHO 4.52 ± 0.26 31 
3.50 Furoyl Lys Arg Arg CHO 4.04 ± 0.86 92 
3.51 2-naphthoyl Lys Arg Arg CHO 4.60 ± 0.24 25 
3.52 4-phenoxybenzoyl Lys Arg Arg CHO <4 >100 
Inhibitors were pre-incubated with DENV NS2B/NS3pro for 15 min. Assay conditions were [E] DENV2 
NS2B/NS3pro, 50 nM; [S] Ac-LKRR-pNa, 500 µM, 50 M HEPES buffer, 37 ˚C, pH 9.5, with 10 mM NaCl and 30% 
glycerol. The above values were calculated from at least three independent experiments (n ≥ 3) with statistical 
significance of p ≤ 0.05. 
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Thus far, it seemed that aliphatic, heterocyclic and aromatic capping groups were equally 
tolerated in the S4 pocket, and there was no clear SAR noted for these substitutions. Additionally, it 
was also noted that substitutions at P4 were relatively well tolerated in comparison with 
replacements at P3, P2 and P1. These two observations suggested that P4 may played only a 
diminutive role in inhibitor potency.  
 
3.4.2.5 Truncated peptidomimetics 
Recently, Kang et al. reported a truncated peptide aldehyde26, Ac-KR-CHO (IC50 = 170 nM), 
which was found to retain good potency against WNV protease. The effect of truncation of the N-
terminal residues of DENV peptide inhibitors was therefore investigated (Table 3.12). 
Unfortunately, the truncated dipeptide (3.53, 3.54) were found to inactive against DENV2 protease. 
In contrast to WNV protease, it seemed that having the P3 and P4 (to a lesser extent) residues were 
critical to maintain inhibitor binding and potency for DENV protease.  
 
Table 3.12 Inhibition of DENV NS2B/NS3pro by truncated analogues of 3.18.  
ID Compound pIC50 ± SEM IC50 (µM) 
P4-Cap P3 P2 P1 P1’ 
3.53  Ac Arg Arg CHO < 4 >100 
3.54  Cbz Arg Arg CHO < 4 >100 
Inhibitors were pre-incubated with DENV NS2B/NS3pro for 15 min. Assay conditions were [E] DENV2 
NS2B/NS3pro, 50 nM; [S] Ac-LKRR-pNa, 500 µM, 50 M HEPES buffer, 37 ˚C, pH 9.5, with 10 mM NaCl and 30% 
glycerol. The above values were calculated from at least three independent experiments (n ≥ 3) with statistical 
significance of p ≤ 0.05. 
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3.4.3 WNV NS3/NS2B protease 
Using the same strategy employed for the peptidomimetic inhibitors for DENV 
NS2B/NS3pro, a small subset of peptidomimetic inhibitors was generated for WNV protease (Table 
3.13). The WNV parent substrate-based inhibitor was a highly potent tripeptide, PhAc-KKR-CHO 
(Ki = 9 nM, IC50 = 51 nM).3  It was worth noting that the parent DENV inhibitor, Phac-KRR-CHO, 
was in fact more potent against WNV protease (IC50 = 366 nM) than DENV protease (IC50 = 10 
µM).  
 
Table 3.13 Peptidomimetic inhibitors of WNV NS2B/NS3pro 
ID Compound pIC50 ± SEM IC50  (µM) 
P4-Cap P3 P2 P1 P1’ 
3.18 PhAc Lys Arg Arg CHO 6.44 ± 0.20 0.366 
3.55 PhAc Lys Lys Arg CHO 7.29 ± 0.13 0.051 
3.56 PhAc Lys Lys 4-GNF CHO <4 > 100 
3.57 PhAc Lys Lys cPhe CHO ND 70%*  
3.30 PhAc Lys 4-AMF Arg CHO 5.24  ± 0.14 5.7 
3.29 PhAc Lys 3-AMF Arg CHO ND 75%*  
3.32 PhAc Lys aPhe Arg CHO <4 > 100  
3.33 PhAc Lys 4-PyA Arg CHO 4.31 ± 0.33 49 µM 
3.34 PhAc Lys 3-PyA Arg CHO <4 > 100  
3.58 PhAc 4-AMF Lys Arg CHO ND 81%*  
3.59 PhAc 3-AMF Lys Arg CHO 5.83 ± 0.11 1.5 
3.60  Ac 3-AMF R CHO 5.15 ± 0.12   7.2 
*Percentage of inhibition at 100 µM. ND = not determined. Inhibitors were pre-incubated with WNV NS2B/NS3pro for 
15 min. Assay conditions were [E] WNV NS2B/NS3pro, 25 nM; [S] Ac-LKKR-pNa, 500 µM, 50 M HEPES buffer, 37 
˚C, pH 9.5, with 10 mM NaCl and 20% glycerol. The above values were calculated from at least three independent 
experiments (n ≥ 3) with statistical significance of p ≤ 0.05. 
 
 
3.4.3.1 Substitutions at P1 
Introduction of aromatic P1 mimetics (3.56, 3.57) led to significant decrease in inhibitor 
potency, reverting the potency of the peptidomimetics to micromolar concentrations. Similar to 
DENV protease, the non-basic 3,4-dichlorophenylalanine (3.57) was more favoured than the basic 
counterpart (3.56, 4-guanidinophenylalanine). This reaffirmed the strategy of exploiting Tyr161 for 
alternative binding interactions with the S1 pocket in lieu of the conventional ionic interaction with 
Asp129. However, the drastic reduction of potency drew caution to the introduction of an aromatic 
moiety, as it was thought that an aromatic moiety may not be tolerated in the S1 pocket. 
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3.4.3.2 Substitutions at P2 
In the WNV protease crystal structure (PDB:3E90), the P2-lysine was found to be fully 
extended with the terminal nitrogen forming an ionic interaction with Asp75 and a hydrogen bond 
with Asn84 in the S2 pocket (Figure 3.22A). Having a P2-Arg was unfavourable for WNV 
protease, where it was observed in the crystal structure (Figure 3.22B) that the arginine side chain 
failed to form strong ionic interactions with Asn84 and Asp75, and instead formed a weak hydrogen 
bond with the carbonyl backbone of Gly83. A series of lysine mimetics with constraints (3.29, 3.30) 
and reduced basicity (3.32-3.34) were introduced to examine the effect of rigidification and 
elimination of charge on the binding and occupation of the S2 pocket. Overall, this series of 
mimetics suffered significant loss of potency, producing inferior peptidomimetics with IC50 in the 
micromolar concentration range. 
 
 (A) (B)  
   
 
Figure 3.22: Interactions of basic P2 residues with S2 residues in WNV 
NS2B/NS3 protease. (A) Interaction of P2-Lys with WNV protease 
(PDB:3E90). (B) Interaction of P2-Arg with WNV protease (PDB:2FP7). 
 
The basic constrained mimetics (3.29, 3.30) were the strongest performers of this series, 
where 4-aminomethyphenylalanine (3.30, IC50 = 5.7 µM) was more favourable as compared to 3-
aminomethylphenylalanine (3.29, 75% inhibition at 100 µM).  The less basic mimetics (3.32-3.34) 
on the other hand were less favoured at this position with IC50 greater than ≥ 49 µM. 4-
aminophenylalanine (3.32) and the pyridylalanine analogues (3.33-3.34) contained a weakly basic 
nitrogen. The amino group of 3.32 could act as both hydrogen bond donor and acceptor. On the 
other hand, the pyridylalanines (3.33,3.34) retained hydrogen bond accepting properties. Therefore, 
these mimetics maintained the ability to form hydrogen bonds with the side chains of Asn84 and 
Asp75, and the amide backbone of Gly83 (as observed in the P3-Lys).   
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Figure 3.23: Structural mimics of lysine. The number of carbon 
atoms between the α-carbon and the “nitrogenous base” was 
highlighted. 
 
4-pyridylalanine (3.33) was found to be more potent (IC50 = 49 µM) as compared to 4-
aminophenylanine (3.32) and 3-pyridylalanine (3.34). It was thought that 4-pyridylalanine was a 
better structural mimic of lysine (Figure 3.23), since it has the correct number of carbon atoms to 
mimic the lysine aliphatic chain atoms, contributing to better binding with the S2 pocket. Previous 
studies by Chappell et al. suggested that complete elimination of charged group in aliphatic 
mimetics led to 100-fold decrease in potency, while longer aliphatic mimetics were well-tolerated 
in the S2 pocket.13 This suggested that the reduced basicity was likely the key factor that marked the 
downfall of these less basic peptidomimetics, as they failed to maintain a strong ionic interaction 
with Asp75.  This again demonstrated that retention of the basic charge at P2 was essential for 
potency and binding, with weaker hydrogen bonding interactions proving to be insufficient to 
engage with the S2 pocket. 
 
3.4.3.3 Substitutions at P3 
The native P3-Lys was observed to be fully extended in the inhibitor-bound crystal 
structure, and was found to engage in hydrogen-bonding interactions with Asn84. Rigidification of 
the side chain was introduced on the basis that this constraint can pre-organise the basic side chain 
to minimise the entropy penalty of binding to the protease. The native lysine was replaced by two 
basic aromatic mimetics (3.58, 3.59). 3-aminomethylphenylalanine (3.59, IC50 = 1.5 µM) was found 
to be the most potent of the series designed for WNV protease, while 4-aminomethylphenylalanine 
(3.58, 81% inhibition at 100 µM) was much less favoured.  Despite retaining a basic moiety, these 
aromatic mimetics failed to maintain the potency of the parent tripeptide inhibitor (PhAc-KKR-
CHO, IC50 = 51 nM). This suggested that the significant potency loss may be due to the presence of 
the aromatic moiety, and it was speculated that the constraint introduced may have a negative steric 
effect in the S3 pocket. In comparison, the P3 replacement with aliphatic mimetic (charged and 
non-charged) reported by Chappell et al. all displayed comparable activities to the parent peptide3. 
This suggested that flexibility of the side chain at the P3 position may be crucial for effective 
binding with the S3 pocket.  
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3.4.3.4 Truncated peptidomimetic 
Kang and co-workers very recently reported a highly potent dipeptide WNV inhibitor Ac-
KR-CHO (IC50 = 170 nM) which was only 3-fold less potent that the parent tetrapeptide (Phac-
KRR-CHO, IC50 = 51 nM).26 Based on this result, Ac-4AMF-R-CHO incorporating a P2-4AMF (the 
best performer of the P2 substitution series) was synthesized. The dipeptidomimetic (3.60, IC50 = 
7.2 µM) was found to be equipotent to its tripeptide counterpart (PhAc-K-4AMF-R-CHO, IC50 = 
5.5 µM).  In agreement with Kang et al., it seemed that the P3 and P4 residues were dispensable 
and could be omitted without compromising the inhibitor activity of the full-length peptide 
inhibitor. Although the dipeptidomimetic (IC50 = 7.2 µM, ClogP = -2.99) was 30-fold less potent 
than Ac-KR-CHO (IC50 = 170 nM, CLogP = -3.66), it has a slightly improved ClogP value, which 
may promote higher cell permeability. Future modifications may allow transition from the 
peptidomimetic to non-peptidic inhibitors with improved potency and pharmacokinetic profiles. 
 
 
3.5 SUMMARY: DENV vs WNV 
A series of peptidomimetic inhibitors was generated for DENV2 NS2B/NS3pro and WNV 
NS2B/Ns3pro in this chapter. In general, substitutions of native residues at P1, P2, and P3 of the 
parent tripeptide inhibitors with less basic mimetics led to considerable reduction in potency at P1, 
and to a lesser extent at P2 and P3 positions. This was not surprising, as it was well established that 
the preservation of the basic P1 arginine was essential for ligand recognition in trypsin-like serine 
proteases.10 Constrained aromatic mimetics in general were not well tolerated at P1, P2 or P3. As 
the surface of the flaviviral proteases was quite shallow and polar, it was thought that having bulky 
hydrophobic moieties may not be sterically beneficial for inhibitor binding.  
Subsite optimization for DENV and WNV protease inhibitors proved to be challenging, with 
systematic substitution at subsites failing to produce inhibitors with significant improvement in 
potency. This again highlighted the challenge in protease inhibitor development where the 
malleability of proteases can render predictions for “locking” the enzyme into a particular 
configuration with an inhibitor a difficult task. This was especially difficult for DENV, where it 
comprised two components (NS2B cofactor and NS3pro enzyme domain) and the mobility of the 
cofactor may have increased the difficulties in targeting the structurally unstable protease. To 
overcome this challenge, manipulation of entropy and enthalpy should be considered in future 
inhibitor studies. Such a strategy has been employed by Ernesto Freire, from which their campaign 
produced highly potent and selective HIV protease inhibitors through manipulation of binding and 
solvation entropies. However, being highly polar and flexible, the basic linear anti-flaviviral 
peptides inhibitors in the present work are likely to be highly solvated by water and with 
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unfavourable binding entropy, leading to weak binding affinity and potency. Measurements of on- 
and off-rates using isothermal titration calorimetry can afford a direct assessment of the entropy 
versus enthalpy properties of inhibitors. Using these parameters as a guide, the linear peptide 
inhibitor could potentially be pre-shaped into the preferred binding conformation and 
hydrophobicity can be introduced to lower solvation entropy. Ultimately, this can potentially 
improve the binding affinity and potency of peptide inhibitors. Due to insufficient cofactor-enzyme 
construct available, such highly protein-consuming studies were not pursued herein. 
 In general, it was observed that the peptidomimetics performed much better against WNV 
protease than DENV2 protease. In previous reports, the DENV protease inhibitors were found to be 
110-fold less potent than their WNV protease counterparts.2, 22 The two-component WNV protease 
and DENV protease (linked to NS2B cofactors) were structurally similar, however their in vitro 
catalytic profiles were quite different.27 DENV protease was 2-50 times less catalytically active than 
WNV protease,2, 24, 28 and WNV proteases was more responsive to small molecules inhibitors.2 It 
was known that the NS2B remained bound to the NS3pro predominantly in WNV protease, while a 
large fraction of the DENV protease was in a catalytically incompetent open state.29, 30 As 
previously discussed, the crystal structure of free DENV protease showed that the NS2B cofactor 
was detached from the NS3 domain, while the inhibitor-protease complex adopted a “closed” 
conformation. This suggested that the active form was “induced” and stabilized through inhibitor 
binding. This led to speculation that the binding affinities of these peptidomimetic aldehydes were 
significantly lower for DENV protease. As the DENV protease was more prone to form the inactive 
“open” form, these peptide inhibitors must first stabilize the “closed” conformation to form the S2 
and S3 binding pockets in order to bind to the active site subsequently at the expense of increasing 
their entropic penalty. However, there was no concrete evidence to prove that the predominance of 
the open form in DENV was also prevalent inside of cells, therefore these compounds may perform 
differently in a cell based inhibition assay which will be investigated further in future studies. 
 The factors that contribute to the observations that similar inhibitors bind to WNV protease 
more tightly than DENV protease remain elusive. To address this issue, Doan and co-workers 
recently reported a study to identify key contributors to specificity differences between DENV2 and 
WNV protease in 2013 (after the completion of this project).31 In that study, a network of important 
residues for binding in the catalytically superior WNV protease was identified and “transplanted” 
onto the active site of DENV protease through systematic site-directed mutagenesis. It was 
hypothesized that the selected mutagenesis would allow DENV protease to gain the catalytic ability 
of WNV protease, increasing the enzyme efficiency, which in turn would increase the binding 
affinity and potency of substrates/inhibitors.  Two set of residues were selected: (1) residues with at 
least one atom within 4 Å of the bound inhibitor (2-Naphthoyl-KKR-CHO), and (2) residues 
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involved in orienting residues of the first set despite not being in direct contact with the inhibitor. 
The mutant DENV proteases displayed slight increases in enzyme efficiency, however they failed 
to improve inhibitor binding.  Puzzled by the findings, they re-examined the crystal structure of 
aprotinin, a highly potent DENV inhibitor, bound to the protease (Figure 3.24, PDB: 3U1J). The 
solved crystal structure contained only a portion of the hydrophilic NS2B cofactor region (residues 
50-69) and was missing the C-terminal residues (residue 70-95), therefore a model of the C-
terminal region was incorporated to allow better understanding of the inhibitor binding.  
 
(A) Aprotinin (B) PhAc-Arg-Arg-Arg-CHO 
  
Figure 3.24: Comparison of interactions between the P3 residues (orange) and the modeled C-
terminal region of NS2B cofactor (cyan). (A) Aprotinin bound to DENV2 protease (B) PhAc-Arg-
Arg-Arg-CHO bound to DENV2 protease. The C-terminal region is highlighted in cyan, and the 
glutamates are shown as sticks. The inhibitor residues are shown in orange. Pictures taken and 
edited from Doan et al. 
 
Indeed, the P3 residue of aprotinin (Arg39) was found to form ionic interactions with E89 
and E91 of the S3 pocket (Figure 3.21A), where it was positioned in such a way that all of its 
guanidinium nitrogen atoms could interact with the acidic S3 pocket (C-terminal region of NS2B). 
Interestingly, this C-terminal region of WNV (M88NDPGAPW95) was different from that of DENV 
(K87NEEEEQT94), where it did not have four consecutive glutamates at this position. This may 
explain why aprotinin bound to DENV much more strongly as compared to WNV due to this 
addition interaction with the DENV NS2B C-terminus. Overall, this suggested that the C-terminus 
of the NS2B was the key determinant for inhibitor binding, with successful targeting of this region 
potentially providing tight-binding and potent inhibitors of DENV protease. 
This interaction however was not observed for the peptide inhibitor (PhAc-KRR-CHO) 
where the lysine formed a weak hydrogen bonding interaction with Met84. Replacing the lysine 
with an arginine (PhAc-RRR-CHO) to mimic the mode of binding of P3-Arg39 of aprotinin in this 
position did not improve binding affinity towards DENV protease (Figure 3.24B), as the terminal 
nitrogen atoms were not positioned correctly to achieve similar interactions to aprotinin in the 
model. 
E89
E91
S85
S79
S83
Figure 3.21: (A) Aprotinin bound to DENV2 protease (B) PhAc-Arg-Arg-Arg-CHO 
bound to DENV2 protease. The C-terminal region is highlighted in cyan, and the 
glutamates are shown as sticks. The inhibitor residues ar  sho n in orange. Pictures 
extracted from Doan et al. 
Arg39
E89
E91
S79
S63S85
P2-ArgP3-Arg
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Figure 3.14: C-terminal region of flaviviral proteases31 
Flaviviral Protease NS2B C-terminal region  
(residues 87-95) 
Dengue Virus Type 1 K87DEERDDT94 
Dengue Virus Type 2 K87NEEEEQT94 
Dengue Virus Type 3 K87DDETENI94 
Dengue Virus Type 4 R87DVEETNM94 
Murray Valley Encephalitis Virus L88NDPGVPW95 
Japanese Encaphalitis Virus L88DDPGVPW95 
West Nile Virus M88NDPGAPW95 
Yellow Fever Virus L87SEEKVPW94 
 
Essentially, this indicated that the peptidic backbone of the tetrapeptide aldehyde inhibitor 
failed to provide the optimal distribution of side chains to promote interactions with the protease in 
a manner similar to aprotinin, in particular with the NS2B C-terminal region (S3 binding pocket). It 
was important to note that aprotinin, due to its macromolecular nature, was also likely to exert 
inhibitory activity through interactions outside the active site, therefore these predictions must be 
approached with caution. 
Xu et al. previously reported a cyclotide inhibitor (CGKRKLC, Ki = 1.4 µM) with a 
disulfide linkage formed between terminal cysteines, and a non-optimal tribasic P3-P1 motif 
(KRK) potentially recognized by DENV protease.32 While this cyclic inhibitor was only moderately 
potent, it was thought that perhaps introduction of an arginine at the P3 position may allow 
achievement of the aprotinin-like interaction with the glutamate-rich C-terminal region due to their 
altered backbone conformation.  
Throughout this chapter, the crystal structure of the active DENV protease  (PDB: 3U1I) 
was used as the template but this did not contain the acidic C-terminal region. Due to the absence of 
this negatively charged region, it was originally predicted that a charged group (e.g Lys) was not 
essential at the P3 position. A series of lysine mimetic with reduced basicity was therefore 
introduced with a substantial reduction of inhibitory potency being observed. The most potent 
inhibitor of the series was PhAc-nitroArg-Arg-Arg-CHO (IC50 = 30 µM). This was somewhat 
consistent with the Doan et al., where arginine (or derivatives) was favourable at P3 position, 
although it was highly likely that the P3-nitroarginine residue was not fully engaged in interactions 
with the acidic C-terminal region based on the prediction31 by Doan et al. Nevertheless, it is 
possible that introduction of an arginine mimetic at this position could gain further interactions with 
the glutamate residues at this region of the DENV protease. A constraint could also potentially be 
introduced to mimic to binding pose of Arg39 of aprotinin, and this could potentially lead to more 
potent DENV protease inhibitors in future. 
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In summary, it was successfully demonstrated that peptidomimetics were useful tools to 
study inhibitor-binding requirements for flaviviral proteases. The non-basic mimetic (3,4-
dichlorophenylalanine) was successfully introduced to form a pi-stacking interaction with Tyr161 at 
P1 position, and alternative binding with the S1 pocket is therefore likely to be possible.  The need 
for a longer arginine mimetic was also identified at the P2 position, with the introduction of a 
homoarginine leading to a slight improvement in inhibitor potency. The study of the P3 position has 
afforded perhaps the most valuable lesson in this chapter for future inhibitor design.  The native P3-
lysine was likely to be non-optimal as it failed to interact with the NS2B cofactor C-terminal region, 
and this study has shown that charged and non-charged lysine mimetics did not improve the 
inhibitor potency.  Fundamentally, the linear peptide aldehydes did not have the right backbone 
conformation to allow targeting of the C-terminal co-factor region of the protease. In light of the 
revelations from the study by Doan and co-workers, future inhibitor design might involve 
introduction of a suitable arginine analogue, coupled with manipulation of the peptide backbone of 
the peptide aldehyde inhibitor to afford optimal binding conformation of the P3 residue to form 
strong electrostatic networks with the NS2B glutamates residues. Some of the biggest issues in the 
development of covalent-binding peptide inhibitors revolve around their lack of in vivo activity due 
to poor oral bioavailability, rapid chemical degradation and a high risk of off-site activity due to the 
presence of a highly reactive electrophilic isostere leading to undesirable side effects (as seen in 
Bortezomib, a covalent proteasome inhibitor). In a later stage (not within the scope of this thesis), in 
vivo characterization employing a viral plaque inhibition assay, serum stability, and toxicity 
(cytochrome P450 inhibition assay) studies of these peptide inhibitors will be carried out. 
 
 
3.6 EXPERIMENTAL SECTION 
 
3.6.1 General procedures 
Protected amino acids and resins (Rink-amide, 2-chlorotrityl and AM resin) were purchased from 
Auspep, Iris Biotech, PepChem, Chem-Impex Ltd and Novabiochem. Other reagents including 
TFA, piperidine, DIPEA, and DMF were obtained from AUSPEP. All the reagents used were 
reagent grade unless stated otherwise. Anhydrous DCM was obtained from an in-house anhydrous 
solvent dispenser. Crude peptides were purified using Shimadzu LC-20AP reversed-phase high 
performance preparative liquid chromatography on a Phenomenex Luna C18 semi-preparative 
column (100 Å, 250 x 10 mm, 5 micron), using a gradient of solvent A (0.1% TFA/water) and 
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solvent B (0.1% TFA/ 10% water/ 90% acetonitrile). Final purified peptides were characterized 
using analytic HPLC, high-resolution mass spectrometry (HRMS) and NMR experiments. 
Analytical HPLC was performed using Shimadzu LCMS-2020 (SIL-30AC autosampler, BM-20A 
controller, and a SPD-M20A diode array detector) using a reversed-phase C18 Agilent column (2.1 
x 75 mm, 5 micron). Equilibration was ran for 1 minutes (100% solvent A) at 0.4 mL/min, followed 
by a linear gradient (0-100% solvent B) over 6 minutes, and lastly washed with 100% solvent B. 
Electrospray ionisation high-resolution mass spectra (ESI-HRMS) measurements were obtained on 
a Bruker microTOF mass spectrometer equipped with an Agilent 1100 Series LC/MSD mass 
detector in positive ion mode by direct infusion in MeCN at 100 µL/h using sodium formate 
clusters as an internal calibrant.  NMR was recorded on a Bruker Avance 600 spectrometer at 298 K 
unless stated otherwise, and spectra were processed using TOPSPIN software (Bruker, Germany). 
 
3.6.2 Molecular modeling studies 
Crystal structures of inhibitor-bound DENV (PDB: 3U1I) and WNV (PDB: 3E90) proteases 
were retrieved from the Protein DataBank (RCSB.org) and used as templates for modeling studies. 
The proteins were prepared using Hermes (GoldSuite5.1) where water molecules were deleted and 
the energy of the protein was re-minimized. The three-dimensional structures of amino acid 
mimetics were generated using OMEGA2 (OpenEye Suite), and superimpositions of these mimetics 
with the native basic residues (P1-Arg, P2-Arg/Lys, P3-Lys) were achieved using ROCS (OpenEye 
Suite). Docking studies were performed using GOLD (GoldSuite 5.1). The models were examined 
through visual inspection using MacPymol (X11, Schrödinger, LCC).  
 
3.6.3 NMR spectroscopy and concentration determination 
NMR characterization. The highly lipophilic peptides tend to form sticky oil, and this renders the 
weighing of the peptide difficult for sample preparation. The peptide solutions were prepared in 600 
µL of D2O/H2O (1:9). The proton NMR was recorded on a Bruker Avance 600 spectrometer at 298 
K unless stated otherwise, and the proton chemical shifts were referenced to DSS (δ 0.00 ppm) in 
water. Suppression of water resonance under low power irradiation during relaxation delay (1.5-3.0 
s) were achieved through WATERGATE NMR experiments. All spectra were processed using the 
TOPSPIN software (Bruker, Germany). Peptide concentration determination. The concentration 
of peptides was determined for further assay purposes using PULCON experiments ran using DRX-
600 Mhz spectrometer. The 90˚ pulse of NMR samples was measured carefully by alternating the 
360˚ pulse. This resulted in a null water signal in standard 1D proton experiments. For each peptide, 
the 90˚ was remeasured with the following default settings: relaxation delay of 30s, receiver gain 
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64-512, 32-64 scans at 298 K. A Watergate pulse sequence was employed to suppress the water 
peak. Spectras were processed using TOPSPIN, where manual correction of phase and integration 
of individual signals were carried out for concentration calculations.  
 
3.6.4 Analysis of data 
All data were processed using Graphpad Prism v6 (Graphpad Software Inc. CA) to generate 
concentration-response curves and statistical analysis. Data were represented by at least three 
experiments (n ≥ 3) unless otherwise stated, and were expressed as the mean of all experiments ± 
SEM. The log concentrations were expressed with 95% confidence intervals (p ≤ 0.05)  
 
3.6.5 Protease inhibition assays 
DENV2	   protease	   assay.	  The inhibitor (5 µL, 100 µM – 10 nM) was mixed with the DENV2 
enzyme (5 µL) in Tris-NaOH buffer containing 50 mM Tris, 1 mM CHAPS and 30% glycerol in a 
384-well plate. The reaction mixture was pre-incubated for 15 minutes at 37 ˚C at pH 9.5. The 
chromogenic substrate, Ac-LKRR-pNA (500 µM), was	   added	   to	   initiate	   the	   reaction	   giving	   a	  final	   volume	   of	   50	   µL.	   	   The	   reaction	   progress	   was	   measured	   by	   the	   release	   of	   the	   para-­‐nitroaniline,	  which	  was	  quantitated	  by	  absorbance	  at	  λ	  =	  405	  nm	  using	  a	  PHERAstar	  Optima	  spectrometer	  (BMG	  Labtech).	  
Table 3.15: Assay protocol for DENV2 protease inhibitors 
Component Volume (µL) 
+ve control -ve control Sample 
Buffer (2X) 25 25 25 
Water 12.5 17.5 10 
Enzyme (500 nM) 5 5 5 
Chaps (20 mM) 2.5 2.5 2.5 
Inhibitor (10x, in DMSO) 0 0 5 
DMSO 2.5 2.5 0 
Substrate (2.5 mM) 2.5 2.5 2.5 
Total volume (µL) 50 50 50 	  	  
WNV	  protease	  assay.	  The inhibitor (5 µL, 100 µM – 10 nM) was mixed with the WNV enzyme 
(2.5 µL) in Tris-NaOH buffer containing 50 mM Tris, 1 mM CHAPS and 20% glycerol in a 384-
well plate. The reaction mixture was pre-incubated for 15 minutes at 37 ˚C at pH 9.5. The 
chromogenic substrate, Ac-LKKR-pNA (500 µM), was	   added	   to	   initiate	   the	   reaction	   giving	   a	  final	   volume	   of	   50	   µL.	   	   The	   reaction	   progress	   was	   measured	   by	   the	   release	   of	   the	   para-­‐nitroaniline,	  which	  was	  quantitated	  by	  absorbance	  at	  λ	  =	  405	  nm	  using	  a	  PHERAstar	  Optima	  spectrometer	  (BMG	  Labtech).	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Table 3.16: Assay protocol for WNV protease inhibitors 
Component Volume (µL) 
+ve control -ve control Sample 
Buffer (2X) 25 25 25 
Water 15 20 12.5 
Enzyme (500 nM) 2.5 2.5 2.5 
Chaps (20 mM) 2.5 2.5 2.5 
Inhibitor (10x, in DMSO) 0 0 5 
DMSO 2.5 2.5 0 
Substrate (2.5 mM) 2.5 2.5 2.5 
Total volume (µL) 50 50 50 
 
3.6.6 Synthesis of chromogenic substrate 
The commercially available 2-chlorotrityl resin (0.76 mmol/g)  was added to anhydrous DCM. 1,4-
phenylenediamine (4 eq) and DIPEA (8 eq) were added to resin and the mixture was stirred under 
nitrogen atmosphere at room temperature for 24 h. The resin was washed with DMF, and the 
unreacted sites were capped by shaking the resin with DCM/MeOH (9:1, 10 mL) for 30 min. The 
resin was then washed with methanol, followed by DCM.  Desired amino acid was coupled onto the 
derivatised resin by shaking the resin with a solution of Fmoc amino acid (4 eq), DIPEA (8 eq) and 
HBTU (4 eq) in DMF for 15 min.  The completion of the coupling was monitored using ninhydrin 
test. Removal of fmoc protecting group was achieved using Piperidine/DMF (1:1) (2 x 5 min). The 
peptide was cleaved from the resin using TFA:water:TIPS (95:2.5:2.5), to which the protecting 
groups were removed at the same time. The para-aminoanilide crude peptide was oxidized to para-
nitroanilide by dissolving the peptide in water/acetonitrile (1:1) and Oxone® (6 eq.), and the mixture 
was stirred overnight. The mixture was purified using rp-HPLC C18 column, with an initial wash 
with 2 void volume of solvent A to desalt the compound, following by a linear gradient (0-100% 
solvent B) to afford the pure chromogenic substrate.  
 
3.6.7 Synthesis of building blocks 
SYNTHESIS OF FMOC-NORCITRULLINE-COOH 
Fmoc-Dab-COOH. Fmoc-Dab(Boc)-COOH (2 g, 4.5 mmol) was dissolved in 10 mL of 
TFA:DCM (1:1) and the mixture was stirred for 2 h. The solvent was removed in vacuo and the 
resulting oil was purified using rp-HPLC to yield the pure product as white solid. (1.3 g, 85%) 1H 
NMR (DMSO-D6) δ = 1.01-1.02 (d, J = 6 Hz, 1H), 1.62-1.73 (m, 1H), 1.80-1.90 (m, 1H), 2.90-
3.04 (m, 3H), 3.93 (br, 1H), 4.14 -4.31 (m, 4H), 6.81 (br, 1H), 7.28-7.36 (m, 2H), 7.38-7.41 (t, J  = 
7.38 Hz, 2H), 7.32 (br, 1H), 7.69-7.74 (m, 2H), 7.85-7.89 (d, J  = 7.32 Hz, 2H). 
 Fmoc-norCitrulline-COOH. Fmoc-Dab-COOH (0.2 g, 0.58 mmol) was dissolved in 5 mL 
of water in a 10 mL reaction vial, to which sodium cyanate (40 mg, 0.60 mmol) was added. The 
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mixture was heated at 80 ˚C under irradiation in microwave for 1 h. The reaction vessel was rapidly 
chilled by passing compressed air through the microwave cavity, and the mixture was acidified to 
pH 2 with 2N HCl. The precipitate was collected through filtration, washed with cold water and 
dried under vacuum the yield the product as white solid. (0.14 g, 64 %) 1H NMR (DMSO-D6) δ = 
1.59-1.67 (m, 1H), 1.73-1.82 (m, 1H), 2.88-3.15 (m, 3H), 4.17-4.29 (m, 4H), 5.43 (br, 1H), 5.96 
(br, 1H), 7.29-7.31 (m, 2H), 7.38 -7.40 (m, 2H), 7.67-7.72 (m, 2H), 7.82-7.84 (m, 2H). 
 
SYNTHESIS OF FMOC-HOMOHOMOSERINE-COOH 
Boc-homohomoserine-OH. Boc-Lys(Cbz)-COOH (2 g, 5.3 mmol) was dissolved in 10 mL 
of MeOH. 0.1 mL of AcOH and 20 mg of palladium on activated charcoal was added. The mixture 
was hydrogenated using Parr hydrogenator at 30 p.s.i for 3 h to yield Boc-Lys-COOH (0.97 g, 75%) 
as a thick oil. The crude oil was used without purification in the next step. Boc-Lys-COOH (0.97 g, 
3.9 mmol) was dissolved in 15 mL of distilled water and 5 mL of 2N NaOH. The pH was 
maintained at 9.0. Sodium nitroprusside (2.3 g, 7.9 mmol) was added and the reaction mixture was 
stirred for 24 h. The pH of the mixture was adjusted to 2.0, 200 mL of ethyl acetate was added. The 
layers were partitioned and aqueous layer was extracted with ethyl acetate (3 x 150 mL). The 
organic layers were combined, washed with 2N HCl (2 x 100 mL), water (2 x 100 mL) and brine (2 
x 100 mL). The organic layer was collected, dried with magnesium sulfate, filtered and 
concentrated in vacuo to yield the product as a thick oil. The crude was purified using column 
chromatography (0-60% ethyl acetate in petroleum spirit) to give the pure product as white solid. 
(0.34 g, 35%) 1H NMR (CDCl3) δ =1.24-1.27 (t, J  = 7.14 Hz, 2H), 1.45 (s, 9H), 1.46-1.76 (m, 4H), 
3.64-368 (t, J  = 6.24 Hz, 2H), 4.10-4.14 (q, J  = 7.14 Hz, 1H). 
 Fmoc-homohomoser-COOH. Boc-homohomoserine-COOH (0.34 g, 1.4 mmol) was 
dissolved in TFA:DCM (1:1) and the mixture was stirred for 3 h. The solvent was removed in 
vacuo to yield a viscous oil. The crude oil was used in the next reaction without further purification. 
The oil was dissolved in 30 mL of water:THF (1:1) and 5 mL of saturated sodium bicarbonate 
solution, and the pH was maintained at 9.5. The mixture was chilled to 0 ˚C, and Fmoc-Osu (1 g, 3 
mmol) was added portionwise. The mixture was stirred vigorously overnight. Ethyl acetate was 
added to the mixture. The aqueous layer and the organic layer partitioned, and the water layer was 
extracted with ethyl acetate (2 x 200 mL). The organic layers were combined, washed with 1N HCl 
solution (2 x 100 mL), water (2 x 100 mL) and brine (2 x 100 mL). The organic layer was then 
dried using magnesium sulfate, filtered and concentrated in vacuo to give the product as a white 
solid (0.21 g, 40%). 1H NMR (CDCl3) δ = 1.22-1.85 (m, 6H), 3.63-3.66 (t, J  = 6.24 Hz, 2H), 4.09-
4.13 (q, J  = 7.14 Hz, 1H), 4.20-4.34 (m, 2H), 7.28-7.90 (m, 9H). 
 
	   156	  
 
SYNTHESIS OF FMOC-L-PHE(BOC-4-AMINOMETHYL)-COOH 
N-acetyl-α-carbothoxy-4-cyano-D,L-phenylalanine ethyl ester. Sodium metal (1.0 g, 45 
mmol) was added portionwise carefully into an anhydrous solution of ethanol (100 mL) in  a three-
necked flask under nitrogen atmosphere in room temperature. Once the sodium metal was fully-
dissolved, the mixture was stirred for 0.5 h to allow the complete formation of sodium ethoxide. 
The solution was cooled to 0˚C, to which diethyl acetamidomalonate (9.5 g, 45 mmol) was added 
portionwise. The resulting slurry was stirred vigorously for 1h, and 4-cyanobenzyl bromide (8.8 g , 
45 mmol) was added. The mixture was heated to a gentle relux for 5 h. Upon completion of the 
reaction, water (200 mL) was added carefully to quench the reaction. The water layer was extracted 
with ethyl acetate, and the organic phase was washed with saturated sodium bicarbonate solution (2 
x 100 mL),  1N HCl (2 x 100 mL), and brine (2 x 100 mL).  The organic layer was dried with 
magnesium sulfate, filtered and the solvent was removed using rotary evaporator to yield the crude 
product as white solid. (9.8 g,  65%) 1H NMR (CDCl3) δ = 1.31 (t, J = 7.0 Hz, 6H), 2.04 (3H, s), 
4.27 (q, J  = 7.1 Hz, 4H), 6.54 (s, 1H), 7.13 (d, J  = 8.2 Hz, 2H), 7.56 (d, J  = 8.0 Hz, 2H).  
 Ac-D,L-Phe(4-CN)-COOH. Sodium hydroxide (1.46 g, 36.4 mmol) was dissolved in 50 
mL of absolute ethanol. To this solution, N-acetyl-α-carbothoxy-4-cyano-D,L-phenylalanine ethyl 
ester (6.0g, 18 mmol)  was added and the mixture was brought to a reflux for 18 h with vigorous 
stirring. The mixture was cooled in an ice bath, and 6N HCl  (10 mL) was slowly added to allow the 
product to form precipitate. The precipitate was broken up, and concentrated HCl was added slowly 
until pH 2 was reached. DCM was added to extract the acidic aqueous solution. The organic layer 
was washed with water (2 x 100 mL), followed by brine (2 x 100 mL). Magnesium sulfate was 
added and the organic layer was filtered and evaporated to give the racemic products as beige solid. 
(2.1 g, 49%) 1H NMR (CDCl3) δ 1.91 (s, 3H), 3.11 (d, J = 9 Hz, 15Hz, 1H), 3.32 (q, J = 5.5 Hz, 
15Hz, 1H), 4.80 (m, 1H), 7.42 (d, J = 8 Hz, 1H), 7.51 (d, J = 8 Hz, 2H), 7.73 (d, J = 8 Hz, 2H). 
 L-Phe(4-CN)-COOH. Ac-D,L-Phe(4-CN)-COOH (2 g, 8.5 mmol) was suspended in 
distilled water 10 mL, to which 2N KOH was added to achieve a final pH of 7.5-8.0. The solution 
was further diluted to 50 mL and aspergillus acylase (Sigma, 0.47 units/mg, 5mg) and CoCL2 (10 
mg) were added to the solution. The mixture was stirred in a heated water bath at 40 ˚C and the 
deacetylation of the L-isomer was monitored using analytic-HPLC. After 17 h, the deacetylation of 
the L-isomer reached 95% and the reaction was quenched by acidify the solution to pH 5. Norite 
(20 mg) was added and the solution was stirred for another 0.5 h. The mixture was filtered over 
celite, cooled to room temperature and acidified to pH 2. The water solution was extracted with 
ethyl acetate to remove the unreacted D-isomer. The water layer was collected, and purified by 
cation-exchange column (DOWEX-50 H+). The sample was loaded, and to column was washed 
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with water (1 L) and ethanol (250 mL). The product was eluted using 0.2 M ammonium hydroxide. 
The pH of the collected fraction was adjusted to pH 5, and freeze-dried to give the pure 
deacetylated L-isomer as beige solid (0.6 g, yield = 73%) 1H NMR (acetone-D5) δ 1.91 (s, 3H), 
3.11 (d, J = 9 Hz, 15Hz, 1H), 3.32 (q, J = 5.5 Hz, 15 Hz, 1H), 4.80 (m, 1H), 7.42 (d, J = 8 Hz, 1H), 
7.51 (d, J = 8 Hz, 2H), 7.73 (d, J = 8 Hz, 2H).   
 Fmoc-L-Phe(4-CN)-COOH. The pure L-isomer (0.6 g, 3 mmol) was dissolved in 
water:THF (1:1) and saturated bicarbonate solution (3 mL) was added. The pH was maintained at 
9.5. The mixture was cooled to 0˚C, and Fmoc-Osu (2 g, 2 eq) was added to the solution. The 
mixture was allowed to warm to room temperature and stirred vigorously overnight. The mixture 
was transferred into a separatory funnel and ethyl acetate was added. The organic layer was washed 
with 1N HCl solution (2 x 100 mL), water (2 x 100 mL), and brine (2 x 100 mL).  The organic layer 
was then collected, dried with magnesium sulfate, filtered and evaporated to give off-white solid as 
the product. (1.2 g, 90%). The crude was used in the next reaction without further purification.  
  Fmoc-L-Phe(Boc-4-aminomethyl)-COOH. The Fmoc-protected intermediate (0.5 g, 1.2 
mmol) was dissolved in MeOH (15 mL) and acetic acid was added (0.2 ml). Palladium on activated 
charcoal (10 mg) was added and the mixture was subjected to hydrogenation using Parr 
hydrogenator at 40 p.s.i for 36 h. The reaction was closely monitored to avoid side deprotection of 
the Fmoc-protecting group. The mixture was filtered through Celite and the solvent was removed in 
vacuo. The crude free product with the free amino-methyl substituent was used without purification 
in the next step. The crude oil was dissolved in 30 mL of water:THF (1:1) and saturated sodium 
bicarbonate (5 mL) was added, where the pH was maintained at 9.5. The mixture was cooled to 0 
˚C, and (Boc)2O (0.5 g, 2 eq) was added. The mixture allowed to warm to room temperature and 
was stirred for 24h. Ethyl acetate was added to extract the crude fully protected amino acid. The 
organic layer was washed with 1N HCl solution (2 x 100 mL), water (2 x 100 mL), followed by 
brine (2 x 100 mL). The organic layer was collected, dried with magnesium sulfate, filtered and 
removed in vacuo to give a thick viscous oil. The crude oil was purified using Prep-HPLC to give 
the final product as a white fluffy powder (0.51g, 81%). 1H NMR (acetone-D5) δ 1.44 (s, 9H) 3.18 
(m, 1H), 3.40 (m, 2H), 4.28 (m, 3H), 4.60 (m, 1H), 6.84 (d, J = 8.5 Hz, 1H), 7.20-7.90 (m, 12H). 
 
3.6.8 Synthesis of P1 building blocks 
The P1 aldehyde building blocks were prepared in a two-step reaction, where the α-carboxylic acid 
group was first converted to a weinreb-amide through treatment with N,O-dimethylhydroylamine 
hydrochloride in the presense of a coupling reagent and base, followed by a reduction using LAH to 
afford the aldehyde building block. Similar protocols were employed for the synthesis of all of the 
aldehyde building blocks. The synthesis of Fmoc-Arg(Pbf)-CHO is used as an example. Fmoc-
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Arg(Pbf)-COOH (0.2 g) was dissolved in DMF (10 mL), to which HBTU (1 eq), N,O-
dimethylhydroxylamine hydrochloride (1 eq) and DIPEA (4 eq) was added and the mixture was 
stirred overnight. Ethyl acetate (100 mL) and water (100 mL) was added, and the organic layer was 
collected. The organic layer was washed with sodium bicarbonate (2 x 50 mL), citric acid (2 x 50 
mL), and brine (2 x 50 mL), dried with magnesium sulfate, filtered, and finally concentrated in 
vacuo to the give the product as a sticky oil. The crude product was carried on to the next step 
without purification. The crude oil was dissolved in anhydrous THF (50 mL) and the temperature 
was maintained at -10 ˚C.  LAH (1.5 eq) was added portion-wise carefully, maintaining the 
temperature below 0 ˚C.  The mixture was stirred under nitrogen atmosphere for 1h, followed by 
careful addition of 10 mL of 10% KHSO4 to quench the reaction. Ethyl acetate was added and the 
layers partitioned. The aqueous layer was extracted two times with ethyl acetate. The organic layer 
was collected, washed with sodium bicarbonate (2 x 50 mL), water (2 x 50 mL) and brine (2 x 50 
mL), dried with magnesium sulfate, filtered and concentrated in vacuo to give the final aldehyde 
building block as sticky residue. The aldehyde was attached onto the resin without further 
purification. 
 
3.6.9 Peptide synthesis 
Manual stepwise solid phase peptide synthesis was used to synthesize a series of peptidomimetic 
aldehydes by employing Fmoc-chemistry. HCAM-resin (substitution 0.40 mmol/g) was used. The 
loading of the first amino acid was achieved by reacting the aldehyde building block with the resin 
in anhydrous DCM under nitrogen atmosphere for 24 h. The resin was washed with DCM, and the 
unreacted sites were capped (MeOH:DCM:DIPEA, 1:8:1). The N-α-Fmoc-protecting group was 
removed using piperidine:DMF (1:1) (2 x 5 min). Coupling of common amino acids or acid capping 
group (phenylacetic acid or acetic acid) was achieved by performed by adding amino acid (4 
equivalent), and HBTU as coupling reagent (4 equivalent) and DIPEA (8 equivalent). The coupling 
of unnatural amino acids or mimetics was performed using 2 equivalent of amino acids, using the 
HATU/DIPEA pre-activation conditions. Each successive coupling step was monitored using the 
quantitative Ninhydrin assay, where double-coupling was performed when coupling yield was 
below 99.6%. After completion of coupling reactions, the resin was washed thoroughly with DMF, 
DCM:MeOH (1:1) and DCM, and dried under vacuum for a final cleavage. The resin was treated 
with TFA:H2O (9:1) for 1 h to cleave the peptide from the resin. The cleavage cocktail did not 
contain typical scavengers (e.g triisopropylsilane) due to their reactivity with the free aldehyde 
group.  The cleavage filtrate was collected and dried under nitrogen condition, followed by addition 
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of diethyl ether to induce precipitation. The precipitate was dissolved in water/acetonitrile and 
lyophilized to give a white solid (sometimes as sticky oil) as the crude peptide.  
 
3.6.10 Characterisations of peptidomimetic inhibitors 
 
Compound 3.18  PhAc-Lys-Arg-Arg-CHO 
1H NMR (600 MHz, DMSO-D6): δ = 0.83-2.50 (m, 14H), 2.71 (m, 2H), 3.03-3.17 (m, 2H), 3.43-
3.51 (m, 4H), 3.71-3.77 (m, 1H), 4.19-4.36 (m, 2H), 5.25 (s, CHOH), 6.51-6.52 (d, J = 4.4 Hz, 1H), 
7.19-7.35 (m, 5H), 7.37-7.57 (m, 4H), 7.60-7.61 (d, J = 8.5 Hz, 1H), 7.65 (br, 2H), 8.06-8.07 (d, J = 
8.04 Hz, 1H), 8.26-8.28 (d, J = 7.8 Hz, 1H), 9.18 (s, 1H), 9.38 (s, 1H). HRMS	   calculated	   for	  [M+2H]2+	  =	  281.1847	  (found	  281.1845).	  Rt	  =	  2.1	  min. 
 
Compound 3.19  PhAc-Lys-Arg-nitroArg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.18-1.81 (m, 12H), 2.79-2.88 (m, 2H), 2.95-3.06 (m, 1H), 
3.51-3.54 (m, 2H), 4.12 -4.22 (m, 1H), 5.78 (s, CHOH),, 6.88-7.48 (m, 6H), 7.94 – 8.04 (m, 6H), 
8.17-8.39 (m, 2H), 9.31 (s, 1H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  303.6772	  (found	  303.6775).	  Rt	  =	  2.0	  min. 
 
Compound 3.20  PhAc-Lys-Arg-AGP-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.31-1.74 (m, 10H),  2.83 (br, 2H), 3.00-3.03 (m, 2H), 
3.10-3.32 (m, 2H), 3.53 (s, 2H), 3.99 (m, 1H), 4.10-4.17 (m, 2H), 7.20-7.21 (d, J = 7.38 Hz, 2H), 
7.23-7.25 (m, 1H), 7.28-7.31 (t, J = 7.5 Hz, 2H), 7.40 (br, 2H), 8.03-8.40 (m, 3H). HRMS	  calculated	  for	  [M+2H]2+	  =	  267.1690	  (found	  267.1692).	  Rt	  =	  1.9	  min. 
 
Compound 3.21  PhAc-Lys-Arg-AGB-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.21-1.76 (m, 12H), 1.89-1.95 (m, 2H),  2.84 (br, 1H), 
2.99-3.06 (m, 2H), 3.23-3.29 (m, 1H), 3.42-3.51 (m, 1H), 3.53 (s, 2H), 4.05-4.24 (m, 1H), 6.81-6.94 
(m, 3H), 6.96-7.04 (m, 1H), 7.19-7.21 (d, J = 7.4 Hz , 2H), 7.24-7.25 (d, J = 5.5 Hz, 1H), 7.28-7.30 
(t, J = 7.2 Hz , 2H), 8.07 -8.08 (d, J = 7.0 Hz, 1H), 8.23-8.31 (m, 2H), 8.36-8.39 (m, 1H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  274.1768	  (found	  274.1764).	  Rt	  =	  2.0	  min. 
 
Compound 3.22  PhAc-Lys-Arg-homoArg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.04-1.98 (m, 16H), 2.85 (br, 2H), 2.97-3.13 (m, 4H), 3.54 
(s,2H), 3.67-3.74 (m, 1H), 4.11-4.20 (m, 1H), 6.94-7.05 (m,2H), 7.20-7.21 (d, J = 8.1 Hz, 2H), 
7.24-7.26 (d, J = 7.44 Hz, 1H), 7.29-7.31 (t, J = 7.14 Hz, 2H), 7.42 (br, 2H), 7.85-7.87 (d, J = 9.48 
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Hz, 1H), 8.16-8.18 (d, J = 7.0 Hz,1H), 8.32-8.33 (d, J = 6.78 Hz, 1H).	   HRMS	   calculated	   for	  [M+2H]2+	  =	  288.1925	  (found	  288.1921).	  Rt	  =	  2.1	  min. 
 
Compound 3.23  PhAc-Lys-Arg-(4-guanidino)Phe-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.05-1.78 (m, 10 H), 2.53-2.58 (t, J = 12.4 Hz,  2H), 1.80-
2.88 (m,  2H), 2.93-3.04 (m,  2H), 3.51-3.52 (d, J = 8.7 Hz , 1 H), 3.91-4.14 (m,  2H), 7.06-7.08 (d, 
J = 8.3 Hz,  2H), 7.10-7.12 (d, J = 8.2 Hz,  2H), 7.17-7.31 (m, 5H), 7.95-7.97 (d, J = 9.1 Hz, 1H), 
8.28-8.36 (m, 2H), 9.31 (s, 1H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  305.1847	  (found	  305.1847).	  Rt	  =	  3.3	  min. 
 
Compound 3.24  PhAc-Lys-Arg-(3-aminomethyl)Phe-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.92-1.78 (m, 10 H), 2.43-2.48 (m, 2H), 2.76-2.80 (m,  
2H), 2.83-3.01 (m, 2H), 3.46-3.51 (m, 2 H), 3.81-4.12 (m, 3H), 7.01-7.31 (m, 9H), 7.95-8.36 (m, 
3H), 9.33 (s, 1H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  291.1816	  (found	  291.1818).	  Rt	  =	  2.3	  min. 
 
Compound 3.25  PhAc-Lys-Arg-(4-aminomethyl)Phe-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.02-1.79 (m,10H), 2.36-2.53 (m, 2H), 2.75-2.79 (m,  2H), 
2.85-3.0 (m, 2H), 3.45-3.55 (m, 2H), 3.91-4.10 (m, 3H), 6.88-7.29 (m, 9H), 7.99-8.32 (m, 3H), 9.34 
(s, 1H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  291.1816	  (found	  291.1819).	  Rt	  =	  2.3	  min. 
 
 
Compound 3.26  PhAc-Lys-Arg-(3,4-dichloro)Phe-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.724-1.769 (m, 10H), 2.44-2.55 (m, 1H), 2.70-2.86 (m, 
3H), 2.92-3.04 (m, 2H), 3.52 (s, 2H), 3.91-4.13 (m, 3H), 7.02-7.37 (m, 8H), 7.91-7.93 (d, J = 7.32 
Hz, 1H), 8.03-8.05 (d, J = 9.54 Hz, 1H), 8.18-8.19 (m, 1H), 9.78 (s, 1H).	   HRMS	   calculated	   for	  [M+2H]2+	  =	  310.6294	  (found	  310.6292).	  Rt	  =	  2.4	  min. 
 
Compound 3.27  PhAc-Lys-homoArg-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.11-1.96 (m, 16H), 2.85 (br, 2H), 2.88-3.00 (m, 2H), 
3.01-3.08 (m, 1H), 3.13-3.21 (m, 1H), 3.39-3.42 (m, 2H), 3.52 (s, 2H), 3.81-4.16 (m, 3H), 5.31 (s, 
CHOH), 6.81-6.96 (m, 2H), 7.02 (s, 2H), 7.16-7.31 (m, 5H), 7.41 (br, 2H), 7.90-7.91 (d, J = 7.5 Hz, 
1H), 8.18-8.19 (d, J = 6.84 Hz, 1H), 8.36-8.37 (d, J = 6.84 Hz, 1H).	   HRMS	   calculated	   for	  [M+2H]2+	  =	  288.1925	  (found	  288.1929).	  Rt	  =	  1.7	  min. 
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Compound 3.28  PhAc-Lys-(4-guanidino)Phe-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.11-1.78 (m, 10H), 2.76-3.19 (m, 4H). 3.38-3.51 (m, 2H), 
3.53 (s, 2H), 3.81-4.09 (m, 3H), 6.79 (br, 1H), 6.97-7.10 (m, 4H), 7.15-7.31 (m, 5H), 7.91-7.92 (d, J 
= 8.46 Hz, 1H), 8.15-8.28 (m, 2H), 8.91 (s, 1H).	   HRMS	   calculated	   for	   [M+2H]2+	  =	   305.1847	  (found	  305.1847).	  Rt	  =	  2.1	  min. 
 
Compound 3.29  PhAc-Lys-(3-aminomethyl)Phe-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.06-1.99 (m, 10H), 2.53-2.56 (t, J = 7.26 Hz, 1H), 2.77-
3.53 (m, 9H), 3.962 -4.012 (m, 3H), 5.35 (s, CHOH), 6.95-7.326 (m, 9H), 7.40 (br, 2H), 8.12-8.33 
(m, 3H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  291.1816	  (found	  291.1813).	  Rt	  =	  2.2	  min. 
 
Compound 3.30  PhAc-Lys-(4-aminomethyl)Phe-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ =  1.12-2.04 (m, 10H), 2.74 (s, 1H), 2.81 (br, 2H), 3.10-3.17 
(m, 1H), 3.34-3.55 (m, 3H), 3.59-4.16 (m, 3H), 5.17 (s, CHOH), 6.75-7.07 (m, 3H), 7.15-7.31 (m, 
8H), 7.40 (br, 2H), 7.75-8.33 (m, 3H), 8.77 (NH, hemiaminal), 9.08 (CHO, aldehyde).	   HRMS	  calculated	  for	  [M+2H]2+	  =	  291.1816	  (found	  291.1816).	  Rt	  =	  2.1	  min. 
 
Compound 3.31  PhAc-Lys-nitroArg-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ =  1.21-1.81 (m, 14H), 2.846 (br, 2H), 2.98-3.45 (m, 4H), 
3.55 (s, 2H), 3.65-4.25 (m, 3H), 5.31 (s, CHOH), 6.82 (br, 1H), 7.01 (s, 3H), 7.19-7.21(d, J = 7.92 
Hz, 2H), 7.23-7.24 (d, J = 7.38 Hz, 1H), 7.27-7.29 (t, J = 7.38 Hz, 1H) 7.41 (br, 2H), 7.85-8.39 (m, 
3H), 9.35 (CHO, aldehyde).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  303.6772	  (found	  303.6770).	  Rt	  =	  1.8	  min. 
 
Compound 3.32  PhAc-Lys-(4-amino)Phe-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ =  1.02-2.17 (m, 10H), 2.71-3.10 (m, 5H), 3.32-3.45 (m, 
1H), 3.52 (s, 2H), 3.60 -4.21 (m, 3H), 5.16 (s, CHOH), 6.95-7.32 (m, 12H), 7.39 (br, 2H), 7.78-7.86 
(m, 1H), 8.09-8.34 (m, 2H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  284.1738	  (found	  284.1736).	  Rt	  =	  1.9	  min. 
 
Compound 3.33  PhAc-Lys-4PyA-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ =  1.14-2.09 (m, 10H), 2.82 (br, 2H), 2.98-3.53(m, 5H), 
3.66-4.10(m, 3H), 7.03 (s, 3H), 7.15-7.31 (m, 5H), 7.41 (br, 2H), 7.75-7.80 (m, 2H), 8.00-8.02 (d, J 
= 7.74 Hz, 1H), 8.35-8.36 (d, J = 6.54 Hz, 1H), 8.41-8.42 (d, J = 6.78 Hz 1H), 8.45-8.46 (d, J = 
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6.72 Hz, 1H), 8.59-8.60 (d, J = 7.80 Hz, 1H), 9.31 (s, CHO, 1H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  277.1660	  (found	  277.1656).	  Rt	  =	  1.9	  min. 
 
Compound 3.34  PhAc-Lys-3PyA -Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ =  1.13 -2.02 (m, 10H), 2.82 (br, 2H), 2.97-3.51 (5H), 3.612-
4.12 (m, 3H), 5.26 (s, CHOH), 7.04 (s, 3H), 7.16-7.17(d, J = 6.9 Hz, 2H), 7.23-7.32 (m, 2H), 7.40 
(br, 2H), 7.67-.7.76 (m, 1H), 8.02-8.03 (d, J = 8.1 Hz, 1H), 8.26-8.29 (t, J = 8.8 Hz, 2H), 8.38-8.39 
(d, J = 5.9 Hz, 1H), 8.42-8.43 (m, 1H), 8.53 (m, 2H), 9.31 (s, CHO).	   HRMS	   calculated	   for	  [M+2H]2+	  =	  277.1660	  (found	  277.1663).	  Rt	  =	  2.0	  min. 
 
Compound 3.35  PhAc-Lys-hArg -AGP-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ =  1.10-1.75 (m, 12H), 2.85 (br, 2H), 2.91-2.99 (m,2H), 
3.12-3.32 (m, 2H), 1.93 (s, 2H), 3.98-4.23 (m, 3H), 6.62-6.75 (m, 2H), 6.92 (br, 1H), 7.19-7.20 (d, J 
=7.4 Hz, 2H), 7.25-7.26 (d, J = 7.3 Hz, 1H), 7.27-7.31 (t, J = 7.1 Hz, 2H), 7.41(br, 2H), 7.62 (br, 
1H), 7.99-8.39 (m, 3H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  274.1768	  (found	  274.1768).	  Rt	  =	  1.7	  min. 
 
Compound 3.36  PhAc-Lys-hArg -AGB-CHO. 
1H NMR (600 MHz, H2O:D2O, 9:1): δ =  1.02-2.21 (m, 14H), 2.84 (br,2H), 2.91-2.97 (m, 2H), 
3.23-3.31 (m, 1H), 3.44-3.61(m, 3H), 4.04-4.27 (m, 3H), 5.25 (s, CHOH), 6.80-6.95 (m, 4H), 7.19-
7.30 (d, J = 7.2 Hz, 2H), 7.23-7.24 (d, J = 7.3 Hz, 1H), 7.27-7.30 (t, J = 7.4 Hz, 2H), 7.41 (br, 2H), 
8.05-8.06 (d, J = 7.3 Hz, 1H), 8.22-8.24 (d, J = 7.6 Hz, 1H), 8.37-8.38 (d, J = 6.4 Hz, 1H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  281.1847	  (found	  281.1849).	  Rt	  =	  1.8	  min. 
 
Compound 3.37  PhAc-(3-aminomethyl)Phe-Arg-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.01-2.15 (m, 8H), 2.63 (s, 2H), 2.69-3.50 (m, 4H), 3.72-
4.07 (m, 2H), 5.30 (s, 1H), 7.01-7.34 (m, 9H), 7.45-7.46 (d, J = 8.1 Hz, 1H), 7.65-7.66 (d, J = 8.2 
Hz, 1H), 7.71-7.75 (m,, 1H), 7.80-7.83 (m, 1H).	   HRMS	   calculated	   for	   [M+2H]2+	   =	   305.1846	  (found	  305.1847).	  Rt	  =	  2.0	  min. 
 
Compound 3.38  PhAc-(4-aminomethyl)Phe-Arg-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.98-2.00 (m, 8H), 2.67 (s, 2H), 2.59-3.33 (m, 4H), 3.69-
4.28 (m, 2H), 5.33 (s, CHOH), 6.91-7.30 (m, 9H), 7.34-7.35 (d, J = 8.4 Hz, 1H), 7.59-7.60 (d, J = 
8.7 Hz, 1H), 7.73-7.77 (m, 1H), 7.79-7.82 (m, 1H).	  HRMS	  calculated	   for	   [M+2H]2+	  =	  305.1847	  (found	  305.1849).	  Rt	  =	  2.1	  min. 
	   163	  
Compound 3.39  PhAc-4PyA-Arg-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.12-2.17 (m, 8H), 2.99-3.52 (m, 6H), 3.61-4.23 (m, 3H), 
5.30 (s, CHOH,  6.83-7.21 (m, 5H), 7.22 (br, 2H), 7.62-7.63 (d, J = 6.5 Hz, 2H), 8.04-8.05 (d, J = 
8.0 Hz, 1H), 8.32-8.37 (m, 2H), 8.39-8.40 (d, J = 7.0 Hz, 1H), 8.50-8.59 (m, 2H), 9.12 (s, 
hemiaminal NH).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  435.2695	  (found	  435.2699).	  Rt	  =	  1.8	  min. 
  
Compound 3.40  PhAc-3PyA-Arg-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.32-2.18 (m, 8H), 3.00-3.11 (m, 3H), 3.15-3.20 (dt, J = 
2.9 Hz, 13.0 Hz, 1H), 3.28-3.31 (dd, J = 2.4 Hz, 14.3 Hz, 1H), 3.38-3.46 (m, 3H), 3.70 -4.24 (m, 
3H), 5.32 (s, CHOH), 7.02 (br, 2H), 7.22-7.25 (m, 5H), 7.72-7.73 (d, J = 5.8 Hz, 2H), 8.06-8.07 (d, 
J = 7.9 Hz, 1H), 8.35-8.36 (d. J = 6.7 Hz, 1H), 8.40-8.57 (m, 4H), 9.14 (s, hemiaminal NH).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  291.1690	  (found	  291.1694).	  Rt	  =	  1.9	  min. 
 
Compound 3.41  PhAc-homohomoSer-Arg-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.01-1.93 (m, 12H), 2.73-3.01 (m, 2H), 3.05-3.09 (m, 1H), 
3.50-3.55 (m, 2H), 4.01 -4.32 (m, 1H), 5.38 (s, CHOH), 6.80-7.39 (m, 6H), 7.54 – 8.01 (m, 6H), 
8.07-8.41 (m, 2H), 9.29 (s, 1H).	   HRMS	   calculated	   for	   [M+2H+H2O]2+	   =	   300.1743	   (found	  300.1740).	  Rt	  =	  3.3	  min. 
 
Compound 3.42  PhAc-norCit-Arg-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.98-2.01 (m, 8H), 2.59-2.68 (m, 2H), 2.95-3.06 (m, 1H), 
3.31-3.59 (m, 2H), 4.01 -4.32 (m, 1H), 5.33 (s, CHOH), 7.18-7.40 (m, 6H), 7.83 – 8.01 (m, 6H), 
8.10-8.39 (m, 2H), 9.33 (s, 1H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  288.6719	  (found	  288.6715).	  Rt	  =	  1.9	  min. 
 
Compound 3.43  Phac-nitroArg-Arg-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.24-2.13 (m, 12H), 2.98-3.10 (m, 2H), 3.10-3.21 (m, 2H), 
3.22-3.43 (m, 1H), 3.53 (d, 1H), 3.64-4.23 (m, 3H), 7.00 (br, 4H), 7.18-7.30 (m, 5H), 7.79-7.94 (m, 
1H), 8.14-8.39 (m, 2H), 9.36 (CHO, aldehyde).	   HRMS	   calculated	   for	   [M+2H]2+	   =	   310.6725	  (found	  310.6722).	  Rt	  =	  1.9	  min. 
 
Compound 3.44  Hexanoyl-Lys-Arg-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.74-0.96, (t, J = 7.32 Hz, 3H), 1.11-1.81 (m, 20H), 2.14-
2.19 (dt, J = 1.9 Hz, 7.4 Hz, 2H), 2.54-2.93 (m, 2H), 3.05-3.21 (m, 3H), 3.39 (m,1H), 3.51-4.17 (m, 
3H), 6.83-7.12 (m,5H), 7.43 (br, 2H), 7.96-7.98 (d, J = 8.1 Hz, 1H), 8.15-8.16 (d, J = 6.5 Hz, 1H), 
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8.27-8.29 (d, J = 7.0 Hz, 1H), 9.08 (s, hemiaminal NH).	   HRMS	   calculated	   for	   [M+2H]2+	   =	  271.2003	  (found	  271.2000).	  Rt	  =	  1.6	  min. 
 
Compound 3.45  4-methylpentanoyl-Lys-Arg-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.76-0.77 (d, J = 6.4 Hz, 6H), 1.29-1.77 (m, 17H), 2.16-
2.23 (m, 2H), 2.88 (br, 2H), 3.06-3.12 (m, 2H), 3.70-4.21 (m, 3H), 6.95-7.13 (m, 4H), 7.37-7.49 (m, 
2H), 7.66-8.32 (m, 3H), 9.39 (s, CHO, aldehyde).	   HRMS	   calculated	   for	   [M+2H]2+	  =	   271.2003	  (found	  271.2003).	  Rt	  =	  1.7	  min. 
 
Compound 3.46  3-methylbutanoyl-Lys-Arg-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.79-0.80 (d, J = 6.7 Hz, 6H), 1.23-1.96 (m, 15H), 2.03-
2.06 (m, 2H), 2.84-2.92 (m, 2H), 3.05-3.13 (m, 2H), 3.15—3.21 (dt, J = 3.0 Hz, 13.0 Hz, 1H), 3.39-
3.46 (m, 1H), 3.68-4.26(m, 3H), 5.33 (s, CHOH), 6.86-7.12 (m, 5H), 7.432 (br, 2H), 7.94-8.32 (m, 
3H), 9.38 (CHO, aldehyde).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  264.1925	  (found	  264.1927).	  Rt	  =	  1.7	  min. 
 
Compound 3.47  Pentanoyl-Lys-Arg-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.76-0.78 (t, J = 7.4 Hz, 3H), 1.13-1.97 (m, 18H), 2.15-
2.20 (dt, J = 1.6 Hz, 7.1 Hz, 2H), 2.84-2.93 (m, 2H), 3.07-3.13 (m, 3H), 3.15-3.21 (dt, J = 2.9 Hz, 
12.9 Hz, 1H), 3.39-3.49 (m, 1H), 3.68-4.24 (m, 2H), 5.33 (s, CHOH), 6.87-7.13 (m, 5H), 7.43 (br, 
2H), 7.94-.8.32 (m, 3H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  264.1925	  (found	  264.1925).	  Rt	  =	  1.6	  min. 
 
Compound 3.48  Cyclopentanoyl-Lys-Arg-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ =1.24-2.19 (m, 23H), 2.57-2.66 (m, 1H), 2.84-2.93 (m, 2H), 
3.05-3.13 (m, 2H), 3.15-3.21 (dt, J = 3.0 Hz, 13.0 Hz, 1H), 3.39-3.49 (m, 2H), 3.79-4.24 (m, 3H), 
5.33 (s, CHOH), 7.01-7.10 (m, 4H), 7.43 (br, 2H), 7.94-8.34 (m, 3H), 9.09 (s, CHO).	   HRMS	  calculated	  for	  [M+2H]2+	  =	  270.1925	  (found	  270.1923).	  Rt	  =	  1.7	  min. 
 
Compound 3.49  Cyclohexanoyl-Lys-Arg-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.00-2.23 (m, 21H), 2.83-2.91 (m, 2H), 2.03-3.13 (m, 2H), 
3.15-3.21 (dt, J = 3.0 Hz, 13.0 Hz, 1H), 3.38-3.48 (m, 2H), 3.68 -3.75 (m, 2H), 3.78-3.87 (m, 1H), 
4.10-4.16 (m, 1H), 4.17-4.26 (m, 1H), 5.33 (s, CHOH), 6.88-7.12 (m, 4H), 7.432 (br, 2H), 7.92-
8.32 (m, 3H), 9.09 (s, 1H).	  HRMS	  calculated	   for	   [M+2H]2+	  =	  277.2003	  (found	  277.2001).	  Rt	  =	  1.8	  min. 
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Compound 3.50  Furoyl-Lys-Arg-Arg-CHO 
1H NMR (600 MHz, DMSO-D6): δ = 1.21-1.77 (m, 14H), 2.72-2.80 (m, 2H), 3.05-3.12 (m, 2H), 
3.12-3.18 (m, 2H), 3.43-3.49 (m, 2H), 3.71-3.77 (m, 1H) 4.31-4.44 (m, 2H), 5.25 (s, CHOH), 6.47-
6.48 (d, J = 4.3 Hz, 2H), 6.64-6.67 (m, 1H), 7.17-7.18 (d, J = 3.4 Hz, 2H), 7.37-7.67 (m, 9H), 7.86-
7.98 (m,1H), 8.13-8.14 (d, J = 8.3 Hz, 1H), 8.28-8.29 (d, J = 7.9 Hz, 1H), 9.39 (s, CHO).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  269.1665	  (found	  269.1665).	  Rt	  =	  2.1	  min. 
 
Compound 3.51  2-naphthoyl-Lys-Arg-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.94-2.23 (m, 14H), 2.88-2.94 (m, 2H), 3.05-3.12 (m, 2H), 
3.15-3.21 (m, 2H), 3.20-3.47 (m, 2H), 3.69-3.88 (m, 2H), 4.21-4.37 (m, 1H), 5.32 (s, CHOH),  
6.99-7.08 (m, 5H), 7.14-7.19 (m, 1H), 7.19-7.23 (m, 1H), 7.28-7.32 (m, 1H), 7.34-7.39 (m, 2H), 
7.41-7.47 (m, 3H), 7.91-8.61 (m, 3H), 9.05 (s, NH, hemiaminal).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  299.1847	  (found	  299.1847).	  Rt	  =	  2.0	  min. 
 
Compound 3.52  4-phenoxybenzoyl-Lys-Arg-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.74-2.24 (m, 14H), 2.88-2.98 (m, 2H), 3.05 -3.14 (m, 
2H), 3.16-3.30 (m, 1H), 3.40-3.44 (t, J = 5.7 Hz, 1H), 3.70-3.78 (m, 1H), 3.82-3.91(1H), 4,27-4.33 
(m, 1H), 5.36 (s, CHOH), 6.87-7.10 (m, 4H), 7.21-7.32 (m, 1H), 7.46 (br, 2H), 7.54-7.64 (m, 2H), 
7.73-7.78 (m, 1H), 7.91-8.03 (m, 3H), 8.17-8.32 (m, 1H), 8.40-8.52 (m, 1H), 8.64-8.74 (m, 1H), 
9.09 (s, 1H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  320.1900	  (found	  320.1901).	  Rt	  =	  2.3	  min. 
  
Compound 3.53  Ac-Arg-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.31-2.20 (m, 11H), 3.03-3.49 (m, 4H), 3.70-3.89 (m, 1H), 
4.10-4.17 (m, 1H), 5.35 (s, CHOH), 6.97-7.15 (m, 4H), 7.94-7.96 (d, J = 8.4 Hz, 2H), 8.18-8.19 (d, 
J = 6.5 Hz, 1H), 9.11 (s, hemiaminal NH).	   HRMS	   calculated	   for	   [M+2H]2+	  =	   179.1215	   (found	  179.1219).	  Rt	  =	  1.3	  min. 
 
Compound 3.54  Cbz-Arg-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.76-2.21 (m, 8H), 2.83-3.32 (m, 4H), 3.38-3.47 (m, 1H), 
3.95-4.02 (m,1H), 6.98-7.52 (m, 3H), 7.95-8.41 (m, 2H), 9.09 (s, hemiaminal), 9.37 (s, CHO, 
aldehyde).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  225.1347	  (found	  225.1344).	  Rt	  =	  1.4	  min. 
 
Compound 3.55  Phac-Lys-Lys-Arg-CHO 
1H NMR (600 MHz, DMSO-D6): δ = 1.19 -2.22 (m, 16H), 2.68-2.75 (m, 4H), 3.34-3.49 (m, 4H), 
3.69-4.33 (m, 3H), 5.25 (s, CHOH), 6.56-6.57 (d, J = 4.7 Hz, 1H), 7.19-7.38 (m, 5H), 7.52-7.71(m, 
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11H), 7.99-8.00 (d, J = 8.2 Hz, 1H), 8.03-8.04 (d, J = 7.9 Hz, 1H), 8.26-8.27 (m, 1H), 9.17 (s, 1H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  267.1816	  (found	  267.1812).	  Rt	  =	  3.3	  min. 
 
Compound 3.56  Phac-Lys-Lys-(4-guanidino)Phe-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.89-2.13 (m, 12H), 2.52-2.59 (m, 1H), 2.68-2.88 (m, 4H), 
2.92-3.03 (m, 1H), 3.52-3.53 (d, J = 3.5 Hz, 2H), 3.90-4.15 (m, 3H), 6.78-6.84 (m, 3H), 7.07-7.08 
(d, J = 8.3 Hz, 1H), 7.12 -7.13 (d, J = 8.3 Hz, 1H), 7.19-7.27 (m, 4H), 7.27 -7.47 (m, 5H), 7.87 – 
7.88 (d, J = 9.5 Hz, 1H), 8.07-8.08 (d, J = 7.6 Hz, 1H), 8.28-8.33 (m, 1H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  291.1816	  (found	  291.1815).	  Rt	  =	  2.1	  min. 
 
Compound 3.57  Phac-Lys-Lys-(3,4-dichloro)Phe-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.72-1.83 (m, 12H), 2.44-2.57 (m, 1H), 2.64-2.87 (m, 5H), 
2.92-3.05 (m, 2H), 3.48- 3.54 (d, J = 11.5 Hz, 2H), 3.64 (s, 2H), 3.81-4.24 (m, 3H), 7.03-7.10 (m, 
1H), 7.16-7.33 (m, 7H), 7.36-7.38 (d, J = 8.28 Hz, 1H), 7.92-7.93 (d, J = 9.8 Hz, 1H), 7.98-7.99 (d, 
J = 10.0 Hz, 1H), 8.13-8.17 (m, 1H), 8.27-8.32 (m, 1H).	   HRMS	   calculated	   for	   [M+2H]2+	   =	  296.6263	  (found	  296.6260).	  Rt	  =	  2.6	  min. 
 
Compound 3.58  Phac-(4-aminomethyl)Pe-Lys-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.03-1.91 (m, 10H), 2.73-2.91 (m, 4H), 3.00-3.13 (m, 2H), 
3.14-3.26 (m, 1H), 3.39-3.48 (m, 3H), 3.71-4.20 (m, 4H), 5.33 (s, CHOH), 6.98-7.26 (m, 10H), 
7.55-7.57 (d, J = 8.5Hz, 1H), 7.91-7.97 (m, 1H), 8.18-8.24, m, 2H).	   HRMS	   calculated	   for	  [M+2H]2+	  =	  291.1816	  (found	  291.1819).	  Rt	  =	  2.1	  min. 
 
Compound 3.59  Phac-(3-aminomethyl)Phe-Lys-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.91-2.17 (m, 10H), 2.62 (s, 2H), 2.68-3.55 (m, 6H), 3.92-
4.19 (m, 2H), 5.31 (s, CHOH), 6.86-7.36 (m, 9H), 7.55-7.57 (d, J = 8.4 Hz, 1H), 7.69-7.70 (d, J = 
8.6 Hz, 1H), 7.81-7.85 (m,, 1H), 7.88-7.89 (m, 1H).	  HRMS	  calculated	   for	   [M+2H]2+	  =	  291.1816	  (found	  291.1813).	  Rt	  =	  2.5	  min. 
 
Compound 3.60  Ac-(4-aminomethyl)Phe-Arg-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.31 – 1.97 (m, 7H), 2.89 (s, 2H), 2.90-3.19 (m, 2H), 3.35-
3.43 (m, 1H), 3.65-3.84 (m, 1H), 4.03-4.07 (m, 1H), 5.18 (s, CHOH), 7.01 (br, 3H), 7.2-7.24 (d, J = 
8.0 Hz, 2H), 7.28-7.30 (d, J = 8.1 Hz, 2H), 7.86-7.91 (m, 2H), 8.16-8.17 (d, J = 7.3 Hz, 1H), 9.08 
(s, 1H).	  HRMS	  calculated	  for	  [M+2H+H2O]2+	  =	  198.1238	  (found	  198.1235).	  Rt	  =	  1.5	  min. 
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ABSTRACT 
   
DENV NS2B/NS3pro and human inflammatory protease Factor B are two unrelated 
enzymes that exhibit optimal catalytic competence under basic conditions (pH 9 - 10.5). Reported 
inhibitors of DENV NS2B/NS3pro (PhAc-KRR-CHO, 2.1) and complement Factor B (Ac-
RL(Tba)LAR-CHO, 4.11) utilized a C-terminal aldehyde electrophilic isostere. 2.1 (IC50 = 10 µM) 
had moderate potency against DENV NS2B/NS3pro1 and the peptidomimetic approach employed 
in Chapter 3 which focused on the optimization of subsite binding at the non-prime binding sites 
failed to produce significant improvement in inhibitory potency. On the other hand, Factor B was a 
recently profiled inflammatory protease2 and development of inhibitors of this enzyme has not been 
extensively pursued. 4.11 (IC50 = 870 nM) was moderately potent and targeted the non-prime 
binding sites. The hexapeptide aldehyde however was non-selective and inhibited thrombin and 
trypsin at comparable concentration. In both proteases, the prime binding sites remain unexploited. 
The aim of this project was to map the binding requirements of the prime binding sites, and to 
improve the potency of the inhibitors through targeting residues in the prime binding pockets. 
Using the methodology developed in Chapter 2 that successfully produced highly potent α-
keto amide tryptase inhibitors, an internal α-keto amide was incorporated into the active peptide 
inhibitor sequences of DENV NS2B/NS3pro and Factor B to target the prime binding pockets of 
these two proteases. In DENV NS2B/NS3pro, replacement of the C-terminal aldehyde in the parent 
inhibitor with an α-keto amide led to complete loss of activity. Introduction of prime-binding 
residues (P1’-P4’) proved to be beneficial (PhAc-KRR-α-keto amide-SGSG-NH2, IC50 = 37 µM), 
however this compound was almost 4-fold less potent than the parent aldehyde inhibitor. Similarly, 
the α-keto amides were inferior Factor B inhibitors compared to the parent aldehyde. Introduction 
of prime-binding residues (Ac-RLTbaLAR-α-keto amide-SNL-NH2, IC50 = 37 µM) did not enhance 
inhibitor potency towards Factor B. Overall, the α-keto amide inhibitors were less potent than their 
parent aldehyde counterparts, indicating that the α-keto amide isostere was not well suited to target 
these atypical serine proteases. The targeting of the prime binding sites also failed to enhance 
inhibitor potency, suggesting that future inhibitor optimisation studies should focus on the non-
prime binding sites. 
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4.1 INTRODUCTION 
 
4.1.1 Electrophilic isosteres 
During protease-mediated catalysis (Figure 4.1), several chemical steps are carried out by 
the enzyme to hydrolyze the scissile P1-P1’ amide bond of the substrate.3 It is important to note that 
amide bonds are very stable and are not cleaved under physiological conditions4, whereas peptides 
have flanking side chains that are captured by proteases and assist the protease to stretch the scissile 
amide bond for hydrolysis.5  
 
	    
Figure 4.1:  The general mechanism for peptide hydrolysis in serine proteases. Enzyme catalytic 
residues are highlighted in blue, and substrate is highlighted in red.  The backbone NHs of Ser195 
and Gly193 (oxyanion residues) form hydrogen bonds with the carbonyl oxygen of the scissile 
amide bond, forming the enzyme-substrate complex  
  
During proteolysis, the substrate first goes through a transition state to form a tetrahedral 
intermediate before the product is formed. At the same time, the protease undergoes structural 
rearrangements to carry out the chemical reaction on the substrate concomitantly.6 In serine 
proteases, the OH of Ser195, a nucleophile, attacks the carbonyl carbon of the scissile bond assisted 
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by the general base His57 forming a tetrahedral complex. The oxyanion residues stabilize the 
intermediate through hydrogen bonds. His51 then transfer a proton to the amine of the intermediate, 
leading to formation of a covalent acyl enzyme intermediate and the resulting amine product is 
released. Subsequently, a water molecule attacks the acylenzyme to form a new tetrahedral 
intermediate through deacylation. The tetrahedral intermediate then collapses assisted by general 
acid catalysis from His51, releasing the free acid product.   
 The transition state intermediate is intrinsically unstable, however it binds much more 
strongly to the protease than either the substrate (in its ground state) or the product.3, 7 As it is now 
known that proteases (and other enzymes) form stronger interactions with the transition state 
intermediates than the substrates, this knowledge has led to development of tight binding “transition 
state analogues” as protease inhibitors.3 These transition state analogues mimic the geometry and 
electronic structure of the tight-binding transition state intermediate and can bind much more tightly 
to the protease than the substrates.  Some examples are the aspartic protease inhibitors, such as HIV 
protease inhibitors (saquinavir, darunavir, ritonavir),8 where the proteases use water as the sole 
nucleophile for proteolysis (Figure 4.2). The majority of these compounds are non-covalent 
“transition state inhibitors”.  
 
   
 
(A) 
 
(B) 
 
(C) 
Figure 4.2. Catalytic mechanism for substrate proteolysis by aspartic proteases. 
Enzyme catalytic residues are highlighted in blue, and substrate is highlighted in red. 
(A) An activated water molecule attacks the scissile amide bond. The resulting 
protonated amide nitrogen forms the (B) zwitterionic intermediate. (C) The 
intermediate collapses to release the free products. 
 
Using saquinavir (Figure 4.3A) as an example, the scissile sp2 amide bond (-CO-NH-) was 
converted to a sp3 hydroxyethylamine (-CHOH-CH2-NH2-, highlighted in red) as in the unstable 
tetrahedral intermediate of amide bond hydrolysis.9 The secondary OH of the hydroxyethylamine 
group was observed to form hydrogen bonds with the catalytic Asp25 and Asp125 of the HIV-1 
protease (Figure 4.3B), hence acting as a transition state isostere.  
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(A)  (B)  
	     
Figure 4.3: Transition state inhibitors of HIV-1 protease. (A) Saquinavir. The scissile 
amide bond was replaced by a hydroxyethylamine transition state isostere (highlighted 
in red). (B) Hydrogen-bonding interactions between hydroxylethylamine and the 
catalytic aspartates of HIV-1 protease. 
 
However, in the case of a serine protease, both water and serine hydroxyl act as nucleophiles 
during proteolysis. Therefore, it is more difficult to mimic a non-covalent transition state as above. 
For many years, serine protease inhibitors were instead based on incorporating an electrophile into 
peptide substrate to receive and form a complex with the nucleophilic serine side chain, thereby 
forming a covalent bond. Several classes of electrophilic isosteres7, 10 (Figure 4.4) have been 
successfully used in inhibitor development for serine proteases.  
 
(A) Chloromethylketone 
 
 
(B) Aldehyde 
 
(C) α-Keto amide 
 
(D) Trifluoromethylketone 
   
 
(E) Boronic acid  
 
 
Type 1 complex Type 2 complex 
 
Figure 4.4: Electrophilic isosteres often used in serine protease inhibitors and their 
mechanism of actions.11 E-OH (in red) represents nucleophilic serine residue of the 
enzyme. 
  
The general strategy involves the coupling of an optimized peptidyl moiety (that engenders 
selectivity for the target protease) with an electrophilic isostere (to confer affinity and inhibitory 
potency) to produce potent and selective inhibitors for the protease of interest.  The reactive 
electrophilic isostere could react irreversibly (e.g. chloromethylketone) or reversibly (e.g. aldehyde, 
boronic acid, α-keto amide) with the catalytic serine residue to form a tetrahedral adduct that 
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mimics the transition state intermediate through covalent interactions (Figure 4.4). Covalent 
inhibitors are commonly avoided due to concerns of off-target inhibition, stemming from reported 
hapten formation for most of the earlier generation of covalent drugs (bromobenzene, 
acetaminophen).11 They remain unpopular in drug discovery programs as they are associated with 
toxicities due to indiscriminant interactions with many nucleophiles (e.g glutathione). A survey of 
current approved drugs by the US Food and Drug Administration (FDA) reveals 39 covalent drugs, 
of which 33% are anti-infectives, 20% target cancer, 15% treat gastrointestinal diseases, and the 
remainder are used in the treatment of central nervous system and cardiovascular disorders.12 
Covalent inhibitors are still useful in treating infectious diseases (bacterial, viral and parasitic). In 
particular, viral proteases are well suited for covalent inhibition, as they are essential for replication 
and their exogenous origin would provide great opportunity for specificity.  
In Chapter 3, a series of peptidomimetic aldehydes were developed as flaviviral protease 
inhibitors with focus on the optimization of the non-prime subsite interactions (P4-P1). Potent 
inhibitors of WNV protease were successfully developed, however attempts to generate potent 
inhibitors for the analogous DENV protease were met with little success. The prime binding sites 
remain unexploited in development of DENV NS2B/NS3pro inhibitors. This led to speculation that 
an aldehyde may not be an optimal electrophilic isostere to target the dengue protease active site 
(serine residue), and also that exploitation of the prime-side binding sites may be necessary to 
increase inhibitor potency. The aim was to improve inhibitor potency against DENV NS2B/NS3pro 
by targeting the prime-side binding pockets to gain favourable interactions with the protease. It was 
hypothesized that incorporation of an α-keto amide as a linker between prime and non-prime 
inhibitor components, could generate peptides that allow exploration and exploitation of the prime 
binding sites.  
Evidently, utilization of α-keto amide has successfully produced highly potent and selective 
tryptase inhibitors previously in Chapter 2, and it was proposed that a similar strategy would afford 
potent DENV inhibitors. Moreover, α-keto amides have been deployed in recently approved 
inhibitors (telaprevir, boceprevir) of a serine protease that is essential for hepatitis C replication and 
are now marketed drugs for the treatment of hepatitis C viral infection.13  
The second target examined in this chapter is a protease of the human complement system,  
Factor B. Factor B plays a key role in the activation of the human complement system and 
misregulation of the complement cascade has been implicated in a range of inflammatory and 
neurodegenerative disorders.14, 15 There is a need for potent and selective Factor B inhibitors as tool 
compounds to provide better understanding of the complement activation pathway, and to further 
characterize the role of Factor B in the alternative activation pathway. The development of 
inhibitors for Factor B has not been extensive, and the reported studies have mainly focused on the 
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non-prime binding sites.2, 16 This highlights the need to establish a more in-depth structure-activity-
relationship (SAR) study with the protease. In early drug development, covalent inhibitors are 
useful tools to establish SARs with the target. Through harnessing the strong covalent interactions 
with the protease, high potency could be achieved to allow efficient mapping and evaluation of non-
covalent binding interactions with the target in other portions of the inhibitor. Therefore, α-keto 
amides inhibitors were sought to establish SARs with the complement protease, with a focus on the 
previously unmapped prime binding sites. The aim was to develop potent and selective inhibitors of 
Factor B by targeting the prime binding sites, where it was hypothesized that selectivity might be 
attained through full exploitation of both prime and non-prime binding sites surrounding the active 
site.  
 
 
4.2 MATERIALS AND METHODS 
 
4.2.1 Synthesis of chromogenic substrates 
Peptide para-nitroanilides have been widely utilized in chromogenic substrates as tools to 
study enzyme kinetics and specificity. The substrate was first cleaved by the enzyme at the scissile 
P1-P1’ amide bond releasing the free para-nitroaniline which absorbs at 405 nm, therefore allowing 
the progress of the reaction to be monitored using PHERAstar Optima spectrophotometer (BMG 
Labtech).  Ac-LKRR-pNA and Ac-SHLGLAR-pNA were synthesized as substrates for DENV2 and 
Factor B proteases respectively, using methods described by Abbenante and co-workers17. 
Commercially available tritylchloride (TCP) resin first reacted with 1,4-phenylenediamine, and 
standard Fmoc-chemistry synthesis carried out on the derivatised resin afforded the desired peptide. 
The reactions proceeded smoothly, often with >99.6% completion for each coupling step as 
monitored by the Ninhydrin test. A standard cleavage cocktail (TFA:water:triisopropylsilane , 
95:2.5:2.5) was used to cleave the peptide from the resin. The crude peptide was lyophilized and 
was usually used in the next step without further purification. The para-aminoanilide group was 
oxidized using 6 equivalent of Oxone® in water (< 50% acetonitrile was added for increased 
solubility of the crude peptide). The oxidized peptide was then subjected to rp-HPLC purification to 
give the pure peptide para-nitroanilde.   
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Scheme 4.1. Synthesis of chromogenic substrate. Reagents and conditions: (a) 1,4-
phenylenediamine, DCM, TCP resin, overnight, N2 (b)(i) Fmoc-AA-COOH, DIPEA HBTU, 
DMF, 0.5 h, r.t. (ii) piperidine/DMF (5:5), r.t, 0.5 h. (c) TFA/water/TIPS (9.5:2.5:2.5). 1 h, r.t. 
(d) Oxone (6 eq), water/acetonitrile (1:1), 6 h.  
 
4.2.3 Synthesis of α-keto amide inhibitors 
The synthesis of α-keto amide inhibitors was reported in Chapter 2. 
 
4.2.4 Recombinant DENV2 and Factor B Proteases 
The recombinant DENV2 NS2B/NS3pro was kindly provided by Dr Keith J Chappell 
(University of Queensland). The protease was constructed, expressed and purified using methods18 
previously developed and reported by Dr Chappell. The DENV2 protease (DENV2 NGC strain) 
comprised the hydrophilic region NS2B cofactor (residues 49-95), a glycine linker (GGGGSGGG), 
and the NS3pro protease (residues 1-185). Factor B protease was purchased from Merck Millipore. 
 
4.2.5 Protease inhibition assays 
DENV NS2B/NS3pro. The assay was performed in a 384-well plate. The total volume of 
the assay was 50 µL, and the buffer contained Tris-NaOH (50 mM), glycerol (30%), Chaps (1 mM),  
DENV protease (50 nM) and Ac-LKRR-pNA (250 µM). The inhibitors were preincubated with the 
enzyme for 50 min at 37 ˚C and pH 7.5. The substrate was added to initiate substrate hydrolysis and 
the release of the chromophore (para-nitroaniline) was measured at λ = 405 nm using a PheraStar 
Optima spectrometer (BMG Labtech).  
Factor B. The assay was performed in a 96-well plate. The total volume of the assay was 
100 µL, and the buffer contained glycine-NaOH (100 mM), NaCl (150 mM), Factor B (50 nM) and 
Ac-SHLGLAR-pNA (500 µM). The inhibitors were preincubated with the enzyme for 50 min at 37 
˚C and pH 8.5. The substrate was added to initiate substrate hydrolysis and the release of the 
chromophore (para-nitroaniline) was measured at λ = 405 nm using a PheraStar Optima 
spectrometer (BMG Labtech).  
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4.2.6 Molecular modelling studies 
Crystal structures of DENV (PDB: 3U1I) and Factor B (PDB: 2OK5) proteases were 
retrieved from the Protein DataBank (RCSB.org) and the protease templates were prepared using 
Hermes (GoldSuite 5.1). Water molecules were deleted and the proteins were energy minimized. 
The three dimensional structures of compounds were generated using OMEGA2 (OpenEye Suite), 
and the energy of each structure was minimized using SybylX1.3.   The model was examined 
through visual inspection using MacPymol (X11, Schrodinger, LCC) 
 
4.2.7 Analysis of data 
All data was processed using Graphpad Prism V.6 (Graphpad Software Inc. CA) to generate 
dose response curves and statistical analysis. Data was represented by at least three experiments (n 
≥ 3) unless otherwise stated, and was expressed as the mean of all experiments ± SEM. The log 
concentrations were expressed with 95% confidence intervals (p ≤ 0.05)  
 
 
4.3 DENV NS2B/NS3pro α-KETO AMIDE INHIBITORS 
 
4.3.2 Characterization of prime-binding sites 
DENV NS2B/NS3pro mediates cleavage of both dengue structural and non-structural 
proteins19 (Figure 4.5). In the native polyprotein sequences, there was high conservation at P2-P1 
(dibasic residues) and P1’  (serine or glycine) positions.20 However, the residues beyond the P2-P1’ 
segment vary in size, polarity and rigidity, especially at P2’ and P3’ positions and their importance 
in protease recognition was unknown.  
 
Processing site Non-prime   Prime 
Capsid M L N I L N R R R R  S A G M I I M L I P 
2A/2B T T L S R T S K K R  S W P L N E A I M A 
2B/3 W Y L W E V K K Q R  A G V L W D V P S P 
3/4A E F K E F A A G R K  S L T L N L I T E M 
4B/5 I M K N T T S T R R  G T G N I G E T L G 
 
Figure 4.5: Native cleavage sequence of substrates for DENV NS2B/NS3pro 
*Identical residues highlighted in red, conserved residues are highlighted in bold. 
Arrow indicates cleavage site. Information gathered from MEROPS.21 
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Thus far, several crystal structures of ligand-free and ligand-bound DENV NS2B/NS3pro 
protease have been reported22, 23. Two ligand-bound complexes, where DENV NS2B/NS3pro was 
co-crystallized with a DENV selective aldehyde inhibitor Bz-Nle-Lys-Arg-Arg-CHO (PDB: 3U1I) 
and a broad spectrum serine protease inhibitor, aprotinin (PDB: 3U1J) have been reported.22 The 
complex with the peptide aldehyde bound in the active site of DENV NS2B/NS3pro provided 
valuable information about the mode of binding at the non-prime binding sites of the protease. In 
the second complex, aprotinin was found to occupy S2-S2’ pockets, but provided little information 
on the prime-binding sites due to conformational disruption of the NS2B cofactor in the prime side 
region, Although aprotinin was a potent inhibitor (Ki = 0.026 µM) of DENV protease, it was 
thought that the compound may inhibit the membrane-associated DENV protease through 
disruptive steric effects in the active site.22 Therefore, the observations made about S1’ and S2’ 
subsite interactions must be considered with caution, as they may not be a true reflection of optimal 
protease-substrate interactions. The binding specificities of prime and non-prime binding sites of 
DENV NS2B/NS3pro have been previously characterized by Wikberg et al., through screening of a 
library of internally quenched synthetic substrate spanning from P4 – P4’ using the native cleavage 
sequences (Figure 4.6).24 The catalytic efficiency of the native polyprotein cleavage site substrates 
was ranked as follow: capsid > NS2B/NS2 > NS2A/NS2B > NS3/NS4A > NS4B/NS5. 
 
Processing site Non-prime   Prime 
Capsid Abz-RRRR  SAGMnY 
2A/2B Abz-SKKR  SWPLnY 
2B/3 Abz-KKQR  AGVLnY 
3/4A Abz-AGRK  SLTLnY 
4B/5 Abz-STRR  GTGNnY 
 
Figure 4.6: Fluorescent-quenched DENV2 NS2B/NS3pro substrates. 
Arrow indicates cleavage sites. nY = nitrotyrosine, Abz = 2-
aminobenzoyl. 
 
Systematic truncation of P4’ from the capsid native cleavage site octapeptide led to the most 
efficient heptapeptide substrate, Abz-RRRR-SAGnY (Km = 4.5 µM, kcat/Km = 11087 M-1s-1). Based 
on this information, Li et al. reported a series of fluorescent-quenched substrates where a 
fluorescent donor was attached at the N-terminal with a quencher at the C-terminus. An optimal 
non-prime sequence spanning from P4 to P1 (Nle-Lys-Arg-Arg) allowed the positional screening of 
the prime side sequence (P1’ to P4’) (Figure 4.7).25 The most efficiently cleaved substrate was 
found to be nKRR-SGSG (P4-P4’).  A strong preference for serine was observed at both P1’ and 
P3’, whereas a small amino acid (glycine) was preferred at P2’ and P4’. This was consistent with 
the observation made by Wikberg et al., where their reported optimal P1’–P4’ residues (SAGM) 
comprised mainly small and non-bulky amino acids. 24 
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Figure 4.7: Predicted binding interactions of fluorescent-quenched octapeptide 
substrate with DENV2 NS2B/NS3pro protease.25  
 
From the substrate specificity profiling studies, it was postulated that mainly small residues 
would be preferred at the prime binding pockets (P1’ to P4’), and P4’ may not be crucial for 
binding.25 The prime binding sites of DENV protease (PDB: 3U1I) were closely examined for 
binding requirements at these positions to identify suitable amino acids as prime targeting residues 
(Figure 4.8, Table 4.1). In general, the prime binding sites were quite shallow and narrow, thus 
explaining why small aliphatic residues were preferred at these positions. The S1’ pocket was non-
prominent and a preference for serine was noted at P1’ position, where the hydroxyl side chain was 
predicted to form a hydrogen bond with His51. 
 
 
Figure 4.8: Prime binding pockets of DENV NS2B/NS3pro (PDB:3U1I). 
Electrostatic potential surface was generated using Pymol (Red= acidic, blue 
= basic, grey = hydrophobic). 
 
 Upon close examination, it was observed that an arginine residue (Arg54) was found at the 
“edge” of the S1’ pocket (Figure 4.7). This suggested that a small acidic residue, such as aspartic 
acid or glutamic acid, may be beneficial for protease binding at this position to form an ionic 
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interaction with Arg54. It must be noted that this basic residue is solvent-exposed and it may first 
need to be desolvated before engaging with an acidic residue. However, the formation of strong 
ionic interactions may compensate for the increased solvation entropy. The S2’ pocket was flanked 
by Gly133 and Val36 to form a hydrophobic groove, which may result in a preference for small and 
hydrophobic residues. Both the S3’ and S4’ pockets were found to be non-prominent and mainly 
hydrophobic. 
 
 
4.3.4 Design and synthesis of DENV NS2B/NS3pro α-keto-amide 
inhibitors 
The overall strategy here was to (1) use the known optimal non-prime P4-P1 peptide 
sequence as a targeting component to bind to DENV protease; (2) incorporate an α-keto amide 
isostere in place of the scissile P1-P1’ amide bond to form a reversible covalent bond with the 
catalytic serine residue; and (3) screen for inhibitor potency and specificity by strategically varying 
the prime side binding residues (Figure 4.9).  
A series of covalent peptides was synthesized as putative DENV NS2B/NS3pro inhibitors (Table 
4.2). A compound (4.1) containing an additional α-methylene group introduced adjacent to the C-
terminal aldehyde (PhAc-KRR-CH2CHO) was first synthesized. It was thought that relative 
position of the electrophilic isostere may be an issue leading to the lack of potency observed in the 
parent aldehyde inhibitor (2.1), and extending the aldehyde isostere may promote better 
engagement with the oxyanion hole residues. 
 
Figure 4.9: Design for putative α-keto amide inhibitor of DENV protease  
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Table 4.1: Summary of prime binding sites of DENV protease 
Pocket Protease residues Observation Suitable amino acid 
S1’ His51, Val52, Arg54 Shallow; slightly basic Small and acidic 
S2’ Val36, Gly133 Shallow; hydrophobic Small and hydrophobic 
S3’ Val52, Thr53 Shallow; hydrophobic Small and hydrophobic 
S4’ Gln27, Leu51 Shallow; hydrophobic Small and hydrophobic 
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Ac-DTLKRR-ketoamide-SWPL-NH2 (4.2), derived from the native cleavage sequence 
spanning from P6 to P4’, was synthesized to identify whether incorporation of the keto-amide was a 
feasible strategy to develop DENV NS2B/NS3pro protease inhibitors. Ac-PRNR-α-keto amide 
(4.3) was synthesized to examine if the α-keto amide isostere, without the prime-binding residues, 
was a suitable isostere for DENV protease inhibition. The non-prime residues were replaced by the 
optimal non-prime P4-P1 sequence (PhAc-KRR-α-keto amide-SWPL-NH2, 4.4) to promote better 
binding affinity towards DENV protease, in addition to downsizing the octapeptide into a smaller 
peptide.  
Table 4.2: Tryptase α-keto amide inhibitors 
ID Inhibitors 
2.1 PhAc-KRR-CHO 
4.1 PhAc-KRR-CH2CHO 
4.2 Ac-DTLKRR-α-keto amide-SWPL-NH2 
4.3 PhAc-KRR-α-keto amide 
4.4 PhAc-KRR-α-keto amide-SWPL-NH2 
4.5 PhAc-KRR-α-keto amide-SGS-NH2 
4.6 PhAc-KRR-α-hydroxy amide-SGS-NH2 
4.7 PhAc-KR(nitro)R-α-keto amide-SGS-NH2 
4.8 PhAc-KRR-α-keto amide-DGS-NH2 
4.9 PhAc-KRR-α-keto amide-EGS-NH2 
4.10 PhAc-KRR-α-keto amide-SGSG-NH2 
 
The prime-side binding pockets (S1’-S3’) was targeted through introduction of the 
previously reported optimal prime residues (PhAc-KRR-α-keto amide-SGS-NH2, 4.5). Following 
this, the P1-P1’ ketoamide isostere was replaced with α-hydroxyl amide (4.6) to examine if the 
latter has similar inhibitory activities as the ketoamide precursor. This was based on the successful 
demonstration in Chapter 2, where the use of α-hydroxy amide succesfully generated a potent 
tryptase inhibitor. In addition, the P1-arginine was masked with a nitro group (4.7) to examine the 
effect of charge removal at this position, where cell-permeability of the resulting less basic peptide 
could be improved if inhibitory action is maintained.  
To test the hypothesis that having an acidic P1’ residue was favourable to form ionic 
interactions with Arg54 of the S1’ pocket, aspartic acid (4.8) and glutamic acid (4.9) were 
introduced in an attempt to improve inhibitor potency against DENV NS2B/NS3pro protease. 
Lastly, an additional P4’-Gly residue (4.10) was introduced to probe the S4’ pocket and to validate 
the prediction where the S4’ pocket was deemed negligible. 
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4.3.3 Optimization of DENV NS2B/NS3pro protease assay 
Under physiological conditions, arginine-α-keto amides exist in three forms (keto, hydrate 
and hemiaminal).2, 26 At basic pH, they are known to undergo irreversible decomposition to form a 
cyclic hydrolysis product (Figure 4.10).26  It was therefore critical to maintain the pH close to 
physiological pH to avoid decomposition of the arginine keto-amide inhibitors. Evaluation of α-
keto amide inhibitors has been conducted at pH 7.0 – 8.5 for Hepatitis C NS3 protease27 and at pH 
7.5 for thrombin, whereas optimal proteolysis for DENV NS2B/NS3pro occurred under basic 
conditions (pH 9-10). Therefore, evaluation of the α-keto amides at pH 9-10 should not be 
favourable due to chemical instability issues. 
 
 
Figure 4.10: Formation of cyclic hydrolysis product of arginine-α-keto amide.26 
 
Previous studies have shown that the catalytic activity of DENV NS2B/NS3pro was much 
lower at pH 7.5.28 The relative catalytic activity of DENV NS2B/NS3pro was therefore measured 
(Figure 4.11) at a lower pH (7.5 and 8.5) and was compared to the standard condition used (pH 9.5). 
Fortunately, reasonable measurable catalytic activity was noted at pH 7.5 (Figure 4.8), allowing the 
evaluation of the keto-amide inhibitors with some confidence.  
 
 
Figure 4.11: The effect of pH in DENV protease substrate processing. The catalytic 
activity observed in the standard pH (9.5) used was normalized as 100%, negative 
control was normalized as 0%. Reduced substrate hydrolysis was observed at pH 8.5 
and 7.5. Assay conditions were [E] DENV2 NS2B/NS3pro, 50 nM; [S] Ac-LKRR-
pNa, 250 µM, 50 mM TRIS-NaOH buffer, 37 ˚C, with 10 mM NaCl and 30% 
glycerol. Error bars represent mean ± SEM of at least two independent experiments.  
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4.3.5 Evaluation of inhibitors 
Introduction of an extra α-methylene group (4.1) was detrimental, where PhAc-KRR-
CH2CHO was found to be completely inactive against DENV protease (Table 4.3). This suggested 
that the relative position of the aldehyde isostere to the oxyanion hole was critical in inhibitor 
binding. Extension of the aldehyde moiety was not tolerated and the parent C-terminal aldehyde 
(2.1) remained most optimal.  
 
Table 4.3: Evaluation of DENV protease α-keto amide inhibitors 
ID Inhibitors pIC50 ± SEM IC50 (µM) 
2.1 PhAc-KRR-CHO 4.99 ± 0.72 10 
4.1 PhAc-KRR-CH2CHO <4 >100 
4.2 Ac-DTLKRR-α-keto amide-SWPL-NH2 4.09 ± 0.29 81  
4.3 PhAc-KRR-α-keto amide <4 >100  
4.4 PhAc-KRR-α-keto amide-SWPL-NH2 ND 28%* 
4.5 PhAc-KRR-α-keto amide-SGS-NH2 ND 63%* 
4.6 PhAc-KRR-α-hydroxy amide-SGS-NH2 ND 38%* 
4.7 PhAc-KR(nitro)R-α-keto amide-SGS-NH2 <4 >100  
4.8 PhAc-KRR-α-keto amide-DGS-NH2 ND 17%* 
4.9 PhAc-KRR-α-keto amide-EGS-NH2 ND 31%* 
4.10 PhAc-KRR-α-keto amide-SGSG-NH2 4.43 ± 0.11 37  
*percentage of inhibition at 100 µM. ND = not determined. Inhibitors were pre-incubated with DENV 
NS2B/NS3pro for 50 min. Assay conditions were [E] DENV2 NS2B/NS3pro, 50 nM; [S] Ac-LKRR-pNa, 250 
µM, 50 M Tris-NaOH buffer, 37 ˚C, pH 7.5, with 10 mM NaCl and 30% glycerol. The above values were 
calculated from at least three independent experiments (n ≥ 3) with statistical significance of p ≤ 0.05.  
 
Compound 4.2 (IC50 = 81 µM) was found to be moderately active against DENV 
NS2B/NS3pro protease. This provided some confidence that an α-keto amide did confer some 
binding towards DENV NS2B/NS3pro, and it was thought that the weak inhibition was due to the 
suboptimal native cleavage sequence failing to occupy the binding sites optimally. Compound 4.3, 
targeting only the non-prime side binding sites, was found to be inactive against DENV protease. 
The complete loss of activity was unexpected, as an α-keto amide shared similar electrophilic 
properties to an aldehyde.12 However, it was thought that the aldehyde may have been more 
sterically favoured to form interactions with the active site. Replacement of the native non-prime 
sequence with the reported optimal non-prime binding sequence (4.4, 28% inhibition at 100 µM) 
was unfavoured. On the other hand, incorporation of optimal non-prime and prime binding 
sequence in 4.5 proved to be beneficial (63% inhibition at 100 µM).   
Replacing the α-keto amide moiety with its synthetic precursor (α-hydroxy amide) gave a 
less potent inhibitor (4.6, 38% inhibition at 100 µM). It was worth noting that although the α-
hydroxy amide was incapable of forming the covalent bond with the protease, it was only one-fold 
less potent than its electrophilic α-keto amide counterpart (4.5). This led to speculation that the α-
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keto amide may not be engaging with the oxyanion hole optimally, as α-keto amides are well-
established protease inhibitors (just like aldehydes) with strong affinity for serine proteases. 
Masking of the P1-arginine group was also not tolerated (4.7), with complete loss of inhibition 
observed. This was not entirely unexpected, as maintaining the key ionic interaction with the S1-
Asp129 was expected to be critical for maintaining inhibitor potency.1  
 Glutamic acid (4.9, 31% inhibition at 100 µM) was preferred at P1’ position compared to 
the shorter aspartic acid (4.8, 17% inhibition at 100 µM). Unfortunately, it was found that both 
substitutions were unfavoured at this position compared to the native P1’-Ser (4.5, 68% inhibition 
at 100 µM). This suggested that both residues had likely failed to target the intended basic Arg54 
residue.  
To summarize, all of the P4-P3’ heptapeptide keto-amide inhibitors performed poorly 
against DENV protease. Despite having additional prime residues, these inhibitors were 
significantly less potent compared to the tetrapeptide aldehyde parent compound (2.1). It was 
therefore speculated that the introduction of a P4’ residue may afford additional binding affinity. 
The optimal P1’-P4’ sequence was utilized and some improvement in inhibitor potency was 
observed in PhAc-KRR-keto-SGSG (4.10, IC50 = 37 µM).  
Compound 4.10 was docked onto the crystal structure of DENV NS2B/NS3pro (PDB: 
3U1I) to examine its interactions with the protease. From the modelling studies (Figure 4.12), one 
of the terminal nitrogens of the P1-Arginine was engaged in an unimodal ionic interaction with the 
S1-Asp129 residue, while the other formed a hydrogen bonding interaction with the carbonyl 
backbone of Phe130. The α-keto amide formed a covalent bond with the nucleophilic Ser135 
residue, hence locking the peptide in place in the active site.  
(A) (B) 
 
 
Figure 4.12: Predicted interactions for PhAc-KRR-α-keto amide-SGSG-NH2 (grey) with DENV 
NS2B/NS3pro using GOLD (GoldSuite5.1). Interacting residues are highlighted in green. The P3-
P2 residues were removed for clarity. (A) Docking pose of 4.10 (PDB:3U1I). (B) Schematic view 
of putative interactions between 4.10 and DENV protease. Electrostatic potential surface was 
generated using Pymol (Red= acidic, blue = basic, grey = hydrophobic). 
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 The P1’-Ser residue did not form a hydrogen bond with S1’-His51, as previously noted by 
Wikberg and co-workers. It was thought that introduction of the α-keto-amide (equivalent to a 
“beta” amino acid) may displace the relative position of the side chain of the prime binding 
residues, resulting in the loss of interaction with the key S1’ residue. Instead, the NH backbone of 
P1’-Ser was predicted to form a hydrogen-bonding interaction with His51. On the other hand, the 
carbonyl backbone of P2’-Gly was predicted to engage in a hydrogen-bonding network with Arg54. 
The initial aim was to introduce an acidic P1’ side chain to gain an ionic interaction with the basic 
Arg54 residue, but the modeling studies suggested that the P1’ residue was now projected away 
from the putative S1’ pocket. This may explain why having P1’ acidic residues (4.8, 4.9) met with 
little success. No interactions were noted for the P3’-Ser residue.  The amide backbone of P4’ on 
the other hand was predicted to form hydrogen bonding interactions with the NHs backbone of 
Val52 and Thr53 (originally predicted in the S3’ pocket).  This may explain why having an 
additional P4’ residue led to improved inhibitor potency. 
In general, it was observed that having prime binding residues did contribute to inhibitor 
potency, where compounds with prime binding residues exhibited higher inhibitory activity against 
DENV NS2B/NS3pro compared to the parent α-keto amide inhibitor (4.3). However, the predicted 
model (Figure 4.12) suggested that the P1’-P4’ prime-binding residues of 4.10 did not adopt the 
typical beta-sheet binding conformation as commonly observed for protease substrates/inhibitors.29 
Due to the size limitations of the DENV protease active site, formed by shallow indentation in the 
substrate-binding groove, there might be an atypical spatial requirement for inhibitor binding 
resulting in a “misplacement” of the side chains with their corresponding binding pockets relative to 
other proteases. Despite the addition of the prime binding moieties (4.10, PhAc-KRR-α-keto 
amide-SGSG, IC50 = 37 µM), there was a lack of improvement of potency compared to the parent 
aldehyde (2.1, PhAc-KRR-CHO, IC50 = 10 µM).  This suggested that utilizing an α-keto amide 
moiety may not be compatible to serve the purpose of targeting the DENV protease, and targeting 
the prime-binding sites may not have a significant advantage in inhibitor binding due to steric issues 
in this case. 
A closer look at the predicted model (Figure 4.13) suggested that the α-keto amide moiety 
was able to form a tetrahedral intermediate with the catalytic Ser135 residue through formation of a 
covalent bond. The polarized carbonyl oxygen formed a hydrogen bond network with the oxyanion 
hole residues (Ser135, Thr132). In addition, the adjacent carbonyl oxygen also formed a hydrogen 
bond with the NH backbone of Thr132. Despite the apparent formation of an effective oxyanion 
hole in the presence of PhAc-KRR-α-keto amide-SGSG-NH2, this observation must be approached 
with caution as covalent and hydrogen-bonding constraints were introduced during the modeling 
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studies employing GOLD (GoldSuite5.1).  In addition, this peptide (4.10, IC50 = 37 µM) was still 
three-fold less potent than the parent aldehyde inhibitor PhAc-KRR-CHO (IC50= 10 µM) which 
remained a more effective inhibitor than all the α-keto amides examined. 
 
 
Figure 4.13: Predicted interactions of the α-keto 
amide isostere with the oxyanion hole residues using 
GOLD (GoldSuite 5.1) (PDB: 3U1I). 
 
4.4 DENV NS2B/NS3PRO - AN ENIGMA 
Thus far, two electrophilic warheads, aldehyde (Chapter 3) and α-keto amide (Chapter 4), 
have been employed in a bid to generate more potent DENV NS2B/NS3pro inhibitors. Despite 
considerable effort, both approaches have failed to generate highly potent inhibitors against DENV 
NS2B/NS3pro.  This was entirely unexpected, as the use of aldehyde electrophilic isostere in an 
analogous flaviviral protease, WNV protease, on the other hand did afford inhibitors that were 
>100-fold more potent.1  Furthermore, electrophilic isosteres are known to bind strongly to other 
serine proteases by forming a covalent bond with the catalytic serine residue, as successfully 
demonstrated in the development of highly potent tryptase inhibitors (both aldehyde and α-keto-
amide) in Chapter 2. This led to the hypothesis that the oxyanion hole of DENV may be defective, 
therefore failing to effectively interact with electrophilic inhibitors in a typical manner. In addition, 
DENV protease exhibited optimal proteolytic activity at elevated pH, which is an uncommon trait 
amongst serine proteases. This suggested that DENV NS2B/NS3pro may have an atypical catalytic 
site, and the oxyanion hole may be the key component that contributes to the unusual behavior in 
the protease.  
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To investigate this hypothesis, the crystal structures of DENV NS2B/NS3pro were 
compared to crystal structure of classic trypsin-like serine protease (Figure 4.15) to elucidate the 
key determinant that rendered DENV protease a difficult target, even for covalent electrophilic 
inhibitors. In thrombin, a typical oxyanion hole was observed, where it comprised of NHs backbone 
of Gly193 and Ser195 (Figure 4.15A). These nitrogen atoms form a partial positively charged 
pocket which activated the carbonyl of the scissile P1-P1’ amide bond by enhancing the 
polarization of the carbonyl group of substrate/inhibitor through hydrogen-bonding interactions. 
This in turn stabilizes the formation of an oxyanion in the high-energy tetrahedral intermediate.   
 
(A) Thrombin (B) DENV  (C) WNV 
   
Figure 4.15: Effective (A) versus defective (B,C) oxyanion holes in ligand-free state. (A) 
Thrombin (PDB:1BMM). (B) DENV (PDB:2FOM). (C) WNV (PDB:2FP7).  
 
In both ligand-free (Figure 4.15A) complex, the NH backbone of Gly193 of thrombin 
pointed correctly towards the polarized carbonyl group of the tetrahedral complex formed between 
the inhibitor and catalytic serine residue. However, the NH backbone of Gly133 (equivalent to 
Gly193 of thrombin) of DENV NS2B/NS3pro was flipped (Figure 4.15B). This might explain why 
the enzyme might not function under physiological conditions, as the oxyanion hole was now non-
functional and unable to stabilize the developing negative charge on the polarized carbonyl group of 
the tetrahedral intermediate. Such a defective oxyanion hole was also present in the crystal structure 
of WNV NS2B/NS4pro (Gly133) (Figure 4.15C), which was also reported to have an optimal 
catalytic pH ~10.  
However, the defective oxyanion hole (Figure 4.15B-C) evidently adopted the correct 
oxyanion hole arrangement in the presence of an inhibitor (Figure 4.16). In the inhibitor-bound 
crystal structures of DENV and WNV proteases (Figure 4.16B-C), the NHs from the backbone of 
the corresponding glycines were now in the correct orientation to “restore” the oxyanion hole which 
was then functional. It was therefore postulated herein that DENV and WNV might have an 
“induced” oxyanion hole, which is only corrected in the presence of an effective ligand, or by a 
conformation induced either at basic pH or perhaps in vivo by a cofactor-induced conformational 
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change. In other words, the ligand-free proteases were “zymogen” like and adopted an inactive 
form that could be “activated” through a conformational change induced by inhibitor binding. 
 
(A) Thrombin (B) DENV  (C) WNV 
   
Figure 4.16: Interactions of ligand with oxyanion hole residues. (A) Typical oxyanion hole 
stabilization in Thrombin (PDB: 1BMM). Possibly faulty transition state intermediate 
formation observed in (B) DENV (PDB: 3U1I); and (C) WNV (PDB:3U1J). 
 
Despite having the correct oxyanion hole in the inhibitor-bound state, the electrophilic 
covalent inhibitor (Bz-Nle-Lys-Arg-Arg-CHO) still failed to bind strongly to the DENV protease. 
The crystal structure (Figure 4.16B) revealed that the polarized carbonyl oxygen of the DENV 
covalent inhibitor was pointing “upwards” but not towards the fully functional oxyanion hole 
(Figure 4.16B). A thorough examination revealed that there was a water molecule and a sulphate 
ion wedged in the oxyanion hole (Figure 4.17).  
 
 
Figure 4.17: Interactions between the P1-Arg of Bz-Nle-Lys-Arg-Arg-CHO 
(green) and the oxyanion hole residues (grey) of DENV protease (PDB:3U1I).  
The water molecule is represented by yellow sphere. 
 
In some cases, “localized” water molecules trapped between inhibitors/substrates and 
protease binding sites could serve as “moieties” of the ligand and/or protease. They may link the 
ligand to the protease to the protease, hence optimizing interactions of the ligand with the binding 
site.30 In this case, the water molecule was within reasonable distance (2.7- 3.4 Å) to the NH 
backbone of Gly133 and the scissile peptide carbonyl group to participate in hydrogen-bonding 
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interactions. It was therefore proposed that a “water-bridged” hydrogen bonding interaction may 
assist the stabilization of scissile peptide carbonyl group.  However, it was also noted that the 
polarized carbonyl oxygen of the WNV NS2B/NS3pro inhibitor was also pointing away from the 
oxyanion hole, and the peptide aldehyde was highly potent against the protease thereby still not 
explaining why the DENV counterpart performed poorly. Nevertheless, the formation of the 
atypical tetrahedral complex was unexpected, and it could be an artifact of the environment that the 
inhibitor-bound crystal structure was prepared in.  
 It has been previously shown that the NS2B cofactor of DENV protease was more prone to 
detach from the NS3pro domain compared to WNV protease, causing structural disruption at the S2 
and S3 binding sites.22, 23 Consequently, the DENV inhibitor must first “stabilize” the NS2B/NS3pro 
upon binding to the complex to aid the formation of the active site, followed by formation of 
interactions with active site residues. As a result, the DENV protease inhibitor was postulated to 
have a much higher binding entropy penalty as compared to the WNV protease, which was 
predominantly found as the active closed form. Despite not engaged in oxyanion stabilization in the 
crystal structure, it was possible that the WNV protease inhibitor, once tethered to the active site 
through a covalent bond, was able to form optimal interactions with the protease without being 
penalized by increased binding entropy, thereby contributing to its superior activity over the DENV 
counterpart. Conversely, the increased entropy penalty coupled with the lack of stabilization by the 
oxyanion hole may explain the incompetent inhibitory profile exhibited by DENV protease 
aldehyde inhibitors. Ultimately, this suggested that to effectively target DENV protease and 
produce potent DENV NS2B/NS3pro inhibitors, oxyanion stabilization has to be achieved to 
compensate for the increased binding entropy penalty.  
 Examination of the crystal structure of the highly potent inhibitor, aprotinin, bound to the 
DENV NS2B/NS3pro protease (Figure 4.18, PDB:3U1J) revealed that the scissile peptide carbonyl 
group of aprotinin pointed correctly towards the fully functional oxyanion hole, thereby achieving 
oxyanion hole stabilization. Despite not forming a covalent bond with the protease, the inhibitor 
was found to be highly potent (Ki = 0.026 µM) compared to the covalent tetrapeptide aldehyde 
inhibitor (Bz-Nle-Lys-Arg-Arg-CHO, IC50 = 15 µM). As aprotinin is a macromolecule, it was 
postulated that it might have attained good inhibition through disruptive steric effects on the 
protease binding sites. However, recent studies by Doan et al. suggested that the binding affinity of 
aprotinin might be contributed by critical ionic interactions of the P3-Arg39 with a previously 
neglected acidic region of the C-terminus of the cofactor NS2B31.  
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Figure 4.18: Interactions of P1 residues with the DENV protease oxyanion 
hole. P1-Arg of the peptide aldehyde, Bz-Nle-Lys-Arg-Arg-Cho 
(PDB:3U1I), was shown in yellow, while the P1-Lys of aprotinin 
(PDB:3U1J) was shown in maroon. The oxyanion was shown in grey. 
 
Nevertheless, the ability of aprotinin to form a proper oxyanion stabilization network led to 
our speculation that the transition state isosteres employed thus far were not suited to achieve such 
an outcome. This modeling study suggested that an incorrectly formed oxyanion hole might not be 
the problem since it was in the correct configuration in the inhibitor-bound state. Instead, there 
could be some inherent problems with the chosen electrophilic isosteres (aldehyde and α-keto 
amide) rendering them incompatible to engage in oxyanion hole stabilization specifically in DENV 
NS2B/NS3pro protease. They may not have the right geometry to project the carbonyl group in the 
right orientation when bound to the protease, and the distortion could be a result of other 
interactions with the protease from another “segment” of the inhibitor. Initially, it was thought that 
introducing prime binding residues through an α-keto amide isostere could potentially “correct” the 
atypical transition state intermediate, and allow stabilization of the polarized carbonyl group. 
However, the resulting interactions with DENV protease did not realize potent inhibition.   The 
lesson to be extracted from this observation was to apply a geometrically compatible isostere 
capable of forming optimal interactions with the oxyanion hole residues. 
Previously, Yin et al. reported a series of warheads to target DENV protease (Table 4.4). 32 
Similar to this project, it was observed that the aldehyde (Ki = 5.8 µM) provided moderate 
inhibition, while C-terminal α-keto amide (Ki = 178 µM) performed poorly against the protease. 
They postulated that the instability of the α-keto amide at the pH used (8.5) may contributed to the 
lack of potency observed, however pH 7.5 was used in this study and chemical instability was not 
likely. It was also possible that the predicted model of the α-keto amide (Figure 4.12, section 4.3.5) 
may not reflect actual interactions with the oxyanion hole residues under the assay conditions due to 
the constraints introduced in the modeling studies. Trifluoromethylketone (Ki = 0.85 µM) and 
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boronic acid (Ki = 0.043 µM) electrophilic insertions were the most potent inhibitors of the series 
reported by Yin et al. with the latter being the most potent electrophilic warhead against DENV 
protease. The trend observed was however not further explained or elaborated by Yin and co-
workers. 
 
Table 4.4: Warhead employed in DENV protease inhibitors 
Compound Ki (µM) 
Bz-nKRR-COOH >500 
Bz-nKRR-CONH2 127.5 
Bz-nKRR-NHSO2CF3 >500 
Bz-nKRR-CHO 5.8 
Bz-nKRR(OH)-CONH-Bn 178 
Bz-nKRR-Benzoxazole 82.9 
Bz-nKRR-Thiazole  42.5 
Bz-nKRR-CF3 0.85 
Bz-nKRR-B(OH)2 0.043 
 
We now believe that the key factor that dictates inhibitor binding and potency is likely to be 
linked to the structural and chemical properties of these isosteres.  Upon forming a covalent bond 
with the oxyanion hole, the aldehyde (Figure 4.19A) and α-keto amide (Figure 4.19B) tetrahedral 
complex comprise only one hydroxyl group (partial developing negative charge) capable of forming 
interactions with the oxyanion hole, and this was clearly not achieved evidently due to the “faulty” 
geometry of the tetrahedral complex seen in the crystal structure previously discussed.  
 
(A) Aldehyde 
 
(B) α-keto amide (A) Boronic acid  (D) Trifluoromethylketone 
 
 
 
 
Figure 4.19: Electrophilic isosteres used against DENV NS2B/NS3pro 
 
Docking studies of the α-keto amide isostere showed that the isostere could adopt a 
tetrahedral conformation (Figure 4.20A) to engage productively with the oxyanion hole residues. 
However it could potentially also form the atypical tetrahedral complex (Figure 4.20B), as observed 
in the crystal structure of the previously discussed aldehyde inhibitor. On the other hand, the 
boronic acid tetrahedral complex comprises two hydroxyl groups, either of which could form 
interactions with the oxyanion hole residues (Figure 4.20C). It is therefore thought that one of the 
hydroxyl groups has successfully engaged in oxyanion hole stabilization and contributed to the 
excellent potency observed.   
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(A)  (B)  (C)  (D)  
    
 
Figure 4.20: Predicted interactions of electrophilic warhead with DENV protease oxyanion hole 
residues (cyan) (PDB:3U1I). (A) α-keto amide engaging in oxyanion hole stabilization. (B) α-keto 
amide failing to form an interaction with the oxyanion hole residues. (C) Boronic acid engaging in 
oxyanion hole stabilization. One of the hydroxyl groups was pointing towards the oxyanion cleft. 
(D) Trifluoromethylketone engaging in oxyanion hole stabilization. The trifluoromethyl group was 
directed away from the oxyanion hole (presumably due to steric hindrance) while the polarized 
carbonyl oxygen was found directed towards the oxyanion hole. 
  
Similarly, the trifluoromethylketone (Figure 4.20D) comprises a hydroxyl group and a 
trifluoromethyl moiety, both capable of forming hydrogen bonding interactions with the oxyanion 
hole in the right geometry. The trifluoromethylketone analogue was reported to be inferior 
compared to the boronic acid isostere, and this could be due to the negative steric effect of the bulky 
trifluoromethyl group (less accommodated in the oxyanion cleft). These novel observations 
suggested that the capability of engaging with the oxyanion hole may be critical for inhibitor 
binding for DENV NS2B/NS3pro, and that the geometry of electrophilic isosteres may be the key 
factor that dictates productive interactions with the oxyanion hole residues.  
 In summary, this thesis has reported the use of two electrophilic isosteres to produce 
moderately active DENV protease inhibitors. In Chapter 3, an aldehyde was utilized as a peptide 
warhead to efficiently map the binding specificities at the non-prime binding sites in the earlier 
inhibitor optimization studies, due to their relatively ease of synthesis. In this chapter, α-keto 
amide was the isostere of choice to serve the purpose of targeting the prime binding sites, however 
this approach failed to improve the potency of the inhibitor despite having the additional prime-
targeting sequence. Ultimately, this suggested that future studies should focus on further 
optimization of the non-prime active sequence, with incorporation of geometrically favoured 
boronic acid as the electrophilic isostere to promote better binding with the protease.  Due to time 
constraints, the use of boronic acid in the development of DENV protease inhibitors was not 
pursued but will be investigated in future studies. 
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4.5 FACTOR B α-KETO AMIDE INHIBITORS 
 
4.5.1 Characterization of prime-binding sites 
Factor B is a trypsin-like serine protease with a preference for basic resides at P1 position.2 
The prime binding pockets of Factor B have yet to be characterized and explored. Based on the 
native C3 cleavage sequence, SHLGLARSNLD, it seemed that small and polar amino acids are 
generally recognized by Factor B at P1’-P4’ positions.2 To map the structural binding requirement 
at the prime binding pockets, Ac-RL(Tba)LAR-CHO was docked onto the crystal structure of 
Factor B (PDB:2OK5). It was crucial to note that the structure of ligand-free Factor B protease had 
only been determined at neutral pH, conditions in which the enzyme was inactive. Therefore 
interpretation of modelling must be approached with caution.  A close examination of the Factor B 
binding site suggested that the putative prime binding pockets were quite shallow and not 
prominent (Figure 4.21, Table 4.5). The S1’ and S4’ pockets were not well-defined. The S2’ pocket 
was found to be acidic (Asp673, Glu610) and shallow, while the S3’ pocket was slightly 
hydrophobic and shallow. 
 
 
Figure 4.21: Putative modeled ligand-binding site in the crystal structure of Factor B (PDB:2OK5). 
Electrostatic potential surface was generated using Pymol (Red= acidic, blue = basic, grey = 
hydrophobic). 
 
 
Table 4.5: Putative prime-side binding pockets of Factor B 
Pocket Protease residues Observation Suitable amino acid 
S1’ Asp673, Gly672, Ser674 Ill-defined Small, polar 
S2’ Asp673, Ser609,  Cys670 Shallow, acidic  Small, basic 
S3’ Glu610, Met487 Shallow, hydrophobic Small, non-polar 
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4.5.2 Design and synthesis of Factor B α-keto amide inhibitors 
The central design (Figure 4.22) involved incorporation of: (1) a previously reported optimal 
non-prime binding arm (Ac-RL(Tba)LAR), (2) an α-keto amide isostere at P1-P1’ position, and (3) 
P1’-P4’ prime residues to target the previously unexploited prime binding sites (Figure 4.19). 
 
 
 
Figure 4.22: Design of putative Factor B α-keto amide inhibitors. 
  
The reported peptide aldehyde inhibitor, Ac-RL(Tba)LAR-CHO (4.11), was synthesized as 
a reference inhibitor for in-house evaluation. A series of α-keto amide peptide inhibitors (Table 4.6) 
was designed and synthesized to target Factor B protease. The first α-keto amide inhibitor in the 
series employed the optimal P6-P1 sequence previously reported, Ac-RL(Tba)LAR-α-keto amide 
(4.12), The α-keto amide isostere was then replaced by α-hydroxy amide (4.13) to examine their 
potential in forming interactions with the nucleophilic catalytic serine residue. The P1 arginine was  
replaced by a non-basic nitro-arginine (4.14) to examine to the effect of removing the charged 
group at P1 position, in an effort to improve the drug-like properties of the inhibitor. Compound 
4.15, incorporating P1’–P3’ (Ser-Asn-Leu) derived from the native cleavage sequence, was 
synthesized to probe the prime binding pockets (S1’-S3’). To target the acidic S2’ pocket, small 
basic residues such as Dap (4.16) and AGB (4.17) were introduced in place of the polar P2’-Asn 
residue in order to form an ionic interaction with the Asp673 in the S2’ pocket. Compound 4.18 
incorporated a P4’ residue to probe the S4’ pocket as potential binding pocket.  
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Table 4.6: Factor B α-keto amide inhibitors 
ID COMPOUND 
4.11 Ac-RL(Tba)LAR-CHO  
4.12 Ac-RL(Tba)LAR-α-keto amide 
4.13 Ac-RL(Tba)LAR-α-hydroxy amide 
4.14 Ac-RL(Tba)LA(nitro)R-α-keto amide 
4.15 Ac-RL(Tba)LAR-α-keto amide-SNL-NH2 
4.16 Ac-RL(Tba)LAR-α-keto amide-S[Dap]L-NH2 
4.17 Ac-RL(Tba)LAR-α-keto amide-S[Agb]L-NH2 
4.18 Ac-RL(Tba)LAR-α-keto amide-SNLD-NH2 
 
4.5.2 Optimization of Factor B protease assay 
Due to susceptibility of the keto-amide peptides to decomposition at basic pH26, the assay 
conditions were optimized to ensure that the inhibitors remained intact throughout the bioassay 
experiments. Previous reports suggested that Factor B displayed optimal catalytic activity at pH 9-
10, and a decrease in pH led to inactivity.  The catalytic activity of Factor B was examined at pH 
9.5, 8.5 and 7.5 (Figure 4.23). Consistent with previous reports2, 16, Factor B was found to the most 
active at basic (pH 9.5), with much less activity at pH 8.5 but just sufficient proteolytic activity for 
measurement of inhibitor activity. There was a complete absence of activity at pH 7.5. Therefore, 
pH 8.5 was chosen for inhibition studies using keto-amide inhibitors, as they were relatively stable 
at this pH.  
 
Figure 4.23: Effect of pH on Factor B substrate hydrolysis.  The catalytic activity observed in 
standard pH used (9.5) was normalized as 100%. Negative control was normalized as 0%. 
Reduced substrate hydrolysis was observed at pH 8.5 and 7.5. Assay conditions were [E] Factor 
B, 50 nM; [S] AcSHLGLAR-pNa, 200 µM, 100 mM glycine-NaOH buffer, 37 ˚C, with 150 
mM NaCl. Error bars represent mean ± SEM of at least two independent experiments. 
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4.5.3 Evaluation of inhibitors 
The parent aldehyde inhibitor, Ac-RL(Tba)LAR-CHO (4.11) was previously reported2 to be 
a highly potent inhibitor of Factor B with an IC50 of 250 nM ([Ac-SHLGLAR-pNa] = 500 µM, pH 
9.5, 37 ˚C). Under the same conditions, the IC50 of 4.11 was determined herein as just 439 nM. At 
pH 8.5, a two-fold decrease in inhibitor potency was noted for 4.11 (IC50 = 867 nM; [Ac-
SHLGLAR-pNa] = 500 µM, pH 8.5, 37 ˚C) (Table 4.7). It was postulated that Factor B protease 
may undergo conformational changes in response to pH changes, which may lead to structural 
changes in the substrate-binding grooves, resulting in slightly less efficient binding of the aldehyde 
inhibitor. The rest of the inhibitors in the series (Table 4.7) were assayed at pH 8.5 due to instability 
issues with the P1-Arg α-keto amide side chain. 
 
Table 4.7: Evaluation of Factor B α-keto amide inhibitors 
ID Compound pIC50 ± SEM IC50 (µM) 
4.11 Ac-RL(Tba)LAR-CHO  (pH 9.5) 6.36 ± 0.08 0.44 
4.11 Ac-RL(Tba)LAR-CHO  (pH 8.5) 6.06 ± 0.08 0.87 
4.12 Ac-RL(Tba)LAR-α-keto amide 4.58 ± 0.70 27 
4.13 Ac-RL(Tba)LAR-α-hydroxy amide < 4 >100 
4.14 Ac-RL(Tba)LA(nitro)R-α-keto amide < 4 >100 
4.15 Ac-RL(Tba)LAR-α-keto amide-SNL-NH2 4.42 ± 0.24 38 
4.16 Ac-RL(Tba)LAR-α-keto amide-S[Dap]L-NH2 4.37 ± 0.11 43 
4.17 Ac-RL(Tba)LAR-α-keto amide-S[Agb]L-NH2 4.33 ± 0.36 47 
4.18 Ac-RL(Tba)LAR-α-keto amide-SNLD-NH2 < 4 >100 
Inhibitors were pre-incubated with Factor B for 50 min. Assay conditions were [E] Factor B, 50 nM; [S] 
AcSHLGLAR-pNa, 200 µM, 100 mM glycine-NaOH buffer, 37 ˚C, with 150 mM NaCl. Error bars represent mean 
± SEM of at least two independent experiments. The above values were calculated from at least three independent 
experiments (n ≥ 3) with statistical significance of p ≤ 0.05. 
  
Compound 4.12, Ac-RL(Tba)LAR-α-ketoamide (IC50 = 27 µM), was found to be 
moderately active against Factor B, but it suffered a 30-fold decrease in inhibitor potency compared 
to the reference aldehyde inhibitor (4.11, IC50 = 867 nM). Similar to DENV protease, it seemed that 
the aldehyde was the more optimal isostere compared to the α-keto amide analogue, despite both 
having similar electrophilic properties. It was suspected that the α-keto amide isostere may not be 
stable in the assay conditions (pH 8.5), in which slight degradation of the isostere has been 
previously reported. Replacement of the α-keto amide isostere with the less reactive α-hydroxy 
amide isostere (4.13) proved to be less favourable, with substantial loss in potency presumably due 
to the loss of covalent bond interaction with the protease. Masking of the P1-Arg residue (4.14) was 
also undesirable with complete loss of activity, highlighting the importance of retaining the ionic 
interaction with the acidic S1 pocket.   
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Despite the addition of three prime residues, the nonapeptide (4.15, Ac-RL(Tba)LAR-α-
keto amide-SNL-NH2, IC50 = 38 µM) was less potent than the parent α-ketoamide inhibitor (4.12, 
IC50 = 27 µM). On the other hand, having a P2’ basic residue (4.16, 4.17) was less favourable 
compared to the native P2’-Ser (4.15, IC50 = 38 µM). This suggested that the basic residues had 
likely failed to target the intended acidic Asp673 residue.  Further attempt to improve inhibitor 
potency through targeting of the S4’ pocket (4.18) proved to be futile. 
Compound 4.15 was docked onto the crystal structure of Factor B (PDB:2OKB) to 
understand the interactions between the prime-side binding residues and the protease binding 
pockets. From the modeling studies (Figure 4.24), the P1-arginine was predicted to engage in an 
unimodal ionic interaction with Asp698, instead of the Asp671 (in close proximity) previously 
observed in the predicted model reported by Ruiz-Gomez and co-workers.2 The same terminal 
nitrogen may also form a hydrogen-bonding interaction with the amide backbone of Thr699. As the 
ligand-free crystal structure (PDB:2OK5) have a defective oxyanion hole, only partial stabilization 
by the NH backbone of catalytic Ser674 was observed for the polarized carbonyl group of the α-
keto amide warhead. Overall, the P1’-P3’ side chains failed to adopt a typical beta-sheet 
conformation to interact with the putative prime-binding pockets. Due to the narrow and shallow 
nature of the prime-side binding pockets, the P1-P1’ backbone had to adopt an atypical binding 
conformation. P2’-Asn (4.15) was predicted to engage in an ionic interaction with an acidic residue 
Glu484 and a hydrogen bond interaction with the amide back bone of His483. This may explain 
why the shortened basic residues Dap (4.16) and AGB (4.17), despite failing to interact with the 
intended Asp673 residue, were equally tolerated at this acidic region. The P3’-Leu on the other 
hand was predicted to interact with Gly672. 
(A) (B) 
  
Figure 4.24: Predicted interactions of Ac-RLTbaLAR-α-keto amide-SNL-NH2 with Factor B 
protease. The non-prime residues were omitted for clarity. (A) Docking pose of compound 4.15. 
(PDB: 2OK5) (b) Schematic view of interactions between compound 4.15 and Factor B. 
Electrostatic potential surface was generated using Pymol (Red= acidic, blue = basic, grey = 
hydrophobic). 
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 Overall, the α-keto amides were inferior inhibitors of Factor B compared to the reference 
aldehyde inhibitor (4.11, IC50 = 867 nM), suggesting that this isostere may not be compatible in 
drug development for Factor B. In addition, attempts to target the prime binding sites in Factor B 
have not been successful. All of the prime-targeting α-keto amide inhibitors (4.15-4.18, IC50 ≥ 38 
µM) were found to be less potent compared to the parent inhibitor (Ac-RLTbaLAR-α-keto amide, 
IC50 = 27 µM), suggesting that this approach was fruitless for improving inhibitor potency.  
 Similar to DENV protease, Factor B was most catalytically competent under basic 
conditions. Interestingly, examination of the crystal structure of Factor B (PDB:2OKB) revealed 
that the oxyanion hole of the free protease was also defective with the NH of Gly672 was found to 
be in the wrong configuration (Figure 4.25).  
 
(A) DENV   (B) Factor B  
  
Figure 4.25: Oxyanion hole residues in (A) DENV 
NS2B/NS3pro (PDB:2FOM); and (B) Factor B (PDB:2OK5). 
 
It was thought that the defective oxyanion hole observed in free proteases (WNV, DENV 
and Factor B) could perhaps be altered by pH due to changes in protonation state of a nearby 
residue (likely His or Lys) dependent on pH. All of the crystal structures of these proteases was 
determined at non-basic pH (5.5-7) conditions, where the proteases were in their catalytically 
incompetent forms. At elevated pH, protonation states of an active site residue or residues in close 
proximity (that could affect the orientation of the active site residues) were likely to change, and 
this might be conducive to reconfiguring the oxyanion hole to a catalytically “active” conformation. 
There is no reported inhibitor-bound crystal structure for Factor B to date, however it seems that the 
oxyanion hole would be “restored” upon inhibitor binding in a similar manner as DENV and WNV 
proteases. Evidently, the aldehyde inhibitor (4.11) was highly potent against the complement Factor 
B protease, unlike the enigmatic DENV protease, suggesting that the oxyanion hole configuration 
may not be a likely issue in future inhibitor development in this case.  
 Based on these results, it was thought that future inhibitor design should refocus on the non-
prime binding sites, where subsite optimizations could be carried out to further map the binding 
requirement at these positions utilizing the original aldehyde as the warhead of choice.  In future 
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studies, a peptidomimetic approach will be carried to probe the occupation of the non-prime 
pockets, allowing transition from peptide to more selective, potent and more non-peptidic inhibitors 
of Factor B. 	  	  	  
4.6 EXPERIMENTAL SECTION 
 
4.6.1 General Procedure 
Protected amino acids and resins (Rink-amide, 2-chlorotrityl and AM resin) were purchased 
from Auspep, Iris Biotech, PepChem, Chem-Impex Ltd and Novabiochem. Other reagents 
including TFA, piperidine, DIPEA, and DMF were obtained from AUSPEP. All the reagents used 
were reagent grade unless stated otherwise. Anhydrous DCM was obtained from an in-house 
anhydrous solvent dispenser. Crude peptides were purified using Shimadzu LC-20AP reversed-
phase high performance preparative liquid chromatography on a Phenomenex Luna C18 semi-
preparative column (100 Å, 250 x 10 mm, 5 micron), using a gradient of solvent A (0.1% 
TFA/water) and solvent B (0.1% TFA/ 10% water/ 90% acetonitrile). Final purified peptides were 
characterized using analytic HPLC, high-resolution mass spectrometry (HRMS) and NMR 
experiments. Analytical HPLC was performed using Shimadzu LCMS-2020 (SIL-30AC 
autosampler, BM-20A controller, and a SPD-M20A diode array detector) using a reverse-phase 
C18 Agilent column (2.1 x 75 mm, 5 micron). Equilibration was ran for 1 minutes (100% solvent 
A) at 0.4mL/min, followed by a linear gradient (0-100% solvent B) over 6 minutes, and lastly 
washed with 100% solvent B. Electrospray ionisation high-resolution mass spectra (ESI-HRMS) 
measurements were obtained on a Bruker microTOF mass spectrometer equipped with an 
Agilent 1100 Series LC/MSD mass detector in positive ion mode by direct infusion in MeCN at 100 
µL/h using sodium formate clusters as an internal calibrant.  NMR spectra was recorded on a 
Bruker Avance 600 spectrometer at 298 K unless stated otherwise, and spectra were processed 
using TOPSPIN software (Bruker, Germany). 
 
4.6.2 NMR spectroscopy and concentration determination 
NMR characterization. The peptide solutions were prepared in 600 µL of D2O/H2O (1:9). 
The proton NMR was recorded on a Bruker Avance 600 spectrometer at 298 K unless stated 
otherwise, and the proton chemical shifts were referenced to DSS (δ 0.00 ppm) in water. Water 
suppression and suppression of water resonance under low power irradiation during relaxation 
delay (1.5-3.0 s) were achieved through WATERGATE NMR experiments. Spectra were processed 
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using TOPSPIN software (Bruker, Germany). Peptide concentration determination. The 
concentration of peptides was determined for assay purposes using PULCON experiments ran using 
DRX-600 Mhz spectrometer. The 90˚ pulse of NMR samples was measured carefully by alternating 
the 360˚ pulse. This resulted in a null water signal in standard 1D proton experiments. For each 
peptide, the 90˚ pulse was remeasured with the following default settings: relaxation delay of 30s, 
receiver gain 64-512, 32-64 scans at 298 K. A Watergate pulse sequence was employed to suppress 
the water peak. Spectra were processed suing TOPSPIN, where manual correction of phase and 
integration of individual signals were carried out for concentration calculations.  
 
4.6.3 Synthesis 
The synthesis of substrate and α-keto amide inhibitors was reported in Chapter 2. 
 
4.6.4 Protease inhibition assay 
DENV	   NS2B/NS3pro. The peptide inhibitors were evaluated using a colorimetric 
inhibition assay in a CORNING3711 384-clear well plate. The peptide substrate, Ac-LKRR-pNA 
was designed in such a way where the native P4-P1 peptide sequence was appended to a para-
nitroanilide chromophore. The inhibitors was pre-incubated with 50 nM of DENV NS2B/NS3pro 
protease in a buffer comprising of 50 mM TRIS-NaOH, 10 mM of NaCl, 30% of glycerol at pH 7.5 
at 37 oC for 50 min. Ac-LKRR-pNA (250 µM) was added to initiate substrate cleavage giving a 
final volume of 50 µL. The reaction was measured using the release of the para-nitroaniline as a 
marker, which was measured at 405 nm using PHERAstar plate reader (BMG Labtech).  
 
Table 4.8: Assay Protocol for DENV protease inhibition assay. 
Component Volume (µL) 
Positive control Negative control Inhibitor well 
Buffer (2x) 25 25 25 
Water 12.5 17.5 7.5 
CHAPS 2.5 2.5 2.5 
Enzyme (500nM stock) 5 0 5 
Inhibitor (in water) 0 0 5 
Substrate (2.5 mM) 5 5 5 
Total volume (µL) 50 50 50 
    
Complement	   Factor	   B. The peptide inhibitors were evaluated using a colorimetric 
inhibition assay in a 96-clear well plate. The peptide substrate, Ac-SHLGLAR-pNA was designed 
in such a way where the native P6-P1 peptide sequence was appended to a para-nitroanilide 
chromophore. The inhibitors was pre-incubated with 50 nM of Factor B in a buffer comprising of 
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100 mM glycine-HCl and 150 mM NaCl pH 8.5 and 37 oC for 50 min. Ac-SHLGLAR-pNA (500 
µM) was added to initiate substrate cleavage giving a final volume of 100 uL. The reaction was 
measured using the release of the para-nitroaniline as a marker, which was measured at 405 nm 
using PHERAstar plate reader (BMG Labtech).  
 
Table 4.9: Assay Protocol for Factor B protease inhibition assay. 
Component Volume (µL) 
Positive control Negative control Inhibitor well 
Buffer (1x) 85 95 80 
Enzyme (500nM stock) 10 0 10 
Inhibitor (10x)  0 0 5 
Substrate (5 mM) 5 5 5 
Total volume (µL) 100 100 100 	  
 
4.6.5 Characterization of inhibitors 
4.6.5.1 DENV NS2B/NS3pro inhibitors 
Compound 4.1 PhAc-KRR-CHCHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.20-1.74 (m, 14H), 2.50-2.57 (m, 1H), 2.67-2.72 (m, 1H), 
2.81-2.89 (m, 2H), 2.99-3.07 (m, 4H), 3.54 (s, 2H), 3.80-3.86 (m, 1H), 4.03-4.21 (m, 2H), 6.97-7.08 
(m, 2H), 7.20-7.22 (d, J = 7.3 Hz, 2H), 7.23-7.26 (t, J = 7.4 Hz, 1H), 7.28-7.32 (t, J = 7.7 Hz, 2H), 
7.43 (br, 2H), 7.89-7.91 (d, J = 9.4 Hz, 1H), 8.02-8.04 (d, J = 9.1 Hz, 1H), 8.13-8.15 (d, J = 6.9 Hz, 
1H), 8.35-8.37 (d, J = 6.7 Hz, 1H), 9.49 (s, 1H).	   HRMS	   calculated	   for	   [M+2H]2+	  =	   288.1925	  (found	  288.1922).	  Rt	  =	  2.8	  min.	  
 
Compound 4.2   Ac-DTLKRR-α-keto amide-SWPL-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.73-2.03 (m, 37H), 2.07 (s, 3H), 2.63-3.01 (m, 10H), 3.3- 
3.79 (m, 6H), 3.97-5.01 (m, 11H), 6.95-7.39 (m, 6H), 7.55-7.78 (m, 2H), 7.79-7.93 (m, 3H), 8.19-
8.77 (m, 10H).	  HRMS	  calculated	  for	  [M+2H]2+	  	  =	  670.8753	  (found	  670.8750).	  Rt	  =	  3.1	  min.	  
 
Compound 4.3 PhAc-KRR-α-keto amide 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.20-1.76 (m, 14H), 2.85 (br, 2H), 2.98-3.12 (m, 4H), 3.54 
(s, 2H), 6.98-7.10 (m, 3H), 7.20-7.21 (d, J = 7.5 Hz, 2H), 7.23-7.26 (t, J = 7.4 Hz, 1H), 7.28-7.21 (t,  
J = 7.3 Hz, 2H), 7.43 (br, 2H), 7.63-7.68 (d, J = 10.2 Hz, 1H), 7.92-7.94 (d, J = 9.9 Hz, 1H), 8.07-
8.09 (d, J = 8.9 Hz, 1H), 8.14-8.15 (d, J = 6.5 Hz, 1H), 8.20-8.21 (d, J = 7.0 Hz, 1H), 8.31-8.35 (m, 
1H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  302.6875	  (found	  302.6874).	  Rt	  =	  2.9	  min.	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Compound 4.4   Phac-KRR-α-keto amide-SWPL-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.75-1.75 (m, 16H) 1.76-2.21 (m,10H), 1.80 (s, 3H), 2.53-
3.01 (m, 4H) 3.02-3.80 (m, 12H), 3.92-4.36 (m, 7H), 6.85-7.76 (m, 15H), 7.90-8.55 (m, 7H). HRMS	  calculated	  for	  [M+2H]2+	  =	  544.3116	  (found	  544.3117).	  Rt	  =	  3.2	  min.	  
 
Compound 4.5 Phac-KRR-α-keto amide-SGS-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.13-1.79 (m, 14H), 1.96 (s, 3H), 2.80-2.89 (br, 2H), 2.98-
3.13 (m, 4H), 3.54 (s, 2H), 3.70-4.21 (m, 12H), 6.87-7.12 (m, 3H), 7.20-7.21 (d, J = 7.3 Hz, 2H), 
7.23-7.26 (t, J = 7.1 Hz, 1H), 7.29-7.31 (t, J = 7.5 Hz, 2H), 7.41 (br, 2H), 7.56-8.50 (m, 6H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  418.2303	  (found	  418.2305).	  Rt	  =	  3.3	  min.	  
 
Compound 4.6   Phac-KRR-α-hydroxy amide-SGS -NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.21-1.76 (m, 14H), 2.85 (br, 2H), 2.97-3.10 (m, 4H), 3.54 
(s, 2H), 3.67-3.91 (m, 6H), 4.03-4.42 (m, 6H), 6.95-7.11 (m, 3H), 7.19-7.32 (m, 6H), 7.42 (br, 2H), 
7.55-7.61 (m, 1H), 7.76-8.51 (m, 6H).	   HRMS	   calculated	   for	   [M+2H]2+	   =	   419.2381	   (found	  419.2380).	  Rt	  =	  3.1	  min.	  
 
Compound 4.7   Phac-KR(nitro)R-α-keto amide-SGS -NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.12-1.85 (m, 14H), 2.83 (br, 2H), 2.98-3.07 (m, 4H),  
3.53 (s, 2H), 3.69-4.33 (m, 12H), 6.98-7.10 (m, 3H), 7.20-7.21 (d, J =7.1 Hz, 2H), 7.23-7.25 (t, J = 
7.4 Hz, 1H), 7.29-7.31 (t, J = 7.1 Hz, 2H), 7.54-8.48 (m, 6H).	  HRMS	  calculated	   for	   [M+2H]2+	  =	  440.7228	  (found	  4410.7230).	  Rt	  =	  3.3	  min.	  
 
Compound 4.8   Phac-KRR-α-keto amide-DGS-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.10-2.11(m, 14H), 2.67-2.74 (m, 2H), 2.85 (br, 2H), 3.02-
3.07 (m, 4H), 3.54 (s, 2H), 3.74-4.04 (m, 10H), 6.99-7.12 (m, 4H), 7.20-7.22 (d, J = 7.1 Hz, 2H), 
7.23-7.26 (t, J = 7.3 Hz, 1H), 7.29-7.30 (d, J = 7.6 Hz, 2H), 7.41 (br, 2H), 7.76-8.56 (m, 6H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  432.2278	  (found	  432.2279).	  Rt	  =	  3.2	  min.	  
 
 
Compound 4.9   Phac-KRR-α-keto amide-EGS-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.23-2.09 (m, 16H), 2.31-2.39 (m, 2H), 2.85 (br, 2H), 
2.98-3.12 (m, 4H), 3.54 (s, 2H), 3.72-4.22 (m, 10H), 6.97-7.09 (m, 3H), 7.20-7.21 (d, J = 8.0 Hz, 
2H), 7.23-7.25 (t, J = 7.4 Hz, 1H), 7.28-7.31 (t, J = 7.3 Hz, 2H), 7.42 (br, 2H), 7.81-8.54 (m, 6H).	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HRMS	  calculated	  for	  [M+2H]2+	  =	  439.2356	  (found	  439.2360).	  Rt	  =	  3.3	  min.	  
 
Compound 4.10  Phac-KRR-α-keto amide-SGSG-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 1.18-2.15 (m, 14H), 2.85 (br, 2H), 2.97-3.11 (m,4H), 3.54 
(s, 2H), 3.71-4.38 (m, 15H), 6.89-7.08 (m, 3H), 7.20-7.21 (d, J = 7.2 Hz, 2H), 7.23-7.26 (t, J = 7.3 
Hz, 1H), 7.19-7.31 (d, J = 7.3 Hz, 2H), 7.38 (br, 2H), 7.73-8.54 (m, 7H).	   HRMS	   calculated	   for	  [M+2H]2+	  =	  446.7411	  (found	  446.7410).	  Rt	  =	  3.1	  min. 
 
4.6.5.1 Factor B inhibitors 
Compound 4.11   Ac-RL[Tba]LAR-CHO 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.76-0.77 (d, J = 6.1 Hz, 6H), 0.8 (d, 9H), 0.82-0.83 (m, 
6H), 1.27-1.28 (d, J = 7.14 Hz, 3H), 1.40-1.80 (m, 15H), 1.92 (s, 3H), 3.06-3.46 (m, 3H), 3.75-4.29 
(m, 6H), 5.33 (s, CHOH, 1H), 7.02-7.13 (m, 4H), 7.78-7.80 (d, J = 8.16 Hz, 1H), 7.90-7.92 (d, J = 
7.3 Hz , 1H), 8.11-8.19 (m,3H), 8.22-8.23 (d, J = 7.2 Hz, 1H).	  HRMS	  calculated	   for	  [M+2H]2+	  =	  381.2740	  (found	  381.2740).	  Rt	  =	  3.0	  min.	  
 
Compound 4.12   Ac-RL(Tba])LAR-α-keto amide 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.75-0.77 (m, 6H), 0.80 (s, 9H), 0.81-0.82 (d, J = 6.2 Hz, 
6H), 1.11-1.74 (d, 22H), 1.92-2.15 (m, 4H), 3.06-3.10 (m, 2H), 6.89-7.19 (m, 2H), 7.61-8.23(m, 
6H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  412.7769	  (found	  412.7770).	  Rt	  =	  3.1	  min.	  
* alpha-protons not visible due to water suppression 
 
Compound 4.13   Ac-RL(Tba)LAR-α-hydroxy amide 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.74-0.78 (t, J = 5.2 Hz, 6H), 0.80 (s, 9H), 0.81-0.83 (t, J = 
6.2 Hz, 6H), 1.22-1.26 (t, J = 6.8 Hz, 3H), 1.39-1.64 (m, 14H), 1.93 (s, 3H), 3.04-3.15 (m, 2H), 
6.18 (br , 1H), 6.76 (br, 1H), 7.03-7.20 (m, 5H), 7.61 (s, 1H), 7.66 (s, 1H), 7.76-7.80 (t, J = 10.4 Hz, 
1H), 7.86-7.87 (d, J = 7.2 Hz, 1H), 8.01-8.06 (m, 1H), 8.13-8.15 (d, J = 7.7 Hz, 1H), 8.16-8.18 (d, J 
= 6.3 Hz, 1H), 8.22-8.23 (d, J = 7.2 Hz, 1H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  413.7848	  (found	  413.7850).	  Rt	  =	  3.0	  min.	  
* alpha-protons not visible due to water suppression 
Compound 4.14   Ac-RL(Tba)LA(nitroR)-α-keto amide 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.73-0.78 (m, 6H), 0.80 (s, 9H), 0.81-0.83 (m, 6H), 1.20-
1.71 (m, 17H), 1.92 (s, 3H), 3.05-3.16 (m, 2H), 6.88 (br, 1H), 7.61 (s,1H), 7.83-8.27 (m, 7H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  435.2695	  (found	  435.2699).	  Rt	  =	  3.3	  min.	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* alpha-protons not visible due to water suppression 
 
Compound 4.15  Ac-RL(Tba)LAR-α-keto amide-SNL-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.72-0.85 (m, 27H), 1.12-1.73 (m, 23H), 1.93 (s, 3H), 
2.63-2.82 (m, 2H), 3.01-3.18 (m, 4H), 3.72-4.29 (m, 13H), 6.79-7.15 (m, 5H), 7.42-7.57 (m,2H), 
7.74-8.62 (m, 10H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  569.8564	  (found	  569.8567).	  Rt	  =	  3.5	  min.	  
 
Compound 4.16   Ac-RL(Tba)LAR-α-keto amide-S(Dap)L-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.74-0.85 (m, 27H), 1.18-1.71 (m, 22H), 1.94 (s, 3H), 
1.96-2.18 (m, 2H), 2.94-3.15 (m,5H), 3.69-4.27 (m, 9H), 6.97-7.13(m, 4H), 7.52-7.70 (m, 5H), 
7.72-8.68 (m, 9H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  555.8590	  (found	  555.8590).	  Rt	  =	  3.4	  min.	  
 
Compound 4.17   Ac-RL[Tba]LAR-α-keto amide-S(Agb)L-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.73-0.85 (m, 27H), 1.19-1.76 (m, 22H), 1.93 (s, 3H), 
3.02-3.23 (m, 5H), 3.73-4.27 (m, 9H), 6.97-7.18 (m, 4H), 7.51-7.61 (m, 1H), 7.73-8.58 (m, 9H).	  HRMS	  calculated	  for	  [M+2H]2+	  =	  583.8777	  (found	  583.8775).	  Rt	  =	  3.2	  min.	  
 
Compound 4.18   Ac-RL(Tba)LAR-α-keto amide-SNLD-NH2 
1H NMR (600 MHz, H2O:D2O, 9:1): δ = 0.70-0.85 (m, 27H), 0.95-1.74 (m, 35H), 1.91-1.93 (m, 
4H), 1.95 (s, 3H), 2.06-2.26 (m, 6H), 2.45-2.80 (m, 15H), 3.01-3.11 (m,5H), 3.71-4.26 (m, 10H), 
6.80-7.61 (m, 6H), 7.62-8.60 (m, 10H).	   HRMS	   calculated	   for	   [M+2H]2+	   =	   627.3699	   (found	  627.3700).	  Rt	  =	  3.6	  min.	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ABSTRACT 
 
A low-medium throughput screening campaign was employed in order to identify potential new 
inhibitors of DENV NS2B/NS3pro. A library of ~2000 structurally diverse natural products was 
assayed against DENV NS2B-NS3pro. During preliminary screening, 15 compounds exhibited 
>35% inhibition at a single concentration (5 µg/mL) and were identified as hits. A series of 
validation studies was carried out to eliminate false positives, especially those known to contribute 
to aggregate-based inhibition. Of the 15 hits, Phloeodictine X (IC50 = 43 nM), an alkaloid extracted 
from the New Caledonia sponge Phloeodictyon sp., was found to be the most potent inhibitor of 
DENV NS2B/NS3 protease.  Phloeodictine X comprises an unusual bicyclic 6-hydroxy-2,3,4,6-
tetrahydropyrrolo[1,2-alpha]pyrimidinium scaffold, a basic guanidinium side chain, and a 
hydrophobic alkyl chain. The mode of inhibition of Phloeodictine X was assessed by generating a 
Michaelis-Menten plot and a Lineweaver-Burk double reciprocal plot, which revealed competitive 
and reversible inhibition. Potential interactions between Phloeodictine X and DENV NS2B/NS3pro 
were studied using ligand-docking into a molecular model of the DENV NS2B/NS3pro crystal 
structure (PDB:3U1I). The guanidinium side chain was predicted to occupy the S1 binding pocket 
of the protease, forming an ionic interaction with Asp129 in an atypical binding conformation 
compared to the P1-Arginine of the substrate-based peptide inhibitor. The conjugated central 
scaffold was positioned slightly off-centre but in parallel to Tyr161, presumably forming a pi-
interaction. In addition, the hydroxyl group attached to C-6 was postulated to engage in a hydrogen 
bonding interaction with the carbonyl backbone of Gly151.  The hydrophobic chain on the other 
hand was found to extend towards the S2’ binding pocket, forming a van der Waals interaction with 
the hydrophobic S2’ residues. Selectivity studies were also conducted to determine the promiscuity 
of Phloeodictine X in binding to other trypsin-like serine proteases. Phloeodictine X was inactive 
against trypsin-like serine proteases (trypsin, tryptase, thrombin, factor B) at 100 nM, however it 
was an active inhibitor of West Nile Virus NS2B/NS3pro (IC50 = 25 nM). In summary, we have 
successfully identified a potent inhibitor of DENV NS2B/NS3pro protease with potency at 
nanomolar concentrations, making it by far the most potent known inhibitor of this protease. Future 
studies will involve development of drug-like drug candidates based on Phloeodictine X through 
chemical modifications and SAR studies. 
Addendum  
Since the submission of thesis, further inhibitor characterization studies have been carried out. It 
has recently come to light that there was a minor contaminant present in the Phloeodictine X stock 
solution provided to me for use in the studies reported in this thesis. This casts some doubt about 
the inhibitory potency of Phloeodictine X originally measured herein, and these results should 
therefore be questioned in follow up work with authentic and highly pure Phloeodictine X.  
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5.1 INTRODUCTION 
 
It is estimated that 50-100 million people are infected with the four strains of the Dengue 
virus (DENV) globally each year, and 500,000 of the infected patients develop dengue hemorrhagic 
fever and dengue shock symptom leading to 22,000 deaths and substantial work hours lost due to 
ill-health.1 A primary concern is that there is no vaccine or antiviral agent available in the 
marketplace to treat this infection at this time. There is an urgent need for a safe and effective 
antiviral agent to treat dengue infections. Most of the currently reported DENV NS2B/NS3pro 
protease inhibitors target the active site, and were designed to inhibit the protease in competition 
with the substrate for the substrate-binding groove.2-5 Previous work from our group has afforded 
the moderately potent tetrapeptide aldehyde DENV protease inhibitor, PhAc-Lys-Arg-Arg-CHO 
(IC50 = 10 µM). In Chapter 2, the basic residues (P3, P2, P1) were replaced with amino acid 
mimetics in attempts to enhance the cell-permeability of this highly-charged peptide. In Chapter 3, 
we attempted to target the prime-binding sites (S1’, S2’, S3’) by introducing a bridging non-
cleavable electrophilic isostere (α-keto amide) in place of the scissile P1-P1’ bond.  Despite 
considerable effort, these approaches failed to produce highly potent inhibitors of DENV protease 
activity.  
In this chapter, the aim was to identify alternative compounds that inhibit DENV protease. 
The need for polar and highly charged molecules to target the active site has so far rendered the 
development of drug-like inhibitors difficult and challenging.  Deviating away from the previously 
employed rational drug-design strategy, a screening campaign was opted to identify active DENV 
NS2B/NS3pro inhibitors that target either the active site or co-factor binding sites. Since a number 
of pharmaceutical companies (including Novartis) have conducted large scale screening campaigns 
using their multi-million compound libraries and yet failed to identify any hits with sub-micromolar 
inhibitor potency against DENV NS2B/NS3pro protease, we reasoned that it might be worth 
screening less drug-like, but structurally diverse, natural product libraries that might enable 
discovery of something potent. Professor Rob Capon (IMB, University of Queensland) kindly 
offered an opportunity to examine one of his 2000 compound natural product libraries featuring 
compounds isolated by his research group from marine sponges.      
 
5.1.1 High-throughput screening for discovery of DENV inhibitors  
High-throughput screening (HTS) is a powerful tool utilized for identification of new lead 
compounds for drug targets of interest.6 This strategy has been employed in the discovery of lead 
molecules targeting DENV NS2B/NS3pro.4, 7, 8 In this approach, a large number of compounds with 
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desired structural and chemical properties within the boundaries of drug-likeness were tested for 
their activity against DENV NS2B/NS3pro using high-throughput inhibition bioassays. In certain 
studies, preliminary virtual screening was conducted to allow a prediction of potentially active 
inhibitors against DENV protease due to the large numbers of compounds in such libraries, 
followed by validation using inhibitor assay screening. In general, the assay screening process is 
divided into two stages: (a) screening of compounds at a one or two concentrations and compounds 
which exhibit inhibition of the protease are identified as positive ‘hits’, usually with IC50 µM. (b) 
Positive hits are then assayed at multiple concentrations to determine their IC50 values, while 
enabling identification and elimination of false positives due to target sequestration, compound 
aggregation or interference with the assay.6 
In 2009, Tomlinson et al. reported a structure-based discovery of a class of non-peptidic 
small molecule Dengue protease inhibitors assisted by virtual screening.8 A chemical library 
containing 2.5 million commercially available small molecules was first filtered to identify non-
zwitterionic compounds at physiological pH and to avoid cell uptake and permeability issues 
associated with ionic compounds. The selected compounds were then docked through modeling into 
the protease active site using the EUDOC program. The top twenty inhibitors were purchased and 
tested in an enzyme inhibition assay, and the active inhibitors were tested in cell-based replication 
assays. The two most potent inhibitors, ARDP0006 and ARDP009 (Figure 5.1), albeit not drug-like, 
were then docked into the active site to analyze their specific interactions with the protease. From 
the EUDOC prediction, ARDP006 was postulated to bind in the S1 pocket (Gly151, Gly153) and 
interact with the catalytic triad (His51, Ser135). ARDP009 was predicted to interact with DENV 
protease in a similar manner, making additional contacts with the residues surrounding the active 
site (Leu115, Asn152, Val155, and Ala160).  
 
(A) 
 
(B) 
 
 ARDP0006 
EC50 = 4.2 ± 1.9 µM 
 ARDP0009 
EC50 = 35 ± 8 µM 
 
 
 
 
Figure 5.1: Postulated bound conformation of the active compounds using the 
EUDOC program. The active site is shown in pink and S1 pocket is in green. 8 
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Knehans et al. reported a fragment-based drug design approach to identify active DENV 
NS2B/NS3pro inhibitors (Figure 5.2).4 Fourteen million compounds from the ZINC database were 
initially filtered using the Lipinski rule-of-five (Ro5) to ensure drug-like properties, followed by 
generation of molecular fragments of these compounds. The fragments were then auto-docked into 
the DENV NS3pro binding site to identify fragments with high binding affinity in silico. The high-
scoring fragments (targeting either the S1 or S2 pocket) were identified and covalently linked to 
generate DENV protease inhibitors targeting both S1 and S2 pockets. Similar compounds were 
identified using a similarity search, and these putative inhibitors were also evaluated for protease 
inhibition.  
 
 Step 1 
Fragment docking 
Step 2 
Substructure search 
Step 3 
Similarity search 
ZINC v.9 
 
 
DEN2: IC50 = 300 µM 
 
Compound A 
DEN2: IC50 = 7.7 µM 
WNV: IC50 = 6.3 µM 
 
Compound B 
DEN2: IC50 = 37.9 µM 
WNV: IC50 = 39.0 µM 
Figure 5.2: Virtual screening strategy employed by Knehans et al. to discover potent inhibitors of 
DENV protease, Compound A and Compound B. 4 
 
The two most potent inhibitors, compound A and compound B were found to be active 
against both DENV and WNV NS2B/NS3pro protease with no noted selectivity. The mode of 
interactions of Compound A was predicted through molecular docking, where it was proposed to 
form an electrostatic interaction with Asp129 of the S1 pocket (Figure 5.3). The phenylguanidine 
group was also predicted to form a pi-stacking interaction with Tyr161. The opposite phenyl group 
on the other hand was proposed to interact with the catalytic His51 residue by arene-arene 
interactions, and the guanidine moiety engaged in a hydrogen bonding interaction with Asn152. 
Compound B was expected to bind to DENV protease in a similar manner.Interestingly, it is noted 
that Compound A shares striking structural and chemical similarities with Nafamostat Mesylate. 
Nafamostat Mesylate is a broad spectrum serine protease inhibitor,9 and it is expected that 
Compound A might similarly be a non-selective inhibitor, although it has not been tested against 
other host serine proteases.  
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In summary, high-throughput screening has proven to be a useful tool to discover inhibitors 
of DENV NS2B/NS3pro protease. It is apparent that most of the reported screening campaigns have 
been confined to identification of active site inhibitors, where fragments or small molecules with 
the appropriate corresponding chemical and structural properties were actively and extensively 
sought to occupy the active site. These approaches were met with modest success, as only weakly 
potent inhibitors (with activity at micromolar concentrations) were identified from synthetic 
compound libraries.  
 
 
 
Compound A 
 
Nafamostat mesylate 
Figure 5.3: Model of postulated binding interactions of Compound A 
(purple) with DENV2 protease.4  The surface of the protease is in grey and 
key residues are highlighted in orange.  
 
 
The unrealized expectations from current drug development strategies for DENV 
NS2B/NS3pro prompted an alternative lead-generation strategy.  It was considered tactical in this 
project to broaden the scope of the screening campaign, instead of “cherry-picking” Lipinski-type 
molecular libraries that embody chemical characteristics deemed unsuitable for binding DENV 
NS2B/NS3pro protease based on our knowledge of substrate-binding requirements for this enzyme. 
Natural products used to be a rich source of drug leads in the 20th century (49% of new chemical 
entities introduced from 1981-2002),6, 10 and they are known to be valuable anti-infectives.6, 10, 11 In 
some ways it is unfortunate that natural products were dropped by major pharmaceutical companies 
in the last 15 years as sources for new drugs, reasons being the longer timeframes relative to 
combinatorial and fragment libraries for hit discovery (2.5 years vs 1-1.5 years) and problems with 
false hits and deconvoluting mixtures. Despite the advent of diversity-oriented synthesis by 
Schreiber and colleagues, natural products still provide perhaps the best sources of novel structural 
and chemical diversity.  It was this great molecular diversity that originally enabled high-
throughput functional screening to be successful for discovery of highly potent molecules screening 
campaigns against many other targets.12-14 Natural products are known to provide selective and 
specific biological activities based on mechanism of actions. In some cases, novel modes of action 
O
O
H
N NH2
NH
N
H
H2N
NH
O
O
H
N NH2
NH
HN
NH2
	   215	  
through allosteric binding sites were identified for natural products that would otherwise not have 
been found.10  In collaboration with Professor Rob Capon (Institute for Molecular Bioscience, 
University of Queensland), a low-medium throughput screening campaign was conducted, 
involving a library of ~2000 compounds comprising natural products extracted from a variety of 
sources (plants, marine organisms and insects). This library was selected to maximise high chemical 
and structural diversity while adhering to the margins of drug-like properties in order to generate 
potential drug leads for DENV NS2B/NS3pro protease. 	  
 
5.2 MATERIAL AND METHODS 
5.2.1 Design of screening campaign  
The screening campaign is divided into three major stages (Figure 5.4) involving an initial 
screening assay for hits identification, followed by validation of the hits to assess their potency. 
This project 
Step 1: Initial screening 
Enzymatic inhibition assay 
Each compound is assayed at a single concentration.  >35% inhibition using the positive control as the reference is 
considered a "hit” 
 
Step 2: Validation studies 
“False positive” test 
Due to the concern of aggregate-based inhibition, key test (prolonged incubation time) will be applied to eliminate 
the possibility of a false positive 
 
Full-dose response curve  
The IC50 of the “hits” will be determined 
 
 
Step 3: Inhibitor characterization of best “hit” 
Mode of inhibition 
The mode of inhibition of the most potent “hit” determined from the validation studies will be examined using 
Michaelis-Menten plot and Lineweaver-Burk double reciprocal plot.  
 
Selectivity assessment 
The most potent hit will be assayed against a group of host serine proteases (trypsin, tryptase, Factor B, thrombin) 
and a related flaviviral protease (WNV NS2B/NS3pro protease). 
 
Docking studies 
The best hit will be docked into DENV NS2B/NS3 protease in order to understand their interactions. 
 
Future Studies 
Structural activity relationship studies 
Structural modifications 
The chemical and structural properties of the “hits” will be modified in order to improve potency, increase binding 
affinity and enhance their drug-like properties. 
Figure 5.4: Summary of high-throughput screening studies in the discovery of DENV 
NS2B/NS3pro inhibitor. 
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In	   the	   third	   stage,	   the	   inhibitor	   profile	   of	   the	   most	   potent	   hit	   will	   then	   be	   fully	  characterized	  to	  assess	  its	  mode	  of	  inhibition	  through	  competition	  bioassay,	  docking	  studies,	  and	  selectivity	  studies	  against	  other	  proteases.	   	  In	  a	  later	  stage	  (not	  within	  the	  scope	  of	  this	  thesis),	   structure-­‐activity	   relationship	   studies	   will	   be	   conducted	   on	   the	   selected	   hit(s)	   to	  afford	  more	  drug-­‐like	  inhibitors	  against	  DENV	  NS2B/NS3pro.	  	  
5.2.2. Preliminary screening   
In the initial screening stage, ~2000 natural products were screened against DENV 
NS2B/NS3pro protease at a single concentration (5 µg/mL). The compounds were pre-incubated 
with DENV NS2B/NS3pro protease for 30 minutes in duplicate, to which a chromogenic substrate 
(Ac-LKRR-pNA) was added (Figure 5.5). A flat-bottom 384-clear well plate molded into black 
matrix was used to avoid crosstalk in bottom-reading absorbance in the assay. The hydrolysis of the 
substrate was measured by the hydrolyzed chromogenic species, para-nitroaniline (pNa) at λ = 405 
nm. As this was a colorimetric assay, it was crucial that the compounds assayed did not interfere 
with the absorbance measurement at 405 nm. As a preventative measure, the absorbance spectra 
(350 – 650 nm) of each of the compounds was profiled, and any compound that displayed high 
absorbance at 400-420 nm region was deemed incompatible with the chromogenic assay and was 
dismissed as a potential hit. Any compound that contributed to >35% inhibition in substrate 
hydrolysis was considered a “hit”.  
 
Figure 5.5: Enzymatic assay protocol 
Initial	  screening	  using	  384	  well	  plate	  (duplicate) 
Inhibitor	  (2.5	  µL)	  is	  added	  to	  each	  well 
Buffer	  (40	  uL)	  is	  added	   
Enzyme	  (5	  uL)	  is	  added 
Substrate	  (2.5	  uL)	  is	  added 
“Hits”	  which	  exhibit	  inhibition	  identified 
	  
	  
	  
	  
Absorbance	  spectra	  of	  each	  compound	  is	  characterized 
pNa	  hydrolysis	  is	  measured	  at	  405	  nm 
Incubation	  for	  30	  min 
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5.2.3 Validation studies 
HTS is extremely useful in drug discovery where accelerated lead identification can be 
achieved. At the same time, a large number of peculiar molecules are also introduced in this 
approach, some afford positive outcomes in further optimizations, others fail to improve upon 
extensive optimization attempts.15 One of the biggest concerns in early high-throughput screening 
studies is false-positive hit. The presence of reactive species in the compounds often leads to false 
positives. In some cases, certain compounds are prone to aggregate and the resulting aggregate may 
inhibit diverse proteases indiscriminately. To ensure that the hits are not false positives, several 
tests could be conducted as the inhibitory activity of an aggregate-based inhibitor was reported to 
display sensitivity towards changes in detergent, enzyme concentration, and incubation time. In this 
study, a key test was employed to determine false-positives. The inhibitor pre-incubation time with 
the protease was prolonged, where an increased inhibition is diagnostic of an aggregate-based 
compound. The IC50 of the hits was then determined by doing a full concentration-response 
inhibition assay to more closely inspect their inhibitory properties. 
 
5.2.4 Inhibitor profiling of selected hits 
The identified hits could bind to either the active site (Figure 5.6) or allosteric binding sites 
(Figure 5.7), for example the cofactor-binding region. The mode of inhibition of the most potent hit 
can be assessed through a substrate-competitive enzymatic assay. A competitive binding mode 
would confirm that the hit is an active site inhibitor since it competes competitively with the 
substrate to bind with the protease. On the other hand, a non-competitive binding mode would lead 
to assumptions that the hit binds to an allosteric binding site.  It is crucial that the hit displays 
selectivity towards DENV NS2B/NS3pro, to avoid off-target inhibition especially towards human 
host proteases. Selectivity studies were conducted, where the hits were assayed against a number of 
host serine proteases (trypsin, tryptase, factor B, thrombin) and also a homologous flaviviral serine 
protease, WNV NS2B/NS3pro protease. This selectivity study also served as a secondary false 
positive test, as aggregate-based inhibitors are known to show promiscuous behaviour across 
diverse enzymes. 
 
5.2.5 Future studies 
In a later stage of the drug discovery program, SAR studies will be conducted on the 
selected hit. The aim will be to improve binding affinity, inhibitor potency and selectivity of the 
compound. As these compounds are natural products with potentially challenging synthesis, and 
likely poor drug-like properties due to the selection criteria used in this particular screen, 
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simplification of the structure by generating more synthetically feasible analogues will be attempted. 
Concurrently, drug-like properties will be attained through chemical modifications 
 
 
Figure 5.6: DENV NS2B/NS3 protease active site. The surface of the S1 and S2 pockets is highly 
acidic, contributing to the preference of arginine at both P1 and P2 position. The S3 pocket is polar 
in nature, with a preference for lysine is noted at this pocket where it interacts with Met83. 
Competitive inhibitors of DENV NS2B/NS3pro protease were expected to be positively-charged in 
nature, or with polar functional groups capable of forming hydrogen bond networks with the polar 
acidic surface of the protease. Electrostatic potential surface was generated using Pymol (Red= 
acidic, blue = basic, grey = hydrophobic). 
 
Site 1 Site 2 
  
  
Figure 5.7. Allosteric binding sites. Two cofactor binding sites critical for proteolytic activity 
have been identified, whereupon alanine mutagenesis at those sites led to almost complete 
inactivation of the protease. Left: Site 1. Site 1 (NS2B59-62) is located at the “back” of the active site 
(Figure 5.5A), and was found to occupy adjacent pockets of NS3 protease. Small aromatic 
compounds could be utilized to displace the cofactor from site 1, prevent the proper folding of the 
protease and lead to inactivation. Right: Site 2. Site 2 (NS2B75-87) on the other hand is a beta-loop 
that binds to a deep pocket adjacent to the active site. This region is also partially involved in the 
formation of the active site, suggesting that displacement of the cofactor at this region may lead to 
interference in substrate binding. Hydrophobic compounds are desirable as potential Site 2 
inhibitors. 
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5.3 RESULTS AND DISCUSSION  
 
5.3.1 Identification of protease inhibitors 
Using a low-medium throughput enzymatic assay, a natural product library kindly provided 
by Professor Rob Capon was assayed against DENV NS2B/NS3pro at a single concentration (5 
µg/mL). From the preliminary screening campaign, 15 hits that displays ≥35% of inhibition against 
DENV NS2B/NS3pro were identified (Table 5.1, Figure 5.8). These compounds can be categorized 
into five major classes, terpenes (5.1-5.4), long-chained compounds (5.5-5.6), dopamine derivatives 
(5.7-5.8), polyphenols (compound 5.9-5.13) and alkaloids (5.14-5.15) (Figure 5.7). 
  
Table 5.1: Identification of hits from preliminary screening. 
ID Name Preliminary Screening 
Concentration tested 
(µM) 
% inhibition 
5.1 Puupehenone 15 71 ± 1 
5.2 Lintenolide A 10 45 ± 8 
5.3 Lintenolide C 12 35 ± 6 
5.4 16-epi-Lintenolide C 12 49  ± 3 
5.5 Thiocyanatin A 14 36 ± 6 
5.6 Bisepoxyoctadecenal 17 40  ± 1 
5.7 N-lauroyldopamine 15 40  ± 2 
5.8 N-linolenoyldopamine 12 37  ± 4 
5.9 Lamelllarin S 11 50 ± 9 
5.10 Lamellarin A1 10 100 ± 2 
5.11 Ningalin C 8.6 90 ± 3 
5.12 Ningalin D 7.0 65 ± 2 
5.13 Ningalin B 11 55 ± 20 
5.14 Phloeodictine X 12 82 ± 13 
5.15 Stylissadine B 3.0 76 ± 6 
 
In general, the terpenes exhibited moderate inhibition (35-71%) against DENV 
NS2B/NS3pro protease. On the other hand, the two long-chained compounds, Thiocyanatin (5.5) 
and Bisepoxyoctadecanal (5.6), exhibited ~40% of inhibition. Two dopamine derivatives (5.7, 5.8) 
were also found to be moderately active against DENV protease. A series of polyphenols from the 
Lamellarin (5.9-5.10) and Ningalin (5.11-5.13) families were also identified as inhibitors of DENV 
protease. Lamellarin A1 (5.10) was found to inhibit DENV protease completely at the concentration 
of 10 µM. Two alkaloids, Phloeodictine X (5.14) and Stylissadine B (5.15) were also found to be 
inhibitors of the DENV protease, the former showing 82% inhibition at 12 µM and the latter being 
more potent with 76% inhibition noted at 3 µM.  
 
 
	   220	  
 
Terpenes 
5.1 5.2 5.3 5.4 
 
   
71% inhibition at 15 µM 
Puupehenone 
MW: 328.4 
Log P: 1.96 
tPSA: 46.53 
CLogP: 2.9 
 
45% inhibition at 10 µM 
Lintenolide A 
MW: 460.6 
Log P: 4.36 
tPSA: 82.06 
CLogP: 1.3 
35% at 12 µM 
Lintenolide C 
MW: 402.6 
Log P: 4.99 
tPSA: 55.76 
CLogP: 1.6 
49% inhibition at 12 µM 
16-epi-lintenolide C 
MW: 402.6 
Log P: 4.99 
tPSA: 55.76 
CLogP: 1.6 
  
 
 
  
Aliphatic-chained compounds 
5.5 5.6 
 
 
 
 
37% inhibition at 14 µM 
Thiocyanatin A 
MW: 356.6 
Log P: 6.09 
tPSA: 67.81 
CLogP: 5.3 
40% inhibition at 17 µM 
Bisepoxyoctadecenal 
MW: 296.4 
Log P: 3.21 
tPSA: 42.13 
CLogP: 4.5 
    
 
 
 
Dopamine analogues 
5.7 5.8 
 
 
 
40% inhibition at 15 µM 
N-Lauroyldopamine 
MW: 335.5 
Log P: 4.92 
tPSA: 69.56 
CLogP: 5.0 
37% inhibition at 12 µM 
N-Linolenoyldopamine 
MW: 413.6 
Log P: 6.47 
tPSA: 69.56 
CLogP: 6.8 
 
 
 
 
Figure 5.8: Inhibitors of DENV NS2B/NS3pro protease 	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Polyphenols 
5.9 5.10 
 
 
50% inhibition at 10 µM 
Lamellarin S 
MW: 473.4 
Log P: 1.94 
tPSA: 139.92 
CLogP: 3.7 
100 % inhibition at 10 µM 
Lamellarin A1 
MW: 487.5 
Log P: 2.2 
tPSA: 128.92 
CLogP: 4.1 
    
5.11 5.12 5.13 
   
90% inhibition at 8.6 µM 
Ningalin C 
MW: 581.5 
Log P: 1.87 
tPSA: 199.22 
CLogP: 1.7 
65% inhibition at 7 µM 
Ningalin D 
MW: 713.6 
Log P: 1.94 
tPSA: 239.68 
CLogP: 3.4 
55% inhibition at 11 µM 
Ningalin B 
MW: 461.4 
Log P: 2.01 
tPSA: 150.92 
CLogP: 3.1 
 
 
Alkaloids 
5.14 5.15 
 
 
82% inhibition at 11 µM 
Phloeodictine X 
MW: 434.7 
Log P: NA 
tPSA: 93.93 
CLogP: 6.5 
76% inhibition at 3 µM 
Stylissadine B 
MW: 1642.2 
Log P: NA 
tPSA: 431.27 
CLogP: 0.72 
Figure 5.8: (continued): Inhibitors identified for DENV NS2B/NS3pro protease.  
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5.3.2 Validation Studies 
5.3.2.1 IC50 determination 
The IC50 for each of the identified hits was next determined in order to profile their 
inhibitory properties for competition with substrate (Figure 5.9, Table 5.2). In general, the terpenes  
(5.1-5.4; IC50 = 10 – 20 µM) were found to be moderately active against DENV NS2B/NS3pro 
protease. Other biological activities of these terpenes have been previously studied and they were 
found to be cytotoxic and antibacterial (Table 5.3).16-18  The two long-chained compounds 
(Compound 5.5-5.6) were less active with IC50 > 30 µM, and previously noted to be anti-parasitic. 
On the other hand, the dopamine analogues (5.7-5.8) were the least potent of the fifteen hits with 
IC50 ≥ 50 µM.  The polyphenols were moderately active against DENV protease with IC50 ranging 
5-50 µM, and they were previously reported to have antitumour and cytotoxic activity.19 It must be 
noted that polyphenols are known to form aggregates in solution and could potentially bind 
indiscriminately to protein, leading to false-positives.15 Not surprisingly, the best performing 
compounds were found to be the alkaloids, due to prior knowledge where basic compounds are 
desirable as active site inhibitors for this viral enzyme and the need to form ionic interactions with 
the acidic S1 and/or S2 binding pockets. Phloeodictine X (5.14, IC50 = 43 nM) was found to be the 
most potent inhibitor in this study, being highly active at nanomolar concentrations. It is by far the 
most potent inhibitor of this enzyme known to date. Stylissadine B (5.15, IC50 = 1.1 µM) on the 
other hand was less active inhibitor potency at low micromolar concentrations. It is noted that none 
of these hits has been previously identified as an anti-viral compound.  
Other biological activities of Phloedictine X (5.14, sometimes referred to as 
Phloeodictyne20) have been previously reported.21, 22 This alkaloid was reported to have significant 
inhibitory activity in vitro towards both gram-positive and gram-negative bacteria (Staphilococcus 
aureus (MIC = 3 µg/ml), Esherichia coli (MIC = 3 µg/ml), Pseudomonas aeruginosa (MIC = 30 
µg/ml). It was also active against fungi (Candida albicans (MIC = 2.5 µg/ml), Cryptococcus 
neoformans (MIC = 0.2 µg/ml), and Aspergillus fumigatus (MIC = 3.2 µg/ml)), which cause severe 
infections in immunocompromised individuals with organ transplant, AIDS and cancer. In addition, 
Phloeodictine X was also found to be anti-parasitic (IC50 = 0.62 µM), where it is equipotent to 
chloroquine sulfate, a commonly used antimalarial agent against the FCB1 strain of the malaria 
parasite, Plasmodium falciparum. Phloeodictine X was also shown to be moderately cytotoxic 
against tumour cell lines (KB human nasopharyngeal carcinoma cells (IC50 = 2.2 µg/ml) and A-549 
cells (IC50 = 9.7 µM), indicative of its antiplasmodial potential.21 In the present study, Phloeodictine 
X was identified as a highly potent inhibitor of dengue NS3 protease. Although not a drug-like 
inhibitor, this finding may be a useful clue that will encourage future work towards creating drug-
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like inhibitors of this enzyme as anti-viral agents. It was decided to further profiling this compound 
for its properties against this enzyme. 
 
 
Figure 5.9: Concentration-response curves for inhibition of DENV NS2B/NS3pro (% 
substrate cleavage vs increasing concentration of inhibitor). Inhibitors were pre-
incubated for 30 minutes. Assay conditions were: [E] DENV NS2B/NS3pro, 50 nM; 
[S] Ac-LKRR-pNa, 125 µM, 50 mM Tris-NaOH buffer, 37 ˚C, pH 9.5, with 10 mM 
NaCl and 30% glycerol. Error bars represent mean  ± SEM of at least three 
independent experiments. 
  
   Table 5.2 Inhibition of DENV NS2B/NS3pro protease by compounds 5.1-5.15. 
Compound pIC50 ± SEM 
 
IC50 (µM) 
5.1 5.0 ± 0.3 10 .1 
5.2 4.7 ± 0.2 19.4 
5.3 4.8 ± 0.2 16.3 
5.4 4.9 ± 0.2 13.7 
5.5 NA NA 
5.6 4.5 ± 0.2 31.3 
5.7 NA NA 
5.8 NA NA 
5.9 4.8 ±  0.2 14.4 
5.10 4.3 ± 0.3 49.0 
5.11 5.1 ± 0.2 8.20 
5.12 5.3 ± 0.2 4.50 
5.13 4.7 ± 0.3 17.8 
5.14 7.4 ± 0.2 0.043 
5.15 5.9 ± 0.3 1.10 
Inhibitors were pre-incubated for 30 minutes. Assay conditions were: [E] DENV NS2B/NS3pro, 50 nM; [S] 
Ac-LKRR-pNa, 125 µM, 50 mM Tris-NaOH buffer, 37 ˚C, pH 9.5, with 10 mM NaCl and 30% glycerol. 
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Table 5.3: Reported non-viral biological activities of 5.1-5.15 in current literature. 
Class ID Compound Origin Biological 
activity 
Ref. 
Terpenes 5.1 Puupuhenone Deep water 
marine sponges 
S.hartmani, 
Hyrtios 
Cytotoxic, 
antibacterial and 
inhibitors of 
angiogenesis 
 
16 17 
 
 
5.2 Lintenolide A Caribbean sponge 
Cacospongia cf. 
linteiformis. 
 
Ichthyotoxicity 
and antifeedant 
activity 
18 
 5.3 Lintenolide C 
5.4 16-epi-Lintenolide C 
Long-
chained 
compound 
5.5 Thiocyanatin A Marine sponges 
Oceanapia sp. 
Nematocidal 
activity 
23 
5.6 Bisepoxyactadecanal - -  
 
 
Dopamine 
analogues 
5.7 N-Lauroyldopamine - -  
5.8 N-linolenoyldopamine - -  
 
 
Polyphenols 5.9 Lamellarin S Australian 
tunicate 
Didemnum sp. 
Cytotoxic and 
antitumour 
19 24 
5.10 Lamerallin A1 prosobranch 
mollusc 
Lamellaria sp. 
Cytotoxic and 
antitumour 
 
5.11 Ningalin C Western 
Australian 
ascidian of the 
genus Didemnum 
 
Cytotoxic and 
antitumour 
 
 
5.12 Ningalin D  
5.13 Ningalin B  
Alkaloids 5.14 Phloeodictine X New Caledonian 
sponge, 
Phloedictyon sp. 
Antibacterial, 
antifungal and 
cytotoxic 
21, 22 
5.15 Stylissadine B Australian marine 
sponge Stylissa 
flabellata 
Specific 
antagonist of 
P2X7 receptor 
25 
	  	  
	  
5.3.2.2 False positives in enzyme assay 
Aggregate-based false positives are among the biggest concerns in any HTS program, since 
they frequently show activity across a plethora of targets. Aggregate-based compounds are mostly 
polyaromatics, polyphenolics, highly lipophilic or highly conjugated molecules. They form 
aggregates in aqueous solutions, and in turn regularly bind to proteins in a bioassay, producing a 
false positive result that is of little use for drug development. In addition, they usually behave non-
competitively in biochemical screening assays with limited structure-activity relationships and poor 
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enzyme selectivity. In fact, they are usually broad spectrum inhibitors of multiple enzymes.6, 15, 26 It 
is therefore crucial to eliminate aggregate-based inhibition in our screening campaign. Coan and 
Shoichet proposed four criteria for determining aggregate-based inhibitors in a biochemical assay 
(Table 5.4): (a) decrease in inhibition in the presence of Triton X-100, (b) inhibition of three diverse 
enzymes, (c) decrease in inhibition with a ten-fold increase in enzyme concentration, and (d) 
increase in inhibition with prolonged incubation time.27 
 
Table 5.4: Assays for detection of false-positive inhibitors.27 
Key Test Aggregate-based inhibitor 
Sensitivity to detergent Introduction of detergent offsets the inhibitor potency significantly 
Sensitivity to enzyme 
concentration 
10-fold increase of enzyme concentration would lead to decrease of 
inhibition from 50% to <40% 
Inhibition of dissimilar 
enzymes 
Inhibit a wide variety of enzymes with unrelated structure, function and 
ligand recognition 
Incubation effect Pro-longed incubation leads to > 50-fold increase in IC50 
 
To exclude aggregate-based inhibition, the ‘hit’ compounds were first subjected to 
prolonged incubation times (1.5 h), instead of the standard 0.5 h incubation time used with DENV 
NS2B/NS3pro protease for single concentrations of the same compounds, to examine for an 
increase in inhibition (Figure 5.10). Prolonged incubation of aggregate-based inhibitors is known to 
increase the potency of the compounds by as much as 50-fold. Fortunately, most of the hits in this 
present study maintained similar inhibition with prolonged incubation times, suggesting that they 
are unlikely to be aggregate-based inhibitors. On the other hand, 5.10 and 5.12, which are 
polyphenolics were found to show increased inhibitory activity.  It is important to note that 
inhibitors with slow on-rates or covalent inhibitors may also display higher inhibition upon longer 
incubation times 15, therefore any conclusions must be drawn tentatively.  
 
 
Figure 5.10: Effect of prolonged incubation on inhibition by 5.1-5.15. The compounds were pre-
incubated with DENV NS2B/NS3pro (50 nM) for 0.5h (standard) vs. 1.5h (prolonged). All of the 
compounds assayed at 2 µM, except for compound 5.14 (100 nM). Assay conditions were: [E] 
DENV NS2B/NS3pro, 50 nM; [S] Ac-LKRR-pNa, 125 µM, 50 mM Tris-NaOH buffer, 37 ˚C, pH 
9.5, with 10 mM NaCl and 30% glycerol. The percentage of residual activity was expressed relative 
to 100% activity in the absence of inhibitor. 
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5.4 CHARACTERIZATION OF PHLOEODICTINE X 
 
5.4.1 Structural and chemical properties 
The most active inhibitor was Phloeodictine X (IC50 = 43 nM; [Ac-LKRR-pNa] = 125 µM, pH 9.5, 
37 ˚C). It comprises a bicyclic 6-hydroxy- 2,3,4,6-tetrahydropyrrolo[1,2-a]-pyrimidinium central 
skeleton, coupled with a hydrophobic alkyl substituent (red) at position C-6 and a hydrophilic, 
positively charged, guanidino alkyl chain (blue) substituted at position N-1 21 (Figure 5.11). The 
fused bicyclic skeleton is unusual in organic chemistry, with the positive charge at N-1 being 
delocalized over N-1, C-9 and N-5. It is however known, for example as the octahydro form of 
hydrolizine found in swainsonine28 and castanospermine29. Interestingly, castanospermine is a 
known DENV infection inhibitor, however it functions as an inhibitor by unfolding the structural 
proteins prM and E causing disruption in viral secretion. Adenopeptin, an alkaloid peptide extracted 
from a filamentus fungus (Chrysosporium sp.), was also noted to share a very similar skeleton30, 
pyrrolo[1,2,alpha]pyrimidine, and it was reported to have anti-tumour activity.  
 
 
Phloeodictine X 
IC50 = 43 nm 
	  	  
Swainsonine 
 
Castanospermine 
 
Pyrrolo[1,2,alpha]pyrimidines 
 
Figure 5.11: Similar scaffolds found in nature 
 
Phloeodictine X does not have drug-like or lead-like properties. Traditionally, Lipinski’s 
Rule of Five (Ro5) is used as the barometer of drug-likeness to assess compounds 6, 31-33. Ro5 is an 
established drug-likeness filter derived from an empirical analysis of initially, around 2200 drug 
candidates that reached phase II trials and are in the World Drug Index (WDI). Since then many 
more compounds have been examined and also fit the rules (Table 5.5) for a molecule to be 
bioavailable with acceptable cell-permeability.33  In contemporary drug design, drug-like leads that 
obey these rules serve as a good starting points for drug development.32 Compounds with molecular 
weight < 500, logP < 5, H-bond donors ≤5, H-bond acceptors ≤12 are considered to be most 
attractive, while the rule of three (Ro3) is used for smaller fragments (100-350 g/mol,  cLogP 1-
3).33  Two additional parameters34 introduced by Veber and colleagues were polar surface area (PSA 
< 140 Å2) and rotatable bonds (<10 or 12), and these further and usefully refined Ro5 predictions. 
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Table 5.5: Rules of three and five compared for Phloeodictine X  
Parameters “Lead-like” 
Rule of Three 
“Drug-like” 
Rule of Five 
Phoeodictine X 
cLogP < 3 < 5 6.5* 
Molecular Weight < 300 < 500 g/mol 435 
Hydrogen-bond donor < 3 ≤ 5 6 
Hydrogen-bond acceptor < 3 ≤ 10 6 
*calculated LogP generated by ChemDraw 
 
Phloeodictine X was thus not “lead-like” and violates three rules of the Ro5 (Table 5.5), 
namely the calculated log P (cLogP = 6.5), which is above the drug-like upper-limit (<5), number 
of H-bond donors (6), and it also exceed the number of hydrogen bond donor and rotatable bond 
allowed. In his studies, Lipinski observed that a few natural products displayed good bioavailability 
despite violating the Ro5. In fact, Ganesan observed that 17 of 24 orally-bioavailable natural 
products progressed (between 1970-2006) to market without modifications, yet disobeyed the Ro5 
(Table 5.6).35   
 
Table 5.6: Successful natural product leads vs Phloeodictine X.35 
Natural product MW cLog P Hd Ha Rot PSA 
Validamycin 498 -5.2 12 14 7 253 
Mildecamycin 814 2.1 3 16 14 206 
Pseudomonic acid 501 2.5 4 9 17 146 
Taxol 854 3.0 4 14 14 221 
Echinocandin B 1060 1.8 14 16 20 368 
Rapamycin 914 4.3 3 13 6 195 
Cyclosporine A 1203 5.2 5 12 15 279 
Lipstatin 492 7.5 1 5 21 82 
Avermectin 873 2.3 3 14 8 170 
FK506 804 3.3 3 12 7 178 
Daptomycin 1621 -3.7 22 29 35 702 
Calicheamicin 1368 3.2 8 23 24 308 
Average 917 2.2 7 15 16 259 
 
Phloeodictine X 
 
434.7 
 
6.5 
 
6 
 
6 
 
14 
 
93.93 
*MW = molecular weight; Hd = hydrogen bond donor; Ha = hydrogen bond acceptor;  
Rot = rotatable bond; PSA = polar surface area. Violations of Ro5 are highlighted in red.  
 
Fundamentally, the Ro5 is an empirically derived guideline only for predicting passive oral 
adsorption. In certain cases, compounds can gain oral adsorption through active transports, and such 
mechanisms could be employed by highly bioavailable natural products despite breaking the Ro5. 
Phloeodictine X maintains the number of hydrogen-bond acceptors within the limit, however it 
exceeds the number hydrogen-bond donors. However, these hydrogen donors and acceptors can be 
strategically positioned to form an intramolecular hydrogen bonding network as seen in some orally 
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bioavailable natural products, thereby increasing cell-permeability by reducing access to solvent 
(reducing desolvation penalty) and polar surface area.  In addition, the use of hydrogen-bond 
donors/acceptors as metrics for bioavailability is subjective since it depends upon where they are in 
a molecule and whether they can be solvated. It is also interesting to note that these natural product 
leads display strict compliance with regard to the Log P cutoff, where the average Log P of the 
twelve natural products is 2.2 (average molecular weight = 917g/mol). This further highlights the 
importance of keeping Log P within the Lipinski’s rule in drug discovery, since this enhances 
membrane permeability.  
On average, the natural product leads were observed to violate two of the Lipinski’s rule of 
five and 3-4 of the 6 parameters listed above. Phloeodictine X seems to fall within the mean of all 
of the bioavailable parameters in natural product leads (Table 5.6), except that the value of log P 
(6.5) is slightly higher than the average (2.2). It remains to be seen whether this compound is cell 
permeable and orally bioavailable. Due to its di-positive change, it is not expected to be orally 
bioavailable and thus needs to be derivatised. 
 
5.4.2 Mode of inhibition of Phloeodictine X 
Competitive reversible inhibitors tend to be more favourable as drug candidates due to the 
non-covalent nature and thus reduced likelihood of causing toxicity through promiscuous 
irreversible interactions with proteins.6, 36 In general, they tend to bind to proteases by engaging in 
electrostatic bonds, hydrogen bonds and hydrophobic interactions, and exist in an equilibrium 
between protease-bound and unbound forms. Reversible inhibitors can be further classified into 
three main classes: competitive, non-competitive and uncompetitive. In competitive binding, the 
inhibitor behaves similarly to, and competes with, a substrate by binding to the active site substrate-
binding groove in a reversible manner.  Non-competitive inhibitors target a more removed or 
allosteric binding site, while uncompetitive inhibitors are believed to bind to the enzyme-substrate 
complex. On the other hand, irreversible inhibitors are less attractive as drug candidates since they 
tend to have a reactive isostere that binds strongly to a protease via covalent bonds, contributing to 
their excellent binding and potency. Due to the reactive nature of the isostere, they would be 
expected to bind covalently and indiscriminately with other nucleophiles or electrophiles en route to 
the protease, often leading to undesirable toxic side effects.36 
The mode of inhibition of Phloeodictine X was examined through enzyme kinetic studies 
(Figure 5.12). From the Michealis-Menten plot (Figure 5.12A), Vmax was 297 ± 30 µMs-1 and it was 
found that increasing concentrations of Phloeodictine X led to decreasing enzymatic activity. It was 
noted that inhibition of Phloeodictine X was completely suppressed at high substrate concentrations. 
This suggests that the inhibitory action of Phloeodictine X is reversible, and indicated that it binds 
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to DENV NS2B/NS3pro protease in the substrate-binding cleft. A subsequent analysis using a 
Lineweaver-Burk plot (Figure 5.12B) revealed an intersection at a single point on the y-axes, which 
is the hallmark of competitive inhibition.36 In competitive inhibition, the y-intercept (1/Vmax) is the 
same in the presence or absence of inhibitor, as Vmax is not affected by competition between 
inhibitor and substrate.  In summary, these studies have shown that Phloeodictine X is a competitive 
and reversible inhibitor of DENV NS2B/NS3pro protease, indicating that it likely binds to the 
substrate-binding active site of the protease. This is not surprising as Phloeodictine X contains two 
basic substituents, which meets the critical binding requirement at P1 and/or P2 to interact with the 
acidic residues in the S1 and/or S2 pocket of DENV NS2B/NS3pro protease. Furthermore, it does 
not contain any reactive species that are able to form an irreversible covalent bond with the protease, 
in agreement with the kinetic studies. 
 
(A) 
 
(B) 
 
 
Figure 5.12: Enzymatic kinetics of an untransformed steady state (A) and double reciprocal (B) 
plots of initial velocity of DENV NS2B/NS3pro protease in the presence of phloeodictine X at 
different concentrations. Assay conditions were: [E] DENV NS2B/NS3pro, 50 nM; [S] Ac-LKRR-
pNa, 0-500 µM, 50 mM Tris-NaOH buffer, 37 ˚C, pH 9.5, with 10 mM NaCl and 30% glycerol. 
Error bars represent mean ± SEM of at least three independent experiments 
 
5.4.3 Putative binding mode of phloeodictine X in DENV NS3/NS2B 
Since Phloeodictine X was reversibly competitive with substrate in inhibiting DENV 
NS2B/NS3pro protease, it likely fits into the substrate-binding active site groove. In order to 
understand how Phloeodictine X binds to DENV NS2B/NS3pro protease, it was docked into the 
protease (PDB: 3U1I) using GOLD (GoldSuite 5.1) (Figure 5.13A).  A constraint was introduced to 
fix the ligand in the active site, by defining it as an area within a 10Å radius of the catalytic Ser135 
residue.   
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(A) 
 
(B) 
 
Figure 5.13: Modeling of phloeodictine X bound to DENV NS2B/NS3pro protease. (A) 
Superimposition of the docked compound 5.14 (green) and crystal structure of bound 
reference inhibitor, Bz-Nle-Lys-Arg-Arg-CHO (yellow). (B) Interactions of Compound 5.14 
(green) with the residues in the active site of DENV NS2B/NS3pro (yellow). Model was 
derived from crystal structure pdb: 3U1I. Electrostatic potential surface was generated using 
Pymol (Red= acidic, blue = basic, grey = hydrophobic). 
 
 
From the docking studies, twenty ligand binding poses were observed and the highest 
scoring pose was selected to examine the binding interaction between phloeodictine X and DENV 
NS2B/NS3pro. In the top-scoring binding pose, phloeodictine X was found to occupy the S1 pocket 
and prime binding site around the S2’ pocket of the protease (Figure 5.13B). The guanidine 
substituent was predicted to interact with Asp129 of the S1 pocket, in a manner dissimilar to the P1-
arginine of the reported pentapeptide aldehyde inhibitor, Bz-Nle-Lys-Arg-Arg-CHO (Figure 5.14). 
 
  
Peptide inhibitor P1-Arginine Phloeodictine basic side chain 
Figure 5.14: Basic moiety targeting the S1 pocket of DENV protease. 
Electrostatic potential surface was generated using Pymol (Red= 
acidic, blue = basic, grey = hydrophobic). 
 
 
Instead, the guanidine side chain was found to “bridge” over the S1 pocket and formed a 
bimodal ionic interaction with the Asp129 residue from the back, unlike the P1-arginine of the 
peptide-aldehyde which remains conformationally constricted to stay accommodated in the S1 
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pocket while maintaining a unimodal ionic interaction with the carboxylate of Asp129. Interestingly, 
the central bicyclic scaffold was positioned on top of the Tyr161. The scaffold has a conjugated 
electron system and therefore may form a pi-stacking interaction with the aromatic ring of Tyr161. 
The hydroxyl group attached to C-6 was found to engage in a hydrogen-bonding interaction with 
the carbonyl backbone of Gly151.  Previous studies37 suggested that Gly151 may play an important 
role in stabilization of the transition state intermediate and stabilization of the E2-F2 strands of the 
protease fold, whereupon substitution with Ala led to inactivation of the protease.  On the other 
hand, the hydrophobic alkyl substituent was found to be extended towards the prime binding sites 
around the S2’ position. The hydrophobic side chain was postulated to form van der Waals 
interactions with surrounding hydrophobic residues (Val36, Thr34, Pro102) around S2’ (Figure 
5.15, Table 5.7). 
 
 
Figure 5.15:  Schematic representation of interactions between phloeodictine X  
(black) and DENV NS2B/NS3pro (blue).  
 
 
Table 5.7: Putative interactions between phloeodictine X and DENV NS2B/NS3pro  
Phloeodictine X NS2B/NS3pro residues Distance (Å) Comment 
NH2-7’ Asp129-OD1 3.4 S1 pocket 
NH2-7’ Asp129-OD1 3.2 S1 pocket 
C1-C9 Tyr161 4.1 - 4.4 S1 pocket 
C6-OH Gly151 3.3  
C8’’ Val-36 3.8 S2’ pocket 
C11’ Pro-102 4.0 S2’ pocket 
C12’ Thr-34 3.7 S2’ pocket 
 
 
5.4.4 Protease selectivity for inhibition by Phloeodictine X 
Phoeodictine X was assayed against another flaviviral protease, WNV NS2B/NS3pro 
(Figure 5.16A). It was found to be equipotent against WNV NS2B/NS3pro (IC50 25 nM) as with 
DENV NS2B/NS3pro. This is not surprising as these two proteases share high sequence identity 
and structural homology, and their active sites are very similar with a preference for substrates with 
basic amino acids at positions P1, P2 and P3 38. Phloeodictine X was docked into WNV 
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NS2B/NS3pro to examine putative interactions (Figure 5.16C). The modeling studies suggest that 
Phloeodictine X binds to both DENV NS2B/NS3pro and WNV NS2B/NS3pro in a similar manner. 
The central scaffold was positioned on top of the S1 pocket in both proteases, with the guanidine 
chain interacts with S1 Asp129 and the alkyl side chain projected towards prime binding pockets.  
The selectivity of phloeodictine X was assessed against a group of mammalian host 
proteases unrelated to DENV NS2B/NS3pro protease in terms of structure, function and ligand 
recognition (Table 5.8). In addition, this also serves as a secondary test to further validate the initial 
false positive studies as false positives often display promiscuous inhibitory activities against 
diverse enzymes. Phloeodictine X was assayed against host proteases (trypsin, tryptase, thrombin 
and complement Factor B) at 100 nM and was found to be inactive against all of them. This 
suggests that the alkaloid may be a flaviviral protease specific inhibitor, where off-site targeting of 
host proteases leading to undesirable side effects is less likely. 
 
(A) 
 
 
(B) 
 
(C) 
 
Figure 5.16: Phloeodictine X inhibits two flaviviral proteases. (A) Concentration-response 
curve for Phloedictine X against WNV NS2B/NS3pro (red) and DENV NS2B/NS3pro (blue). 
Error bars represent mean ± SEM of three independent experiments. Phloeodictine X docked 
into (B) DENV NS2B/NS3pro, and (C) WNV NS2B/NS3pro. Electrostatic potential surface 
was generated using Pymol (Red= acidic, blue = basic, grey = hydrophobic). 
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Table 5.8: Inhibitory Activity of Phloeodictine X against host protease 
Serine Protease % of inhibition at 100nm 
Trypsin 0% 
Tryptase 0% 
Thrombin 0% 
Factor B 0% 
 
 
5.5 FUTURE DIRECTIONS 
In summary, we have successfully identified a highly potent DENV2 NS2B/NS3pro 
protease inhibitor with activity at nanomolar concentrations, which is the most potent inhibitor 
known. Kinetic analysis revealed that phloeodictine X is a competitive inhibitor with the substrate 
examined, indicating that it binds in the substrate-binding active site of the enzyme. Moreover, it 
did not inhibit other trypsin-like human serine proteases, boding well for selective inhibition of viral 
proteases. It is important to note that a variety of biological actions, such as cytotoxicity, antifungal 
and antibacterial activities, have been reported for Phloeodictine X. This implies that off-site 
activities may be an issue for Phloeodictine X as a drug candidate. Due to a limited supply of 
Phloeodictine X (an extract from marine sponges) and time constraints, in vivo virus plaque assays, 
chemical stability and toxicity studies were not pursued. Improvement of potency and drug-like 
properties may first be needed in future studies in order to develop appropriate analogues with 
potent antiviral activity in cells and animals, where full in vivo characterization will be carried out. 
 
5.5.1 SAR studies 
Components of phloeodictine X that were postulated to bind to the S1 and S2’ pockets were 
the basic side chain and hydrophobic alkyl chain respectively (Figure 5.17). To further improve the 
potency and drug like properties of phloeodictine X analogues, structural modifications may be 
needed in future and this may require further knowledge of interactions made with DENV 
NS2B/NS3pro protease.  In addition, the reported synthesis of phloeodictine X proved to be 
synthetically challenging and laborious, with an overall yield of just 8%.39, 40 Therefore, it is of 
interest to generate more synthetically accessible compounds that mimic key components of 
phloeodictine X for future SAR studies. 
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Figure 5.17: Components of Phloeodictione X  
 
In order to mimic the 6-hydroxy- 2,3,4,6-tetrahydropyrrolo[1,2-alpha]pyrimidinium central 
scaffold, several heterocyclic scaffolds can be considered as potential replacements (Figure 5.18). A 
bicyclic moiety, such as indole or benzamidazole, may retain the conjugated pi system required for 
any putative pi-stacking interaction with Tyr161. The guanidine chain could be attached at position-
4 (R2), while either the lipophilic chain (R1) or the hydroxyl group can be introduced at the indole-
nitrogen position. This may allow the correct projection of both side arms to the correct binding site.  
Benzyl alcohol could serve as an alternative scaffold, as it provides an easy strategy for retaining 
the hydroxyl group thought to be important for binding, and allows attachment of a hydrophobic 
alkyl chain at the same time. 
 
    
Phloeodictine X  Indole Benzamidazole Benzyl alcohol 
 
Figure 5.18: Potential replacement scaffolds 
 
The scaffolds were superimposed onto phloeodictine X (green) to examine their suitability 
as potential replacements (Figure 5.19). From the modeling studies, it seems that the projection of 
the hydrophobic alkyl chain deviates significantly away from that of phloeodictine X when a N-
substituted indole (purple) is used as a replacement. It is noted that the alkyl chain and the 
hydroxyl group are both attached to a tetrahedral C-6 in phloeodictine X. As the indole nitrogen can 
only be mono-substituted, it can retain either the alkyl chain or the hydroxyl group. In the 
superimposition studies, the hydroxyl group was omitted to retain the prime-targeting alkyl chain.  
It seems that the indole fails to provide an appropriate geometry to allow the correct projection of 
the alkyl chain.  Similar observations were noted for benzimidazole (orange).   
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Indole	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Figure 5.19: Superimposition of potential scaffolds with Phloeodictine X (green). The 
superimpositions were generated using ROCS (OpenEye Suites). 
 
On the other hand, the benzyl alcohol scaffold (yellow) seems to be structurally suitable as a 
Phloeodictine X skeleton replacement.  The alpha-substituted benzyl alcohol derivative allows the 
retention of both the alkyl chain and the hydroxyl group. From the docking studies, it seems that the 
alkyl chain is now projected correctly and the hydroxyl group placed at a similar position with that 
in Phloeodictine X. It therefore seems to be an attractive replacement due to geometry, ease of 
synthesis of derivatives, and potential for generating more drug-like	   compounds	   than	  Phloeodictine	   X.	   Modifications of the alkyl and basic side chains may also be carried out to 
examine the SAR at these positions. The alkyl chain was postulated to bind to the hydrophobic S2’  
pocket.  
Upon close examination, it was noted that the S2’ pocket is quite spacious could 
accommodate a bulkier hydrophobic group (Figure 5.20). Therefore, further optimizations may 
involve introduction of a bulky aromatic group and varying the length of the alkyl chain to achieve 
more optimal occupation of the prime side binding pocket. The basic side chain containing the 
guanidine moiety was deemed important to form critical ionic interaction with the highly conserved 
Asp129 residue situated in the S1 pocket.  Highly charged groups are often linked to poor cell-
permeability and non-optimal drug-like properties. Therefore, future modifications may involve 
reduction of the basicity of the guanidine moiety, or introduction of a suitable mimetic in place of 
the basic chain. 
 
 
Figure 5.20: Phloeodictine X docked onto DENV protease. Electrostatic potential 
surface was generated using Pymol (Red= acidic, blue = basic, grey = hydrophobic). 
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5.5.2 Inhibition of NS3 protease from different DENV serotypes 
DENV NS2B/NS3pro proteases from DENV 1-4 share about 50-70% sequence homology 
and the S1, S2 and S3 binding pockets flanked by the NS3pro residues are mostly conserved.41 The 
slight difference in binding pockets S2 and S3 arise from the variation in NS2B cofactor residues 
that participate in the pocket formation 42-45. The inhibitory properties of phloeodictine X may be 
different among the four DENV serotypes and it may affect the reorganization of the NS2B cofactor 
to the NS3 protease differently. It is therefore valuable to assess IC50 of phloeodictine X against the 
four DENV serotypes, in addition to providing important information on its selectivity across the 
serotypes. 
 
5.5.3 Co-crystallisation studies  
In the absence of a crystal structure of phloeodictine X bound to DENV NS2B/NS3pro 
protease, molecular modeling studies were employed to gain some insights into their potential 
binding interactions. Despite generation of reasonable binding poses, the true representation of the 
binding conformation of Phloeodictine X remains inconclusive. This makes future SAR studies to 
improve inhibitor potency somewhat challenging. Therefore, future studies may need to involve co-
crystallization of Phloeodictine X with DENV NS2B/NS3pro protease to elucidate interactions that 
would enable for definitive plans for future medicinal chemistry studies.  
 
 
5.6 EXPERIMENTAL SECTION 
 
5.6.1 Chemical compounds for HTS 
The 2000 compounds were kindly provided by Professor Rob Capon’s Laboratory 
(University of Queensland). The purity and NMR spectra of the compounds were assessed by this 
PhD candidate, however they are not available for disclosure due to confidentiality arrangements. 
 
5.6.2 DENV NS2B/NS3pro expression and purification 
The expression and purification of the DENV NS3pro linked to the NS2B cofactor was 
conducted by Dr Keith J. Chappell (University of Queensland) and this was kindly provided for the 
screening campaign. 
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5.6.3 Screening protocol 
5.6.3.1 Preparation of assay plates 
An Agilent Bravo Automated Liquid Handling Platform was used to dispense 2 µL of each 
compound solution provided (0.1 mg/ml) into each well of a 384-well plate with the assistance of 
Dr Andrew Piggott and Ms Zeinab Khalil (University of Queensland).  Each well contained one 
compound at a single concentration, with a duplicate plate also prepared. In each plate, six positive 
control and six negative control wells were incorporated.  
 
5.6.3.2 Absorption spectra characterization 
The enzyme inhibition by compounds was assessed through an in-house colorimetric assay. 
Ac-LKRR-pNA was used as the chromogenic substrate to assess the proteolytic activity of DENV 
NS2B/NS3pro, whereupon hydrolysis produces free para-nitroaniline can be spectrometrically 
detected as absorbance at λ = 405 nm. It is therefore crucial to first characterize the absorbance 
spectra of the compounds to ensure that they do not interfere with the absorbance measurement at 
405 nm. Into each well, the compounds (4 µg/mL) were dissolved in Tris buffer (50 mM Tris-
NaOH, 1 mM CHAPS, 30% glycerol), and absorption spectra of each compound were measured 
from 350 nm to 650 nm using a PHERAstar Optima spectrophotometer (BMG Labtech). 
 
5.6.3.3 Protease Inhibition assay  
After the absorption spectra of the compounds were characterized, DENV NS2B/NS3pro 
protease (50 nM) are added into the well and pre-incubated with the compounds for 30 min at pH 
9.4 in a 50 mM Tris-NaOH buffer, 30% glycerol, and 10 mM NaCl at 37 oC and pH 9.5.  After the 
incubation period, the chromogenic substrate, Ac-LKRR-pNA (125 µM) was added, and the 
hydrolysis of the para-nitroanilide moiety is measured using a PHERAstar Optima spectrometer 
(BMGLabtech) at  λ	  = 405 nm. 
 
Table 5.9: Inhibition assay components. 
Component Volume (µL) 
+ve control -ve control Sample 
Buffer (2X) 25 25 25 
Water 12.5 17.5 12.5 
Enzyme (500 nM) 5 5 5 
Chaps (20 mM) 2.5 2.5 2.5 
Inhibitor (10x, in DMSO) 0 0 2.5 
DMSO 2.5 2.5 0 
Substrate (2.5 mM) 2.5 2.5 2.5 
Total volume (µL) 50 50 50 
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5.6.4 False positive inhibitors 
5.6.4.1 Prolonged incubation 
Using the same protocol as the aforementioned protease inhibition assay, the hits identified 
were incubated for 1.5 h instead of the initial 30 min used. After the incubation period, the 
chromogenic substrate, Ac-LKRR-pNA (125 uM) was added, and the hydrolysis of the pNA moiety 
is measured using a PHERAstar Optima spectrophotometer (BMG Labtech)	  at	  	  λ	  = 405 nm. 
 
5.6.4.2 Inhibition assay against other enzymes   
Trypsin. Phloeodictine X (100 nM) was pre-incubated with Trypsin (100 nM) for 15 min in 
Tris buffer, 150 mM NaCl and 0.1% PEG at pH 7.5 at 37 oC. The chromogenic substrate, Benzoyl-
Arg-pNA (500 µM), was added to initiate the reaction giving a final volume of 100 µL. The 
reaction progress was measured by release of the para-nitroaniline, which was quantitated by 
absorbance at  λ = 405 nm using a PHERAstar Optima spectrometer (BMG Labtech). 
Thrombin. Phloedictine X (100 nM) was pre-incubated with Thrombin (20 µg per well) for 
15 min in Tris buffer, 150 mM NaCl and 0.1% PEG at pH 7.5 and 37 oC. The chromogenic 
substrate, Benzoyl-Arg-pNA (500 µM), was added to initiate the reaction giving a final volume of 
100 µL. The reaction progress was measured by release of the para-nitroaniline, which was 
quantitated by absorbance at λ = 405 nm using a PHERAstar Optima spectrometer (BMG Labtech). 
Tryptase. Phloedictine X (100 nM) was pre-incubated with Tryptase (0.1 µg per well) at pH 
7.5 and 37 oC for 15 min. The assay buffer used contains 0.1 M HEPES, 10% glycerol v/v, 0.1 
mg/mL Heparin, 0.01% Triton X-100 v/v, 0.02% NAN3 w/v, pH 7.5. Chromogenic substrate, Tos-
GPR-pNa (100 µM), was added to initiate the reaction giving a final volume of 100 µL. The 
reaction progress was measured by release of the para-nitroaniline, which was quantitated by 
absorbance at λ = 405 nm using a PHERAstar Optima spectrometer (BMG Labtech). 
Factor B. Phloedictine X (100 nM) was pre-incubated with Factor B (50 nM) in a buffer 
comprising of 100 mM glycine-HCl and 150 mM NaCl pH 9.5 and 37 oC for 15 min. Ac-
SHLGLAR-pNA (500 µM) was added to initiate the reaction giving a final volume of 100 µL. The 
reaction progress was measured by using the release of the para-nitroaniline, which was quantitated 
by absorbance at λ = 405 nm using a PHERAstar Optima (BMG Labtech).  
WNV NS2B/NS3pro. Phloedictine X (1 µM - 0.1 nM) was pre-incubated with WNV 
NS2B/NS2pro protease (25 nM) in a buffer comprising 50 mM Tris-NaOH, 1 mM CHAPS, 30% 
glycerol at pH 9.5 and 37 oC for 15 min. Substrate Ac-LKKR-pNA (500 µM) was added to initiate 
the reaction giving a final volume of 100 µL. The reaction progress was measured by release of the 
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para-nitroaniline, which was quantitated by absorbance at λ = 405 nm using a PHERAstar Optima 
spectrometer (BMG Labtech).  	  	  
5.6.5 Characterization of Phloeodictine X  
5.6.5.1 Steady state kinetics of Phloeodictine X 
Kinetic analysis was performed to determine the inhibition mechanism of Phloeodictine X. The 
concentration of Phloeodictine X was varied (1.25 µM, 500 nM, 250 nM, 50 nM) against different 
concentrations of substrate (1 mM, 500 µM, 250 µM, 125 µM). The initial reaction velocities were 
determined and plotted for each substrate concentration using Graphpad Prism v. 5.1 (Graphpad 
Software, San Diego, CA). Michaelis-Menten and Lineweaver-Burk plots were generated using this 
program. Data are represented by at least four experiments (n ≥ 4) unless otherwise stated, and 
expressed as the mean of all experiments ± SEM. The log ceoncentrations are expressed with 95% 
confidence intervals (p¯≤ 0.05) 
 
5.6.5.2 Docking studies 
Phloeodictine X was docked into DENV NS2B/NS3pro protease using Gold (GoldSuite5.1) 
software to understand how it may interact with the protease.  The correct protonation state of 
Phloeodictine X at pH 9.4 was first determined using MarvinSketch. The three-dimensional 
structure of Phloeodictine X was generated using OMEGA2 (OpenEyes suite), to which the energy 
of the structure was minimized using Sybyls1.3. The DENV NS2B/NS3pro protease structure was 
retrieved from the PDB data bank (3U1I) and was prepared using Hermes (GoldSuite 5.1) where 
water molecules were deleted, and the energy of the protein was re-minimized. The three-
dimensional structure of Phloeodictine X was docked into DENV NS2B/NS3pro protease using 
Gold (GoldSuite 5.1) with 200% efficiency and twenty binding poses were generated.  
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6.0 SUMMARY OF THESIS 
 The purpose of this thesis was to identify novel inhibitors for several problematic serine 
proteases that have been identified as important targets in drug design. Proteases play key roles in 
almost all biological and physiological processes and their misregulation has been linked to a 
plethora of diseases. This thesis followed the concept of using inhibitors of serine proteases in 
inflammatory diseases (e.g. tryptase and factor B) and infectious diseases (DENV NS2B/NS3pro 
and WNV NS2B/NS3pro). In recent decades, immense effort has been invested in drug discovery 
campaigns for these four serine protease targets. However translating early inhibitor hits into 
developed drug candidates has proven to be challenging, and there are no drugs targeting these 
proteases available in the marketplace. This thesis has attempted to address this issue, in which 
several inhibitor discovery strategies were employed towards the aim of designing, synthesizing and 
evaluating mainly peptidic inhibitors targeting these proteases. The outcomes of this thesis would 
provide valuable insights to underpin future drug development, and potentially serve as the “bridge” 
required to progress inhibitors into potential drug candidates. 
In the first part of Chapter 2, a peptidomimetic approach was employed to successfully 
produce a moderately potent hybrid peptide Ac-PRN(4-AMAA)-Gf-NH2 (IC50 = 12 µM) as an 
inhibitor of human tryptase. Previous work has focused on targeting established binding pockets 
(prime and non-prime) of tryptase. Despite successful generation of inhibitors with good binding 
affinity, both selectivity and toxicity issues ultimately hindered their progresses. To promote 
selectivity for tryptase over other serine proteases (and potentially other classes of proteases), an 
unexploited binding pocket was examined. Using modelling studies, a previously unexploited 
binding pocket at S2’ was identified and successfully targeted. The availability of the three-
dimensional structure of the protease also allowed identification of steric features of the binding 
sites and the preferred binding conformation of ligands. Fundamentally, this approach relied on the 
knowledge of the conformation, electronic and topochemical properties of previously reported 
inhibitors, where molecular insights gained from their interactions with the tryptase active site led 
to the design of a novel P1 scaffold (4-aminomethylanthranilic acid, 4-AMAA). Introduction of 4-
AMAA allowed strategic placement of an ionic functional group to target the S1-Asp189 residue, 
and the attachment of both prime- and non-prime targeting moieties.  It was shown that a bioactive 
natural peptide substrate could be successfully transformed into an active peptidomimetic tryptase 
inhibitor.  
The peptidomimetic methodology was also employed in Chapter 3 to systematically 
transform highly basic and hydrophilic peptidic flaviviral substrates into inhibitors of DENV 
NS2B/NS3pro (PhAc-KRR-CHO, IC50 = 10 µM) and WNV NS2B/NS3pro (PhAc-KKR-CHO, IC50 
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= 51 nM). The obvious limitation of these peptides, being highly polar and hydrophilic, was their 
lack of bioavailability, in addition to the DENV NS2B/NS3 inhibitor being only moderately active. 
Peptidomimetics were used as tools to study flaviviral protease-inhibitor binding interactions in 
order to improve inhibitor potency, where novel binding requirements for DENV NS2B/NS3pro 
active site (P1, P2 and P3) were successfully mapped.  In this study, it was proven that having a P1 
basic residue to interact with Asp129 of S1 pocket (known to be a strict requirement for trypsin-like 
serine protease) was not an absolute requirement, since an alternative pi-interaction with S1-Tyr161 
was achieved albeit resulting in reduced inhibitor potency.  A requirement for a longer arginine at 
P2 was also identified. Recently, a previously unmapped acidic C-terminal region of the co-factor 
(situated at S3) was unveiled by Doan et al. to be important for inhibitor binding.  A requirement 
for an elongated arginine mimetic was noted at this position, and introduction of an appropriate 
backbone constraint in future inhibitors may achieve a suitable vector to target the acidic region of 
the cofactor. 
 In the second part of Chapter 2, two electrophilic isosteres (aldehyde and α-keto amide) 
were used to produce highly potent covalent tryptase inhibitors. The incorporation of an internal α-
keto amide in the active peptide sequence (Ac-PRNR-α-keto-amide-G(benzylamine), IC50 = 610 
pM) allowed the successfully mapping of the S2’ pocket. The targeting of the S2’ pocket led to 
improved inhibitor potency, however this did not contribute to significant improvement of 
selectivity for tryptase.  Nevertheless, we have shown that using electrophilic isosteres can allow 
efficient mapping of binding interactions with tryptase, and the use of α-keto amide was especially 
useful for investigating structure-activity relationships at the prime binding sites in tryptase. 
Conventionally, aldehyde and α-keto amide have been extensively used to target both serine and 
cysteine proteases indiscriminately. Gaining selectivity amongst these two protease classes, and 
within the class, has always been a key challenge in developing selective covalent inhibitors. In this 
study, it was shown that incorporation of a selective active binding sequence (P4-P1, Pro-Arg-Asn-
Arg) could produce selective covalent tryptase inhibitors against trypsin.  
Based on the positive outcomes for covalent binding tryptase inhibitors, an α-keto amide 
was also employed in Chapter 4 to probe the prime binding pockets of two unrelated proteases, the 
viral protease DENV NS2B/NS3pro and the human inflammatory protease Factor B. Previously 
reported inhibitors of DENV NS2B/NS3pro (PhAc-KRR-CHO, IC50 = 10 µM) and complement 
Factor B (Ac-RLTbaLAR-CHO, IC50 = 867 nM) utilized a C-terminal aldehyde. The DENV 
NS2B/NS3pro aldehyde inhibitor had only moderate potency, while the complement inhibitor was 
non-selective and also inhibited trypsin and thrombin at comparable concentrations. The targeting 
of prime binding sites failed to achieve improvement in inhibitor potency for both proteases, and 
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the α-keto amide peptides were inferior than the parent aldehyde inhibitors despite the success 
previously observed for tryptase. Docking studies suggested that aldehyde and α-keto amide may 
not be geometrically compatible to form interactions with the DENV NS2B/NS3pro oxyanion hole 
residues, whereas electrophilic isosteres such as boronate esters may make more productive 
interactions with the oxyanion cleft.   Based on the results of Chapter 3 and Chapter 4, it is 
apparent that future DENV NS2B/NS3pro inhibitors should incorporate a geometrically compatible 
electrophilic isostere (perhaps boronates), with a focus on the optimisation of the non-prime binding 
sequence, especially the P3 position to target the previously neglected acidic S3 C-terminus of the 
co-factor region.  The α-keto amides were however inferior inhibitors of Factor B compared to the 
reference aldehyde inhibitor. Interestingly, all of the α-keto amide inhibitors were less favoured  
compared to their aldehyde counterparts, seen in tryptase, DENV NS2B/NS3pro and factor B. As 
both isosteres display similar electrophilic properties, it was postulated that the α-keto amide 
moiety may be slightly less sterically accessible compared to the C-terminal aldehyde to allow the 
serine residue to form a nucleophilic attack.   
 
Table 6.1: Aldehyde inhibitors vs α-keto amide inhibitors in this thesis 
Target Compound pIC50 ± SEM IC50 (µM) 
Tryptase Ac-PRNR-CHO 8.38 ± 0.14 0.004 
Ac-PRNR-α-keto amide 7.19 ± 0.19 0.065 
DENV NS2B/NS3pro PhAc-KRR-CHO 4.99 ± 0.72 10 
PhAc-KRR-α-keto amide <4 >100 
Factor B Ac-RLTbaLAR-CHO 6.06 ± 0.08 0.867 
Ac-RLTbaLAR-α-keto amide 4.58 ± 0.70 27 
 
The development of DENV NS2B/NS3pro inhibitors proved to be challenging, with 
minimal success noted for our peptidomimetic approach (Chapter 3) and for utilization of an 
electrophilic isostere in peptide inhibitors (Chapter 4). A screening campaign was therefore carried 
out in Chapter 5, where an alkaloid  (Phloeodictine X, IC50 = 43 nM) extracted from marine sponge 
Phloeodictyon sp. was successfully identified among a 2000 natural product library as the most 
potent DENV NS2B/NS3pro inhibitor known thus far, with no inhibitory activity against other 
trypsin-like serine proteases even at 100 nM concentrations. Future studies will involve 
improvement of inhibitor potency and drug-like properties beginning from this lead. 
In summary, it was successfully demonstrated in this thesis that several methodologies could 
be employed to afford identification of active protease inhibitors. The peptidomimetic approach 
proved to be useful in generating valuable tools to establish SAR profiles for target proteases and 
for transforming peptide inhibitors into more Lipinski-like compounds.  It was also found that 
reactive elctrophilic isosteres (e.g aldehyde and α-keto amide), traditionally known to bind strongly 
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to proteases, are not universally accepted by all proteases. Despite being strong electrophiles, both 
aldehyde and α-keto amide bind weakly to DENV NS2B/NS3pro. It was postulated that they lack 
the ability to form constructive interactions with the oxyanion hole residues due to geometric 
incompatibility of the intermediate produced after forming a covalent bond with the nucleophilic 
serine residue. Lastly, the screening approach, a popular technique in early drug discovery, proved 
to be advantageous in identifying DENV NS2B/NS3pro inhibitors, where a serendipitous discovery 
of highly potent inhibitor was achieved. This is significant, as many pharmaceutical companies that 
we have collaborated with have previously screened their multimillion compound libraries without 
finding any significant sub-micromolar inhibitors of this viral enzyme. Subsequent optimisation 
will be carried out to transform the new inhibitor lead into a potential drug candidate.   
